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Summary {#efs25005-sec-0001}
=======

The European Commission asked the European Food Safety Authority (EFSA) for a scientific evaluation on the risk to human health of the presence of furan and methylfurans (2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran) in food. To address this request, the EFSA Panel on Contaminants in the Food Chain (CONTAM) decided that the opinion should comprise the: evaluation of the toxicity of furan, and 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran, collectively known as methylfurans, for humans considering all relevant toxicological endpoints;estimation of the dietary exposure of the European Union (EU) population to furan, 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran from food, including the consumption patterns of specific groups of the population if appropriate;assessment of the human health risks for the EU population, including specific groups of the population if appropriate, as the consequence of the estimated dietary exposure.

Furan, 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran are volatile compounds that are formed in foods during thermal processing. Furan can be formed in food from a variety of precursors including ascorbic acid, amino acids, carbohydrates, unsaturated fatty acids and carotenoids. Food characteristics, processing and cooking conditions, and the losses which mainly occur due to evaporation in the preparation of the food at the level of the consumer, determine the final concentration in the food as consumed.

Chronic dietary exposure to furan was estimated using a data set containing 9,663 samples provided by governmental organisations and 7,393 samples provided by commercial organisations. The data sets were comparable and were merged for the assessment. The highest concentrations of furan were found in whole roasted coffee beans, with a mean value of 4,579 μg/kg. High mean concentrations of furan were also found in ground roasted coffee (2,361 μg/kg), unspecified coffee solids (2,186 μg/kg), coffee imitates for brewing (1,922 μg/kg), instant coffee powder (310 μg/kg) and instant coffee imitates (127 μg/kg). Mean concentrations ranging from 20 to 57 μg/kg were found in composite foods (prepared salads, cereal‐based and vegetable‐based), ready‐to‐eat meals for infants and young children, soy sauce, bread and rolls, raw pasta, breakfast cereals, fine bakery wares and spirits. Occurrence data for 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran were not provided, and from the available literature data on the co‐occurrence of furan and methylfurans, a 2‐methylfuran/furan and 3‐methylfuran/furan ratio was calculated only for coffee, infant cereals, jarred baby‐food and cereal flakes. Co‐occurrence data on 2,5‐dimethylfuran were too limited to derive such a ratio.

The highest exposures to furan were estimated in the youngest population group, i.e. infants. The mean dietary exposures calculated for infants ranged from 0.14 to 0.99 μg/kg body weight (bw) per day (minimum lower bound (LB) to maximum upper bound (UB)). Regarding the 95th percentile exposures, which refer to highly exposed consumers within a given dietary survey and age class, the highest estimates were also observed for infants ranging from 0.27 to 1.8 μg/kg bw per day (minimum LB to maximum UB). Chronic dietary exposure of adults, elderly and very elderly was estimated to be on average between 0.11 and 0.75 μg/kg bw per day (minimum LB to maximum UB) and the 95th percentile was between 0.2 and 1.27 μg/kg bw per day (minimum LB to maximum UB) depending on the survey and age group. Ready‐to‐eat meals for infants and small children are the main contributor to the dietary exposure of infants. For adults, elderly and very elderly, the exposure is mainly driven by coffee. Grains and grain‐based products are the food group contributing most for toddlers, other children and adolescents, and it is also the second largest contributor in all other age classes. The influence of reheating commercially processed foods on furan concentrations is limited and depends on the consumer behaviour. Regarding the formation of furan during home cooking, a specific scenario based on toasting bread did not impact on the overall outcome of the exposure assessment. The inclusion of methylfurans, however, may significantly increase exposure. For the exposure scenario for the sum of furan, 2‐methylfuran and 3‐methylfuran, estimates for adults, elderly and very elderly showed the highest increase compared to the baseline scenario. This exposure was mainly driven by the high concentrations of 2‐methylfuran in coffee (four times higher than furan).

After oral exposure to rats, furan is rapidly and extensively absorbed from the gastrointestinal (GI) tract, distributed throughout the body and extensively metabolised. The major contributor to the metabolism of furan is cytochrome P450 2E1 (CYP2E1), resulting in opening of the furan ring and formation of *cis‐*but‐2‐ene‐1,4‐dialdehyde (BDA) which is very reactive. BDA has never been directly measured. However, results with trapping agents and the identification of urinary and biliary metabolites provide strong evidence that BDA is indeed a prime reactive intermediate in the metabolism of furan. BDA reacts readily with amino acids, glutathione (GSH) and biogenic amines and it has direct reactivity towards DNA. However, the data suggest that due to BDA reactivity with protein and non‐protein amino and thiol residues, access to DNA *in vivo* is restricted.

No oral studies have been performed with any of the three methylfurans considered in this opinion to address their kinetics in animals, but it is anticipated that they will be absorbed from the GI tract. Non‐extractable association of 2‐methylfuran with protein and DNA in the liver was reported after intraperitoneal (i.p.) administration. For 2‐methyl‐ and 3‐methylfuran, data from *in vitro* studies are available that show that they may become associated (non‐extractable) with lung and liver microsomal proteins. The reactive metabolic intermediates of 2‐methylfuran and 3‐methylfuran are the *cis*‐enedials 3‐acetylacrolein (4‐oxopent‐2‐enal) and 2‐methylbut‐2‐enedial, respectively. For 2,5‐dimethylfuran ring opening results in the formation of a reactive intermediate, the *cis*‐enedione 3(Z)‐hexene‐2,5‐dione. Similar to BDA, the reactive intermediate formed from 2,5‐dimethylfuran reacts readily with amino acids and with GSH and the corresponding structures for the adducts formed have been reported. For 2‐ and 3‐methylfuran metabolites, only very limited information is available, but from the structures of their primary metabolites and from studies with scavengers, it is anticipated that these will react with tissue components in a similar way to the primary metabolites of furan and 2,5‐dimethylfuran.

In experiments of a duration of up to 90 days, furan is strongly hepatotoxic and moderately nephrotoxic in rodents when applied by oral gavage. Rats seem to be more sensitive towards furan than mice. Furan leads to characteristic changes in serum markers related to hepatotoxicity as well as severe histopathological damage in the liver. After 90 days, significant increases in serum thyroid hormones were observed along with severe histopathological changes in the liver of male rats after a daily dose of 0.12 mg/kg bw, given 5 days a week.

In long‐term studies, furan was associated with toxicity in the liver. Cholangiofibrosis was observed in rats as an early and sensitive response with significant increases after 36 weeks at doses of 0.44 mg/kg bw and above. In mice, hepatocellular adenoma/carcinoma occurred at 104 weeks at doses of 4 mg/kg bw and above. In rats, cholangiocarcinomas were observed at the top dose of 8 mg/kg bw. No relevant malignancies were observed at doses at or below 2 mg/kg bw up to 104 weeks.

Furan did not induce gene mutations in bacteria. In the majority of the *in vitro* studies in mammalian cells, furan was able to induce chromosomal aberrations and sister chromatid exchanges; contrasting results were reported on the requirement for microsomal activation. BDA forms DNA adducts at the exocyclic N atom of the deoxycytosine, deoxyguanosine and deoxyadenosine nucleosides in *in vitro* model systems and in DNA from *Salmonella* Typhimurium TA104. BDA was able to directly induce mutations in bacteria and strand breaks and mutations in mammalian cells *in vitro*. In rodents, furan induced very low levels of DNA adducts in liver and kidney. The chemical structures of these adducts could not be defined but were not identical to those induced by BDA in *in vitro* model systems. Conflicting data were reported for the induction of DNA breaks in the liver. These breaks, likely reflecting oxidative stress‐induced DNA damage, occurred at doses showing mild liver toxicity. Chronic exposure to furan induced chromosomal damage in proliferating splenocytes from mice and rats. The DNA lesions responsible for these effects remain undefined. No clear induction of base substitutions was observed in transgenic rat models. A weak mutagenic activity was suggested by a single study in a transgenic mouse model. An excess of GC \> TA transversions was observed at codon 61 of the *Ha‐ras* oncogene in furan‐induced liver tumours in mice. It is uncertain whether these mutations are the consequence of oxidative damage to DNA or reflect an expansion of pre‐existing spontaneous *Ha‐ras* mutations.

Histological changes in the testes, prostate gland, Leydig cells and seminal vesicles were observed in Wistar rats at 2 mg/kg bw (lowest dose tested) and above given during weaning and post‐puberty. No histological effects in reproductive organs were observed in adult rats and mice up to 8 mg/kg bw.

Furan induces oxidative stress. The binding of BDA to a range of target molecules leads ultimately to cell and tissue damage, mitochondrial dysfunction and fibrosis, primarily in the liver. There is clear evidence for the involvement of indirect mechanisms in the carcinogenic mode of action of furan. These include epigenetic changes, oxidative damage to DNA and regenerative hyperplasia, with all of these effects being accompanied by tissue damage. There is limited evidence of a direct mechanism (i.e. direct interaction with DNA) in the carcinogenic action of furan. The contributing factors in carcinogenesis are likely to vary according to dose, duration of exposure and degree of severity of liver cellular damage, inflammation and compensatory proliferation.

The liver is the primary target organ with respect to acute and short‐term (\< 90 days) toxicity of 2‐ and 3‐methylfuran in rodents. There is also indication for kidney toxicity of 3‐methylfuran after 90 days of exposure. Liver toxicity in male rats given 3‐methylfuran (28 or 90 days) or 2‐methylfuran (28 days) by gavage was found to be the most sensitive adverse endpoint for both compounds. Their toxic potency was reported to be in the same order of magnitude as that for furan. No information on the genotoxic properties of 3‐methylfuran and limited information for 2‐methylfuran and 2,5‐dimethylfuran is available. Both 2‐methylfuran and 2,5‐dimethylfuran showed negative results in bacteria. There is some evidence that both compounds induce chromosomal damage in mammalian cells *in vitro* and there is little evidence that 2,5‐dimethylfuran can induce DNA breaks *in vivo*.

As there are few data available on the effect of furan in humans, the CONTAM Panel used data from experimental animals for the hazard characterisation. For non‐neoplastic effects, the CONTAM Panel selected the BMDL~10~ of 0.064 mg/kg bw per day (correcting for the applied dose regimen of 5 days per week) for the induction of cholangiofibrosis in male rats after 2 years as reference point. For neoplastic effects, the CONTAM Panel considered that the combined data set from two studies on the incidence of hepatocellular adenomas and carcinomas in female mice after 2 years is the most robust data set to derive a reference point and selected the BMDL~10~ of 1.31 mg/kg bw per day (correcting for the applied dose regimen of 5 days per week). In view of some indications for a direct genotoxic mechanism in the carcinogenic mode of action of furan, the CONTAM Panel decided that it was not appropriate to establish a tolerable daily intake (TDI) and used a margin of exposure (MOE) approach. The available information was insufficient to identify a reference point for the methylfurans. However, it was considered appropriate to assume dose additivity for hepatotoxicity of furan, 2‐methylfuran and 3‐methylfuran in the rat.

For non‐neoplastic effects, the calculated MOEs are below 100 in a number of dietary surveys, particularly for the high percentile exposure estimates for the younger age groups (infants and toddlers) and adults (including elderly). The CONTAM Panel concluded that these MOEs indicate a health concern. The CONTAM Panel noted that, with the exception of some surveys, the calculated MOEs for neoplastic effects of furan are smaller than 10,000, which, in accordance with the guidance given by the Scientific Committee, would indicate a health concern. However, there is uncertainty regarding the carcinogenic mode of action of furan. The CONTAM Panel considered the resulting MOEs for hepatocellular adenomas and carcinomas as supporting evidence for its conclusion, based on the hepatotoxicity of furan, that the current exposure to furan indicates a health concern. Based on a scenario for chronic dietary exposure to the sum of furan, 2‐methylfuran and 3‐methylfuran, MOE values for the incidence of cholangiofibrosis were calculated. From these MOE values, it becomes clear that methylfurans may add significantly to the overall exposure and therefore increase the concern for hepatotoxicity.

The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of furan is moderate and that the assessment is likely to be conservative. For methylfurans, due to a lack of data, no full assessment could be performed and the uncertainties in the assessment are large.

The CONTAM Panel recommends producing additional data on the occurrence of methylfurans in food as well as data on the changes of furan and methylfurans concentrations during the distinct stages of coffee preparation for all coffee types. Furthermore, the CONTAM Panel recommends performing studies *in vivo* on the effect of furan on the genome to clarify the carcinogenic mode of action. Further information is also needed on the toxicity, including the genotoxic properties, of methylfurans.

1. Introduction {#efs25005-sec-0003}
===============

1.1. Background and Terms of Reference as provided by the requestor {#efs25005-sec-0004}
-------------------------------------------------------------------

[**BACKGROUND**]{.ul}

Furan is formed in foods during thermal processing. It occurs in a variety of foods such as coffee, canned and jarred foods including baby food containing meat, and various vegetables. 2‐Methylfuran and 3‐methylfuran, have been found concurrently with furan, and apparently are also formed during thermal processing and are likely to undergo a similar metabolic fate to furan.

The Scientific Panel on Contaminants in the Food Chain adopted on 7 December 2004 a report on provisional findings on furan in food.[1](#efs25005-note-1006){ref-type="fn"} They concluded from the available data that there is a relatively small difference between possible human exposures and the doses in experimental animals that produce carcinogenic effects, probably by a genotoxic mechanism. However, a reliable risk assessment would need further data on both toxicity and exposure.

In the meantime, EFSA published on 2 December 2009, an external scientific report on furan in heat processed food products including home cooked food products and ready‐to‐eat products.[2](#efs25005-note-1007){ref-type="fn"}on 18 December 2009, an external scientific/technical report on consumer exposure to furan from heat‐processed foods and kitchen air.[3](#efs25005-note-1008){ref-type="fn"}on 22 August 2011, a scientific report with an update on furan levels in food from monitoring years 2004--2010 and exposure assessment.[4](#efs25005-note-1009){ref-type="fn"}

Furan was evaluated at the meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) which was held in Rome, Italy, from 16 to 25 February 2010.[5](#efs25005-note-1010){ref-type="fn"} The Committee concluded that the estimated margins of exposure (MOE) (480--960) indicate a human health concern for a carcinogenic compound that might act via a DNA‐reactive genotoxic metabolite.

Furthermore, the study report of the latest furan carcinogenicity bioassay, supported by an interagency agreement between the US National Institute of Environmental Health Sciences (NIEHS)/National Toxicology Program (NTP) and the US Food and Drug Administration (FDA) has been finalised and is now available (NCTR, [2015](#efs25005-bib-0195){ref-type="ref"}).

[**TERMS OF REFERENCE**]{.ul}

In accordance with Art. 29 (1) (a) of Regulation (EC) No 178/2002, the Commission asks the European Food Safety Authority (EFSA) for a scientific opinion on the human health risks related to the presence of furan and methylfurans in food.

1.2. Interpretation of the Terms of Reference {#efs25005-sec-0005}
---------------------------------------------

The EFSA Panel on Contaminants in the Food Chain (CONTAM) concluded this opinion should comprise the: evaluation of the toxicity of furan, and 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran, collectively known as methylfurans, for humans considering all relevant toxicological endpoints;estimation of the dietary exposure of the European Union (EU) population to furan, and 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran, collectively known as methylfurans, from food, including the consumption patterns of specific groups of the population if appropriate;assessment of the human health risks for the EU population, including specific groups of the population if appropriate, as the consequence of the estimated dietary exposure.

1.3. Supporting information for the assessment {#efs25005-sec-0006}
----------------------------------------------

### 1.3.1. Chemical and physical properties {#efs25005-sec-0007}

#### 1.3.1.1. Chemical properties {#efs25005-sec-0008}

Furan \[CAS‐number 110‐00‐9, C~4~H~4~O, molecular weight (MW) 68.07 g/mol\] is the parent compound of five‐membered heterocycles containing one oxygen atom. Its structure is stabilised by resonance due to the delocalisation of the electrons of carbon and oxygen present in the p‐orbital in a 6π‐electron system. Its chemical structure is shown in Figure [1](#efs25005-fig-0001){ref-type="fig"}.

Furan is highly susceptible to electrophilic aromatic substitution, mainly at the α‐position, yielding for instance 2‐alkylfurans (Hoydonckx et al., [2012](#efs25005-bib-0129){ref-type="ref"}). It is not clear to what extent such reactions are relevant in foods, as in general, furan is considered to be stable in foods. Hoydonckx et al. ([2012](#efs25005-bib-0129){ref-type="ref"}) summarised the main chemical reactions applied to furan, but these are not relevant in a food context. The compound is highly flammable and may also form explosive peroxides. It is characterised by an ethereal odour.

2‐Methylfuran \[CAS‐number 534‐22‐5, C~5~H~6~O, MW 82.1 g/mol\] is also aromatic in nature, and its chemical properties are comparable to those of furan, although it should be noted it is more prone to electrophilic aromatic substitution (Hoydonckx et al., [2012](#efs25005-bib-0129){ref-type="ref"}). Its chemical structure is shown in Figure [1](#efs25005-fig-0001){ref-type="fig"}. It is reported to be characterised by a medium strength, chocolate like odour.

3‐Methylfuran \[CAS‐number 930‐27‐8, C~5~H~6~O, MW 82.1 g/mol\] (for structure see Figure [1](#efs25005-fig-0001){ref-type="fig"}) is the analogue of 2‐methylfuran. Like furan and 2‐methylfuran, 3‐methylfuran is also aromatic in nature. It can be supposed that its chemical properties are similar, but information is scarce.

2,5‐dimethylfuran \[CAS‐number 625‐86‐5, C~6~H~8~O, MW 96.1 g/mol\] is particularly studied because of its potential use as a liquid fuel as it can be produced from biomass‐derived fructose (Román‐Leshkov et al., [2007](#efs25005-bib-0236){ref-type="ref"}). This dimethylfuran is known as a potent scavenger of singlet oxygen (Noguchi et al., [1977](#efs25005-bib-0199){ref-type="ref"}; Mongin et al., [2016](#efs25005-bib-0187){ref-type="ref"}) and hydroxyl radicals (Okada and Okajima, [1998](#efs25005-bib-0204){ref-type="ref"}).

2‐*Z*‐Butenedial (commonly referred to as *cis*‐but‐2‐ene‐1,4‐dialdehyde (BDA)) \[CAS‐number 3675‐13‐6, C~4~H~4~O~2~, MW 84.1 g/mol\] has been identified as a key metabolite of furan (Chen et al., [1995](#efs25005-bib-0045){ref-type="ref"}). In view of its highly reactive character, it is synthesised *in situ* via the oxidative ring opening of furan using dimethyloxirane (Adger et al., [1991](#efs25005-bib-0003){ref-type="ref"}).

![Chemical structures of furan, 2‐methylfuran, 3‐methylfuran, 2,5‐dimethylfuran and 2‐*Z*‐butenedial](EFS2-15-e05005-g001){#efs25005-fig-0001}

#### 1.3.1.2. Physical properties {#efs25005-sec-0009}

Furan is a colourless liquid with a density of 0.94 g/cm^3^ (20°C), a melting point of −85°C and a boiling point of 31.4°C at 101 kPa (760 mmHg). At 20°C, its vapour pressure is 66 kPa and at 25°C 80 kPa. Its solubility in water at 25°C is 10 g/L, and in acetone, benzene, ether and ethanol is greater than 100 g/L. The log K~ow~ is 1.34 (Hoydonckx et al., [2012](#efs25005-bib-0129){ref-type="ref"}; NTP, [2014](#efs25005-bib-0202){ref-type="ref"}). It can darken upon storage.

2‐Methylfuran is a colourless liquid with a density of 0.92 g/cm^3^ (20°C), a melting point of −88.7°C and a boiling point of 63--64°C at 101 kPa. At 20°C, its vapour pressure amounts 16 kPa (Hoydonckx et al., [2012](#efs25005-bib-0129){ref-type="ref"}). Its solubility in water at 20°C is 3 g/L and the log K~ow~ amounts to 1.85.[6](#efs25005-note-1011){ref-type="fn"} It is readily soluble in organic solvents.

3‐Methylfuran is a colourless liquid with a density of 0.92 g/cm^3^ (18°C) and a boiling point of 65.5°C at 101 kPa (Asahina et al., [1924](#efs25005-bib-0017){ref-type="ref"}). On standing, it can turn yellow (Burness, [1956](#efs25005-bib-0035){ref-type="ref"}). The log K~ow~ is 1.91 and the solubility in water is 3.03 g/L, as estimated using US‐EPA EPI‐suite.[7](#efs25005-note-1012){ref-type="fn"} SciFinder[8](#efs25005-note-1013){ref-type="fn"} reported an estimated solubility in water of 4.4 g/L and an estimated vapour pressure of 21 kPa (25°C). According to The Good Scents Company, 3‐methylfuran is soluble in ethanol, but further details are not provided.[9](#efs25005-note-1014){ref-type="fn"} 2,5‐Dimethylfuran is a colourless to yellow liquid with a density of 0.90 g/cm^3^ (20°C) and a boiling point of 94--96°C (Terent\'ev and Kazitsyna, [1949](#efs25005-bib-0260){ref-type="ref"}) It has an estimated vapour pressure of 8 kPa at 25°C. Its (experimental) log K~ow~ is 2.24 and from this value the solubility in water can be estimated to be approximately 1.5 g/L (US‐EPA‐EPI‐suite). However, SciFinder[8](#efs25005-note-1013){ref-type="fn"} reported an estimated solubility in water of 4.3 g/L. According to The Good Scents Company, 2,5‐dimethylfuran is soluble in ethanol and propylene glycol, but further details are not provided.[9](#efs25005-note-1014){ref-type="fn"}

BDA is a major primary metabolite of furan (see Section [3.1.1.3](#efs25005-sec-0037){ref-type="sec"}), and for this reason, some information on this metabolite is presented here. Its boiling point was reported to be 54--61°C (1 kPa) (Hufford et al., [1952](#efs25005-bib-0132){ref-type="ref"}). In the absence of experimentally determined properties, the following estimations were obtained, using US‐EPA EPI‐suite: a vapour pressure of 0.5 kPa (25°C), log K~ow~ 0.14 and a solubility in water of 9.8 g/L. However, different values were reported on SciFinder,[8](#efs25005-note-1013){ref-type="fn"} namely a vapour pressure of 0.08 kPa (25°C), and a solubility in water of 124 g/L.

### 1.3.2. Analytical methods {#efs25005-sec-0010}

Currently, no official standard methods are available for the analysis of furan and methylfurans in foods. Neither are there certified reference materials available. In 2008, the European Commission organised a proficiency test for furan using baby food as a sample in which 22 laboratories participated with 16 returning satisfactory results (Kubiak et al., [2008a](#efs25005-bib-0152){ref-type="ref"},b). Commercial proficiency tests for furan using coffee or baby foods samples are organised by organisations such as Fapas.[10](#efs25005-note-1015){ref-type="fn"} No proficiency tests were identified for methylfurans.

Laboratories use their in house‐validated analytical methods. Three analytical approaches are used most often for the determination of furan and methylfuran in foods. All of them are based on a mass‐spectrometric (MS) detection and quantification using stable isotope dilution assays with *d*4*‐*furan, *d*3‐2‐methylfuran and *d*3‐3‐methylfuran for, respectively, furan, 2‐methylfuran and 3‐methylfuran based on selective ion monitoring (SIM). For 2,5‐dimethylfuran, the use of deuterated analogues is not applied, probably because analytical standards are not available commercially. Separation is accomplished by capillary gas chromatography (GC).

The approaches differ in the isolation of the volatile analytes from the matrix. In the Goldmann et al. ([2005](#efs25005-bib-0112){ref-type="ref"}) method, solid‐phase microextraction (SPME) (using typically a carboxen/polydimethylsiloxane fibre) is used in combination with cryofocusing. Bianchi et al. ([2006](#efs25005-bib-0027){ref-type="ref"}) used a similar approach but omitted the cryofocusing step. Becalski et al. ([2005](#efs25005-bib-0023){ref-type="ref"}, [2010](#efs25005-bib-0024){ref-type="ref"}) used a static headspace approach without the use of SPME, which is similar to the method proposed by FDA ([2004b](#efs25005-bib-0091){ref-type="ref"}). The static head space approach and the use of SPME both proved to be fit for purpose as observed in a proficiency test organised by the Joint Research Centre of the European Commission in 2008 (Kubiak et al., [2008a](#efs25005-bib-0152){ref-type="ref"},b). The limits of detection (LOD) of these methods typically range from 5 μg/kg to as low as 0.01 μg/kg, and limits of quantification (LOQ) from 25 μg/kg to 0.03 μg/kg (Kubiak et al., [2008a](#efs25005-bib-0152){ref-type="ref"},b) for furan. For methylated furans, similar limits were reported (e.g. Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"}) reported an LOD for 2‐methylfuran amounting 0.05 μg/kg). These analytical limits are dependent upon the food matrix analysed (Becalski et al., [2016](#efs25005-bib-0026){ref-type="ref"}). Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"}) also reported the presence of trace amounts of furan present in blank samples and therefore considered only samples with concentrations exceeding 1 μg/kg as relevant.

Special care should be taken during the analysis because of the high volatility of the analyte and the internal standards. In addition, the possibility of artefactual furan formation should be considered. Adams et al. ([2012](#efs25005-bib-0002){ref-type="ref"}) reported the artefactual furan formation on the SPME fibre from volatile precursors, especially at high fibre desorption temperatures. Also the additional formation of furan during the equilibration of the sample in the headspace vials has been reported (Senyuva and Gokmen, [2005](#efs25005-bib-0241){ref-type="ref"}).

Märk et al. ([2006](#efs25005-bib-0176){ref-type="ref"}) used proton‐transfer reaction mass spectrometry (PTR‐MS) as an analytical tool to quantify furan and methylfuran. This technique could even be applied as an on‐line quality monitoring system as no chromatographic separation of the analytes is required.

### 1.3.3. Previous assessments {#efs25005-sec-0011}

Furan was evaluated by the International Agency for Research on Cancer (IARC) (IARC, [1995](#efs25005-bib-0134){ref-type="ref"}). The IARC concluded that the evidence in humans for the carcinogenicity of furan was inadequate but there was sufficient evidence in experimental animals to classify furan as 'possibly carcinogenic to humans' (Group 2B).

In 2000, the US National Academy of Sciences (NAS) published a monograph on furan as an airborne contaminant in spacecraft and concluded that '...furan, or an active metabolite of furan, affects DNA indirectly through a mechanism involving cytotoxicity and does not react directly with the DNA in target cells'. In assessing the risk of furan‐induced cancers, the assumption was made that 'an exposure concentration that adequately controls the risk of cholangiocarcinomas will also control leukemias and hepatocellular adenomas and carcinomas'. Biliary hyperplasia induced by furan in male rats in a 13 week NTP study (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}) was used as a precursor lesion to the cholangiocarcinomas. From these data, a benchmark dose lower confidence limit for 1% increase in cancer incidence (BMDL~01~) of 0.09 mg/kg body weight (bw) per day was calculated (NAS, [2000](#efs25005-bib-0194){ref-type="ref"}).

During investigations relating to a review of a petition for certain uses of irradiation in food, the US Food and Drug Administration (FDA) identified furan in a number of foods that undergo heat treatment, such as canned and jarred foods. In May 2004, the FDA published a request for submission of data and information on furan (FDA, [2004a](#efs25005-bib-0090){ref-type="ref"}). The EFSA CONTAM Panel considered this as an emerging issue in food safety and decided to compile a scientific report comprising all the available data at the time on methods of analysis, occurrence, formation, exposure and toxicity (EFSA, [2004](#efs25005-bib-0063){ref-type="ref"}). From the limited data available at the time, the EFSA CONTAM Panel concluded that the weight of evidence indicates that furan‐induced carcinogenicity is probably attributable to a genotoxic mechanism. However, chronic toxicity leading to regenerative cell proliferation may indirectly amplify the tumour response. Furthermore, the CONTAM Panel concluded that there was a relatively small difference between possible human exposures and the doses in experimental animals that produce carcinogenic effects. However, for a reliable risk assessment, further data would be needed on both toxicity and exposure.

JECFA evaluated furan at its 72nd meeting in 2010 (FAO/WHO, [2011](#efs25005-bib-0089){ref-type="ref"}). The Committee concluded that furan is hepatotoxic and hepatocarcinogenic in rats and mice and considered carcinogenicity the critical endpoint for use in human health risk assessment. The Committee performed a benchmark dose (BMD) analysis of liver tumour incidence data from an oral bioassay in mice. The calculated benchmark dose lower confidence limits for 10% increase in cancer incidence (BMDL~10~) ranged from 1.34 to 1.89 mg/kg bw per day. The Committee used the value of 1.34 mg/kg bw per day, adjusted to 0.96 mg/kg bw per day to account for the dosing schedule used in the study, as the reference point to calculate MOEs. Dietary exposure estimates for mean exposure of the general population was 1 μg/kg bw per day and for high exposure 2 μg/kg bw per day, inclusive of children. The resulting MOEs were between 960 and 480 for the average and high dietary exposures, respectively. The Committee considered that these MOEs indicate a human health concern for furan which is a carcinogenic compound that might act via a DNA‐reactive genotoxic metabolite.

In 2012, the Norwegian Food Safety Authority published a risk assessment of furan exposure in the Norwegian population (VKM, [2012](#efs25005-bib-0269){ref-type="ref"}). On the basis of the available data, the VKM considered that the rat cholangiocarcinomas may be relevant for assessing human risk from furan and concluded that a genotoxic mechanism in furan‐induced carcinogenesis cannot be excluded. There was a high incidence (near 100%) of cholangiocarcinomas at all doses tested after a 2‐year treatment with furan (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}). Since this endpoint showed a dose--response relationship after 9 months of exposure, the VKM chose this as the critical endpoint. They calculated a BMDL~10~ of 0.14 mg furan/kg bw per day. In applying a correction factor of 7 for shorter than full life‐time study duration (9 months instead of 2 years), a point of departure of 0.02 mg/kg bw per day was chosen. The resulting MOEs for 12‐month infants were between 29 and 13, and in adults, between 74 and 26 for average and high dietary exposures, respectively.

In addition, a number of risk assessments are available in which national exposure assessments were carried out (e.g. Lachenmeier et al., [2009](#efs25005-bib-0155){ref-type="ref"}; Bakhiya and Appel, [2010](#efs25005-bib-0019){ref-type="ref"}a,b; Minorczyk et al., [2012](#efs25005-bib-0185){ref-type="ref"}; Scholl et al., [2012a](#efs25005-bib-0238){ref-type="ref"},[b](#efs25005-bib-0239){ref-type="ref"}; Waizenegger et al., [2012](#efs25005-bib-0271){ref-type="ref"}; Health Canada, [2016](#efs25005-bib-0121){ref-type="ref"}).

### 1.3.4. European legislation {#efs25005-sec-0012}

In order to protect public health, Article 2 of the Council Regulation (EEC) No 315/93[11](#efs25005-note-1016){ref-type="fn"} stipulates that, where necessary, maximum tolerances for specific contaminants shall be established. Thus, a number of maximum tolerances for contaminants, natural plant toxicants as well as for process contaminants such as 3‐monochloropropane‐1,2‐diol are currently laid down in Commission Regulation (EC) No 1881/2006[12](#efs25005-note-7012){ref-type="fn"}. Furan in food is currently not covered by this EU Regulation.

Commission Recommendation 2007/196/EC[13](#efs25005-note-1017){ref-type="fn"} recommended that Member States should perform monitoring of the presence of furan in foodstuffs that have undergone heat treatment during the years 2007 and 2008. Results of this monitoring were published in an EFSA report (EFSA, [2011d](#efs25005-bib-0072){ref-type="ref"}), and included data for commercial foodstuffs as purchased without any further preparation[14](#efs25005-note-1018){ref-type="fn"} and commercial foodstuffs analysed as consumed after further preparation in the laboratory.[15](#efs25005-note-1019){ref-type="fn"}

Both 2‐methylfuran and 2, 5‐dimethylfuran were on the Union list of flavourings and source materials for use in food and their conditions of use. However, they were removed from the Union list by Commission Regulation (EU) 246/2014[16](#efs25005-note-8016){ref-type="fn"}, since their applications had been withdrawn by the industry. 'The Good Scents Company' (a website maintained by the flavourings industry) reported that 3‐methylfuran is not for use in flavourings.[9](#efs25005-note-1014){ref-type="fn"}

### 1.3.5. Precursors of furan and methylfurans in food {#efs25005-sec-0013}

Furan can be formed in food from a variety of precursors including ascorbic acid, amino acids, carbohydrates, unsaturated fatty acids and carotenoids. The pathways described below have been investigated in model systems and have been confirmed for foods. These pathways have been simplified for clarity in Figures [2](#efs25005-fig-0002){ref-type="fig"}--[6](#efs25005-fig-0006){ref-type="fig"}. The conditions for the formation of furan and methylfurans have been described in Section [3.2.3](#efs25005-sec-0060){ref-type="sec"}.

The formation from unsaturated fatty acids and probably carotenoids originated from the formation of 4‐hydroxyalk‐2‐enals, particularly 4‐hydroxy‐but‐2‐enal, which is produced from the oxidation of but‐2‐enal which in turn can be produced from the oxidation of polyunsaturated omega‐3 fatty acids (Owczarek‐Fendor et al., [2010b](#efs25005-bib-0206){ref-type="ref"}) (Figure [2](#efs25005-fig-0002){ref-type="fig"}). 4‐Hydroxyalk‐2‐enals and other lipid peroxidation products are known to occur in palatable foods (Frankel, [2012](#efs25005-bib-0093){ref-type="ref"}).

![Suggested formation pathway of furan from polyunsaturated lipids (adapted from Perez Locas and Yaylayan, [2004](#efs25005-bib-0216){ref-type="ref"}; Owczarek‐Fendor et al., [2010b](#efs25005-bib-0206){ref-type="ref"})](EFS2-15-e05005-g002){#efs25005-fig-0002}

Furan formation was reported during the thermal degradation of serine and cysteine (Perez Locas and Yaylayan, [2004](#efs25005-bib-0216){ref-type="ref"}). The formation pathway from serine involves the formation of acetaldehyde and glycolaldehyde which are both prone to aldol‐condensation giving rise to the crucial intermediate 2‐deoxyaldotetrose, which upon cyclisation and dehydration yields furan (Figure [3](#efs25005-fig-0003){ref-type="fig"}). Cysteine is supposed to react with a similar pathway (Perez Locas and Yaylayan, [2004](#efs25005-bib-0216){ref-type="ref"}).

![Suggested formation pathway of furan from serine (adapted from Perez Locas and Yaylayan, [2004](#efs25005-bib-0216){ref-type="ref"}; Limacher et al., [2008](#efs25005-bib-0164){ref-type="ref"})](EFS2-15-e05005-g003){#efs25005-fig-0003}

Other amino acids can also give rise to the formation of furan. Aspartic acid, alanine and threonine can degrade to acetaldehyde, but require an external source of glycolaldehyde (e.g. sugars) to form the 2‐deoxyaldotetrose intermediate (Perez Locas and Yaylayan, [2004](#efs25005-bib-0216){ref-type="ref"}).

Although amino compounds will favour the formation of furan from sugars (via the Maillard reaction), sugars on their own are able to generate furan. Various pathways have been suggested involving both the recombination of sugar fragmentation products from the intact sugar skeleton (Limacher et al., [2008](#efs25005-bib-0164){ref-type="ref"}) and the degradation of the intact sugar skeleton (Limacher et al., [2008](#efs25005-bib-0164){ref-type="ref"}; Van Lancker et al., [2011](#efs25005-bib-0266){ref-type="ref"}). The fragmentation pathway involves mainly the condensation of acetaldehyde and glycolaldehyde (Limacher et al., [2008](#efs25005-bib-0164){ref-type="ref"}). The formation from the intact sugar skeleton involves various parallel pathways, which depend on the type of sugar (Limacher et al., [2008](#efs25005-bib-0164){ref-type="ref"}). These reactions involve the formation of deoxy‐intermediates via dehydration reaction followed by cyclisation reactions and further dehydration. Finally, losses of mainly the C1 and C2 carbons of the sugar chain result in the formation of furan. The formation of furan in dry heating conditions is typically much higher than in pressure sterilisation conditions (Figure [4](#efs25005-fig-0004){ref-type="fig"}).

![Suggested formation pathway of furan from hexoses (adapted from Limacher et al., [2008](#efs25005-bib-0164){ref-type="ref"})](EFS2-15-e05005-g004){#efs25005-fig-0004}

Furan formation from ascorbic acid is believed to start with the hydrolytic ring opening of ascorbic acid and elimination of water to form 4‐deoxyascorbic acid. This intermediate can generate 2‐deoxyaldotetrose. Alternatively, 4‐deoxyascorbic acid can result in the formation of 2‐furfural which in turn is a furan precursor (Limacher et al., [2007](#efs25005-bib-0163){ref-type="ref"}) (Figure [5](#efs25005-fig-0005){ref-type="fig"}).

![Suggested formation pathway of furan from ascorbic acid (adapted from Limacher et al., [2007](#efs25005-bib-0163){ref-type="ref"})](EFS2-15-e05005-g005){#efs25005-fig-0005}

The formation of methylfurans in food has received considerably less attention, although it was recently shown that 2‐methylfuran was the dominant furan in coffee (Becalski et al., [2016](#efs25005-bib-0026){ref-type="ref"}). Accordingly, the formation of methylfurans is less well understood. For 2‐methylfuran, a pathway based on the aldol condensation of the Strecker aldehydes lactaldehyde (originating from threonine) and acetaldehyde -- similar to the glycoaldehyde/acetaldehyde pathway for furan -- has been suggested (Märk et al., [2006](#efs25005-bib-0176){ref-type="ref"}) (Figure [6](#efs25005-fig-0006){ref-type="fig"}). Indeed, as model systems devoid of amino acids produced little or no methylfurans (Märk et al., [2006](#efs25005-bib-0176){ref-type="ref"}; Limacher et al., [2008](#efs25005-bib-0164){ref-type="ref"}), the presence of amino acids seems to play a key role in their formation. Limacher et al. ([2007](#efs25005-bib-0163){ref-type="ref"}) reported the formation of 2‐methylfuran from the degradation of ascorbic acid, but acknowledged it was a minor degradation pathway. Märk et al. ([2006](#efs25005-bib-0176){ref-type="ref"}) reported the formation of methylfuran from linolenic acid in the presence of α‐tocopherol or ferric ions. On basis of the findings of Adams et al. ([2011](#efs25005-bib-0001){ref-type="ref"}), showing in model systems that α,β‐unsaturated aldehydes are potential precursors of the corresponding alkylated furans under roasting conditions, it could be suggested that 2‐pentenal may be a relevant precursor formed via the oxidation of linolenic acid. The formation pathway from 2‐pentenal proceeds similarly to the formation of furan outlined in Figure [2](#efs25005-fig-0002){ref-type="fig"}, requiring oxidative conditions. Adams et al. ([2011](#efs25005-bib-0001){ref-type="ref"}) moreover showed that amino acids, such as phenylalanine catalyse the formation of alkylfurans from their corresponding α,β‐unsaturated aldehydes, although the impact for 2‐methylfuran from 2‐pentenal was not significant. No methylfuran formation was observed from linoleic acid in the presence of ferric ions or butylated hydroxytoluene (Märk et al., [2006](#efs25005-bib-0176){ref-type="ref"}).

![Suggested formation pathway of 2‐methylfuran (adapted from Märk et al., [2006](#efs25005-bib-0176){ref-type="ref"})](EFS2-15-e05005-g006){#efs25005-fig-0006}

### 1.3.6. Production, use and environmental fate {#efs25005-sec-0014}

#### 1.3.6.1. Industrial production and use {#efs25005-sec-0015}

Furan is produced by decarbonylation of furfural using Pd catalysis. It can also be manufactured by partial oxidation of 1,3‐butadiene. It is mainly used for the production of α‐acetylfuran, 2,5‐dimethoxy‐2,5‐dihydrofuran, 2,2‐difurylpropane, 2,2‐di(tetrahydrofurfuryl)propane, pyrrole derivatives and thiophene. It is used as an intermediate in the production of pharmaceuticals, agricultural chemicals, lacquers and stabilisers or as a solvent for resins (IARC, [1995](#efs25005-bib-0134){ref-type="ref"}; Hoydonckx et al., [2012](#efs25005-bib-0129){ref-type="ref"}).

2‐Methylfuran is used as a solvent and as a raw material in the production of antimalarial drugs (chloroquine), methylfurfural, nitrogen and sulfur heterocycles, and functionally substituted aliphatic compounds. It is produced as a side product of furfuryl alcohol production.

2,5‐Dimethylfuran is a potential biofuel that can be obtained from bio‐based sources, such as fructose, via consecutive dehydration and hydrogenolysis reactions (Román‐Leshkov et al., [2007](#efs25005-bib-0236){ref-type="ref"}). Furan and 2‐methylfuran are also considered as potential biofuels (Liu et al., [2014](#efs25005-bib-0165){ref-type="ref"}).

#### 1.3.6.2. Environmental fate {#efs25005-sec-0016}

Furan and methylfurans are released into the atmosphere mainly from anthropogenic sources. Important sources are exhaust gas from diesel and gasoline engines and combustion of waste and biomass (e.g. wood) (IARC, [1995](#efs25005-bib-0134){ref-type="ref"}; Villanueva et al., [2009](#efs25005-bib-0268){ref-type="ref"}; Tapia et al., [2011](#efs25005-bib-0258){ref-type="ref"}). In addition to air, furan has been detected in river water and industrial effluents (IARC, [1995](#efs25005-bib-0134){ref-type="ref"}).

2. Data and methodologies {#efs25005-sec-0017}
=========================

The CONTAM Panel applied the general principles for the assessment of chemicals in food as described by WHO/IPCS ([2009](#efs25005-bib-0279){ref-type="ref"}) and any EFSA guidance documents pertaining to risk assessment and relevant for the present assessment (see Appendix [A.3](#efs25005-sec-0095){ref-type="sec"}).

2.1. Supporting information for the assessment and information to be used in the dietary exposure assessment {#efs25005-sec-0018}
------------------------------------------------------------------------------------------------------------

### 2.1.1. Collection, selection of evidence {#efs25005-sec-0019}

A search for recent reviews was conducted to identify scientific publications dealing with methods of analysis, chemistry, formation in food, exposure and occurrence of furan in food. Since it was expected to receive only limited information on the occurrence of methylfurans in food during the EFSA call for data (see Section [2.3.1](#efs25005-sec-0026){ref-type="sec"}), a search for original studies was also carried out. It was noted, that the information on dietary exposure of furan and methylfurans and on formation and methods of analysis of methylfurans was not sufficiently covered by the reviews. Therefore, specific searches were also conducted for these topics (see Appendix [A](#efs25005-sec-1083){ref-type="sec"}, Section [A.1](#efs25005-sec-0083){ref-type="sec"}). During the development of the exposure assessment, the Working Group (WG) identified the need for data on the influence of coffee preparation on furan levels in liquid coffee. An additional search was conducted to retrieve this information (see Appendix [A](#efs25005-sec-1083){ref-type="sec"}, Section [A.1](#efs25005-sec-0083){ref-type="sec"}).

The literature search was performed in May 2016 (March 2017 for information on coffee). Web of Science[17](#efs25005-note-1020){ref-type="fn"} and PubMed[18](#efs25005-note-1021){ref-type="fn"} were identified as databases appropriate for retrieving literature for the present evaluation. The references resulting from the literature search were imported and saved using a software package (EndNote[19](#efs25005-note-1022){ref-type="fn"}), which allows effective management of references and citations. Additionally, reviews and relevant scientific evaluations by national or international bodies were considered for the current risk assessment, i.e. IARC ([1995](#efs25005-bib-0134){ref-type="ref"}), NAS, [2000](#efs25005-bib-0194){ref-type="ref"}, FDA ([2004a](#efs25005-bib-0090){ref-type="ref"}), FAO/WHO ([2011](#efs25005-bib-0089){ref-type="ref"}) and VKM, [2012](#efs25005-bib-0269){ref-type="ref"}. When relevant papers were identified during the risk assessment process (e.g. from other studies or reviews), they were also considered.

The references obtained were screened using title and abstract to identify relevant literature.

The VCF database[20](#efs25005-note-1023){ref-type="fn"} on volatile compounds in food was consulted to identify papers on the occurrence of methylfurans.

EFSA also organised an Info Session with invited stakeholders to support the work of the CONTAM Panel and its working group in drafting this scientific opinion. The aim of this meeting was to collect information and data which are not readily available in the public domain regarding dietary exposure, home‐cooking and toxicity. Further information is available in EFSA\'s Register of Questions.[21](#efs25005-note-1024){ref-type="fn"}

### 2.1.2. Appraisal of evidence {#efs25005-sec-0020}

The information retrieved was screened and evaluated by relevant domain experts from the CONTAM WG on furan in food and was used for the present assessment.

2.2. Hazard identification and characterisation {#efs25005-sec-0021}
-----------------------------------------------

### 2.2.1. Collection and selection of evidence {#efs25005-sec-0022}

EFSA outsourced an extensive literature search related to the toxicity of furan and its methyl analogues (contract: RC/EFSA/BIOCONTAM/2016/02). The aim of the assignment was to identify and collect all relevant literature regarding furan, 2‐methylfuran and 3‐methylfuran covering the following areas: Area 1: Data on toxicokinetics (absorption, distribution, metabolism and excretion (ADME)) in experimental animals and humans and from *in vitro* studies.Area 2: Data on oral toxicity in experimental animals.Area 3: Data on *in vitro* and *in vivo* genotoxicity and mode of action (MoA).Area 4: Data on observations in humans (including epidemiological studies, case reports and biomarkers of exposure).

The used methodology and the results are detailed in NFI ([2017](#efs25005-bib-0197){ref-type="ref"}).

In addition to the literature searches outsourced by EFSA, a search for studies regarding the toxicity of 2,5‐dimethylfuran and the genotoxicity of BDA was conducted (see Appendix [A](#efs25005-sec-1083){ref-type="sec"}, Section [A.2](#efs25005-sec-0087){ref-type="sec"}). The literature search was performed in June 2016 using Web of Science[17](#efs25005-note-1020){ref-type="fn"} and PubMed.[18](#efs25005-note-1021){ref-type="fn"} The references resulting from the literature search were imported and saved using a software package (EndNote[19](#efs25005-note-1022){ref-type="fn"}), which allows effective management of references and citations.

It was regularly checked (last check May 2017) whether new papers had become available during the development of this scientific opinion.

Reviews, relevant scientific evaluations and toxicity studies by national or international bodies were also considered for the current risk assessment (see Section [2.1.1](#efs25005-sec-0019){ref-type="sec"}). When relevant papers were identified during the risk assessment process (e.g. from other studies or reviews), they were also considered.

In addition, an Info Session with invited stakeholders was organised (see Section [2.1.1](#efs25005-sec-0019){ref-type="sec"}).

### 2.2.2. Appraisal of evidence {#efs25005-sec-0023}

The information retrieved has been screened and evaluated by relevant domain experts from the CONTAM WG on furan in food and has been used for the present assessment. Any limitations in the information used are documented in this scientific opinion.

Selection of the scientific papers for inclusion or exclusion was based on consideration of the extent to which the study was relevant to the assessment or on general study quality considerations (e.g. sufficient details on the methodology, performance and outcome of the study, on dosing, substance studied and route of administration and on statistical description of the results), irrespective of the results. Appendix [A](#efs25005-sec-1083){ref-type="sec"}, Section [A.2.3](#efs25005-sec-0094){ref-type="sec"}, provides an overview of the scientific papers (excluding abstracts and reviews) that emerged from the literature searches and seemed to be related to the toxicity and toxicokinetics of furan and methylfurans but upon examination were not included in the opinion as they did not meet the criteria stated above.

### 2.2.3. Benchmark dose analysis {#efs25005-sec-0024}

Benchmark dose analysis was done according to EFSA guidance (EFSA Scientific Committee, [2017](#efs25005-bib-0078){ref-type="ref"}) and using the R package bmdModeling (see Appendix [C](#efs25005-sec-0097){ref-type="sec"}).

2.3. Occurrence data submitted to EFSA {#efs25005-sec-0025}
--------------------------------------

### 2.3.1. Data collection and validation {#efs25005-sec-0026}

At the time of receiving the request for the scientific opinion from the European Commission, data on 2‐methylfuran and 3‐methylfuran were not available in the EFSA Chemical Occurrence database, and available data on furan were limited. The EFSA Evidence Management Unit (DATA Unit) initiated an ad hoc collection of data to compile occurrence data on furan, 2‐methylfuran and 3‐methylfuran levels in food.[22](#efs25005-note-1025){ref-type="fn"} The European national food authorities and similar bodies, research institutions, academia and food business operators were invited to submit data. As 2,5‐dimethylfuran was not included in the initial request from the European Commission, the submission of occurrence data for 2,5‐dimethylfuran was not requested by EFSA.

The data submission to EFSA followed the requirements of the EFSA Guidance on Standard Sample Description for Food and Feed (EFSA, [2010a](#efs25005-bib-0066){ref-type="ref"}); occurrence data were managed following the EFSA standard operational procedures (SOPs) on 'Data collection and validation' and on 'Data analysis of food consumption and occurrence data'. In accordance with Commission Recommendation 2007/196/EC[13](#efs25005-note-1017){ref-type="fn"} on the monitoring of the presence of furan in foodstuffs, data providers were also requested to indicate whether commercial foodstuffs were analysed as purchased, disregarding any further preparation, or whether they were analysed as consumed after further preparation in the laboratory.

All data on furan and its methyl analogues in food available in the EFSA database by the end of November 2016 were used for the present assessment. Data received after this date were not included.

### 2.3.2. Data analysis {#efs25005-sec-0027}

The data received were carefully evaluated by EFSA in view of cleaning and validating the data. Special attention was paid to the identification of duplicates and to the accuracy of different parameters such as 'Analytical methods', 'Reporting unit' and the coding of the different samples under FoodEx classification. The available information was also carefully analysed in order to identify those samples that were analysed either as purchased or as consumed. Upon identification of potential inconsistencies, data providers were contacted to provide further clarification. The outcome of the data analysis is shown in Section [3.2.1](#efs25005-sec-0056){ref-type="sec"}.

The left‐censored data (analytical data below the LOD/LOQ) were treated by the substitution method as recommended in the 'Principles and Methods for the Risk Assessment of Chemicals in Food' (WHO/IPCS, [2009](#efs25005-bib-0279){ref-type="ref"}). The same method is described in the EFSA scientific report 'Management of left‐censored data in dietary exposure assessment of chemical substances' (EFSA, [2010b](#efs25005-bib-0067){ref-type="ref"}), as an option in the treatment of left‐censored data. The guidance suggests that the lower bound (LB) and upper bound (UB) approach should be used for chemicals likely to be present in the food (e.g. naturally occurring contaminants, nutrients and mycotoxins). At the LB, results below the LOQ or LOD were replaced by zero; at the UB, the results below the LOD were replaced by the LOD and those below the LOQ were replaced by the value reported as LOQ. Additionally, a middle bound (MB) approach was used by assigning a value of LOD/2 or LOQ/2 to the left‐censored data. The use of different cut‐off values on the reported LOQs was also evaluated in order to reduce the uncertainty associated to the exposure estimations.

2.4. Food consumption data {#efs25005-sec-0028}
--------------------------

The EFSA Comprehensive European Food Consumption Database (Comprehensive Database) provides a compilation of existing national information on food consumption at individual level. It was first built in 2010 (EFSA, [2011a](#efs25005-bib-0069){ref-type="ref"}; Huybrechts et al., [2011](#efs25005-bib-0133){ref-type="ref"}; Merten et al., [2011](#efs25005-bib-0183){ref-type="ref"}). Details on how the Comprehensive Database is used are published in the Guidance of EFSA (EFSA, [2011a](#efs25005-bib-0069){ref-type="ref"}). The latest version of the Comprehensive Database[23](#efs25005-note-1026){ref-type="fn"} was used with subjects classified in different age classes as follows: Infants: \< 12 months oldToddlers: ≥ 12 months to \< 36 months oldOther children: ≥ 36 months to \< 10 years oldAdolescents: ≥ 10 years to \< 18 years oldAdults: ≥ 18 years to \< 65 years oldElderly: ≥ 65 years to \< 75 years oldVery elderly: ≥ 75 years old.

Two additional surveys provided information on specific population groups: 'Pregnant women' (≥ 15 years to ≤ 45 years old; Latvia) and 'Lactating women' (≥ 28 years to ≤ 39 years old; Greece).

Overall, the food consumption data gathered by EFSA in the Comprehensive Database are the most complete and detailed data currently available in the EU. Consumption data were collected using single or repeated 24‐ or 48‐h dietary recalls or dietary records covering from 3 to 7 days per subject. As a result of the differences in the methods used for data collection, direct country‐to‐country comparisons can be misleading.

2.5. Food classification {#efs25005-sec-0029}
------------------------

Consumption data were classified according to the FoodEx classification system (EFSA, [2011b](#efs25005-bib-0070){ref-type="ref"}). FoodEx is a food classification system developed by EFSA in 2009 with the objective of simplifying the linkage between occurrence and food consumption data when assessing the exposure to hazardous substances. It contains 20 main food groups (first level), which are further divided into subgroups having 140 items at the second level, 1,261 items at the third level and reaching about 1,800 items (food names or generic food names) at the fourth level.

In 2011, a new version of FoodEx, named FoodEx2, was developed and is described in the scientific document 'Report on the development of a Food Classification and Description System for exposure assessment and guidance on its implementation and use' (EFSA, [2011c](#efs25005-bib-0071){ref-type="ref"}). The last release of FoodEx2 complements the previous hierarchical classification system of basic codes with more detailed food levels and gives the possibility of reporting additional information through the use of facets and facet descriptors such as processing or packaging (EFSA, [2015](#efs25005-bib-0074){ref-type="ref"}).

As the occurrence data were submitted to EFSA according to the FoodEx classification and only part of the food consumption data are currently coded according to the FoodEx2 classification, the occurrence data and the food consumption data were grouped at the most relevant level of the FoodEx classification. Where available, the FoodEx2 classification and its facet descriptors were also used to better identify consumption data referring to very specific foods such as commercially processed foods (e.g. canned and jarred foods) or toasted bread.

2.6. Exposure assessment {#efs25005-sec-0030}
------------------------

The CONTAM Panel considered that only chronic dietary exposure had to be assessed. As suggested by the EFSA WG on Food Consumption and Exposure (EFSA, [2011a](#efs25005-bib-0069){ref-type="ref"}), dietary surveys with only 1 day per subject were excluded from the current assessment because they are not adequate to assess repeated exposure. Similarly, subjects who participated only 1 day in the dietary studies, when the protocol prescribed more reporting days per individual, were also excluded from the chronic exposure assessment. When, for one particular country and age class, two different dietary surveys were available only the most recent one was used.

For calculating the chronic dietary exposure, food consumption and body weight data at the individual level were accessed in the Comprehensive Database. Occurrence data and consumption data were linked at the relevant FoodEx level (see also Section [2.5](#efs25005-sec-0029){ref-type="sec"}). For each individual of the selected surveys, the mean occurrence values of the different food samples collected (pooled European occurrence data) were combined with the average daily consumption of the corresponding food items, and the resulting exposures per food were summed in order to obtain the total chronic exposure at individual level (standardised by using the individual body weight). The mean and the 95th percentile of the individual exposures were subsequently calculated for each dietary survey and each age class separately.

Before linking the consumption data to the corresponding occurrence data, the following adjustments to the consumption data were made to reduce uncertainty and reach more accurate exposure estimates: Consumption events for cereal‐based food for infants and young children were adjusted by a factor of 0.25 (when reconstituted with water) or 0.15 (when reconstituted with milk) when the eating occasions were reported as consumed (liquid) since the occurrence data also referred to the analysis of the food as purchased.A number of consumption events reported for unspecified potatoes and potatoes products, unspecified alcoholic beverages or unspecified non‐alcoholic beverages was reclassified to a food category that was considered more appropriate for the assessment of furan.A number of consumption events for boiled potatoes, main‐crop potatoes and new potatoes referred to powders, flakes, dried products or instant products. In view of the analysis on commercially processed products, classification as mashed potato powder was considered more appropriate for the assessment of furan.Where a consumption event for a specific coffee beverage (e.g. cappuccino) was prepared from an instant powder, this consumption event was reclassified to the instant coffee beverages as this is considered more appropriate in the framework of the current assessment.Legume vegetables, which are normally part of the vegetables and vegetable products, were reclassified to legumes (dried or green) in order to better match the available occurrence data for furan.Human milk was not considered for the assessment due to lack of data available.

All analyses were made using the SAS Statistical Software (SAS enterprise guide 5.1).

2.7. Risk characterisation {#efs25005-sec-0031}
--------------------------

The CONTAM Panel applied the general principles of the risk characterisation process for chemicals in food as described by WHO/IPCS ([2009](#efs25005-bib-0279){ref-type="ref"}) and the relevant EFSA guidance documents (see Appendix [A.3](#efs25005-sec-0095){ref-type="sec"}).

3. Assessment {#efs25005-sec-0032}
=============

The CONTAM Panel noted that the available information on 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran is limited and these compounds are therefore only described when information is available.

3.1. Hazard identification and characterisation {#efs25005-sec-0033}
-----------------------------------------------

The CONTAM Panel noted that due to the high volatility of furan at room temperature, the handling of any furan preparation for treatment or sampling for analysis with/of furan is considered as critical. In some studies, it cannot be excluded that the outcome may have been influenced by losses of furan due to this effect. This issue is addressed in the uncertainty Section [3.5](#efs25005-sec-0013){ref-type="sec"}.

### 3.1.1. Toxicokinetics {#efs25005-sec-0034}

The kinetics of furan and to a lesser extent also 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran have been studied in rodents, in hepatocyte cultures, in subcellular fractions and in various chemical model systems.

#### 3.1.1.1. Absorption {#efs25005-sec-0035}

**A. Furan**

***Oral exposure***

After administration of \[2,5‐^14^C\] furan (chemical and radiochemical purity both ≥ 99%) to male F344 rats at a dose level of 8 mg/kg bw (\~ 0.37 MBq/kg bw), furan was quickly absorbed from the gastrointestinal (GI) tract to an extent of at least 80%. This estimate is based on excretion of radioactivity in exhaled air and urine and retention of radioactivity in tissues at 24 h post‐dosing. Radioactivity in faeces (22% of the dose) was not characterised and may have contained some unabsorbed furan (Burka et al., [1991](#efs25005-bib-0034){ref-type="ref"}).

***Inhalation exposure***

In dogs, approximately 95% of the inhaled furan is retained in the body and this percentage decreased to 91% when ventilation rate was increased. An inverse relationship was observed between retention and concentration in inhaled air (Egle and Gochberg, [1979a](#efs25005-bib-0079){ref-type="ref"}). Since absorption is virtually complete, the CONTAM Panel considered that the differences related to inhalation rate or concentration as reported by the study authors were of no biological significance.

**B. Methylfurans**

***Inhalation exposure***

In dogs, approximately 89% of the inhaled 2‐methylfuran is retained in the body and this percentage decreased to 83% when ventilation rate was increased (Egle and Gochberg, [1979b](#efs25005-bib-0080){ref-type="ref"}). For 2,5‐dimethylfuran, retention values of 63% decreasing to 57% were recorded with increasing ventilation rates. However, the limited set‐up of the experiments in this report and the high absorption of the substances do not allow firm conclusions on dependency on inhalation rate. The Panel considered that the slight differences related to inhalation rate were of no biological significance.

For 2‐methylfuran and 2,5‐dimethylfuran, the retention was not dependent on the concentration applied (Egle and Gochberg, [1979b](#efs25005-bib-0080){ref-type="ref"}).

#### 3.1.1.2. Distribution {#efs25005-sec-0036}

**A. Furan**

*In vivo* kinetics of furan in blood and liver were studied by Churchwell et al. ([2015](#efs25005-bib-0049){ref-type="ref"}) in rats for up to 8 h after a single oral exposure to 0.92 mg (= 13.5 μmol) unlabelled furan/kg bw. The highest blood concentration (63 pmol/mL) was observed at 15 min post‐dosing (the 1st time point). In the liver, C~max~ (547 pmol/g tissue) was observed 30 min post‐dosing. Over the observation period, liver concentrations were on average approximately six times higher than concentrations in blood, but concentrations in liver varied strongly between animals and between lobes. After 8 h, no furan could be detected in either blood or liver (LOD: \~ 0.75 pmol/mL in blood and \~ 1 pmol/g tissue in liver)

The distribution of furan‐related radioactivity retained after 24 h in various tissues in rats was studied after gavage dosing with ^14^C‐labelled furan (8 mg/kg bw (118 μmol/kg bw; 0.37 MBq/kg bw). The tissue distribution of total radioactivity (in percentage of the dose) was: liver 13%, kidney 0.45%, large intestine 0.13%, small intestine 0.15%, stomach (forestomach + glandular stomach) 0.09%, blood 0.42% and lung 0.02%. In total, the radioactivity in these tissues comprised 15 % of the dose after 24 h. Remaining tissues contained additional radioactivity approximating to 4% of the dose. No furan could be extracted from the blood, and from the liver, only 20% of the radioactivity could be extracted, but similar to blood this fraction did not contain furan. Seven days after treatment, the radioactivity had almost returned to the LOD. In a repeated dosing study (daily single dose for 8 days), 24 h after the last dose, concentrations in the liver were up by a factor of 4, and in blood and kidney up by a factor of 7 as compared to the concentrations after one dose (Burka et al., [1991](#efs25005-bib-0034){ref-type="ref"}).

After intraperitoneal (i.p.) administration of 4.1 mmol/kg bw furan to mice (ca. 280 mg/kg bw in sesame oil), furan levels were approximately 120, 490 and 50 nmol/g tissue in the kidney and approximately 190, 120 and 40 nmol/g tissue in the liver at 1, 2 or 5 h post‐dosing, respectively. No metabolites or other tissues were examined (Wiley et al., [1984](#efs25005-bib-0280){ref-type="ref"}).

**B. Methylfurans**

After i.p. administration of 4.1 mmol/kg bw 3‐methylfuran to mice (ca. 336 mg/kg bw in sesame oil), methylfuran concentrations were approximately 150, 380 and 50 nmol/g tissue in the kidney and approximately 240, 410 and 60 nmol/g tissue in the liver at 1, 2 or 5 h post‐dosing, respectively. No metabolites or other tissues were examined (Wiley et al., [1984](#efs25005-bib-0280){ref-type="ref"}).

Rats were dosed with ^14^C‐labelled 2‐methylfuran via i.p. injection at dose levels of 50--200 mg/kg bw (Ravindranath et al., [1986](#efs25005-bib-0231){ref-type="ref"}). At 12 h post‐dosing, total radioactivity was approx. four times higher in liver than in kidneys, and about 7 or 10 times higher in liver than in blood and lungs, respectively, at all dose levels. Peak levels of total radioactivity after a dose of 100 mg labelled 2‐methylfuran were reached after 2 h in kidneys, blood and lungs, but only after 8 h in the liver. Protein‐associated radioactivity reached a maximum value in all tissues after 8 h. Again, the liver had higher levels of total and non‐extractable radioactivity than the other three tissues. At 24 h post‐dosing, the concentration of total ^14^C had fallen to 58%, 67% or 83% of the peak levels in liver, kidneys and lungs.

The liver had the highest levels of ^14^C‐associated with DNA (equivalent to approximately 35 nmol 2‐methylfuran/mg DNA at an i.p. dose of 200 mg/kg). Minimal association of ^14^C with DNA was observed in the lungs. The peak of DNA associated ^14^C in the liver (32 nmol/mg DNA after 100 mg/kg bw) occurred at 1 h post‐dosing and in the kidneys at 4 h post‐dosing. At 24 h post‐dosing, the DNA‐associated ^14^C‐levels had dropped to 51% or 63% of the peak levels in liver and kidney, respectively (Ravindranath et al., [1986](#efs25005-bib-0231){ref-type="ref"}).

#### 3.1.1.3. Metabolism {#efs25005-sec-0037}

**A. Furan**

Figure [7](#efs25005-fig-0007){ref-type="fig"} shows a graphical representation of the metabolites and adducts of furan.

Oral administration of ^14^C‐labelled furan to rats resulted in an elimination of 26% of the dose as exhaled carbon dioxide. In addition, approximately 10% of the dose could not be extracted from liver tissue components (protein; DNA) and 20% of the dose was eliminated as urinary metabolites (Burka et al., [1991](#efs25005-bib-0034){ref-type="ref"}). The authors speculated that the carbon dioxide was formed after oxidative ring opening of furan. Although no direct evidence was available at that time, the authors suggested that similar to 2‐ and 3‐methylfuran (Ravindranath et al., [1984](#efs25005-bib-0230){ref-type="ref"}), furan itself could be converted into a reactive intermediate BDA and the formation of this dialdehyde was later confirmed in studies with rat liver microsomes using a trapping agent. No evidence for the formation of an epoxide was obtained, thus if such an intermediate was to play a role, it has to be very short‐lived (Chen et al., [1995](#efs25005-bib-0045){ref-type="ref"}).

**B. Methylfurans**

Ravindranath et al. ([1984](#efs25005-bib-0230){ref-type="ref"}) showed that rat lung and liver microsomes can bioactivate 2‐ and 3‐methylfuran into reactive species. Using semicarbazide as a trapping agent, the reactive metabolites were identified as 3‐acetylacrolein (= 4‐oxopent‐2‐enal) for 2‐methylfuran and 2‐methylbut‐2‐enedial for 3‐methylfuran. Similar studies with 2‐methylfuran (Ravindranath and Boyd, [1985](#efs25005-bib-0228){ref-type="ref"}) showed that kidney microsomes can also bioactivate 2‐methylfuran. 3‐Acetylacrolein is very reactive towards microsomal protein and strongly inhibits bioactivation of 2‐methylfuran leading to the conclusion that 2‐methylfuran is a suicide substrate for cytochrome P450 (CYP). 2‐Methylfuran bioactivation by liver microsomes was strongly induced after pretreatment with phenobarbital, but not 3‐methylcholanthrene, and inhibited by piperonyl butoxide and even more by *N*‐octylimidazole (Ravindranath and Boyd, [1985](#efs25005-bib-0228){ref-type="ref"}).

Palmen and Evelo ([1996](#efs25005-bib-0209){ref-type="ref"}) demonstrated that in aqueous incubates, 2‐methylfuran has no direct reactivity with glutathione (GSH). 2‐Methylfuran triggered partial depletion of GSH in haemolysates and also in intact human erythrocytes; in the latter case, only when co‐incubated with a (rat) microsomal bioactivating system. The authors concluded that 2‐methylfuran has to be bioactivated in order to deplete GSH, and that reactive metabolites can be generated in the erythrocyte cytosol, or in microsomal systems.

From general knowledge on biotransformation, it can be predicted that the alkylfurans may also be oxidised at the side‐chain resulting in the formation of furyl alcohols, which can be further oxidised to give the corresponding aldehydes and acids. However, these additional routes of metabolism and their consequences for the toxicity of the substances have not been studied.

**C. Enzymes involved in furan biotransformation**

As demonstrated using inducers or inhibitors of CYPs, the major contributor to the metabolism of furan is CYP2E1 (previously known as CYP‐J) (Garle and Fry, [1990](#efs25005-bib-0101){ref-type="ref"}; Carfagna et al., [1993](#efs25005-bib-0041){ref-type="ref"}; Parmar and Burka, [1993](#efs25005-bib-0215){ref-type="ref"}). A fair correlation was observed between the conversion of *p*‐nitrophenol, a standard substrate for CYP2E1 and the metabolism of furan in human microsomal incubations. Using various human recombinant CYPs, it was demonstrated that CYP2E1 was at least 5--10 times more active than CYP2D6, 3A4, 2J2, 1A2 and 2B6 forms. Minimal catalytic activity was observed for various other CYP forms (Gates et al., [2012](#efs25005-bib-0102){ref-type="ref"}). Parmar and Burka ([1993](#efs25005-bib-0215){ref-type="ref"}) demonstrated that CYP‐catalysed biotransformation of furan results in inactivation of CYPs and that CYP2E1 is more heavily affected than other CYPs. A mechanistic explanation for CYP inactivation, based on quantum chemical methods involving the generation of furan‐epoxide and covalent binding of this intermediate to the haem centre and nucleophilic amino acid residues has been suggested by Taxak et al. ([2013](#efs25005-bib-0259){ref-type="ref"}). From metabolism studies with 2‐methylfuran with inducers and inhibitors of CYP2E1 (Ravindranath and Boyd, [1985](#efs25005-bib-0228){ref-type="ref"}), it may be anticipated that also this alkylated furan and possibly also 3‐methylfuran are metabolised predominantly by CYP2E1, but contrary to furan, studies with purified CYP enzymes are not available for these two alkylfurans. Therefore, there is no direct evidence for an involvement of CYP2E1 in the biotransformation of 2‐ and 3‐methylfuran.

![Metabolites and adducts of furan (compiled after Moro et al. ([2012a](#efs25005-bib-0188){ref-type="ref"},[b](#efs25005-bib-0189){ref-type="ref"}), Peterson et al. ([2011](#efs25005-bib-0220){ref-type="ref"}), Byrns et al. ([2002](#efs25005-bib-0037){ref-type="ref"}), Neuwirth et al. ([2012](#efs25005-bib-0196){ref-type="ref"}) and Phillips et al. ([2014](#efs25005-bib-0221){ref-type="ref"}))\
Structural elements related to furan or BDA are in bold. Red‐coloured atoms belong to the abbreviated part of the molecules. Molecules with underlined names have been reported to occur in urine or bile after *in vivo* administration of furan to animals. Cys, Glu, Gln and Lys: cysteine, glutamate, glutamine and lysine; NAC:*N*‐acetylcysteine, NAL:*N*‐acetyllysine; NAT:*N*‐acetyltransferase, BDA:*cis*‐but‐2‐enedial; GSH or G: glutathione; dA deoxyadenosine; dG deoxyguanosine; dC deoxycytidine. Note that the Figure contains some representative structures especially from substances observed *in vivo*. Several structures that were only observed *in vitro* or in chemical systems have not been included in the presentation.](EFS2-15-e05005-g007){#efs25005-fig-0007}

#### 3.1.1.4. Binding of furan and methylfuran metabolites to tissue components {#efs25005-sec-0038}

**A. Binding to amino acids, glutathione and biogenic amines**

***Furan metabolites***

BDA is a reactive α,β‐unsaturated dialdehyde, which has reactivity towards tissue components such as free amino acids and proteins. Garle and Fry ([1990](#efs25005-bib-0101){ref-type="ref"}) demonstrated that rat liver microsomes can metabolise furan to a GSH‐reactive substance, which they did not further identify. Also, in hepatocytes *in vitro*, GSH can be depleted after exposure to furan (Carfagna et al., [1993](#efs25005-bib-0041){ref-type="ref"}), which is also indicative (but not definitive proof) of interaction of furan metabolites with this scavenger molecule. In chemical model systems, BDA reacted with GSH to form several complex (cyclic) structures, but in microsomal systems, only two bis*‐*GSH‐BDA adducts (an *N*‐alkyl‐3‐ and an *N*‐alkyl‐2‐thiopyrrole adduct) were observed (Chen et al., [1997](#efs25005-bib-0046){ref-type="ref"}). Additionally, a mono‐GSH‐BDA adduct has been observed in microsomal incubations with furan (Peterson et al., [2005](#efs25005-bib-0218){ref-type="ref"}). This mono‐GSH‐BDA adduct was observed in urine of rats treated with furan, indicating that also *in vivo* furan is converted to BDA. No urinary elimination of bis‐GSH‐BDA adducts was observed, but since these have a MW of around 660 g/mol, these could be preferentially excreted via the bile (Peterson et al., [2006](#efs25005-bib-0219){ref-type="ref"}). Metabolites found in rat bile, however, do not seem to include the bis‐GSH‐BDA adducts that were reported by Chen et al. ([1997](#efs25005-bib-0046){ref-type="ref"}) and Peterson et al. ([2006](#efs25005-bib-0219){ref-type="ref"}). Possible breakdown products of these have been reported such as cysteinylglycinyl‐BDA‐GSH, cysteinyl‐BDA‐GSH or cysteinylglycinyl‐BDA‐glutamate (Hamberger et al., [2010](#efs25005-bib-0119){ref-type="ref"}). Among the observed mono‐GSH adducts, cyclic reaction products were observed in which the thiol group had reacted with the double bond in BDA and a primary nitrogen had reacted with the two aldehydes, resulting in the formation of an N‐alkylated pyrrole or pyrrolinone moiety in microsomal incubates (Peterson et al., [2005](#efs25005-bib-0218){ref-type="ref"}) and in rat urine or bile (Peterson et al., [2006](#efs25005-bib-0219){ref-type="ref"}; Hamberger et al., [2010](#efs25005-bib-0119){ref-type="ref"}).

Apart from reactions with GSH, BDA has also been demonstrated to be reactive towards amino acids with primary amino groups in the side chain or/and to cysteine. As with the cyclic GSH conjugates these adducts contain N‐alkylated pyrrole or pyrrolinone moieties resulting e.g. from interaction with the amino groups from lysine or glutamine with the two aldehyde functions. Lysine‐BDA‐cysteine adducts as well as adducts of the N‐acetylated forms of these amino acids (*N*‐acetyllysinyl‐BDA‐*N*‐acetylcysteinyl (NAL‐BDA‐NAC)) have been demonstrated to be formed in chemical model systems (Chen et al., [1997](#efs25005-bib-0046){ref-type="ref"}). In concordance with this, BDA adducts of N‐acetylated lysine and cysteine were formed in human microsomal incubates (Gates et al., [2012](#efs25005-bib-0102){ref-type="ref"}) and could be detected in rat bile (Hamberger et al., [2010](#efs25005-bib-0119){ref-type="ref"}) after exposure *in vivo*. In chemical model systems, BDA together with GSH, can also react with other amines, such as asparagine, ornithine, putrescine, cadaverine, spermine or spermidine (Peterson et al., [2011](#efs25005-bib-0220){ref-type="ref"}). In contrast, in incubates of furan with rat hepatocytes next to mono‐GSH‐BDA, adducts of GSH‐BDA with ornithine (both at the Nδ‐ amino and the Nα‐amino; \~ 50% and \~ 25% of the total amount of amine adducts measured, respectively), lysine (Nε‐amino \~ 20%; Nα‐amino \~ 2%), spermidine (N^1^‐amino \~ 8%) and putrescine (\< 1%) but no adducts to asparagine, cadaverine or spermine were found (Peterson et al., [2011](#efs25005-bib-0220){ref-type="ref"}). Lu et al. ([2009](#efs25005-bib-0167){ref-type="ref"}) reported occurrence of a GSH‐BDA‐glutamine adduct in media of furan‐treated rat hepatocytes. Human hepatocytes (freshly isolated or cryopreserved) have higher or similar capacity to metabolise furan than rat and mouse hepatocytes (Kedderis and Held, [1996](#efs25005-bib-0145){ref-type="ref"}; Gates et al., [2014](#efs25005-bib-0103){ref-type="ref"}). In media of cryopreserved human and cryopreserved rat and mouse hepatocytes incubated with furan, the BDA adducts observed are similar as those reported by Peterson et al. ([2011](#efs25005-bib-0220){ref-type="ref"}), but they vary in the amounts formed (Gates et al., [2014](#efs25005-bib-0103){ref-type="ref"}). Also, between hepatocytes from different human donors, there was a great difference in rate of formation of BDA adducts formation, despite similar levels of hepatocellular CYP2E1 activity (Gates et al., [2014](#efs25005-bib-0103){ref-type="ref"}). Therefore, these authors speculated that in humans alternative metabolic routes may be active to scavenge BDA (e.g. scavenging of the α,β‐unsaturated dialdehyde BDA by various CYPs) before it can react with e.g. GSH or amino acids. Of the amino‐adducts in urine from rats exposed to furan, next to NAC‐BDA‐lys, lower levels of NAC‐BDA‐spermidine, but no ornithine adducts could be found (Peterson et al., [2011](#efs25005-bib-0220){ref-type="ref"}). For the cysteine‐containing adducts also the corresponding sulfoxides have been reported in bile of rats and in urine of rats, mice and humans (Kellert et al., [2008b](#efs25005-bib-0148){ref-type="ref"}; Lu et al., [2009](#efs25005-bib-0167){ref-type="ref"}; Hamberger et al., [2010](#efs25005-bib-0119){ref-type="ref"}; Peterson et al., [2011](#efs25005-bib-0220){ref-type="ref"}; Grill et al., [2015](#efs25005-bib-0113){ref-type="ref"}). Lu and Peterson ([2010](#efs25005-bib-0166){ref-type="ref"}) provided evidence that the cys‐BDA‐lys adduct is an important intermediate in the formation of the N‐acetylated, de‐aminated or sulfoxidated urinary metabolites of furan *in vivo*.

Urinary and biliary metabolites of furan could have arisen from reaction of BDA with GSH and free amino acids (cysteine, lysine and ornithine) in the cytosol (Kellert et al., [2008b](#efs25005-bib-0148){ref-type="ref"}; Hamberger et al., [2010](#efs25005-bib-0119){ref-type="ref"}). Based on the ratio of N^ε^‐lysine‐adducts over N^α^‐lysine‐adducts, the lysine adducts are mainly formed with the N^ε^‐amino group, rather than with the N^α^‐amino group. Based on changes in this ratio over time after furan exposure, Lu et al. ([2009](#efs25005-bib-0167){ref-type="ref"}) argued that these lysine adducts arise from direct adduct formation with free lysine, especially shortly after exposure, but that at later points in time the observed adduct arises from degradation of BDA‐damaged proteins.

***Methylfurans metabolites***

Ravindranath et al. ([1984](#efs25005-bib-0230){ref-type="ref"}) showed that reactive metabolites from 2‐ and 3‐methylfuran can bind (non‐extractable) to microsomal proteins. Cysteine was a very efficient scavenger of the reactive metabolite of 2‐methylfuran and to a lesser extent also GSH and semicarbazide (as a model compound). N‐acetylcysteine was less effective than GSH and lysine was a less effective scavenger than semicarbazide. Effective scavenging of acetylacrolein by cysteine was also observed in *in vivo* studies in rats exposed to 100 mg 2‐methylfuran /kg bw i.p. after treatment with various modulators of liver GSH synthesis (diethylmaleate (DEM), buthionine sulfoximine (BSO) and/or oxothiazolidinecarboxylate (OTZ)) (Ravindranath and Boyd, [1991](#efs25005-bib-0229){ref-type="ref"}).

Bile of rats dosed i.p. with 60 mg/kg bw of 2,5‐dimethylfuran contained a NAL‐dimethylpyrrole‐GSH conjugate after addition (*ex vivo*) of NAL to the bile sample. No GSH‐containing precursor for this metabolite could be detected, and also no other GSH‐containing conjugates with a putative reactive intermediate moiety were found in the bile, using liquid chromatography with tandem mass spectrometry (LC--MS/MS). The same pyrrole‐containing conjugate was also observed in microsomal incubates fortified with NAL and GSH and in a system in which 2,5‐dimethylfuran was chemically oxidised with subsequent treatment of the reaction products with NAL and GSH. However, no information was obtained as to the chemical nature of the reactive primary intermediate (Li et al., [2015](#efs25005-bib-0162){ref-type="ref"}). From similar *in vitro* studies but using 4‐bromobenzylamine instead of NAL, Wang et al. ([2014b](#efs25005-bib-0273){ref-type="ref"}) concluded that the reactive intermediate formed from 2,5‐dimethylfuran by chemical or enzymatic oxidation could be (3*Z*)‐hex‐3‐ene‐2,5‐dione.

**B. Binding to proteins**

***Furan***

Parmar and Burka ([1993](#efs25005-bib-0215){ref-type="ref"}) reported non‐extractable binding of ^14^C‐furan metabolites to proteins in microsomal incubates, with concomitant loss of enzymatic activities. The radioactivity became associated with CYP apoproteins as well as to the haem moieties. The level of binding depended on pretreatment of rats with a range of CYP‐activity modifiers before microsome isolation and on the presence of scavenging agents (e.g. primary amines and GSH).

Burka et al. ([1991](#efs25005-bib-0034){ref-type="ref"}) observed that approximately 13% of the dose of ^14^C was still present in the liver 24 h after an oral dose of 8 mg/kg bw to rats. About 80% of this was non‐extractable and assumed to be covalently bound to tissue macromolecules, in particular to liver proteins.

Using immunoblotting on hepatocyte protein extracts, Lu et al. ([2009](#efs25005-bib-0167){ref-type="ref"}) also demonstrated that the GSH‐BDA is sufficiently stable and reactive to become bound to proteins. The GSH‐BDA adduct may also migrate outside the cell and react with lysine or glutamine in cell culture media. Therefore, the authors further argued that BDA‐GSH adducts could also react with nucleophiles elsewhere in the tissue or in the body.

Phillips et al. ([2014](#efs25005-bib-0221){ref-type="ref"}) studied the reactivity of BDA in the presence or absence of GSH against cytochrome *c* in aqueous solutions. With BDA alone, the predominant addition was 66 g/mol, which corresponds to a pyrrolinone‐modification of lysine (lys‐BDA) that may occur at various locations in the protein. To a much lower extent also additions of 48 (e.g. lys‐BDA‐lys cross‐link) or 84 g/mol (e.g. linear lys‐BDA‐mono‐adduct) were observed. Other tentatively identified adducts were with glutamine, histidine and arginine residues. Multiple adducts were also observed, (i.e. several BDA molecules reacted with different amino acid residues within one cytochrome *c* molecule) and adducts to adjacent lysine residues condensed further into bicyclic pyrrole‐pyrrolinone adducts. The addition of GSH to the incubates decreased the overall extent of adduct formation, and increased the mass of the protein with an addition of 355 g/mol. In the latter incubates, still some non‐GSH containing adducts were observed, but these were far less abundant than GSH‐BDA adducts. The 355 g/mol adducts were identified as GSH‐BDA‐lys adducts, again at several positions in the protein. The sites of lysine adduct formation were more selective for GSH‐BDA than for BDA itself (either in the absence or in presence of GSH). In the presence of GSH, double adducts (two times a 66 g/mol addition) and an addition of 84 g/mol were much less abundant than in the absence of GSH. The authors noted that cytochrome *c* has only two cysteine residues and both are already associated with the haem group of cytochrome *c*. Therefore, they considered that for cytochrome *c* the formation of a cys‐BDA‐lys crosslink is unlikely.

Nunes et al. ([2016](#efs25005-bib-0203){ref-type="ref"}) treated rats daily with 0, 0.92, 2 or 4.4 mg furan/kg bw by gavage for 90, 180 or 360 days. In tryptic digests of liver histone H2B, a GSH‐BDA‐modified lysine 107 residue was observed, which was absent in the livers of the non‐exposed animals. The amount of GSH‐BDA‐modified peptide was dose‐related. No BDA‐modified (i.e. without the GSH moiety) peptides were seen. In recombinant human histone H2B homologue, incubated *in vitro* with BDA in the absence of GSH, no BDA‐modified lysine residue at position 108 (homologous to the rat lysine 107 residue) was observed. However, in incubates of histone octamer or free human histone H2B with BDA + GSH, the GSH‐BDA‐modified lysine residue 108 was found in a concentration‐dependent way. The authors suggested that GSH‐BDA has a higher reactivity towards proteins than BDA itself, and speculated that the higher reactivity of GSH‐BDA might also result in reactivity towards DNA bases. However, no data to support this are available and the results regarding reactivity towards proteins of free BDA as compared to GSH‐BDA are also opposite to those of Phillips et al. ([2014](#efs25005-bib-0221){ref-type="ref"}; see above).

***Methylfurans***

2,5‐Dimethylfuran (0, 20, 35 or 70 mg/kg bw) was given to male mice by i.p. injection. Adduct formation was studied in proteins in liver, kidneys, heart, serum and lungs at different time‐points up to 36 h post‐dosing. 2,5‐Dimethylfuran adducts with cysteine‐ (at the SH group) and lysine‐ (at the Nε position) residues were found in all tissues examined but in liver proteins they were the most abundant. The occurrence of the adducts in liver proteins reached a peak at 2 h post dosing and decreased gradually thereafter. Adduct formation was dose‐related and also corresponded with serum alanine aminotransaminase (ALT) activity. The same lysine or cysteine adducts could be detected in supernatants of liver microsomes from non‐exposed mice, treated with 2,5‐dimethylfuran in the presence of lysine or cysteine. No adducts were found in the absence of reduced nicotinamide adenine dinucleotide phosphate, demonstrating that enzymatic activity is necessary for this bioactivation of 2,5‐dimethylfuran (Wang et al., [2015](#efs25005-bib-0274){ref-type="ref"}).

**C. Binding to DNA**

Formation of BDA‐nucleoside adducts has been extensively characterised. In chemical model systems, BDA reacts with the purified nucleosides deoxycytosine (dC), deoxyguanosine (dG) and deoxyadenosine (dA), but not deoxythymidine (dT), to form pairs of diastereomeric adducts. At pH = 6.5, BDA reacted only with dC, and this reaction was not pH dependent (Byrns et al., [2002](#efs25005-bib-0037){ref-type="ref"}). Reaction of BDA with dG and dA was pH‐dependent, in particular for dG, but at pH 7.0--7.5 there still was a preference of adduct formation of dC over the purines. At pH 8.0, BDA reaction rates with these nucleosides are in the order dG \> dC \>\> dA (Byrns et al., [2002](#efs25005-bib-0037){ref-type="ref"}).

A general mechanism for the nucleoside adduct formation is proposed involving reaction of the C1 atom of BDA with the exocyclic N atom of the nucleoside (N^4^ of dC, N^2^ of dG and N^6^ of dA) followed by addition of the adjacent endocyclic nitrogen atoms (N^3^ of dC, N^1^ of dG and dA) at the BDA double bond and a subsequent ring closure of the added element to result in formation of an oxadiazabicyclo(3.3.0)‐octaimine ring system (Gingipalli and Dedon, [2001](#efs25005-bib-0109){ref-type="ref"}; Byrns et al., [2002](#efs25005-bib-0037){ref-type="ref"}). While adducts with dC are stable (half‐lives of 96 h at pH 2.8, 275 h at pH 7.4 and 13 h at pH 12), adducts with dG and dA rearrange quickly (half‐lives of 2.2--3.4 h for dG and 6 h for dA at pH 7.4; Gingipalli and Dedon, [2001](#efs25005-bib-0109){ref-type="ref"}; Byrns et al., [2002](#efs25005-bib-0037){ref-type="ref"}) and the initial ethano‐adducts of dG and dA decompose to form substituted etheno‐acetaldehyde adducts. These secondary adducts retain a reactive aldehyde with the potential to form crosslinks. The etheno‐acetaldehyde adducts also retain the BDA‐carbon atoms (Byrns et al., [2004](#efs25005-bib-0038){ref-type="ref"}, [2006](#efs25005-bib-0039){ref-type="ref"}).

Bohnert et al. ([2004](#efs25005-bib-0028){ref-type="ref"}) provided additional kinetic and spectroscopic data of the reactions of *cis*‐ and *trans*‐BDA. Several products were observed after reaction of BDA (both isomers) with dA and dC at pH 7.4 in aqueous buffer systems. Apart from the mono‐adducts that were also found by Byrns et al. ([2002](#efs25005-bib-0037){ref-type="ref"}), these included an additional pair of fluorescent compounds with similar high‐performance liquid chromatography (HPLC) retention times and with identical mass, each of which contains two molecules of BDA. The fluorescent adducts of dA contained the oxadiazabicyclo(3.3.0)‐octaimine ring system (see above), which was also found in the dC adducts. The reaction of *trans*‐BDA with dC produced two interchanging diastereomers at reaction rates that were nearly 10‐fold faster than the reaction with the *cis*‐isomer. However, it was noted that *trans*‐BDA is an endogenous oxidation product of deoxyribose and not a metabolite of furan.

The preferred reactivity of BDA with dC rather than dG and dA, as reported by Byrns et al. ([2002](#efs25005-bib-0037){ref-type="ref"}) was also observed by Pluskota‐Karwatka et al. ([2015](#efs25005-bib-0224){ref-type="ref"}). Similar oxadiazabiclyclooctaimine adducts were reported as before. Pluskota‐Karwatka et al. ([2015](#efs25005-bib-0224){ref-type="ref"}) also mentioned that the BDA‐dC adduct can be converted into deoxyuridine by loss of the adducted BDA and subsequent deamination.

Sviatenko et al. ([2012](#efs25005-bib-0254){ref-type="ref"}) applied quantum chemical computer assisted analysis to study the chemical interaction between BDA and dA. A similar technique was applied to study the interactions between BDA and dG (Sviatenko et al., [2014](#efs25005-bib-0255){ref-type="ref"}). For the reactions of BDA with dA and dG, the authors calculated that the primary reaction products would consist of four diastereoisomeric adducts for each nucleoside (for an example of these structure see Figure [7](#efs25005-fig-0007){ref-type="fig"}). Upon acidic or basic hydrolysis, the primary adducts of BDA‐dA and BDA dG, respectively, are converted into more stable secondary adducts that contain free aldehyde groups. Calculated UV and NMR spectra of the primary and secondary adducts as well as the predicted structures match well with experimental observations from published literature.

BDA‐dC and ‐dA adducts were also found in purified DNA treated with BDA and in DNA of *Salmonella* Typhimurium TA104 after exposure to BDA (Byrns et al., [2006](#efs25005-bib-0039){ref-type="ref"}).

Upon extensive extraction of rat liver homogenates and removal of the proteins, no radioactivity was associated with the residual liver DNA, not even after a (massive) i.p. dose of 243.5 MBq/kg bw (8 mg furan/kg bw; 2.07 GBq/mmol) of radioactive furan. This would indicate either absence or a low extent of binding of furan to DNA or an unstable nature of possible furan adducts (Burka et al., [1991](#efs25005-bib-0034){ref-type="ref"}).

Following administration by gavage of a single dose (0.1 or 2 mg/kg bw; 1.11 or 22.2 MBq/kg bw; 0.74 GBq/mmol) of \[3,4‐^14^C\]‐furan to F344 rats, a dose‐dependent increase of ^14^C was found in liver DNA at levels of 1.6 or 32.5 adducts/10^8^ nucleotides at 2 h post‐dosing. The authors suggested that furan radioactivity was covalently bound to DNA. Metabolic incorporation into DNA bases during DNA synthesis occurred only to a minor extent. From differences in MS peaks, the authors concluded that the DNA adducts induced by furan *in vivo* were not the BDA‐dC, ‐dG or ‐dA adducts that have been reported in *in vitro* studies, but their identity could not further be established. Binding of furan to DNA was also reported in the kidneys at half the levels observed in the liver. Screening studies for the presence of DNA‐BDA cross‐links did not provide information that such cross‐links were formed, either *in vivo* or in BDA‐calf thymus incubates (Neuwirth et al., [2012](#efs25005-bib-0196){ref-type="ref"}).

The ability of BDA to form DNA adducts in the liver was investigated by Churchwell et al. ([2015](#efs25005-bib-0049){ref-type="ref"}) in Fisher 344 rats administered furan by gavage (single doses ranging from 0.92 to 9.2 mg/kg). In addition, rats were gavaged (5 days per week) with 4.4 mg/kg bw for different lengths of time (45--360 days). Following both single dose or repeated exposure regimens, at 24 h after the last dose, livers were collected and analysed for the presence of BDA‐dC adducts by LC--MS/MS. The BDA‐dC levels did not increase (LOD: 0.4 adducts per 10^8^ nucleotides) compared to the level present in liver DNA from control animals (1--2 adducts per 10^8^ nucleotides).

In chemically defined systems, oligonucleotides containing a single‐furan‐modified nucleoside were selectively oxidised at the furan moiety to a reactive BDA‐like aldehyde. Fast and efficient formation of an interstrand DNA cross‐link was observed in the presence of a complementary DNA strand (Halila et al., [2005](#efs25005-bib-0117){ref-type="ref"}; Stevens and Madder, [2009](#efs25005-bib-0252){ref-type="ref"}). However, the BDA‐derived nucleoside adducts observed *in vitro* by Gingipalli and Dedon ([2001](#efs25005-bib-0109){ref-type="ref"}) and Byrns et al. ([2002](#efs25005-bib-0037){ref-type="ref"}, [2004](#efs25005-bib-0038){ref-type="ref"}) in single DNA strands have chemical structures that differ from the reactive BDA moieties that ultimately are formed upon oxidation of the furan‐modified oligonucleotides as described by Halila et al. ([2005](#efs25005-bib-0117){ref-type="ref"}) and Stevens and Madder ([2009](#efs25005-bib-0252){ref-type="ref"}). Therefore, the relevance for the *in vivo* toxicity of furan of the observed interstrand cross‐linking in oligonucleotides in the experimental designs from Halila et al. ([2005](#efs25005-bib-0117){ref-type="ref"}) and Stevens and Madder ([2009](#efs25005-bib-0252){ref-type="ref"}) is not clear. On the other hand, ~~a~~ccording to Stevens and Madder ([2009](#efs25005-bib-0252){ref-type="ref"}), the adducts in the complementary oligonucleotide strands resemble the adducts formed by direct reaction of BDA with nucleotides.

#### 3.1.1.5. Elimination {#efs25005-sec-0039}

**A. Furan**

After a single oral dose of 8 mg \[^14^C\]‐furan/kg bw (0.37 MBq/kg bw) in rats, 11% of the dose was exhaled as unchanged furan within the first hour post‐dosing and an additional 3% was exhaled during the next 23 h (Burka et al., [1991](#efs25005-bib-0034){ref-type="ref"}). Exhaled carbon dioxide represented 26% of the dose. Urine contained 20% of the dose and comprised more than 10 peaks representing mixtures of metabolites, but these could not be further identified. The faeces contained 22% of the dose (not characterised). After 8 days of repeated dosing, the fraction of the dose eliminated via urine, increased from 20% to 33%. No change was observed in the extent of faecal elimination. Radioactivity from the liver was eliminated with a half‐life of 1.8 days. For blood and kidney, no half‐lives could be estimated. Hamberger et al. ([2010](#efs25005-bib-0119){ref-type="ref"}) reported that in rats orally dosed with 5 mg furan/kg bw, several metabolites could be detected in bile. Some of these reached a peak within 1 h of dosing; others continued to increase in the bile during the 4 h observation period. The presence of parent furan was not studied. No indication was given or could be obtained as to the fraction of the dose that was eliminated via this route.

In a study by Churchwell et al. ([2015](#efs25005-bib-0049){ref-type="ref"}), over the 8 h period of observation, the concentration in blood decreased log‐linearly with a half‐life of 1.3 h. The elimination in liver showed 2 log‐linear phases with half‐lives of 0.55 and 0.62 h, respectively. However, it is debatable whether this small difference has any biological meaning, given the high variability in furan concentrations in the liver.

A rapid elimination of furan from blood was also reported by Becalski et al. ([2013](#efs25005-bib-0025){ref-type="ref"}), who gavage‐dosed rats with 2.9 mg/kg bw deuterated furan in corn oil. At 0.5 h post‐dosing, furan blood levels were approximately 13--42 ng/g and at 1.5 h post‐dosing, these levels had dropped to approximately 5 ng/g. Over the next 4.5 h, the furan blood concentration declined gradually to background level.

#### 3.1.1.6. Biomarkers/biomonitoring {#efs25005-sec-0040}

Kellert et al. ([2008b](#efs25005-bib-0148){ref-type="ref"}) argued that estimation of human exposure to furan from concentration data in food is not reliable, because of the volatility of furan. They advocated a biomarker approach for furan exposure estimation. They treated rats with furan (0 or 40 mg/kg bw; n = 5) and analysed the urinary metabolite profile by principal component analysis. They observed a treatment‐related increase in mass spectrometer peaks for 13 compounds. For seven of these, the increase was statistically significant. Five urinary metabolites could be identified, all of them contained BDA in the form of a pyrrole nucleus. The pyrrole was formed by condensation of BDA with the N^ε^‐amino‐group of lysine or the N^α^‐amino‐group of the glutamic acid moiety in GSH. In four of these metabolites, the double bond in BDA had also reacted with GSH‐thiol. One of these four products was an S‐methylated β‐lyase cleavage product. Two of the metabolites found (NAL‐BDA and NAL‐BDA‐NAC) were also observed in urine from control animals. The authors could not explain this observation, but argued that presence of furan in the feed was not a likely source.

The adducts of BDA with GSH or the cysteine‐BDA‐lysine crosslink adducts and downstream reaction products thereof (N‐acetylated; S‐oxidated, β‐lyase cleaved followed by S‐methylation) have been proposed as possible biomarkers for furan exposure (Kellert et al., [2008b](#efs25005-bib-0148){ref-type="ref"}; Lu and Peterson, [2010](#efs25005-bib-0166){ref-type="ref"}). Kellert et al. ([2008b](#efs25005-bib-0148){ref-type="ref"}) further argued that the pattern of lysine‐containing adducts as eliminated via urine indicated that these are formed from BDA interaction with proteins, rather than with free amino acids, thereby being indicative of markers of past exposure, because shortly after exposure only a decrease in urinary excretion rate was observed for several GSH‐BDA conjugates, while the elimination of the lysine adducts did not show a decrease between 24 and 48 h post‐exposure.

Becalski et al. ([2013](#efs25005-bib-0025){ref-type="ref"}) demonstrated that furan in animal feed does not contribute to the furan body burden in rats. Administration of 120 ng/kg bw of deuterated furan to rats did not result in detectable levels of labelled furan in blood or liver, while native furan was found at 0.09--0.18 ng/g blood or 0.04--0.12 ng/g liver. The labelled dose corresponded to 20 ng/animal. This is an exposure similar to that resulting from the consumption of control feed with a background furan content of approximately 2 ng/g feed. Based on this, the authors speculated that furan was formed from an endogenous source. If substantiated, endogenous formation of furan is likely to have implications regarding biomonitoring.

Grill et al. ([2015](#efs25005-bib-0113){ref-type="ref"}) analysed the urine of smoking and non‐smoking human subjects (one cohort from Minnesota, one from Shanghai and one from Singapore) for the presence of furan metabolites. A BDA‐N^ε^‐lysine adduct and its N‐acetylated conjugate were observed and also NAC‐BDA‐lys together with the corresponding sulfoxide. The BDA‐lys adducts were the most abundant metabolites and were clearly elevated in urine from smokers as compared to non‐smokers in the Shanghai and Singapore cohorts, but not in the Minnesota cohort. Interference with other components in the urine hampered its quantification in 50% of the urine samples, notably all from USA, while the samples where the metabolite could be properly quantified were from Shanghai or Singapore. A similar rise in NAC‐BDA‐lys adduct and its sulfoxide was observed in smokers' urine. For the USA samples, the concentration of NAC‐BDA‐lys sulfoxide was much higher than for the Asian samples. The urinary level of NAC‐BDA‐lys dropped significantly during the first 20 days after cessation of smoking, but remained higher than the level in urine from non‐smokers during the following 60 days, which the authors considered to be an indication of slow release from furan‐damaged proteins. In urine from furan‐treated rats and mice, the metabolic pattern for furan metabolites was different from that in humans: in rats and mice also NAL‐BDA‐NAC and their sulfoxides were observed, which were not seen in human urine. In mice urine, the prime metabolite was NAC‐BDA, while in rats the prime metabolite was the NAL‐BDA adduct. The non‐acetylated BDA‐lys adduct was not detectable in either mice or rat urine.

Mochalski and Unterkofler ([2016](#efs25005-bib-0186){ref-type="ref"}) determined 19 volatile substances among which furan, 2‐methylfuran and 3‐methylfuran in the urine of 10 male and 9 female volunteers. Urine samples were collected in glass vials, which were immediately closed after urine production. Volatiles were analysed using headspace microextraction and GC‐SRI‐TOF‐MS. The three furans were found in all samples. Analytical results are given in Table [1](#efs25005-tbl-0001){ref-type="table"}.

###### 

Levels of furan, 2‐methylfuran and 3‐methylfuran in urine as reported by Mochalski and Unterkofler ([2016](#efs25005-bib-0186){ref-type="ref"})

  Compound        Concentration in urine range (median)   Limit of detection (nmol/L)   
  --------------- --------------------------------------- ----------------------------- -----
  Furan           1.06--28.8 (11.3)                       0.1--4.75 (0.87)              1.0
  2‐Methylfuran   1.74--6.88 (4.06)                       0.2--0.93 (0.34)              0.1
  3‐Methylfuran   1.03--5.59 (2.97)                       0.12--0.92 (0.24)             0.1

John Wiley & Sons, Ltd

For furan, the levels ranged from 1.06 to 28.8 nmol/L (median 11.3 nmol/L) or from 0.1 to 4.75 nmol/mmol creatinine (median 0.87 nmol/mmol). For 2‐methylfuran and 3‐methylfuran, the concentrations ranged from 1.74 to 6.88 nmol/L (median 4.06 nmol/L) and from 1.03 to 5.59 nmol/L (median 2.97 nmol/L), respectively. No information was provided as to the possible source of the furans found, apart from the statement that all volunteers were non‐smokers. It was not stated whether there was a gender difference in urinary excretion of furans.

Two limited studies measuring urinary and plasma levels of furan were identified (Jun et al., [2008](#efs25005-bib-0125){ref-type="ref"}; Lee et al., [2009](#efs25005-bib-0159){ref-type="ref"}); however, the reported levels were inconsistent and therefore of limited value for this opinion.

#### 3.1.1.7. Physiologically based pharmacokinetic (PBPK) modelling {#efs25005-sec-0041}

Based on data from inhalation absorption studies and data on rate of metabolism of furan in hepatocyte suspensions, Kedderis et al. ([1993](#efs25005-bib-0146){ref-type="ref"}) developed a PBPK model for rats. The model predicted that for an oral bolus dose of 8 mg/kg bw in rats, 84% of the dose would be metabolised and 16% of the dose would be exhaled unchanged, which is similar to the extent of metabolism and exhalation of furan in rats as observed by Burka et al. ([1991](#efs25005-bib-0034){ref-type="ref"}) after the same oral bolus dose. The model also predicted that in rats for furan blood concentrations of 1 μM, the rate‐limiting step in the metabolism is the hepatic blood flow, rather than the maximum metabolic capacity of the liver. From the data presented, it can be calculated that the metabolism becomes saturated (90% of V~max~) at a blood concentration of 3.6 μM using a K~m~ of 0.4 μM as determined in rat hepatocyte suspensions.

This model was modified to predict liver dosimetry in mice, rats and humans (Kedderis and Held, [1996](#efs25005-bib-0145){ref-type="ref"}). Metabolic parameters used were for V~max~ 48, 18 or 19--44 nmol/h per 10^6^ isolated hepatocytes, and for K~m~ values 1.0, 0.4 or 2.1--3.3 μM, for mice, rats and humans (3 samples), respectively. The modified models predicted absorption of furan from inhaled air containing 10 ppm (27.8 mg/m^3^) for 4 h to be 4.1, 1.4 or 0.4 mg/kg bw, resulting in a liver exposure to furan metabolites of 1,075, 480 or 168 μM for mice, rats and humans. According to the humanised model, for air concentrations up to 300 ppm (830 mg/m^3^) the exposure of the liver to furan metabolites is not dependent on V~max~ but only on hepatic blood flow, that restricts the availability of substrate for biotransformation. The authors argue that induction status of CYP2E1 is therefore not relevant for individual differences in the rate of hepatic furan bioactivation in humans. Kedderis ([1997](#efs25005-bib-0144){ref-type="ref"}) also applied the humanised model for the estimation of hepatic furan bioactivation for an oral furan bolus dose of 2 mg/kg bw. For this route, the extent of bioactivation of furan would be flow‐limited and independent on the CYP2E1 induction status of the liver. However, the modelling conditions for the latter prediction were not reported, especially not with respect to the furan absorption rate from the GI tract. Nevertheless, the conclusion that the metabolic clearance rate of furan depends on the delivery of furan to the liver, rather than on hepatic CYP2E1 activity, was supported by a generic PBPK model (Poulin and Krishnan, [1998](#efs25005-bib-0308){ref-type="ref"}).

#### 3.1.1.8. Summary and discussion {#efs25005-sec-0042}

After oral exposure of rats, furan is rapidly and extensively absorbed from the GI tract and distributed throughout the body. At 24 h after exposure, major tissues where furan‐related material can be found are liver and kidneys and to a lesser extent lungs and intestines. Furan is extensively metabolised in the body and from a dose of 8 mg/kg bw to the rat, only 11% was exhaled as unchanged furan. The remainder was eliminated as carbon dioxide or as polar metabolites in urine or bile/faeces. At 24 h post‐dosing, no unchanged furan could be detected in liver or blood of rats, and this is in line with the very short half‐life of the substance in these tissues: approximately 40 min in liver and approximately 1.3 h in blood. Although at 24 h post‐dosing some furan‐related material could be extracted from liver tissue, 80% of the residual material in the liver appeared to be non‐extractable. Extensive non‐extractable association of furan and 2‐methylfuran in the liver was also reported after i.p. administration. For 2‐methyl and 3‐methylfuran, data from *in vitro* studies are available that show that they may become associated (non‐extractable) with lung and liver microsomal proteins.

No oral studies have been performed with 2‐ or 3‐methylfuran or with 2,5‐dimethylfuran to address their kinetics in animals, but inhalation studies in dogs with furan and 2‐methylfuran and to a lesser extent also with 2,5‐dimethylfuran indicate that these three alkylated furans will be absorbed from the gastrointestinal tract but the extent of this is unclear.

As indicated above, the major route for elimination of furan is via metabolic conversion. By analogy with 2‐methylfuran and 3‐methylfuran, it was suggested that this metabolism would involve opening of the furan ring to result in the formation of a very reactive *cis‐*enedial intermediate, i.e. BDA. This metabolite has never been directly measured. However, results with trapping agents and the identification of urinary and biliary metabolites, in comparison to reaction products of BDA with various biomacromolecules or amino acids in purified chemical model systems, provide strong evidence that BDA is indeed a prime reactive intermediate in the metabolism of furan. The corresponding reactive metabolic intermediates of 2‐ and 3‐methylfuran are the *cis‐*enedials 3‐acetyl acrolein (4‐oxopent‐2‐enal) and 2‐methylbut‐2‐enedial, respectively. Also for 2,5‐dimethylfuran, ring opening results in the formation of a reactive intermediate, 3(*Z*)‐hexene‐2,5‐dione. Induction‐inhibition studies, but also studies with various recombinant CYPs indicate that CYP2E1 is by far the most important (but not exclusively) monooxygenase that catalyses the conversion of furan into BDA.

As a result of its reactivity, BDA reacts very quickly with amino acids and GSH. The same applies for the reactive intermediate formed from 2,5‐dimethylfuran. For the intermediates of 2‐methyl‐ and 3‐methylfuran, reactivity towards amino acids and GSH has not been studied in great depth. However, it may be anticipated based on structural similarity and similar reactivity towards scavengers such as semicarbazide, cysteine, NAC and microsomal proteins, that these will react with tissue components in a similar way to the primary metabolites of furan and 2,5‐dimethylfuran. A plethora of low molecular weight reaction products has been reported. Reactive (alkyl)furan metabolites may react with: amino acids (in particular lysine): reacts with the two terminal aldehyde groups of BDA to give a cyclic pyrrole derivative. This reaction may involve the side chain terminal amino group of the amino acid or the amino acid in α‐position to the carboxylic acid. For these reaction products, the corresponding N‐acetylated forms have been reported. BDA can also react with free amino groups in proteins (in particular from lysine). The same reactions have been reported for the *cis*‐enedione formed from 2,5‐dimethylfuran.GSH or cysteine: react directly with the double bond in these α,β‐unsaturated carbonyls at their thiol group. The latter reaction does not take away the reactivity of the two aldehydes, and consequentially, these GSH or cysteine adducts may react further, either with the amino groups from free amino acids or with amino groups protruding from protein amino acid residues. Since cysteine or GSH have several reactive functional groups, also bicyclic adducts have been reported, in which the thiol group is connected to the BDA double bond and the free amino group has reacted with the two BDA aldehydes, resulting in a pyrrole ring.

Reactivity of BDA towards biogenic amines has also been reported.

As a result of the reactivity towards amino acids, GSH, biogenic amines and proteins, the urinary excretion is biphasic: in first instance, the main excretion of urinary furan metabolites consists of metabolites that were formed from BDA and free amino acids or GSH within the cell, but later on the urinary excretion of furan‐related material is a result from protein turn‐over that liberates the furan‐damaged amino acid residues. Also, the elimination of furan (radioactivity) from, e.g. liver is biphasic with a rapid elimination of non‐bound radioactivity and a slower and more prolonged elimination of protein‐bound furan.

More intriguing is the possibility of furan metabolites reacting with DNA, which could be an important factor in the genotoxicity and formation of tumours. Studies in chemical model systems have demonstrated that BDA can readily react with dC and to a lesser extent dG and dA, but not dT. Again, a plethora of reaction products was obtained. While BDA‐dC is rather stable (with a half‐life of about 300 h at pH = 7.4), the adducts of dG and dA rearrange rather quickly with half‐lives of 2.2--3.4 h for dG and 6 h for dA at physiological pH. Nevertheless, these adducts retain the BDA‐carbon atoms and this should reveal their presence in studies in which radioactive furan is given to animals *in vivo*. When purified DNA or bacterial cultures are exposed to BDA, DNA adduct formation can be demonstrated.

Although it is clear that BDA has direct reactivity towards DNA, it is not clear from the available data that BDA‐DNA adducts will be formed after exposure of rats to furan *in vivo*. In earlier *in vivo* studies with rats, at 24 h post‐dosing, furan radioactivity in liver was associated with protein but not with DNA, not even when a dose as high as 243.5 MBq/kg bw (8 mg/kg; 2.07 GBq/mmol) was administered. In a study in which rats were treated with furan, using accelerator mass spectrometry, the presence of DNA adducts in the liver (1.6 or 32 adducts per 10^8^ nucleotides) and kidneys (0.5 or 13 adducts per 10^8^ nucleotides) at 2 h post‐dosing with 0.1 or 2 mg radiolabelled furan/kg bw (1.11 or 22.2 MBq/kg bw; 0.74 GBq/mmol), respectively, was demonstrated. However, the adducts observed could not be identified as either BDA‐dC, BDA‐dG or BDA‐dA adducts. The possibility was suggested that the observed adducts were related to DNA‐DNA or DNA‐protein cross‐links, but no definitive evidence for this was presented. In another study in rats, no increase in BDA‐dC levels (LOD: 0.4 adducts per 10^8^ nucleotides) above the level present in commercial control DNA and in liver DNA from control animals (\~ 1--2 adducts per 10^8^ nucleotides) was observed in livers of rats following administration after a single dose of furan (ranging from 0.92 to 9.2 mg/kg), as well as after repeated dosing (5 days per week) with 4.4 mg/kg bw for 45--360 days, as determined using LC--MS/MS. In any case, the potency of covalent binding to DNA *in vivo* is not very high or the reaction products are very short‐lived. The data further suggest that BDA reacts readily with protein and non‐protein amino and thiol residues in liver, thereby restricting access to DNA.

Based on the studies in rats, and on furan metabolism rates measured in rodent and human hepatocytes, a PBPK model has been constructed for rats, mice and humans. Applying this model, the rate of exhalation of furan in rats after an oral bolus dose was well described. The model further predicts that after an oral bolus dose of 2 mg/kg bw the exposure of the liver to furan metabolites depends on the blood flow to the liver rather than the metabolic capacity of the liver since at the blood concentrations reached, the metabolic capacity of the liver is far from saturated. The efficient metabolism of furan will result in an effective first‐pass elimination and will therefore limit the systemic exposure to furan after oral intake. The bioactivation of furan depends less on the liver CYP2E1 activity (the main furan‐metabolising enzyme) than on liver blood flow. Activity of GSH conjugating enzymes may be of less relevance, because BDA has a high rate of spontaneous reactivity towards GSH.

It has been argued that estimation of furan exposure based on concentration in foods is not reliable, and biomarkers of exposure might be an alternative. However, from the available kinetics data, it is not possible to conclude on a methodology to reliably estimate exposure to furan in humans from the excretion of furan or furan metabolites. The main reason for this is that there is no information as to the quantity of metabolites in human excreta, not for total amounts of metabolites and also not for individual metabolites. Even for rats, this information is not available, since virtually all metabolism studies have focused only on qualitative determination and identification of furan metabolites in urine or bile and did not pay attention to quantitative aspects of metabolism and excretion. Nevertheless, several studies have suggested that three metabolites might be good candidates for biomonitoring furan exposure: NAL‐BDA‐NAC, its sulfoxidation product and the sulfoxidated α‐keto‐derivative of NAC‐BDA‐lys. The urinary metabolite pattern may also provide information on the level of past exposure, because several metabolites seem to emerge from protein breakdown rather than direct adduct formation to small biomolecules (amino acids; GSH), which are probably more rapidly eliminated. However, further work is needed to validate the use of these metabolites as biomarkers of exposure. A few studies have also tried to monitor unmetabolised furan in human blood and urine. In many samples furan was not detectable. In addition, the volatility of furan requires very stringent treatment of samples, because otherwise artificially low furan levels might result. Given the short half‐life of furan, at least in rats, but probably also in humans, looking at unchanged furan would only provide an indication for very recent exposure to furan. It is further noted that furan may also be formed endogenously, which may need to be taken into account.

**Concluding remarks**

After oral administration, furan is extensively oxidised in the liver to form a reactive intermediate metabolite BDA. BDA may be further metabolised to carbon dioxide. Alternatively, it can spontaneously react with free amino‐ or thiol groups in low molecular weight tissue components (e.g. GSH, cysteine, lysine and other amino acids and biogenic amines). The resulting reaction products can be eliminated from the body via urine or bile. A study with oral dosing indicated that approx. 55% of an oral gavage dose may be eliminated via these two routes, predominantly within the first 24 h after exposure. The rate of metabolism is determined by the delivery of furan to the liver, and not by its enzymatic capacity. From the data available, it may be assumed that the fraction of an oral dose that is converted to BDA will be dose dependent, but this has not been studied. The relative extent of formation and elimination of the BDA secondary reaction products has not been investigated, but several of these (e.g. NAL‐BDA‐NAC) have been suggested to be useful biomarkers of exposure. BDA can form adducts with protein (including histones) after exposure to furan *in vivo*, especially with lysine, and form adducts with free nucleosides (in particular with deoxyribose guanosine, ‐cytosine and --adenine) and DNA adducts in purified DNA and bacteria. In one *in vivo* study, binding of furan to DNA has been reported, but this result could not be reproduced in another study. The DNA adducts found were different from the BDA adducts formed with the free nucleosides and could not be identified. No DNA‐DNA cross‐links have been reported.

In addition, for 2‐methyl‐, 3‐methyl‐ and 2,5‐dimethylfuran, oxidative opening of the furan ring has been reported with similar reactivity towards amino acids and GSH. For these alkylfurans, also oxidation of the methyl‐ring substituent groups may be expected, but there are no quantitative or qualitative studies available that address these routes of biotransformation.

The relevance of these findings for the toxicity and genotoxicity of furan and the alkylfurans will be discussed in Sections [3.1.2.4](#efs25005-sec-0047){ref-type="sec"} and [3.1.4](#efs25005-sec-0050){ref-type="sec"}.

### 3.1.2. Toxicity in experimental animals {#efs25005-sec-0043}

#### 3.1.2.1. Acute toxicity (single exposure) {#efs25005-sec-0044}

In adult male Sprague--Dawley rats and male Swiss mice, furan was injected i.p., while another group of adult male Swiss mice inhaled air enriched with furan vapour (Egle and Gochberg, [1979a](#efs25005-bib-0079){ref-type="ref"}). The i.p. LD~50~ values were 5.2 mg/kg bw in rats and 7.0 mg/kg bw in mice. The LC~50~ value as a vapour was 0.12 mg/L in mice. In the lungs, fluid accumulation and inflammatory reactions were found after inhalation.

Wiley et al. ([1984](#efs25005-bib-0280){ref-type="ref"}) injected furan i.p. in male ICR mice. Twenty‐four hours after a dose of 347 mg/kg bw, the animals were sacrificed. Histopathological inspection revealed slight proximal tubular necrosis of the kidneys and massive centrilobular necrosis of the liver. Dosage of 3‐methylfuran (254 mg/kg bw) claimed to be 'equimolar' was reported not to lead to significant damage in these organs. The CONTAM Panel noted that the dose levels mentioned in the abstract and in the text are inconsistent and not equimolar. The CONTAM Panel noted that the dose level for furan by far exceeded the LD~50~ value reported by Egle and Gochberg ([1979a](#efs25005-bib-0079){ref-type="ref"}).

Bronchiolar necrosis was observed 8 h after i.p. application of 100--200 mg/kg bw of 3‐methylfuran to NIH Swiss mice (age and gender not specified) (Boyd et al., [1978](#efs25005-bib-0031){ref-type="ref"}). Gammal et al. ([1984](#efs25005-bib-0100){ref-type="ref"}) administered 213 or 254 mg/kg bw of 3‐methylfuran i.p. to adult male ICR mice. After 24 h, severe bronchiolar necrosis was observed.

#### 3.1.2.2. Subacute and subchronic toxicity (\< 90 days duration) {#efs25005-sec-0045}

**A. Furan**

Several short‐term toxicity studies with furan were identified, which are described below and summarised in Table [2](#efs25005-tbl-0002){ref-type="table"}.

Wilson et al. ([1992](#efs25005-bib-0282){ref-type="ref"}) published results from treatment of male mice or male and female rats at the highest NTP bioassay dose in each species (15 mg/kg bw per day or 8 mg/kg bw per day, respectively) 5 days a week by gavage. In male and female rats, necrosis and inflammation were observed along the subcapsular visceral surface of the left or caudate liver lobes after one week. A similar picture was evident in mice after 3 weeks. After 6 weeks of furan treatment, male and female rats exhibited bile duct hyperplasia and metaplasia in the areas of fibrosis along the subcapsular visceral surface of the left or caudate liver lobes. This was not observed in mice. The fold increase in hepatocyte labelling index (DNA synthesis) in treated animals relative to the combined controls measured at weeks 1, 3 and 6 was 25‐, 12‐ and 3‐fold in male mice, 3‐, 9‐ and 7‐fold in male rats, and 13‐, 11‐ and 16‐fold in female rats, respectively.

In a study carried out for the NTP ([1993](#efs25005-bib-0201){ref-type="ref"}), adult F344/N rats and B6C3F~1~ mice were treated with furan, dissolved in corn oil, by gavage. Groups of five male rats received doses of 0, 5, 10, 20, 40 or 80 mg of furan/kg bw per day and groups of five female rats and five mice of each sex received doses of 0, 10, 20, 40, 80 and 160 mg/kg bw per day over 16 days, 5 days a week. All male and female mice and female rats which had received 160 mg/kg bw, all male and female rats and all male and four out of five female mice which had received 80 mg/kg bw per day, and three out of five male mice which had received 40 mg/kg bw per day died by day 8. All furan‐treated animals showed motor inactivity or reduced activity. Final mean body weights of male rats which had received 20 mg/kg bw per day and of male and female rats which had received 40 mg/kg bw were significantly lower than in the controls. Final mean body weights of male mice which had received 10 or 20 mg/kg bw per day were significantly greater than controls. At necropsy, mottled and enlarged livers were observed in male rats after 20, 40 or 80 mg/kg bw and in female rats after 40, 80 or 160 mg/kg bw. No treatment‐related lesions were observed in mice.

In a second experiment carried out for the NTP ([1993](#efs25005-bib-0201){ref-type="ref"}), groups of 10 rats of each sex and groups of 10 female mice received 0, 4, 8, 15, 30 or 60 mg of furan per kg bw in corn oil by gavage 5 days per week for 13 weeks. Groups of 10 male mice received 0, 2, 4, 8, 15 or 30 mg of furan per kg bw in corn oil by gavage 5 days per week for 13 weeks. Nine male and four female rats that received 60 mg/kg bw died before the end of the experiment. There were no treatment‐related deaths in mice. Significantly lower final mean body weights were observed in male rats that received 15 or 30 mg/kg bw, in female rats that received 60 mg/kg bw and in male mice that received 30 mg/kg bw compared to controls. Relative and absolute liver weights were increased in all furan‐treated groups in both species, as were relative and absolute kidney weights in all furan‐treated groups of female rats. Thymus weights were decreased in all furan‐treated groups of rats. In rats, furan administration resulted in bile duct hyperplasia, cholangiofibrosis, cytomegaly and degeneration of hepatocytes, and nodular hyperplasia of hepatocytes. Kidney tubular dilatation and necrosis were observed in rats that received 30 or 60 mg/kg bw. In rats, exposed to 60 mg/kg bw furan, thymic atrophy and testicular or ovarian atrophy were also observed. In mice, similar hepatic lesions were found in all furan‐treated dose groups, while bile duct hyperplasia and cholangiofibrosis were observed in groups of mice receiving 30 or 60 mg/kg bw.

The CONTAM Panel noted that even at the lowest dose levels (4 mg/kg bw in rats; 2 mg/kg bw in mice), significant hepatic lesions were found.

Sirica et al. ([1994b](#efs25005-bib-0249){ref-type="ref"}) applied 45 mg furan/kg bw by gavage to young adult male Fischer 344 rats over 6 weeks, 5 days a week. Furan reduced liver weight and led to pronounced cholangiofibrosis with associated metaplasia mainly found in the right liver lobe together with biliary cirrhosis. In contrast to normal cholangiolar structures, the metaplastic cholangia‐like cells were surrounded by a basement membrane positive for both laminin and type IV collagen. The cells were stained positive for gamma‐glutamyl transpeptidase and cytokeratin 8, while cytokeratin 19 was strongly expressed in all of the biliary epithelial cells, but in just some of the metaplastic cells.

In a first experiment, 50‐day‐old female B6C3F~1~ mice received furan by daily gavage, 5 days per week over a period of 3 weeks (15 days of treatment) at doses of 4, 8 or 15 mg/kg bw per day (Fransson‐Steen et al., [1997](#efs25005-bib-0094){ref-type="ref"}). In a second experiment, 15 mg/kg bw furan was initially applied by gavage for three consecutive days followed by 2 weeks with five consecutive days per week and over a final week with two consecutive days. Thus, animals were exposed for five and two consecutive days immediately prior to necropsy in the first and second experiments, respectively. In the second experiment, a separate group received 100 mg/kg of the non‐specific CYP‐inhibitor, aminobenzotriazole (ABT), 7 days per week beginning 5 days before the start of furan dosing.

In the first experiment, ALT and sorbitol dehydrogenase[24](#efs25005-note-1027){ref-type="fn"} (SDH) were measured in the serum and the apoptotic index in the liver, and all were significantly increased at 8 mg/kg bw and above. At the two highest dose levels, histopathological examination revealed minor subcapsular inflammation as well as sporadic necrosis. In the second experiment, 15 mg/kg bw furan resulted in a significant increase in liver weight, while serum levels of ALT, SDH and total bile acids were increased at this dose level. Co‐treatment with ABT attenuated these effects while it caused a mild lipid vacuolisation of the liver. The labelling index of hepatocellular nuclei was increased significantly at 15 mg/kg bw, the apoptotic index at 8 and 15 mg/kg bw. Co‐treatment with ABT abrogated these effects completely.

Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) treated female B6C3F1 mice with 0.5 1, 2 and 4 mg furan/kg bw by gavage over 3 weeks, 5 days per week. There was a dose‐dependent and significant hepatotoxicity (measured as serum ALT) at and above 0.5 mg/kg bw and a mild subcapsular inflammation of the liver at the lowest dose. Cell proliferation as measured by 5‐bromo‐2‐deoxyuridine (BrdU) incorporation was enhanced at 8 mg/kg bw applied in a long‐term carcinogenicity study.

Cordelli et al. ([2010](#efs25005-bib-0056){ref-type="ref"}) gave furan by daily gavage over 28 days, 5 days a week, to male B6C3F1 mice at dose levels of 2, 4, 8 and 15 mg/kg bw per day. The animals were sacrificed and the livers were removed for further investigation, 24 h after the last gavage. Histopathological inspection revealed some necrosis and regenerative hyperplasia (at 8 and 15 mg/kg bw) and an increase in apoptotic figures (at 15 mg/kg bw). Furthermore, at the highest dose level, an increase in nuclear ploidy was found. DNA methylation and the number of γ‐H2AX foci were unchanged. At the highest dose level, overexpression of DNA damage response‐related genes was noted. At a very high single dose level of 250 mg/kg bw diffuse alteration of liver parenchyma with areas of necrosis and steatosis in surrounding hepatocytes was found 3 h after application.

Hickling et al. ([2010b](#efs25005-bib-0124){ref-type="ref"}) administered furan to adult male Sprague--Dawley Crl CD1 BR rats by gavage in corn oil at 30 mg/kg bw (five daily doses per week, per gavage in corn oil). After 8 h, 1, 3, 7, 10, 12 and 20 days, and 1, 2 and 3 months of treatment, animals were sacrificed and livers were examined. The administration of furan caused centrilobular and subcapsular injury (necrosis) and subsequent proliferation of hepatocytes. Later, a rapid proliferation of ductular cells expanding into the parenchymal area accompanied by a subtype of liver fibroblasts occurred. The ductular structures either differentiated into hepatocytes or transformed into ductular cholangiofibrotic structures.

Mally et al. ([2010](#efs25005-bib-0173){ref-type="ref"}) treated male Fischer 344 rats orally (gavage) at doses of 0.1, 0.5 and 2 mg/kg bw for 28 days (5 days per week), with an interim sacrifice after 5 days of treatment. An off‐dose recovery group (0 and 2 mg/kg bw dose groups only) was kept for additional 2 weeks (recovery period) after the end of the 4‐week treatment period. Statistically significant proliferative changes were restricted to rats treated with furan at 2 mg/kg bw. An approximate twofold and threefold increase in BrdU labelling above background was observed in the low‐ (0.1 mg/kg bw) and mid‐ (0.5 mg/kg bw) dose group, respectively. Furthermore, the authors observed an increased mitotic activity in the subcapsular regions of the left and caudate lobe accompanied by an occasional apoptotic cell and inflammatory foci with accumulation of mononuclear cells.

Selmanoglu et al. ([2012](#efs25005-bib-0240){ref-type="ref"}) treated juvenile male Wistar rats by gavage with 2, 4 or 8 mg/kg bw per day over 90 days. A 7 days per week dose schedule was applied (Karacaoğlu, [2016](#efs25005-bib-0306){ref-type="ref"}, E‐mail communication, 25 October 2016). Reduced liver weights and significant changes in serum ALT, alkaline phosphatase (ALP) and low‐density lipoprotein (LDL) were observed at 4 mg/kg bw and above. At the lowest dose level (2 mg/kg bw), hepatic tumour necrosis factor (TNF)‐α was significantly increased and numerous histopathological alterations of the liver as well as morphological changes of the glomerula (kidney) were found.

Gill et al. ([2010](#efs25005-bib-0105){ref-type="ref"}) treated male and female Fischer 344 rats over 90 days by gavage with 0.03, 0.12, 0.5, 2.0 and 8.0 mg/kg bw per day, 5 days per week. The liver was found to be the major target organ with changes in serum enzymes, increased liver weight and various histological lesions (pattern and severity changing with the dose level). There was a significant increase in serum thyroxine (T4) and triiodothyronine (T3) in males. The CONTAM Panel noted that there was no clear dose response for changes in T3. The increase in thyroid hormones was not accompanied by histological thyroid changes. At a dose level above 0.5 mg/kg bw, changes in clinical biochemistry and haematological parameters were observed, while mild histopathological alterations in the liver were observed at a dose level of \> 0.12 mg/kg bw per day and at 0.12 mg/kg bw per day and above in the caudate lobe. At this dose level, serum T4 was increased significantly in male rats, and further increased with increasing furan doses.

Gill et al. ([2011](#efs25005-bib-0106){ref-type="ref"}) published a study where male and female B6C3F1 mice were treated by gavage over 90 days with 0.03, 0.12, 0.5, 2.0 and 8.0 mg/kg bw per day, 5 days per week. Serum ALT was increased at the highest dose level and liver weights were increased at the highest dose in females only. At the two highest dose levels, histological changes in the liver were observed in both sexes and also at 0.5 mg/kg bw in males. For the kidney, clinical parameters were also altered, but they were not accompanied by histological changes. At 0.5 mg/kg bw, blood urea nitrogen (BUN) was decreased in both sexes. The CONTAM Panel noted that the levels reported for controls (10.96--11.45 g/L) are not in agreement with published data for BUN in mice (e.g. 80--330 mg/L; University of Minnesota Reference Values, <https://www.ahc.umn.edu/rar/refvalues.html>). In male mice, Gill et al. ([2011](#efs25005-bib-0106){ref-type="ref"}) found an increase in blood phosphorous (controls: 0.8--0.9 mmol/L) at a dose of 0.12 mg/kg bw of furan. The CONTAM Panel noted that phosphorous measurement in serum is highly vulnerable to blood sample handling. Likewise, haemolysis can cause an up to 30% increase in phosphorous measurements (UK Association for Clinical Biochemistry, 2012[25](#efs25005-note-1028){ref-type="fn"}). Upon request, the corresponding author stated that the dimension given in the paper was erroneous and should read mmol/L instead of g/L (Gill, [2017](#efs25005-bib-0302){ref-type="ref"}, e‐mail communication, 31 January 2017).

Karacaoglu et al. ([2012](#efs25005-bib-0143){ref-type="ref"}) treated male Wistar rats with 2, 4 and 8 mg/kg bw by gavage over 90 days. A 7 days per week dose schedule was applied (Karacaoğlu, [2016](#efs25005-bib-0306){ref-type="ref"}, e‐mail communication, 25 October 2016). At the highest dose, there was significant congestion in the islets of Langerhans in the pancreas, while the organ weights of adrenal glands and pancreas were unchanged.

Kockaya et al. ([2012](#efs25005-bib-0150){ref-type="ref"}) treated young male Wistar rats orally (gavage) with doses of 2, 4 and 8 mg/kg bw per day for 90 days. A 7 days per week dose schedule was applied (Karacaoğlu, [2016](#efs25005-bib-0306){ref-type="ref"}, E‐mail communication, 25 October 2016). At the end of the experiment, thymus of the rats were examined morphologically, histopathologically and immunohistochemically. At the two highest doses, relative thymus weights were decreased significantly. A histopathological examination revealed various changes in the thymus at these dose levels including enlargement of interstitial connective tissue, decrease in thymic lymphocyte counts and haemorrhage.

Alam et al. ([2017](#efs25005-bib-0005){ref-type="ref"}) treated male Sprague--Dawley rats by gavage with 16 mg/kg bw over 30 days. Furan treatment resulted in significantly elevated red blood cell count, haemoglobin, white blood cell count, lymphocytes and granulocytes and reduced phagocytic parameters in white blood cells. It decreased serum total protein, albumin, globulin, immunoglobulin M (IgM), IgG and interleukin 4 (IL4), with a significant increase in serum TNFα and 8‐oxodeoxyguanosine. In the spleen, furan decreased the GSH content and GST activity and increased the malondialdehyde levels. Histopathologically, furan led to a moderate depletion in splenic lymphoid cells.

###### 

Effects of orally administered furan (by gavage) in acute, subacute and subchronic (&le 90 days) studies in experimental animals

+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| Species (number of animals per group)      | Dosage (mg/kg bw)                                          | Duration/time of observation                                           | Outcome[a](#efs25005-note-0007){ref-type="fn"}                                                                                                      | NOAEL *(LOAEL*) in mg/kg bw per day[b](#efs25005-note-0008){ref-type="fn"} | Reference                                                          |
+============================================+============================================================+========================================================================+=====================================================================================================================================================+============================================================================+====================================================================+
| B6C3F1/CrIBR male mouse (5)                | Single 30 (rats), 50 (mice)                                | 12, 24, 48 h, 4 and 8 days                                             | Increased plasma liver enzymes after 12 h and later                                                                                                 | One dose level only                                                        | Wilson et al. ([1992](#efs25005-bib-0282){ref-type="ref"})         |
|                                            |                                                            |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
| Fischer 344/CrIBR male rat (5)             |                                                            |                                                                        | LI increased after 48 h                                                                                                                             |                                                                            |                                                                    |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| B6C3F1/CrIBR male mouse (5)                | Single, 15, 27, 39. 50 (mice) 0, 8, 15, 22, 30 (rats)      | 24 h                                                                   | Increased plasma liver enzymes at 27 mg/kg bw (male mice) and 15 mg/kg bw (male rats)                                                               | *(15; mice) (8; rats)*                                                     |                                                                    |
|                                            |                                                            |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
| Fischer 344/CrIBR male rat (5)             |                                                            |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| B6C3F1/CrIBR male mouse (5)                | 30 (rats), 50 (mice)                                       | 6 weeks, 5 days a week                                                 | Hepatic necrosis and inflammation, bile duct hyperplasia and metaplasia in rats                                                                     | One dose level only                                                        |                                                                    |
|                                            |                                                            |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
| Fischer 344/CrIBR male and female rat (5)  |                                                            |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| B6C3F1/CrIBR male mouse (5)                | 30 (rats), 50 (mice)                                       | 1, 3 and 6 weeks, 5 days a week                                        | increased hepatocellular LI (proliferation)                                                                                                         | One dose level only                                                        |                                                                    |
|                                            |                                                            |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
| Fischer 344/CrIBR male rat (5)             |                                                            |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| B6C3F1 male and female mouse (5)           | 0, 5, 10, 20, 40 or 80 mg (male rats)                      | 16 days, 5 days a week                                                 | Rats (observation): mottled and enlarged livers                                                                                                     | Range‐finding study                                                        | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                   |
|                                            |                                                            |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
| Fischer 344 male and female rat (5)        | 0, 10, 20, 40, 80 and 160 (mice and female rats)           |                                                                        | Mice: no organ changes                                                                                                                              |                                                                            |                                                                    |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| B6C3F1 male and female mouse (10)          | 0, 4, 8, 15, 30 or 60 (rats and female mice)               | 13 weeks, 5 days a week                                                | Increase in relative and absolute liver weight, histopathological changes in the liver                                                              | *(2; male mice) (4; rats and female mice)*                                 | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                   |
|                                            |                                                            |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
| Fischer 344 male and female rat (10)       | 0, 2, 4, 8, 15 or 30 (male mice)                           |                                                                        |                                                                                                                                                     |                                                                            |                                                                    |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| Fischer 344 male rat (3--6)                | 45                                                         | 6 weeks, 5 days a week                                                 | Reduced liver weight, cholangiofibrosis, biliary metaplasia, biliary cirrhosis                                                                      | One dose level only                                                        | Sirica et al. ([1994b](#efs25005-bib-0249){ref-type="ref"})        |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| B6C3F1 female mouse (6--11)                | 4, 8 and 15                                                | 3 weeks, 5 days a week                                                 | **Increase in serum ALT, SDH, apoptotic index, subcapsular inflammation**                                                                           | **4**                                                                      | Fransson‐Steen et al. ([1997](#efs25005-bib-0094){ref-type="ref"}) |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| 15                                         | 3--5 days a week over 2 weeks -- 2 days (15 days in total) | **Increase in liver weight, serum ALT, SDH and bile acids**            | One dose level only                                                                                                                                 |                                                                            |                                                                    |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| B6C3F1 female mouse (15)                   | 0.5, 1, 2 and 4                                            | 3 weeks, 5 days a week                                                 | **Increased serum ALT, subcapsular inflammation**                                                                                                   | *(0.5)*                                                                    | Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})          |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| B6C3F1 male mouse (3--11)                  | 2, 4, 8 and 15                                             | 28 days, 5 days a week                                                 | **Hepatic necrosis, hepatocellular proliferation**                                                                                                  | **4**                                                                      | Cordelli et al. ([2010](#efs25005-bib-0056){ref-type="ref"})       |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| Sprague--Dawley Crl CD1 BR male rat (3--5) | 30                                                         | 8 h, 1, 3, 7, 10, 12 and 20 days, and 1, 2 and 3 months, 5 days a week | Hepatic necrosis, hepatocellular and biliary proliferation                                                                                          | one dose level only                                                        | Hickling et al. ([2010b](#efs25005-bib-0124){ref-type="ref"})      |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| Fischer 344 male rat (3--5)                | 0.1, 0.5, 2                                                | 28 days, 5 days a week                                                 | **Increased DNA synthesis, increased subcapsular mitosis, apoptosis and inflammation**                                                              | *(0.1)*                                                                    | Mally et al. ([2010](#efs25005-bib-0173){ref-type="ref"})          |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| Wistar juvenile male rat (8)               | 2, 4 and 8                                                 | 90 days, 7 days a week                                                 | **Increased hepatic TNF‐α**                                                                                                                         | *(2)*                                                                      | Selmanoglu et al. ([2012](#efs25005-bib-0240){ref-type="ref"})     |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| Fischer 344 male and female rat (12)       | 0.03, 0.12, 0.5, 2 and 8                                   | 90 days, 5 days a week                                                 | **Increase in serum T4 in males** [c](#efs25005-note-0009){ref-type="fn"}                                                                           | **0.03**                                                                   | Gill et al. ([2010](#efs25005-bib-0105){ref-type="ref"})           |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| B6C3F1 male and female mouse (16)          | 0.03, 0.12, 0.5, 2 and 8                                   | 90 days, 5 days a week                                                 | **Distinct histopathological changes, changes in clinical blood parameters (BUN and phosphorous in serum)** [c](#efs25005-note-0009){ref-type="fn"} | **0.12**                                                                   | Gill et al. ([2011](#efs25005-bib-0106){ref-type="ref"})           |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| Wistar male rat (8)                        | 2, 4 and 8                                                 | 90 days, 7 days a week                                                 | **Islet of Langerhans congestion**                                                                                                                  | **4**                                                                      | Karacaoglu et al. ([2012](#efs25005-bib-0143){ref-type="ref"})     |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| Wistar juvenile male rat (8)               | 2, 4 and 8                                                 | 90 days, 7 days a week                                                 | **Decrease in relative thymus weight, histological changes in the thymus**                                                                          | **2**                                                                      | Kockaya et al. ([2012](#efs25005-bib-0150){ref-type="ref"})        |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+
| Sprague--Dawley male (10)                  | 16                                                         | 30 days[d](#efs25005-note-0010){ref-type="fn"}                         | Changes in blood cells, blood cell phagocytic activity, serum immune parameters, oxidative stress in the spleen, changes in splenic lymphoid cells  | One dose level only                                                        | Alam et al. ([2017](#efs25005-bib-0005){ref-type="ref"})           |
+--------------------------------------------+------------------------------------------------------------+------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------+----------------------------------------------------------------------------+--------------------------------------------------------------------+

ALP: alkaline phosphatase; ALT: alanine aminotransaminase; BUN: blood urea nitrogen; LDL: low‐density lipoprotein; LI: labelling index; LOAEL: lowest‐observed‐adverse‐effect level; NOAEL: no‐observed‐adverse‐effect level; SDH: sorbitol dehydrogenase; TNF: tumour necrosis factor.

Most sensitive endpoint given in bold.

LOAEL (in italics) or NOAEL (in bold) for the most sensitive endpoint affected schedule.

See comments under 'Summary'.

Information on dose regimen not available.

John Wiley & Sons, Ltd

**B. Methylfurans**

The CONTAM Panel identified three short‐term toxicity studies on methylfurans, which are described below. All the no‐observed‐adverse‐effect levels (NOAEL) mentioned in this section are based on limited data and should therefore be considered as preliminary.

Gill et al. ([2014](#efs25005-bib-0107){ref-type="ref"}) treated male Fischer 344 rats (n = 10/group) by gavage with 0.4, 1.5, 3, 6, 12 and 25 mg 2‐methylfuran/kg bw per day over 28 days, 5 days a week. Mild histological hepatic lesions such as apoptotic hepatocytes, abnormally pigment Kupffer cells and inflammatory infiltrations were observed at 1.5 mg/kg bw and increased in severity with increasing dose levels. Furthermore, serum cholesterol and T3, T4 were also increased at this dose level. In the thyroid gland, no histopathological changes were found. The CONTAM panel noted that the dose responses for T3 and cholesterol were rather flat, while there was a dose‐dependent statistically significant increase of T4 at lower doses which disappeared at higher doses (inconsistent dose response). Thus, a NOAEL of 0.4 mg/kg bw per day could be identified by the CONTAM Panel. A slight increase in peripheral eosinophils observed at this dose level could not be confirmed at higher dosage.

Gill et al. ([2015](#efs25005-bib-0108){ref-type="ref"}) treated male Fischer 344 rats (n = 10/group) by gavage with 0.1, 0.3, 1.5, 3, 6, 12 and 25 mg 3‐methylfuran/kg bw per day over 28 days, 5 days a week. Statistically significant histological changes of the liver were noted at 1.5 mg/kg bw per day and gross changes were noted beginning at 3 mg/kg bw per day. At the highest dose, alterations in serum enzyme activities indicating hepatic toxicity were observed. There was also a significant increase in serum T3 and T4 without histopathological changes in the thyroid. From these data, a NOAEL of 0.3 mg/kg bw per day could be derived for hepatic histopathological changes in the rat.

Gill et al. ([2017](#efs25005-bib-0302){ref-type="ref"}, in preparation) treated male and female Fischer 344 rats (n = 12/group) by gavage daily (5 days per week) for 90 days with 3‐methylfuran at final doses of 0.0 0.02, 0.075, 0.25, 1.0 and 4.0** **mg/kg bw per day. Based on a severity score, statistically significant differences were found for some types of hepatic lesions (zone 1 hepatocytes with eosinophilic, i.e. altered cytoplasm and hyperchromasia) in the 1.0 mg/kg bw male rats while in females, statistical differences appeared at the 4.0 mg/kg bw dose. Furthermore, the authors reported a number of hepatic histopathological observations which were not statistically significant when based on a severity score. These included very mild lesions characterised by hyperchromasia of chromatin with enlarged nucleoli and increased cytoplasmic eosinophilia in the 0.25 mg/kg bw dose group, in the left and caudate lobes of the males. Small numbers of cells were pale or had mild microvesicular steatosis. The numbers of hepatic mitoses were slightly increased and slight proliferation of oval cells was noted in the left and caudate lobes. In females at the same dose level (0.25 mg/kg bw), similar mild changes and slight oval cell proliferation were observed. There was no statistical analysis or long‐term comparison with controls. The extent and severity of the alterations increased with increasing doses. In the 4.0 mg/kg bw group, massive nodular changes of the liver were observed. Serum ALP and bilirubin were significantly enhanced in males at 1.0 mg/kg bw and in females et 4.0 mg/kg bw. In the highest dose group, serum parameters indicative of diminished renal function, i.e. serum creatinine (at 4.0 mg/kg bw) and uric acid (at 1.0 mg/kg bw) were also increased in males. Based on these findings, including statistically non‐significant histopathological observations in the liver, the authors suggested a NOAEL of 0.075 mg/kg bw per day. Based on benchmark dose modelling, the authors also derived BMDL~10~ values of 0.08 mg/kg bw for liver focal necrosis and oval cell hyperplasia in the left lobe in males, and of 0.05--0.17 mg/kg bw for liver lesions (oval cell hyperplasia and karyocytomegaly in the left lobe) in females.

**C. Observed effects for methylfurans compared to other alkylfurans**

The CONTAM Panel reviewed the literature on the toxicity of several alkylated furans in order to obtain more information on possible structure--activity relationships with respect to the pattern of adverse effects. Appendix [B](#efs25005-sec-0096){ref-type="sec"} gives an overview of the reported effects for different alkylfurans. Such information was expected to be possibly instrumental in addressing the question if certain alkylated furans could eventually be considered together with furan. For this purpose, also non‐oral routes of exposure were considered, since the number of oral studies with alkylated furans is very limited and it was expected that such studies might provide more insight into MoAs of the compounds of interest.

For 2‐ and 3‐methylfuran, pulmonary and hepatic toxicity was shown. Pulmonary toxicity was observed upon inhalation but also upon i.p. application. There is also indication for kidney toxicity of 3‐methylfuran after 90 days exposure. 2‐ and 3‐Ethylfuran exhibited renal, pulmonary and hepatic toxicity in different species. For 3‐pentylfuran, adverse renal and hepatic but not pulmonary effects were reported (no inhalation studies). Thus, no clear structure--effect relationship for the alkylated furans with respect to the pattern of adverse effects/the target organs could be derived.

**D. Summary**

Taken together, in experiments of a duration of up to 90 days, furan is strongly hepatotoxic and moderately nephrotoxic in rodents when applied by oral gavage. Rats seem to be more sensitive towards furan than mice. Furan leads to characteristic changes in serum markers related to hepatotoxicity as well as severe histopathological damage in the liver. These effects are particularly pronounced in centrilobular and subcapsular areas and can be attenuated by suppression of CYP activity. After 90 days, distinct histopathological changes and significant increases in serum thyroid hormones were seen in male rats even after a daily dose of 0.12 mg/kg bw, given 5 days a week. For effects of this type, a NOAEL of 0.03 mg/kg bw per day for furan was derived by the authors. The observations in B6C3F1 mice were not considered sufficient by the CONTAM Panel for dose--response analysis since they were not quantified (histopathology).

2‐ and 3‐Methylfuran exerted toxicity in the liver, kidney and lung in rodents. After oral application to rats, furan, 2‐methylfuran and 3‐methylfuran led to a similar overall picture of liver toxicity. Although the studies on methylfurans are not sufficiently robust to identify a specific reference point for the individual compounds, they show that the toxic potencies are in the same order of magnitude, whether expressed as dose or molarity.

#### 3.1.2.3. Long‐term toxicity (including carcinogenicity) {#efs25005-sec-0046}

There have been two long‐term toxicity studies carried out under the NTP, one in 1993 and a follow‐up study in 2015. The findings of these studies are described below and the details are shown in Tables [3](#efs25005-tbl-0003){ref-type="table"}--[6](#efs25005-tbl-0006){ref-type="table"}. The first NTP study was carried out on male and female Fischer 344/N rats and B6C3F~1~ mice. Furan was given by gavage in corn oil 5 days per week for 104 weeks. The doses in rats were 0, 2, 4 and 8 and in mice were 0, 8 and 15 mg/kg bw. There was clear evidence of carcinogenicity and survival decreasing with increasing dose.

In the rat study, cholangiocarcinomas were found in both males and females at all doses of furan (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}). Hepatocellular carcinomas were observed at 4 and 8 mg/kg bw in the males but none occurred in the female rats (Maronpot et al., [1991](#efs25005-bib-0178){ref-type="ref"}). Male rats developed hepatocellular adenomas at 4 and 8 mg/kg bw but these only occurred in the females at the highest dose (Maronpot et al., [1991](#efs25005-bib-0178){ref-type="ref"}). When combined (hepatocellular adenoma/carcinoma), the results were significant for males at the two higher doses and for females at the highest dose only (Table [3](#efs25005-tbl-0003){ref-type="table"}). Mononuclear cell leukaemia was observed in both males and females at the two higher doses. A high incidence of mesothelioma of the tunica vaginalis (including in the control) was also reported.[26](#efs25005-note-1029){ref-type="fn"} Overall, males are more sensitive than female rats. Other non‐malignant effects were observed as shown in Tables [3](#efs25005-tbl-0003){ref-type="table"} and [6](#efs25005-tbl-0006){ref-type="table"}.

Histologically, it is difficult to distinguish between cholangiocarcinoma and cholangiofibrosis and a consensus report by Thoolen et al. ([2010](#efs25005-bib-0262){ref-type="ref"}) provided clear guidelines for a standardised nomenclature and differential diagnosis of microscopic lesions in the hepatobiliary system of commonly used laboratory rodents. Samples (23 from 2 mg/kg bw and 6 from 8 mg/kg bw) from the NTP study (1993) were re‐examined following the guidelines described by Thoolen et al. ([2010](#efs25005-bib-0262){ref-type="ref"}) and it is now clear that cholangiocarcinomas were only observed at the highest dose (NCTR, [2015](#efs25005-bib-0195){ref-type="ref"}; Von Tungeln et al., [2017](#efs25005-bib-0270){ref-type="ref"}) while cholangiofibrosis was observed at the lower doses.

As the first study used exposure to furan that induced effects at all doses, a second study was undertaken to determine the dose--response relationship in male rats using a significantly lower dose range, 0, 0.02, 0.044, 0.092, 0.2, 0.44, 0.92 and 2 mg/kg bw per day, 5 days per week for 104 weeks. Interim analyses were carried out at 36 and 60 weeks. The doses were chosen to ensure a range of concentrations that would give a lower tumour incidence in order to establish the dose response relationship. The group sizes in this study were not equal with higher numbers of animals in the lower dose groups to maximise the chance of detecting tumours in these low exposed groups. There was a dose‐related decrease in survival but this did not reach significance.

In the NCTR study, mononuclear cell leukaemia was observed in all groups, including the control. There was a statistically significant increase at doses of 0.092 mg/kg bw and above. However, the incidence was within the historical control range for this endpoint and rat strain within the same laboratory (NCTR, [2015](#efs25005-bib-0195){ref-type="ref"}). The Fischer 344 rat is known to develop a high incidence of mononuclear cell leukaemia (Caldwell, [1999](#efs25005-bib-0040){ref-type="ref"}). This tumour type is unique to the rat and occurs in aged, untreated F‐344 rats at a high and variable rate. It is common only to the Fischer 344 strain. Significant increases in C‐cell adenoma or carcinoma, and malignant mesothelioma of the tunica vaginalis were noted at the top dose of 2 mg/kg bw. Bearing in mind the high spontaneous incidence of mesotheliomas, C‐cell adenoma and carcinoma and of the observed leukaemias in the Fischer 344 rat specifically the relevance of these tumours to human risk assessment is questionable. There were no treatment‐related neoplastic changes at 36 or 60 weeks. There were no significant increases in hepatocellular adenoma or carcinoma observed in the NCTR study (Von Tungeln et al., [2017](#efs25005-bib-0270){ref-type="ref"}). The cholangiocarcinomas, observed at the highest dose (8 mg/kg bw per day) in the NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) study after reclassification, were not seen in the NCTR study with dose levels up to 2 mg/kg bw per day (2015; Von Tungeln et al., [2017](#efs25005-bib-0270){ref-type="ref"}).

Of the non‐neoplastic effects, the most sensitive endpoint was cholangiofibrosis with increases observed from 0.2 mg/kg bw and above. The dose response was non‐linear showing a low incidence (1%) at 0.092 mg/kg bw and a high incidence (≥ 76%) from 0.2 mg/kg bw and above. Cholangiofibrosis was also noted at 36 and 60 weeks with the severity increasing with time from minimal (36 weeks) to minimal to mild (60 weeks). Other significant changes observed were biliary tract hyperplasia, cytoplasmic vacuolisation of oval cells and regenerative hypertrophy (Table [3](#efs25005-tbl-0003){ref-type="table"}). Interim analyses at 36 and 60 weeks showed similar responses with the significance at lower doses increasing with the time (NCTR, [2015](#efs25005-bib-0195){ref-type="ref"}; Von Tungeln et al., [2017](#efs25005-bib-0270){ref-type="ref"}).

In a separate study, male rats were exposed to 30 mg/kg bw furan by gavage (n = 50) in corn oil 5 days per week for 13 weeks and then followed up for 9, 15 and 24 months (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}). Cholangiocarcinomas were observed in all rats at all time points. Hepatocellular carcinoma was first noted at 15 months.

In the equivalent mouse studies, both male and female mice developed hepatocellular adenomas and adenomas/carcinomas at both doses tested (8 and 15 mg/kg bw; Table [4](#efs25005-tbl-0004){ref-type="table"}). Male mice also showed hepatocellular carcinomas at both doses (Table [4](#efs25005-tbl-0004){ref-type="table"}; NTP, [1993](#efs25005-bib-0201){ref-type="ref"}). Carcinomas were only observed in female mice at the higher dose. In a later study, female mice were treated by gavage with 0, 0.5, 1.0, 2.0, 4.0 and 8 mg/kg bw per day furan in corn oil 5 days per week for 104 weeks. Hepatocellular adenomas were observed at the two highest doses and hepatocellular carcinomas only at 8 mg/kg bw. The combined hepatocellular adenoma/carcinoma incidence was significant at 4 and 8 mg/kg bw (Moser et al., [2009](#efs25005-bib-0192){ref-type="ref"}).

Johansson et al. ([1997](#efs25005-bib-0138){ref-type="ref"}) undertook a study in preweaning B6C3F1 mice to investigate the dose--response relationship to furan over 95 weeks. In this study, they compared single (400 mg/kg bw on post‐natal day (PND) 15) vs multiple (6 doses of 200 mg/kg bw administered on PND 3, 6, 9, 12, 15 and 18) exposures to furan. The single exposure group showed an overall increase in multiplicity of liver tumours but not in prevalence. Neither of these observations was significant. In the multiple dosed group, a statistically significant increase in both multiplicity and prevalence of liver tumours was noted. PCR analysis of the tumours revealed mutations on codon 61 of the *Ha‐ras1* gene in 82% of the single dose group while only 32% of the multiple does group had the *Ha‐ras1* mutation. Their findings confirm the hepatocarcinogenicity of furan in mice and suggest that the dose of carcinogen may influence the activation of *Ha‐ras1* that results in liver tumours.

Morton et al. ([2002](#efs25005-bib-0191){ref-type="ref"}) used furan as an exemplar chemical to evaluate the Eker rat as a model for short‐term exposure to nephrotoxins and carcinogens. Rats were exposed to 8 mg/kg bw furan in olive oil for 5 days/week for 4 or 6 months. Furan treatment did not result in any increase in the number or incidence of preneoplastic or neoplastic lesions at all sites and at either time.

Høie et al. ([2016](#efs25005-bib-0127){ref-type="ref"}) investigated the tumourigenic potential of 2,5‐dimethylfuran administered orally to the C57BL/6J‐*Apc* ^*Min/+*^ mouse (Min). The study included Min mouse and Min mouse expressing the human sulfotransferase 1A1 and 1A2 (Min/hSULT mice). In untreated Min/hSULT mice, the spontaneous tumours in the small intestine were smaller, but not fewer, compared to the Min mouse. Colonic tumour incidence and tumour load were also decreased in the untreated Min/hSULT mice. Mice were exposed to 5, 25 and 50 mg/kg bw by gavage in corn oil three times per week for 6 weeks (a total of 18 doses), no consistent significant changes in intestinal or colon tumours or in aberrant crypt foci were seen in male or female Min mice exposed to 2,5‐dimethylfuran. There was a significant increase in the incidence of colonic tumours in the female, but not the male, mice expressing hSULT at the medium dose but this was not significant at either the low or high doses. Exposure to 2,5‐dimethylfuran increased the tumour number in the middle to distal part of the small intestine and colon, the area where the majority of the spontaneous tumours are found. These effects of 2,5‐dimethylfuran in Min/hSULT females were suggested to be due to the low background level of tumours in the untreated females. There were no effects of 2,5‐dimethylfuran in the Min mice. Overall the data for the tumourigenicity of 2,5‐dimethylfuran in metabolically competent mice were not convincing.

In summary, most of the cholangiocarcinomas in rats reported in the NTP study were later reclassified as cholangiofibrosis and only at the top dose of 8 mg/kg bw, cholangiocarcinomas were confirmed. In the NCTR study where a lower dose range was used, cholangiofibrosis was observed at doses of 0.2 mg/kg bw and above and no neoplastic findings of relevance to human risk assessment were observed. In the mouse studies, hepatocellular adenomas and carcinomas were observed. The male rats and mice appear more sensitive to furan exposure for hepatocellular adenoma and carcinoma development. In a short‐term tumour model system, 2,5‐dimethylfuran did not enhance colorectal tumour formation.

###### 

Incidence of neoplastic lesions and statistical analysis results derived from male and female F344/N rats and male F344/N Nctr[e](#efs25005-note-0016){ref-type="fn"} rats from 2‐year carcinogenicity assays with furan

+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Lesion[a](#efs25005-note-0012){ref-type="fn"}                                  | Dosage (mg/kg bw per day) | Incidence[b](#efs25005-note-0013){ref-type="fn"} | Reference       |                                                                                                                |
+================================================================================+===========================+==================================================+=================+================================================================================================================+
| Cholangiocarcinoma before re‐evaluation[c](#efs25005-note-0014){ref-type="fn"} | 0                         | 0/50                                             | 0/50            | NTP ([1993](#efs25005-bib-0201){ref-type="ref"}), Maronpot et al. ([1991](#efs25005-bib-0178){ref-type="ref"}) |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **2**                     | **43/50\*\*\***                                  | **49/50\*\*\*** |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 4                         | **48/50\*\*\***                                  | **50/50\*\*\*** |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **8**                     | **49/50\*\*\***                                  | **48/50\*\*\*** |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Hepatocellular adenoma/carcinoma                                               | 0                         | 1/50                                             | 0/50            | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                                                               |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 2                         | 5/50                                             | 2/50            |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **4**                     | **22/50\*\*\***                                  | 4/50            |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **8**                     | **35/50\*\*\***                                  | **8/50\*\***    |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Interstitial cell adenoma of testes[d](#efs25005-note-0015){ref-type="fn"}     | 0                         | 41/50                                            |                 | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                                                               |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 2                         | 36/50                                            |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 4                         | 39/50                                            |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 8                         | 43/50                                            |                 |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Hepatocellular carcinoma                                                       | 0                         | 0/50                                             | 0/50            | Maronpot et al. ([1991](#efs25005-bib-0178){ref-type="ref"})                                                   |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 2                         | 1/50                                             | 0/50            |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **4**                     | **6/50\***                                       | 0/50            |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **8**                     | **18/50\*\*\***                                  | 1/50            |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Hepatocellular adenoma                                                         | 0                         | 1/50                                             | 0/50            | Maronpot et al. ([1991](#efs25005-bib-0178){ref-type="ref"})                                                   |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 2                         | 4/50                                             | 2/50            |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **4**                     | **18/50\*\*\***                                  | 4/50            |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **8**                     | **27/50\*\*\***                                  | **7/50\*\***    |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Mononuclear cell leukaemia                                                     | 0                         | 8/50                                             | 8/50            | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                                                               |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 2                         | 11/50                                            | 9/50            |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **4**                     | **17/50\***                                      | **17/50\***     |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **8**                     | **25/50\*\*\***                                  | **21/50\*\***   |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Malignant mesothelioma                                                         | 0                         | 1/50                                             | --              | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                                                               |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 2                         | 1/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 4                         | 3/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 8                         | 3/50                                             |                 |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Mononuclear cell leukaemia                                                     | 0                         | 47/150                                           | --              | NCTR ([2015](#efs25005-bib-0195){ref-type="ref"})                                                              |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.02                      | 56/150                                           |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.044                     | 36/100                                           |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **0.092**                 | **44/100\***                                     |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **0.2**                   | **29/50\*\*\***                                  |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.44                      | 18/50                                            |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **0.92**                  | **27/50\*\*\***                                  |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **2**                     | **28/50\*\*\***                                  |                 |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Malignant mesothelioma of the tunica vaginalis                                 | 0                         | 6/150                                            | --              | NCTR ([2015](#efs25005-bib-0195){ref-type="ref"})                                                              |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.02                      | 8/150                                            |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.044                     | 1/100                                            |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.092                     | 2/100                                            |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.2                       | 0/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.44                      | 2/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.92                      | 2/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **2**                     | **6/50\***                                       |                 |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| Follicular cell adenoma                                                        | 0                         | 0/150                                            | --              | NCTR ([2015](#efs25005-bib-0195){ref-type="ref"})                                                              |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.02                      | 2/150                                            |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.044                     | 5/99                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.092                     | 0/100                                            |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.2                       | 1/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.44                      | 1/49                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.92                      | 0/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 2                         | 0/50                                             |                 |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| C‐cell adenoma                                                                 | 0                         | 11/150                                           | --              | NCTR ([2015](#efs25005-bib-0195){ref-type="ref"})                                                              |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.02                      | 15/150                                           |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.044                     | 9/99                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.092                     | 13/100                                           |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.2                       | 7/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.44                      | 8/49                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.92                      | 1/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **2**                     | **8/50\***                                       |                 |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+
| C‐cell adenoma or carcinoma                                                    | 0                         | 12/150                                           | --              | NCTR ([2015](#efs25005-bib-0195){ref-type="ref"})                                                              |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.02                      | 21/150                                           |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.044                     | 11/99                                            |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.092                     | 14/100                                           |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.2                       | 8/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.44                      | 9/49                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | 0.92                      | 1/50                                             |                 |                                                                                                                |
|                                                                                |                           |                                                  |                 |                                                                                                                |
|                                                                                | **2**                     | **9/50\***                                       |                 |                                                                                                                |
+--------------------------------------------------------------------------------+---------------------------+--------------------------------------------------+-----------------+----------------------------------------------------------------------------------------------------------------+

bw: body weight.

Only the major tumour sites and/or those showing significant effects at the lower dose are listed.

\*Equals significant at \> 0.05; \*\*equals significant at \> 0.01; \*\*\*equals significant at \> 0.001.

Re‐examination of 23 of these samples at a later date revealed that only in the highest dose cholangiocarcinomas were present.

This was the terminology used in the paper, however, this is equivalent to mesotheliomas of the tunica vaginalis

Von Tungeln et al. ([2017](#efs25005-bib-0270){ref-type="ref"}) specified that the F344/N NCTR substrain differs from the Charles River substrain used in the previous furan bioassay (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}). However, the NCTR F344/N sub‐strain has tumourigenic responses that are comparable to those of other F344/N substrains used in previously reported carcinogenicity bioassays such as acrylamide.
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###### 

Tumour incidence and statistical analysis results derived from B6C3F~1~ mice from 2‐year carcinogenicity assays with furan

+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+-----------------------------------------------------------+
| Tumour[a](#efs25005-note-0018){ref-type="fn"} | Dosage (mg/kg bw per day) | Incidence[b](#efs25005-note-0019){ref-type="fn"} | Reference       |                                                           |
+===============================================+===========================+==================================================+=================+===========================================================+
| Hepatocellular adenoma                        | 0                         | --                                               | 3/36            | Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 0.5                       |                                                  | 4/72            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 1.0                       |                                                  | 4/53            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 2.0                       |                                                  | 4/41            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **4.0**                   |                                                  | **11/36\***     |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **8.0**                   |                                                  | **25/39\*\*\*** |                                                           |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+-----------------------------------------------------------+
| Hepatocellular carcinoma                      | 0                         | **--**                                           | 0/36            | Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 0.5                       |                                                  | 4/72            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 1.0                       |                                                  | 2/53            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 2.0                       |                                                  | 1/41            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 4.0                       |                                                  | 2/36            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **8.0**                   |                                                  | **11/39\*\*\*** |                                                           |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+-----------------------------------------------------------+
| Hepatocellular adenoma or carcinoma           | 0                         | --                                               | 3/36            | Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 0.5                       |                                                  | 8/72            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 1.0                       |                                                  | 6/53            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 2.0                       |                                                  | 5/41            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **4.0**                   |                                                  | **12/36\***     |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **8.0**                   |                                                  | **29/39\*\*\*** |                                                           |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+-----------------------------------------------------------+
| Hepatocellular carcinoma                      | 0                         | 7/50                                             | 2/50            | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})          |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **8**                     | **32/50\*\*\***                                  | 7/50            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **15**                    | **34/50\*\*\***                                  | **27/50\*\*\*** |                                                           |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+-----------------------------------------------------------+
| Hepatocellular adenoma                        | 0                         | 20/50                                            | 5/50            | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})          |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **8**                     | **33/50\*\***                                    | **31/50\*\*\*** |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **15**                    | **42/50\*\*\***                                  | **48/50\*\*\*** |                                                           |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+-----------------------------------------------------------+
| Benign Pheochromocytoma                       | 0                         | 1/49                                             | 2/50            | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})          |
|                                               |                           |                                                  |                 |                                                           |
|                                               | 8                         | 6/50                                             | 1/50            |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **15**                    | **10/50\*\*\***                                  | 6/50            |                                                           |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+-----------------------------------------------------------+
| Hepatocellular adenoma/carcinoma              | 0                         | 26/50                                            | 7/50            | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})          |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **8**                     | **44/50\*\*\***                                  | **34/50\*\*\*** |                                                           |
|                                               |                           |                                                  |                 |                                                           |
|                                               | **15**                    | **50/50\*\*\***                                  | **50/50\*\*\*** |                                                           |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+-----------------------------------------------------------+

bw: body weight.

Only the major tumour sites and/or those showing significant effects at the lower dose are listed.

\*Equals significant at \> 0.05; \*\*equals significant at \> 0.01; \*\*\*equals significant at \> 0.001.
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###### 

Summary of non‐neoplastic lesions in rats and mice taken from NTP ([1993](#efs25005-bib-0201){ref-type="ref"})

+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Lesion                                        | Dosage (mg/kg bw per day) | Incidence[a](#efs25005-note-0021){ref-type="fn"} |                 |
+===============================================+===========================+==================================================+=================+
| Biliary tract cysts                           | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **44/50\*\***                                    | **49/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | **47/50\*\***                                    | **50/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **46/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Biliary tract fibrosis, multifocal            | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **44/50\*\***                                    | **49/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | **48/50\*\***                                    | **50/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **49/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Biliary tract hyperplasia                     | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **44/50\*\***                                    | **49/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | **48/50\*\***                                    | **48/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **49/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Biliary tract inflammation chronic multifocal | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **44/50\*\***                                    | **49/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | **48/50\*\***                                    | **50/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **49/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Biliary tract metaplasia                      | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **44/50\*\*\***                                  | **49/50\*\*\*** |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | **48/50\*\*\***                                  | **50/50\*\*\*** |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\*\***                                  | **49/50\*\*\*** |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Hepatocyte cytomegaly                         | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **35/50\*\***                                    | **44/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | **46/50\*\***                                    | **50/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **49/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Hepatocyte degeneration                       | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **33/50\*\***                                    | **35/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | **46/50\*\***                                    | **49/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **47/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Hepatocyte hyperplasia, multifocal            | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | 2                         | 33/50                                            | 32/50           |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | **46/50\*\***                                    | **47/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **46/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Hepatocyte necrosis, multifocal               | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **32/50\*\***                                    | **18/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | **46/50\*\***                                    | **46/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **47/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Hepatocyte vacuolisation, cytoplasmic         | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **39/50\*\***                                    | **43/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | 4                         | 45/50\*\*                                        | **49/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **47/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Kupffer cell pigmentation, multifocal         | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **2**                     | **44/50\*\***                                    | **49/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **4**                     | 48/50\*\*                                        | 50/50\*\*       |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **49/50\*\***                                    | **48/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| **Mice**                                      |                           |                                                  |                 |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Multifocal hyperplasia liver                  | 0                         | 1/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **44/50\*\***                                    | 7/50            |
|                                               |                           |                                                  |                 |
|                                               | **15**                    | **49/50\*\***                                    | 11/50           |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Biliary tract fibrosis                        | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **45/50\*\***                                    | **47/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **15**                    | **49/50\*\***                                    | **50/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Biliary tract hyperplasia                     | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **46/50\*\***                                    | **47/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **15**                    | **49/50\*\***                                    | **50/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Biliary tract inflammation                    | 0                         | 0/50                                             | 2/50            |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **44/50\*\***                                    | **48/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **15**                    | **49/50\*\***                                    | **50/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Hepatocyte hepatomegaly                       | 0                         | 8/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **45/50\*\***                                    | **48/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **15**                    | **50/50\*\***                                    | **50/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Hepatocyte degeneration                       | 0                         | 0/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **43/50\*\***                                    | **47/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **1**5                    | **43/50\*\***                                    | **48/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Hepatocyte necrosis                           | 0                         | 2/50                                             | 0/50            |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **39/50\*\***                                    | **44/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **15**                    | **41/50\*\***                                    | **47/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+
| Kupffer cell pigmentation                     | 0                         | 2/50                                             | 5/50            |
|                                               |                           |                                                  |                 |
|                                               | **8**                     | **43/50\*\***                                    | **48/50\*\***   |
|                                               |                           |                                                  |                 |
|                                               | **15**                    | **50/50\*\***                                    | **50/50\*\***   |
+-----------------------------------------------+---------------------------+--------------------------------------------------+-----------------+

bw: body weight.

\*\*equals significant at \> 0.01; \*\*\*equals significant at \> 0.001.
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###### 

Summary of non‐neoplastic lesions in male rats taken from NCTR ([2015](#efs25005-bib-0195){ref-type="ref"})

+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Lesion                            | Dosage (mg/kg bw per day) | Incidence/time of assessment[a](#efs25005-note-0023){ref-type="fn"} |                 |                 |
+===================================+===========================+=====================================================================+=================+=================+
| Cholangiofibrosis                 | 0                         | 0/20                                                                | 0/20            | 0/149           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 0/20                                                                | 0/10            | 0/150           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 0/10            | 0/99            |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 0/20                                                                | 0/10            | 1/100           |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.2**                   | 0/20                                                                | 0/10            | **38/50\*\*\*** |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.44**                  | **6/20\*\*\***                                                      | **10/10\*\*\*** | **49/49\*\*\*** |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  | **17/20\*\*\***                                                     | **10/10\*\*\*** | **47/50\*\*\*** |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **19/20\*\*\***                                                     | **8/10\*\*\***  | **49/49\*\*\*** |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Oval cell hyperplasia             | 0                         | 0/20                                                                | 0/20            | 14/149          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 0/20                                                                | 0/10            | 15/150          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 0/10            | 10/99           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 0/20                                                                | 0/10            | 8/100           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.2                       | 0/20                                                                | 0/10            | 7/50            |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.44                      | 0/20                                                                | 0/10            | 6/49            |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  | 1/20                                                                | **3/10\***      | **14/50\*\*\*** |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **16/20\*\*\***                                                     | **7/10\*\*\***  | **33/49\*\*\*** |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Mixed cell foci                   | 0                         | 0/20                                                                | 1/20            | 7/149           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 0/20                                                                | 0/10            | 7/150           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 1/10            | 6/99            |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 0/20                                                                | 0/10            | 3/100           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.2                       | 1/20                                                                | 1/10            | 5/50            |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.44                      | 0/20                                                                | 1/10            | 3/49            |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.92                      | 1/20                                                                | 3/10            | 6/50            |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **5/20\***                                                          | **6/10\*\***    | **13/49\*\*\*** |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Biliary tract hyperplasia         | 0                         | 1/20                                                                | 7/20            | 89/149          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 1/20                                                                | 3/10            | 86/150          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 1/10            | 5,999           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 1/20                                                                | 2/10            | 56/100          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.2                       | 0/20                                                                | 1/10            | 29/50           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.44                      | 0/20                                                                | 2/10            | 25/49           |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  | **6/20\***                                                          | 3/10            | 32/50           |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **19/20\*\*\***                                                     | **8/10\***      | **43/49\*\*\*** |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Bile duct subcapsular hyperplasia | 0                         | 0/20                                                                | 0/20            | --              |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.2                       | 1/20                                                                | 1/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.44**                  | **12/20\*\*\***                                                     | **9/10\*\*\***  |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  | **19/20\*\*\***                                                     | **10/10\*\*\*** |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **20/20\*\*\***                                                     | **7/10\*\*\***  |                 |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Hepatocyte hypertrophy            | 0                         | 0/20                                                                | 0/20            | --              |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.2                       | 1/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.44**                  | 0/20                                                                | **5/10\*\***    |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  | 2/20                                                                | **4/10\*\***    |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **12/20\*\*\***                                                     | **8/10\*\*\***  |                 |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Periportal cytoplasmic alteration | 0                         | 0/20                                                                | 0/20            | --              |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 0/20                                                                | 1/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.2                       | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.44                      | 0/20                                                                | 1/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  | 7/20\*\*                                                            | **7/10\*\*\***  |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **19/20\*\*\***                                                     | **8/10\*\*\***  |                 |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Subcapsular fibrosis              | 0                         | 0/20                                                                | 0/20            | --              |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.2**                   | 3/20                                                                | **4/10\*\***    |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.44**                  | **14/20\*\*\***                                                     | **9/10\*\***    |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  | **20/20\*\*\***                                                     | **10/10\*\***   |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **20/20\*\*\***                                                     | **7/10\*\*\***  |                 |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Subcapsular chronic inflammation  | 0                         | 0/20                                                                | 0/20            | --              |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.2**                   | 2/20                                                                | **8/10\*\*\***  |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.44**                  | **14/20\*\*\***                                                     | **9/10\*\***    |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  | **20/20\*\*\***                                                     | **10/10\*\***   |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **20/20\*\*\***                                                     | **7/10\*\*\***  |                 |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Subcapsular pigmentation          | 0                         | 0/20                                                                | 0/20            | --              |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     | 0/20                                                                | 0/10            |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.2**                   | 2/20                                                                | **8/10\*\*\***  |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.44**                  | **14/20\*\*\***                                                     | **9/10\*\***    |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  | **20/20\*\*\***                                                     | **10/10\*\***   |                 |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     | **20/20\*\*\***                                                     | **7/10\*\*\***  |                 |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Basophilic foci                   | 0                         | --                                                                  | --              | 28/149          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      |                                                                     |                 | 16/150          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     |                                                                     |                 | 19/99           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     |                                                                     |                 | 18/100          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.2                       |                                                                     |                 | 11/50           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.44                      |                                                                     |                 | 13/49           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.92                      |                                                                     |                 | 10/50           |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     |                                                                     |                 | **21/49\*\*\*** |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Regenerative hyperplasia          | 0                         | --                                                                  | --              | 0/149           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      |                                                                     |                 | 1/150           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     |                                                                     |                 | 1/99            |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     |                                                                     |                 | 2/100           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.2                       |                                                                     |                 | 1/50            |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.44                      |                                                                     |                 | 1/49            |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  |                                                                     |                 | **7/50\*\*\***  |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     |                                                                     |                 | **12/49\*\*\*** |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+
| Cytoplasmic vacuolisation         | 0                         | --                                                                  | --              | 23/149          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.02                      |                                                                     |                 | 23/150          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.044                     |                                                                     |                 | 14/99           |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.092                     |                                                                     |                 | 19/100          |
|                                   |                           |                                                                     |                 |                 |
|                                   | 0.2                       |                                                                     |                 | 12/50           |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.44**                  |                                                                     |                 | **18/49\*\*\*** |
|                                   |                           |                                                                     |                 |                 |
|                                   | **0.92**                  |                                                                     |                 | **23/50\*\*\*** |
|                                   |                           |                                                                     |                 |                 |
|                                   | **2**                     |                                                                     |                 | **37/49\*\*\*** |
+-----------------------------------+---------------------------+---------------------------------------------------------------------+-----------------+-----------------+

bw: body weight.

\*Equals significant at \> 0.05; \*\*equals significant at \> 0.01; \*\*\*equals significant at \> 0.001.

John Wiley & Sons, Ltd

#### 3.1.2.4. Genotoxicity {#efs25005-sec-0047}

**A. Furan**

The genotoxicity of furan has been studied in bacteria, and mammalian cells *in vitro*, and *in vivo*. The available studies are summarised below and further details are given in Table [7](#efs25005-tbl-0007){ref-type="table"}.

The CONTAM Panel noted that *in vitro* studies with furan are often hampered by the properties of the compound. First, the high volatility of the furan exhibiting a boiling temperature of 31.4°C leads to its rapid evaporation from the test vessels under open conditions. In closed systems that used to prevent evaporation of furan, however, an equilibrium between the liquid and the gas phase is rapidly achieved, thus markedly decreasing the initial concentration of furan in the liquid phase. Finally, reducing the headspace in order to avoid this effect may cause a lack of oxygen which is required for CYP‐catalysed metabolic activation of furan. Thus, quantitative considerations based on *in vitro* experiments with furan must be made with caution.

***Bacteria***

Furan did not induce gene mutations in *S. *Typhimurium strains TA100, TA1535, TA1537 and TA98 in the presence or absence of exogenous metabolic activation (S9) (Mortelmans et al., [1986](#efs25005-bib-0190){ref-type="ref"}; NTP, [1993](#efs25005-bib-0201){ref-type="ref"}). In another report, positive results were reported only in strain TA98 (but not in strain TA100) in the presence of S9 (Shinohara et al., [1986](#efs25005-bib-0245){ref-type="ref"}). Finally, a weak positive effect was reported only in strain TA100 both in the presence and absence of S9 fraction (Lee et al., [1994](#efs25005-bib-0158){ref-type="ref"}).

***In vitro genotoxicity in mammalian cells***

*In vitro* tests for genotoxicity in mammalian cells were generally positive. In the NTP study (1993), furan induced trifluorothymidine resistance in mouse L5178Y lymphoma cells in the absence of S9 (McGregor et al., [1988](#efs25005-bib-0182){ref-type="ref"}), sister chromatid exchanges (SCEs) and chromosomal aberrations (CA) in Chinese hamster ovary (CHO) cells, with and without S9 (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}).

In another report, an increase in CA (chromatid breaks and chromatid exchanges) was observed in CHO cells exposed to furan (up to 200 mM) only in the presence of S9 (Stich et al., [1981](#efs25005-bib-0253){ref-type="ref"}).

Furan induced SCEs in a modified V79 cell line that stably expressed human CYP2E1 and SULT1A1. No information on the activity of CYP2E1 was reported. The increment in the number of SCEs was small and showed no clear dose response, with only a marginal increase in the hCYP2E1‐SULT1A1‐expressing cells in comparison to the parental cell line (Glatt et al., [2005](#efs25005-bib-0110){ref-type="ref"}).

In the presence or absence of metabolic activation, no significant increase in the frequency of micronuclei was observed in human lymphocytes derived from two non‐smoking women (Durling et al., [2007](#efs25005-bib-0062){ref-type="ref"}).

The genotoxicity of furan was also investigated in L5178Y *tk* ^*+/‐*^ mouse lymphoma cells. Furan did not induce mutations at the *tk* locus, micronuclei, and DNA strand breaks as measured by Comet assays (Kellert et al., [2008a](#efs25005-bib-0147){ref-type="ref"}). The CONTAM Panel noted that all the assays were performed at furan concentrations devoid of any cytotoxic effects.

***In vivo studies***

Furan did not induce sex‐linked recessive lethal mutations in germ cells of male *Drosophila melanogaster* when administered either by feeding or by injection (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}; Foureman et al., [1994](#efs25005-bib-0092){ref-type="ref"}).

Furan did not induce unscheduled DNA synthesis (UDS) in hepatocytes isolated after single gavage treatment of male F344 rats or male B6C3F1 mice (Wilson et al., [1992](#efs25005-bib-0282){ref-type="ref"}).

In male B6C3F~1~ mice, furan administered by i.p. induced CA but not SCEs in bone marrow cells. The CONTAM Panel noted that the significant increase in the frequency of CA was observed only at the highest tested dose and required the use of an extended harvesting protocol to maximise the detection of these effects (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}).

Furan administered by i.p or subcutaneous injection to BALB/c and CBA mice did not induce micronuclei in peripheral blood (a single sampling time of 42 h was used; Durling et al., [2007](#efs25005-bib-0062){ref-type="ref"}).

Furan was administered by gavage to Sprague--Dawley rats from 8 h up to 20 days and for 1, 2 and 3 months. Increased DNA 8‐oxodeoxyguanosine levels as measured by immunofluorescence were observed in the liver. This increase was associated with inflammation in areas adjacent to, as well as within, necrotic regions. Persistence of DNA oxidation was also observed in cholangiofibrotic lesions, biliary epithelia, metaplastic ducts and hepatocytes in proximity of inflamed areas in animals sampled at the end of 3‐month treatment or after 1‐month recovery (Hickling et al., [2010a](#efs25005-bib-0123){ref-type="ref"}).

Furan induced micronuclei and double‐strand breaks (DSBs) as measured by γ‐H2AX foci (a known biomarker for DNA‐strand breaks) in mitogen‐stimulated splenocytes from B6C3F1 mice treated by gavage for 4 weeks. Negative results were obtained in quiescent spleen lymphocytes. No induction of single strand breaks (SSBs) or DNA crosslinks as measured by Comet assays were observed (Leopardi et al., [2010](#efs25005-bib-0161){ref-type="ref"}). The CONTAM Panel noted that this study represents evidence of genotoxicity of orally administered furan in mice. It also indicates that for primary DNA damage in the spleen to be converted into frank DSBs and chromosomal damage requires DNA replication.

Furan‐induced DNA damage was investigated in the liver of B6C3F1 mice following a 28‐day repeated exposure by gavage. No induction of DSBs (as measured by γ‐H2AX induction) or SSBs and DNA crosslinks was observed in liver cells following the 28‐day treatment. In contrast, an increase of SSBs and DNA crosslinks, as measured by Comet assays, was observed in the liver of mice receiving a single very high oral dose of 250 mg/kg bw. Increased expression of DNA repair genes following the 28‐day treatment was also observed (Cordelli et al., [2010](#efs25005-bib-0056){ref-type="ref"}).

Following a 2 h administration by gavage of a single dose of \[3,4‐^14^C\]‐furan to F344 rats, a dose‐dependent increase of ^14^C was found by mass spectrometry in liver and kidney DNA, suggesting that furan metabolites were able to bind covalently to DNA (Neuwirth et al., [2012](#efs25005-bib-0196){ref-type="ref"}). The number of DNA adducts induced in the liver were 1.6 and 32.5 adducts/10^8^ nucleotides at 0.1 and 2.0 mg/kg bw of furan. However, individual DNA adducts could not be identified and it was demonstrated that these adducts are not identical to those induced in chemical model systems by the reactive BDA metabolite. Metabolic incorporation of furan into DNA bases during DNA synthesis occurred only to a minor extent. In a parallel oral 28‐day study, furan induced an increase in CA in proliferating splenocytes. No increase in micronuclei, CA, SCEs or strand breaks by Comet assays were observed in bone marrow and peripheral blood (Neuwirth et al., [2012](#efs25005-bib-0196){ref-type="ref"}). At 2 mg/kg bw, furan produced an increase in DNA strand breaks in the liver as measured in the Comet assay. This occurred, however, after a 14‐day recovery period following a 28‐day exposure (Neuwirth et al., [2012](#efs25005-bib-0196){ref-type="ref"}). The CONTAM Panel recognises that this study provides some evidence of the ability of furan to covalently bind to DNA *in vivo*. However, in view of the low number of furan‐induced DNA adducts their biological significance remains to be clarified. Finally, this study confirms in splenocytes from furan‐treated rats the previously observed increase in chromosomal damage in proliferating mouse splenocytes (Leopardi et al., [2010](#efs25005-bib-0161){ref-type="ref"}).

DNA‐protein crosslinks were studied by injecting furan into turkey eggs at 23 days of incubation. Hepatocytes were prepared from the embryos 24 h later and analysed by alkaline Comet assays (tail length and moment) for the presence of strand breaks and DNA protein crosslinks. Furan treatment produced a reduction in DNA migration suggesting the formation of DNA crosslinks. Comet tail length was increased following treatment with proteinase K indicating that these were due to DNA‐protein crosslinks (Jeffrey et al., [2012](#efs25005-bib-0137){ref-type="ref"}).

Furan administered to F344 rats by gavage for 4 days increased DNA strand breaks (as measured by Comet assays) in the liver but not in the bone marrow (Ding et al., [2012](#efs25005-bib-0059){ref-type="ref"}). Maximal DNA damage was observed 1 h after the last furan treatment and decreased with time (3, 6 and 8 h) to reach control levels by 16 h. Comet assays were performed also in the presence of Fpg and EndoIII (enzymes involved in the repair of oxidised bases). In both cases, the number of SSBs increased (in the range 12--16 and 4--16 mg/kg bw for Fpg and EndoIII, respectively) indicating the presence of oxidised purines and pyrimidines. No induction of micronuclei was observed in the peripheral blood (although signs of toxicity were present in the bone marrow). The CONTAM Panel noted that furan‐induced DNA strand breaks, identified by Comet assays, in the liver show a relatively short half‐life.

The potential of furan to produce systemic genotoxicity was evaluated by treating female Big Blue transgenic F344 rats by gavage for 1 and 8 weeks (five times a week) with doses of furan used in the cancer bioassay (2 and 8 mg/kg bw) and two higher doses (16 and 30 mg/kg bw). No increases of micronuclei in peripheral blood, *Hprt* mutations in lymphocytes, *Pig‐A* mutations in spleen lymphocytes and peripheral red blood cells, and transgene *cII* mutations in the liver were observed. In line with the Ding et al. ([2012](#efs25005-bib-0059){ref-type="ref"}) study, liver DNA damage as measured by Comet assay was increased at the two highest doses (McDaniel et al., [2012](#efs25005-bib-0181){ref-type="ref"}).

Furan was administered to female Big Blue *cII* transgenic B6C3F1 mice by gavage either for 6 weeks with 5 daily doses or for 3 weeks with a single weekly dose (15 mg/kg bw). Furan did not increase mutation frequency under either treatment regimen. However, in the 6‐week protocol, there was a change in the liver *cII* mutational spectrum (a significant reduction in GC\>AT transitions and an increase in CG\>GC transversions). A much larger furan‐dependent shift in mutational spectra was observed in the liver of mice receiving three weekly doses of furan (a significant increase in transversions including GC\>TA, GC\>CG and AT\>TA). The mutagenic potential of BDA in the same target gene was also investigated by *in vitro* treatment of mouse embryo fibroblasts derived from this transgenic mouse strain. Again, no increase in mutation frequency was observed, but BDA treatment induced a shift in mutational spectrum with a significant increase in AT\>CG transversions (Terrell et al., [2014](#efs25005-bib-0261){ref-type="ref"}).

*Gpt* and Spi^‐^ mutations were measured in the liver of *gpt* delta rats treated with furan at doses of 2 and 8 mg/kg bw for 13 weeks. No increase in mutation frequencies was observed and mutational spectra did not identify furan‐specific *gpt* mutations. In the high dose group, the number and areas of glutathione *S*‐transferase placental form (GST‐P)‐positive foci, the number of PCNA‐positive hepatocytes and the mRNA levels of cyclin d1 and cyclin e1 were increased. Cholangiofibrosis was only observed in the caudate lobe. The authors conclude that cell proliferation, but not genotoxic mechanisms, contribute to the early stages of furan‐induced hepatocarcinogenesis (Hibi et al., [2017](#efs25005-bib-0122){ref-type="ref"}).

Analysis of liver neoplasms (hepatocellular adenomas/carcinomas) induced by furan in B6C3F1 mice (from the NTP [1993](#efs25005-bib-0201){ref-type="ref"} study) showed the presence of dominant transforming oncogenes (13/29, 45%). Activating *Ha‐ras* mutations were found both in codon 61 and in codon 117, the majority being GC\>TA transversions. The authors concluded that the spectrum of furan‐induced mutations in the *Ha‐ras* oncogene differs from that of untreated animals, mostly because the localisation of mutations in untreated animals occurs only at codon 61 (Reynolds et al., [1987](#efs25005-bib-0233){ref-type="ref"}).

The presence of *Ha‐ras* mutations was also analysed in DNA from liver tumours induced in preweaning B6C3F1 mice administered a single or multiple (6x) doses of furan. Mutations in codon 61 of the *Ha‐ras* gene were present in 82% of liver neoplasms (adenoma + carcinoma) occurring in mice treated with a single dose, while in the concomitant controls these occurred in 33% of the animals and in the historical ones in 54% of the animals. In contrast, in mice treated with multiple doses only 32% of the tumours had codon 61 *Ha‐ras1* mutations. The majority of mutations associated with furan exposure in codon 61 were G\>T transversions (74%) followed by A\>G transitions (22%). A single G\>T transversion in codon 117 was also identified in an adenoma induced by this multiple treatment. In historical controls, the majority of codon 61 *Ha‐ras1* mutations were transversions followed by transitions (58% and 30%, respectively) (Johansson et al., [1997](#efs25005-bib-0138){ref-type="ref"}).

To verify whether furan treatment caused an early expansion of pre‐existing spontaneous *Ha‐ras* mutations, allele‐specific competitive blocker polymerase chain reaction (ACB‐PCR) was used to quantify C[A]{.ul}A\>C[T]{.ul}A and [C]{.ul}AA\>[A]{.ul}AA mutations in codon 61 of the *Ha‐ras* gene. Mutation analyses were performed in liver DNA from female B6C3F1 mice treated by gavage with furan over a 3‐week period. No difference in mutation frequencies at codon 61 was identified between controls and furan‐treated groups (Banda et al., [2013](#efs25005-bib-0021){ref-type="ref"}). The CONTAM Panel noted the limitations of the study including the low sensitivity of the technique.

Treatment of Sprague--Dawley rats by gavage with furan for 30 days resulted in large increases (10‐fold) in serum levels of 8‐oxodeoxyguanosine as measured by enzyme‐linked immunosorbent assay (ELISA) (Alam et al., [2017](#efs25005-bib-0005){ref-type="ref"}).

Treatment (i.p.) of BALB/c mice with furan for 7 days resulted in increased serum levels of reactive oxygen species (ROS) and 8‐oxodeoxyguanosine as measured by ELISA (Wang et al., [2014a](#efs25005-bib-0272){ref-type="ref"}).

###### 

Genotoxicity of furan

+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Test system                                                                                                                                                   | Cells/animals                                                       | Concentration/treatment                                                                                                                                                   | Result                                                                                                                                                                             | Comments                                                                                                                                                                                                                                                                                                                     | Reference                                                                                                        |
+===============================================================================================================================================================+=====================================================================+===========================================================================================================================================================================+====================================================================================================================================================================================+==============================================================================================================================================================================================================================================================================================================================+==================================================================================================================+
| ***In vitro*** (bacteria)                                                                                                                                     |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Bacterial reverse mutation assay (Ames test)                                                                                                                  | *S. *Typhimurium TA98, TA100, TA1535, TA1537                        | 33--10,000 μg/plate                                                                                                                                                       | **Negative**                                                                                                                                                                       | Aroclor 1,254‐induced male Sprague--Dawley rat and Syrian hamster liver S9                                                                                                                                                                                                                                                   | NTP ([1993](#efs25005-bib-0201){ref-type="ref"}); Mortelmans et al. ([1986](#efs25005-bib-0190){ref-type="ref"}) |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Ames test                                                                                                                                                     | *S. *Typhimurium TA98, TA100                                        | 56--225,000 μg/plate                                                                                                                                                      | **Positive:** only in TA98 (+S9)                                                                                                                                                   | Positive only at the lowest dose in TA98                                                                                                                                                                                                                                                                                     | Shinohara et al. ([1986](#efs25005-bib-0245){ref-type="ref"})                                                    |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     | +/− S9                                                                                                                                                                    |                                                                                                                                                                                    | Clear effect only + S9                                                                                                                                                                                                                                                                                                       |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Ames test                                                                                                                                                     | *S. *Typhimurium TA98, TA100                                        | 54, 272, 1,361, 6,807 μg/ plate                                                                                                                                           | **Positive:** only in TA100 (+/− S9)                                                                                                                                               | Weak effects                                                                                                                                                                                                                                                                                                                 | Lee et al. ([1994](#efs25005-bib-0158){ref-type="ref"})                                                          |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| ***In vitro*** (mammalian cells)                                                                                                                              |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Forward mutation assay                                                                                                                                        | L5178Y tk^+^/tk^−^ mouse lymphoma cell line                         | 125--3,800 μg/mL (−S9)                                                                                                                                                    | **Positive**: ≥ 1,139 μg/mL                                                                                                                                                        | Relative total growth was about 77%                                                                                                                                                                                                                                                                                          | McGregor et al. ([1988](#efs25005-bib-0182){ref-type="ref"})                                                     |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    | Not tested: + S9                                                                                                                                                                                                                                                                                                             |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| SCEs                                                                                                                                                          | CHO cells                                                           | 1.6, 5, 16, 50, 160, 500 μg/mL                                                                                                                                            | **Positive** --S9: 1.6--160 μg/mL                                                                                                                                                  | S9 from Aroclor 1,254‐induced Sprague--Dawley rat liver                                                                                                                                                                                                                                                                      | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                                                                 |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           | +S9: only at 500 μg/mL                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| CA                                                                                                                                                            | CHO cells                                                           | 100, 160, 300, 500, 1,000 μg/mL                                                                                                                                           | **Positive** −S9: 100--500 μg/mL                                                                                                                                                   | S9 from Aroclor 1,254‐induced Sprague--Dawley rat liver                                                                                                                                                                                                                                                                      | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                                                                 |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           | +S9: ≥ 500 μg/mL                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| CA                                                                                                                                                            | CHO cells                                                           | 3 h exposures, up to 13,614 μg/mL +/− S9 from Aroclor 1,254‐induced rat liver                                                                                             | **Positive**: Chromatid breaks and chromatid exchanges only in the presence of S9                                                                                                  | No information on toxicity                                                                                                                                                                                                                                                                                                   | Stich et al. ([1981](#efs25005-bib-0253){ref-type="ref"})                                                        |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| SCEs                                                                                                                                                          | V79‐Mz‐hCYP2E1‐SULT1 cell line                                      | 0.2--1,089 μg/mL                                                                                                                                                          | **Positive**: both V79‐hCYP2E1‐SULT1 and parental V79‐Mz cell line                                                                                                                 | Unusual constant increase over the whole dose range. Marginal increase in comparison to the parental V79‐Mz cell line                                                                                                                                                                                                        | Glatt et al. ([2005](#efs25005-bib-0110){ref-type="ref"})                                                        |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Micronucleus assay                                                                                                                                            | Lymphocytes from two non‐smoking women                              | 136, 340, 511, 681, 1021, 1,361, 6,807 μg/mL +/− rat liver homogenate.                                                                                                    | **Negative**                                                                                                                                                                       | Aroclor 1,254‐induced rat liver might contain low CYP2E1 activity. Cytotoxicity: 1,361 and 6,807 μg/mL                                                                                                                                                                                                                       | Durling et al. ([2007](#efs25005-bib-0062){ref-type="ref"})                                                      |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Micronucleus assay, *tk* ^*+/*^ *tk* ^*−*^ mutation assay and DNA breaks by Comet assays                                                                      | L5178Y *tk* ^*+*^ */tk* ^*−*^ mouse lymphoma cell line              | 15--211 μg/mL (\~ 225--3,100 μM)                                                                                                                                          | **Negative**                                                                                                                                                                       | Only assayed in the absence of S9. No cytotoxicity was observed at any of the tested doses                                                                                                                                                                                                                                   | Kellert et al. ([2008a](#efs25005-bib-0147){ref-type="ref"})                                                     |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| ***In vivo***                                                                                                                                                 |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Sex‐linked recessive lethal assay                                                                                                                             | *Drosophila melanogaster*                                           | Feeding (10,000 mg/kg) and injection (25,000 mg/kg)                                                                                                                       | **Negative**                                                                                                                                                                       | --                                                                                                                                                                                                                                                                                                                           | NTP ([1993](#efs25005-bib-0201){ref-type="ref"}), Foureman et al. ([1994](#efs25005-bib-0092){ref-type="ref"})   |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Unscheduled DNA synthesis in hepatocytes                                                                                                                      | Hepatocytes from furan‐treated male F344 rats or B6C3F1 mice        | Single gavage treatment: 5, 30, 100 mg/kg bw (rats) and 10, 50, 100, 200 mg/kg bw (mice)                                                                                  | **Negative**                                                                                                                                                                       | --                                                                                                                                                                                                                                                                                                                           | Wilson et al. ([1992](#efs25005-bib-0282){ref-type="ref"})                                                       |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| SCEs in bone marrow                                                                                                                                           | Male B6C3F1 mice                                                    | i.p.: 87.5, 175, 350 mg/kg bw (23 h sampling) and 25, 50,100 mg/kg bw (42 h sampling)                                                                                     | **Negative**                                                                                                                                                                       | --                                                                                                                                                                                                                                                                                                                           | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                                                                 |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| CA in bone marrow                                                                                                                                             | Male B6C3F1 mice                                                    | i.p.: 87.5, 175, 350 mg/kg bw (17 h harvest); 62.5, 125, 250 mg/kg bw (36 h harvest)                                                                                      | **Positive:** only at 250 mg/kg furan with 36 h sampling time (2 experiments)                                                                                                      | --                                                                                                                                                                                                                                                                                                                           | NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                                                                 |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Micronucleus assay in peripheral erythrocytes (flow cytometer‐based)                                                                                          | BALB/c and CBA mice                                                 | BALB/c mice: i.p. (0, 50, 75, 90, 110, 125, 150, 175, 200, 250, 300 mg/kg bw) and s.c. (0, 150 and 275 mg/kg bw)                                                          | **Negative**                                                                                                                                                                       | No significant depression of cell proliferation in any of the experiments. A single sampling time (42 h) was used                                                                                                                                                                                                            | Durling et al. ([2007](#efs25005-bib-0062){ref-type="ref"})                                                      |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     | CBA mice: i.p. (0 and 225 mg/kg bw)                                                                                                                                       |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Measurements of DNA 8‐oxodeoxyguanosine in liver by immune fluorescence                                                                                       | Sprague--Dawley rats                                                | Gavage (30 mg/kg bw per day, 5 daily doses per week). Time points: 1, 3, 7, 10, 12, 20 days and 1, 2 and 3 months                                                         | **Positive:** Increased DNA 8‐oxodeoxyguanosine levels in areas of centrilobular necrosis. Persistence of DNA oxidation after recovery time in areas affected by cholangiofibrosis | --                                                                                                                                                                                                                                                                                                                           | Hickling et al. ([2010a](#efs25005-bib-0123){ref-type="ref"})                                                    |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     | In addition, a 3‐month treatment + 1‐month off was included                                                                                                               |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Micronuclei, SSBs and DNA cross‐links by Comet assays, DSBs by γ‐H2AX foci in the spleen.                                                                     | B6C3F1 mice                                                         | Gavage for 4 weeks with 2, 4, 8 and 15 mg/kg bw per day                                                                                                                   | **Positive:** micronuclei in mitogen‐stimulated splenocytes (4--15 mg/kg)                                                                                                          | All assays gave negative results in quiescent spleen lymphocytes                                                                                                                                                                                                                                                             | Leopardi et al. ([2010](#efs25005-bib-0161){ref-type="ref"})                                                     |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           | **Positive**: γ‐H2AX foci (8 and 15 mg/kg)                                                                                                                                         |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           | **Negative**: Comet assays                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| DSBs by γ‐H2AX foci; SSBs and DNA crosslinks by Comet assays in the liver.                                                                                    | B6C3F1 mice                                                         | Gavage for 28 days (2, 4, 8, 15 mg/kg bw per day, 5 days per week)                                                                                                        | **Negative:** γ‐H2AX foci and Comet assays (28‐day exposure)                                                                                                                       | 28‐day exposure: Increased polyploidy in liver cells                                                                                                                                                                                                                                                                         | Cordelli et al. ([2010](#efs25005-bib-0056){ref-type="ref"})                                                     |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     | Single oral dose (15, 100, 250 mg/kg bw)                                                                                                                                  | **Positive:** DNA breaks and crosslinks (acute exposure at 250 mg/kg bw)                                                                                                           | Increased expression of several DNA repair genes                                                                                                                                                                                                                                                                             |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| DNA adducts, micronuclei, CAs, SCEs and SSBs and DNA crosslinks by Comet assays                                                                               | F344 rats                                                           | Adducts determination: \[3,4 ^14^C\]‐furan (0.1 and 2 mg/kg bw) for 2 h by gavage. Genotoxicity: Oral administration of 0.1, 0.5 and 2 mg/kg bw per day for 5 and 28 days | **Positive:** some evidence of DNA adducts in the liver and kidney                                                                                                                 | DNA adducts apparent in ^14^ C‐furan treated rats are not the same of those induced by BDA (MS peaks are not identical). Some indication of DNA damage in the liver by Comet assay (a reduction of tail moment and tail intensity after 28 days of furan treatment and increased DNA strand breaks after two weeks recovery) | Neuwirth et al. ([2012](#efs25005-bib-0196){ref-type="ref"})                                                     |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           | **Positive**: CAs in proliferating splenocytes                                                                                                                                     |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           | **Negative**: micronuclei, CAs, SCEs and Comet assays in bone marrow and peripheral blood                                                                                          |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| DNA‐protein crosslinks by Comet assays                                                                                                                        | Turkey eggs                                                         | Furan injection in eggs at 23 days incubation (136--1,360 μg). Hepatocytes preparation 24 h later                                                                         | **Positive:** Formation of DNA protein crosslinks                                                                                                                                  | --                                                                                                                                                                                                                                                                                                                           | Jeffrey et al. ([2012](#efs25005-bib-0137){ref-type="ref"})                                                      |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Micronucleus and Comet assay +/‐Fpg and EndoIII in liver and bone marrow.                                                                                     | F344 rats                                                           | Gavage for 4 days (2, 4, 8, 12, 16 mg/kg bw per day)                                                                                                                      | **Positive:** Comet assays in the liver (8--16 mg/kg bw per day)                                                                                                                   | Increased proliferation in the liver. Up‐ and down‐regulation of several DNA repair, apoptotic and cell cycle genes                                                                                                                                                                                                          | Ding et al. ([2012](#efs25005-bib-0059){ref-type="ref"})                                                         |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           | **Negative:** Comet assays in the bone marrow and micronuclei in peripheral blood                                                                                                  |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Micronuclei in normochromatic erythrocytes and reticulocytes, mutation assays at *Pig‐A* and *Hprt*, liver *cII* transgene mutation assay, liver Comet assay. | Transgenic Big Blue rats                                            | Gavage for 1 and 8 weeks (2, 8, 16, 30 mg/kg bw per day; 5 days per week) and sampling time 24 h after the end of the treatment                                           | **Positive**: Comet assay in the liver (16 and 30 mg/kg bw per day)                                                                                                                | Measurements of mutations at *Hprt*,*Pig‐A* and *cII* transgene and micronuclei were performed after 1 or 8 weeks of treatment                                                                                                                                                                                               | McDaniel et al. ([2012](#efs25005-bib-0181){ref-type="ref"})                                                     |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           | **Negative:** micronuclei and mutation assays                                                                                                                                      |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Mutations in the *cII* transgene in the liver                                                                                                                 | Transgenic Big Blue B6C3F1 mice                                     | Gavage for 6 weeks (15 mg/kg bw per day; 5 days per week, 24 h sampling time) and for 3 weeks (once weekly, 1 week sampling time)                                         | **Negative**: no increase in mutation frequency under either treatment condition                                                                                                   | Small increase in GC\>CG transversions (6‐week treatment); a larger shift with increases in GC\>TA, GC\>CG, AT\>TA transversions in the 3‐week protocol                                                                                                                                                                      | Terrell et al. ([2014](#efs25005-bib-0261){ref-type="ref"})                                                      |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           |                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
|                                                                                                                                                               |                                                                     |                                                                                                                                                                           | **Positive**: changes in mutational spectra                                                                                                                                        |                                                                                                                                                                                                                                                                                                                              |                                                                                                                  |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Mutations in the *gpt* transgene and Spi^‐^ in the liver                                                                                                      | Transgenic *gpt* F344 male and female rats                          | Gavage for 13 weeks (0, 2, 8 mg/kg bw per day)                                                                                                                            | **Negative**: no increase in mutation frequencies. No changes in mutational spectra at the *gpt* gene                                                                              | Increased number of GST‐P foci, PCNA+ hepatocytes and cyclin d1 and cyclin e1 at 8 mg/kg bw per day. Cholangiofibrosis observed in the caudate lobe                                                                                                                                                                          | Hibi et al. ([2017](#efs25005-bib-0122){ref-type="ref"})                                                         |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Analysis of *Ha‐ras* mutations                                                                                                                                | Liver of furan‐treated B6C3F1 mice                                  | Samples from NTP study (1993)                                                                                                                                             | **Positive:** 9 *Ha‐ras* mutations: 4/5 GC\>TA transversions at codon 61 and 2 GC\>CG + 2 GC\>TA transversions at codon 117                                                        | The localisation of *Ha‐ras* mutations in furan‐treated livers differs from that of untreated animals (100% vs 60% mutations at codon 61 in untreated and furan‐treated animals, respectively).                                                                                                                              | Reynolds et al. ([1987](#efs25005-bib-0233){ref-type="ref"})                                                     |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Analysis of *Ha‐ras* mutations                                                                                                                                | Liver tumours induced in infant B6C3F1 mice (adenomas + carcinomas) | Treatment in preweaning mice (day 15): i.p. 400 mg/kg bw (single dose) or 6 doses of 200 mg/kg bw (at day 15).                                                            | **Positive:** only in single dose exp: codon 61 mutations were 23/28 (82%) (vs 1/3 (33%) in parallel controls) (mostly C\>A transversions)                                         | Statistically significant increased incidence and multiplicity of hepatocellular neoplasms in the multiple treatment group and only increased multiplicity in the single dose group                                                                                                                                          | Johansson et al. ([1997](#efs25005-bib-0138){ref-type="ref"})                                                    |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| Analysis of *Ha‐ras* mutations by ACB‐PCR                                                                                                                     | Liver of furan‐treated B6C3F1 mice                                  | Gavage: 0, 1, 2, 4 and 8 mg/kg bw per day (5 days per week) over a 3‐week period                                                                                          | **Negative:** No increase in mutations frequency at codon 61 ([C]{.ul}AA\>[A]{.ul}AA and C[A]{.ul}A\>C[T]{.ul}A)                                                                   | Relatively insensitive assay                                                                                                                                                                                                                                                                                                 | Banda et al. ([2013](#efs25005-bib-0021){ref-type="ref"})                                                        |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| DNA adduct formation (BDA‐dC adduct)                                                                                                                          | Serum and liver of furan‐treated Fischer 344 rats                   | Gavage: 0.92--9.2 mg/kg bw (single dose) and 4.4 mg/kg bw per day (multiple doses, 45--360 days)                                                                          | **Negative:** No increase over background levels                                                                                                                                   | Background levels in untreated rats: 1.2--2.4 adducts ×10^8^ nucleotides                                                                                                                                                                                                                                                     | Churchwell et al. ([2015](#efs25005-bib-0049){ref-type="ref"})                                                   |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| 8‐Oxodeoxyguanosine                                                                                                                                           | Serum of furan‐treated Sprague--Dawley rats                         | Gavage. 16 mg/kg bw per day over 30 days                                                                                                                                  | **Positive:** large increases in 8‐oxodeoxyguanosine levels                                                                                                                        | Method: ELISA kit                                                                                                                                                                                                                                                                                                            | Alam et al. ([2017](#efs25005-bib-0005){ref-type="ref"})                                                         |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+
| ROS and 8‐oxodeoxyguanosine                                                                                                                                   | Serum of furan‐treated BALB/c mice                                  | i.p. 8 mg/kg bw per day over 7 days                                                                                                                                       | **Positive:** increased ROS levels; threefold increase in 8‐oxodeoxyguanosine                                                                                                      | Method: ELISA kit                                                                                                                                                                                                                                                                                                            | Wang et al. ([2014a](#efs25005-bib-0272){ref-type="ref"})                                                        |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------+

A: adenosine; ACB‐PCR: Allele‐specific competitive blocker‐polymerase chain reaction; BDA: *cis*‐but‐2‐ene‐1,4‐dialdehyde; bw: body weight; C: cytidine; CA: chromosomal aberrations; CHO: Chinese hamster ovary; dC: 2'‐deoxycytidine; DSB: double strand break; ELISA: enzyme‐linked immunosorbent assay; G: guanosine; i.p.: intraperitoneal; ROS: reactive oxygen species; s.c.: subcutaneous; SCE: sister chromatid exchange; SSB: single strand break; T: thymidine.
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**B.** ***cis*** **‐2‐Butene‐1,4‐dial (BDA)**

The genotoxicity of BDA has been studied in bacteria and mammalian cells *in vitro* and the available studies are summarised below and further details are given in Table [8](#efs25005-tbl-0008){ref-type="table"}. The reactivity of BDA with DNA is discussed in Section [3.1.1.4](#efs25005-sec-0038){ref-type="sec"}.

In the absence of exogenous metabolic activation, BDA induced a dose‐dependent increase of mutations in *S. *Typhimurium TA104. Pre‐incubation of BDA with GSH inhibited the toxic and mutagenic effects of the compound. In contrast, BDA was not mutagenic in *S. *Typhimurium strains TA97, TA98, TA100 and TA102 (Peterson et al., [2000](#efs25005-bib-0217){ref-type="ref"}).

dC and dA adducts were detected in calf thymus DNA treated *in vitro* with BDA. These adducts were also present in DNA isolated from *S. *Typhimurium strain TA104 treated with BDA (Byrns et al., [2006](#efs25005-bib-0039){ref-type="ref"}).

The DNA damaging capacity of BDA was investigated by alkaline elution in CHO‐K1 cells. Both SSBs and DNA crosslinks were observed at non‐toxic doses (Marinari et al., [1984](#efs25005-bib-0174){ref-type="ref"}). The ability to form DNA‐protein crosslinks observed in CHO cells was not confirmed by Kellert et al. ([2008a](#efs25005-bib-0147){ref-type="ref"}) in a Comet assay.

Genotoxicity of BDA was investigated in L5178Y *tk* ^*+/−*^ mouse lymphoma cells. A concentration‐dependent increase in mutation frequency at the *tk* locus and in the number of DNA breaks as measured by Comet assays was observed. No concentration related increases were observed for micronuclei (Kellert et al., [2008a](#efs25005-bib-0147){ref-type="ref"}).

No increase in mutation frequency at the *cII* locus was observed in BDA‐treated mouse embryo fibroblasts derived from Big Blue B6C3F1 mice. However, BDA treatment induced a shift in mutational spectrum with a concentration‐dependent increase in AT \> CG transversions only (Terrell et al., [2014](#efs25005-bib-0261){ref-type="ref"}).

###### 

Genotoxicity of *cis*‐2‐Butene‐1,4‐dial (BDA) *in vitro*

+----------------------------------------------+----------------------------------------------------------------------------+----------------------------------+---------------------------------------------------------------------------------------------+------------------------------------------------------------------------------+--------------------------------------------------------------+
| Test system                                  | Experimental system                                                        | Concentration/treatment          | Result                                                                                      | Comments                                                                     | Reference                                                    |
+==============================================+============================================================================+==================================+=============================================================================================+==============================================================================+==============================================================+
| Formation of ICLs                            | *In situ* oxidation of furan containing oligonucleotide                    |                                  | **Positive:** formation of DNA interstrand cross‐link in duplex oligonucleotides            | --                                                                           | Halila et al. ([2005](#efs25005-bib-0117){ref-type="ref"})   |
+----------------------------------------------+----------------------------------------------------------------------------+----------------------------------+---------------------------------------------------------------------------------------------+------------------------------------------------------------------------------+--------------------------------------------------------------+
| Formation of dC and dA adducts               | Calf thymus DNA and DNA from BDA‐treated *S*. Typhimurium TA104            |                                  | **Positive:** formation of DNA adducts in both systems                                      | --                                                                           | Byrns et al. ([2006](#efs25005-bib-0039){ref-type="ref"})    |
+----------------------------------------------+----------------------------------------------------------------------------+----------------------------------+---------------------------------------------------------------------------------------------+------------------------------------------------------------------------------+--------------------------------------------------------------+
| Bacterial reverse mutation assay (Ames test) | *S. *Typhimurium TA104                                                     | 118, 143, 177, 244, 362 μg/plate | **Positive**                                                                                | Toxic at doses \> 177 μg/plate                                               | Peterson et al. ([2000](#efs25005-bib-0217){ref-type="ref"}) |
|                                              |                                                                            |                                  |                                                                                             |                                                                              |                                                              |
|                                              |                                                                            |                                  |                                                                                             | BDA mutagenic potential revealed in a specific strain sensitive to aldehydes |                                                              |
+----------------------------------------------+----------------------------------------------------------------------------+----------------------------------+---------------------------------------------------------------------------------------------+------------------------------------------------------------------------------+--------------------------------------------------------------+
| SSBs and crosslinks by alkaline elution      | CHO‐K1                                                                     | 14, 42, 126 μg/mL                | **Positive:** both end‐points                                                               | High concentrations (in the mM range) but no apparent toxicity               | Marinari et al. ([1984](#efs25005-bib-0174){ref-type="ref"}) |
+----------------------------------------------+----------------------------------------------------------------------------+----------------------------------+---------------------------------------------------------------------------------------------+------------------------------------------------------------------------------+--------------------------------------------------------------+
| Forward mutation                             | L5178Y tk^+/−^ mouse lymphoma cells                                        | 0.5, 1.1, 2.1, 4.2 μg/mL         | **Positive:** Comet and mutation (at ≥ 70% survival)                                        | --                                                                           | Kellert et al. ([2008a](#efs25005-bib-0147){ref-type="ref"}) |
|                                              |                                                                            |                                  |                                                                                             |                                                                              |                                                              |
| Comet and micronucleus assays                |                                                                            |                                  | **Negative:** micronucleus assays and crosslinks                                            |                                                                              |                                                              |
+----------------------------------------------+----------------------------------------------------------------------------+----------------------------------+---------------------------------------------------------------------------------------------+------------------------------------------------------------------------------+--------------------------------------------------------------+
| Mutation induction at the *cII* transgene    | *In vitro* treatment of mouse embryo fibroblasts from Big Blue B6C3F1 mice | 0.2 and 0.4 μg/mL                | **Negative:** no increase in mutation frequency **Positive**::change in mutational spectrum | Increase in AT \> CG transversions                                           | Terrell et al. ([2014](#efs25005-bib-0261){ref-type="ref"})  |
+----------------------------------------------+----------------------------------------------------------------------------+----------------------------------+---------------------------------------------------------------------------------------------+------------------------------------------------------------------------------+--------------------------------------------------------------+

BDA: *cis*‐but‐2‐ene‐1,4‐dialdehyde; CHO: Chinese hamster ovary; dA: 2'‐deoxyadenosine; dC: 2'‐deoxycytidine; dG: 2'‐deoxyguanosine; SSB: single strand break; ICL: inter‐strand crosslink.
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**C. 2‐Methylfuran**

The genotoxicity of 2‐methylfuran has been studied in bacteria and mammalian cells *in vitro* and the available studies are summarised below and further details are given in Table [9](#efs25005-tbl-0009){ref-type="table"}.

2‐Methylfuran was negative for induction of gene mutations in *S. *Typhimurium strains TA100, TA102 and TA98 in the presence or absence of exogenous metabolic activation. A pre‐incubation assay in closed vials was used to prevent the loss of 2‐methylfuran (Aeschbacher et al., [1989](#efs25005-bib-0004){ref-type="ref"}). Negative results were also reported by Shinohara et al. ([1986](#efs25005-bib-0245){ref-type="ref"}) in strains TA100 and TA98 and by Zeiger et al. ([1992](#efs25005-bib-0286){ref-type="ref"}) in strains TA100, TA98, TA97 and TA1535. Equivocal results were reported for strain TA104 (Zeiger et al., [1992](#efs25005-bib-0286){ref-type="ref"}).

CHO cells exposed to 2‐methylfuran showed an increased number of CA (chromatid breaks and chromatid exchanges) in the absence of S9 (Stich et al., [1981](#efs25005-bib-0253){ref-type="ref"}). The CONTAM Panel noticed the lack of requirement of metabolic activation of 2‐methylfuran clastogenicity which is remarkable because of the lack of chemical reactivity of unmetabolised 2‐methylfuran.

**D. 2,5‐Dimethylfuran**

The genotoxicity of 2,5‐dimethylfuran has been studied in bacteria, mammalian cells *in vitro*, and *in vivo*. The available studies are summarised below and further details are given in Table [9](#efs25005-tbl-0009){ref-type="table"}.

2,5‐Dimethylfuran was negative for induction of gene mutations in *S. *Typhimurium strains TA100, TA1535, TA97 and TA98 in the presence or absence of exogenous metabolic activation. A pre‐incubation assay in closed vials was used to prevent the loss of 2,5‐dimethylfuran (Zeiger et al., [1992](#efs25005-bib-0286){ref-type="ref"}). These negative results were confirmed in another study with *S. *Typhimurium strains TA100 and TA98 (Shinohara et al., [1986](#efs25005-bib-0245){ref-type="ref"}).

CHO cells exposed to 2,5‐dimethylfuran (up to 1,922 μg/mL) showed an increased number of CA (chromatid breaks and chromatid exchanges). The clastogenic activity was significantly decreased in the presence of S9 (Stich et al., [1981](#efs25005-bib-0253){ref-type="ref"}). The CONTAM Panel noticed that, similarly to 2‐methylfuran, 2,5‐dimethylfuran clastogenicity does not seem to require S9‐mediated metabolic activation.

The ability of 2,5‐dimethylfuran to induce micronuclei was investigated in *in vitro* cultures of murine erythropoietic cells. Exposure to 2,5‐dimethylfuran induced an increase in micronuclei frequency both in the absence and presence of S9 (Fromowitz et al., [2012](#efs25005-bib-0096){ref-type="ref"}).

2,5‐Dimethylfuran induced a concentration‐dependent increase in DNA breaks as measured by Comet assays in V79 cells, irrespective of the co‐expression in these cells of the human CYP2E1 and SULT1A1 sulfotransferase (Huffman et al., [2016](#efs25005-bib-0131){ref-type="ref"}).

A single oral dose of 2,5‐dimethylfuran was administered by gavage to wild‐type and FVBN mice expressing the human SULT1A1/A2 (hSULT mice). Induction of DNA damage was evaluated *in vivo* by alkaline single cell gel electrophoresis (Comet assays) 2 h after the end of treatment. No genotoxicity is associated with 2,5‐dimethylfuran exposure of wild‐type mice, while increased levels of DNA damage were observed in the kidney and colon, but not in the liver, of 2,5‐dimethylfuran treated hSULT mice. These increases were modest and occurred at a single 2,5‐dimethylfuran dose (150 mg/kg bw). No evidence of interstrand crosslinks formation was observed (Høie et al., [2015](#efs25005-bib-0126){ref-type="ref"}). The authors anticipated that 2,5‐dimethylfuran can be hydroxylated at the methyl groups and subsequently conjugated with sulfate involving SULT1A1 which may lead to genotoxic breakdown products.

2,5‐Dimethylfuran has been shown to act as a scavenger of singlet oxygen (Noguchi et al., [1977](#efs25005-bib-0199){ref-type="ref"}; Mongin et al., [2016](#efs25005-bib-0187){ref-type="ref"}) and hydroxyl radicals (Okada and Okajima, [1998](#efs25005-bib-0204){ref-type="ref"}). In a limited *in vitro* study, DNA adducts induced by benzo \[A\] pyrene were decreased in the presence of 2,5 dimethylfuran used as scavenger of singlet oxygen (Bryla and Weyand, [1991](#efs25005-bib-0033){ref-type="ref"}). The CONTAM Panel noted that the possible role of 2,5‐dimethylfuran as a scavenger of singlet oxygen *in vivo* remains to be determined.

###### 

Genotoxicity of 2‐methylfuran and, 2,5‐dimethylfuran

+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| Compound          | Test system                                  | Cells/animals                                             | Concentration/treatment                     | Result                                                          | Comments                                                                                                                       | Reference                                                       |
+===================+==============================================+===========================================================+=============================================+=================================================================+================================================================================================================================+=================================================================+
| 2‐Methylfuran     | Bacterial reverse mutation assay (Ames test) | *S. *Typhimurium TA98, TA100, TA102                       | 0.9--90,000 μg (+/−S9)                      | **Negative**                                                    | Use of a pre‐incubation assay to maximise the reaction of volatile compounds with bacteria                                     | Aeschbacher et al. ([1989](#efs25005-bib-0004){ref-type="ref"}) |
|                   |                                              |                                                           |                                             |                                                                 |                                                                                                                                |                                                                 |
|                   |                                              |                                                           |                                             |                                                                 | Pre‐incubation assay                                                                                                           |                                                                 |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| 2‐Methylfuran     | Ames test                                    | *S. *Typhimurium TA98, TA100, TA1535, TA102 TA104         | 33--6,666 μg/plate (+/−S9)                  | **Negative:** TA98, TA100, TA1535, TA102                        | Questionable response in strain TA104                                                                                          | Zeiger et al. ([1992](#efs25005-bib-0286){ref-type="ref"})      |
|                   |                                              |                                                           |                                             |                                                                 |                                                                                                                                |                                                                 |
|                   |                                              |                                                           |                                             |                                                                 | Pre‐incubation assay                                                                                                           |                                                                 |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| 2‐Methylfuran     | Ames test                                    | *S. *Typhimurium TA98, TA100                              | 14--55 μg (+/−S9)                           | **Negative**                                                    | --                                                                                                                             | Shinohara et al. ([1986](#efs25005-bib-0245){ref-type="ref"})   |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| 2‐Methylfuran     | Chromosome aberrations                       | CHO cells                                                 | 4,105--12,315 μg/mL                         | **Positive** (+/−S9):                                           | Increased chromatid breaks and chromatid exchanges. Decreased clastogenicity in the presence of S9. No information on toxicity | Stich et al. ([1981](#efs25005-bib-0253){ref-type="ref"})       |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| 2,5‐Dimethylfuran | Ames test                                    | *S. *Typhimurium TA97, TA98, TA100, TA1535                | 10--3,333 μg/plate (+/−S9)                  | **Negative**                                                    | Pre‐incubation assay                                                                                                           | Zeiger et al. ([1992](#efs25005-bib-0286){ref-type="ref"})      |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| 2,5‐Methylfuran   | Ames test                                    | *S. *Typhimurium TA98, TA100,                             | 16--64 μg (+/−S9)                           | **Negative**                                                    | --                                                                                                                             | Shinohara et al. ([1986](#efs25005-bib-0245){ref-type="ref"})   |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| 2,5‐Dimethylfuran | Chromosome aberrations                       | CHO cells                                                 | 2,5‐Dimethylfuran (up to 1,922 μg/mL)       | **Positive** (+/−S9):                                           | Increased chromatid breaks and chromatid exchanges. Decreased clastogenicity in the presence of S9. No information on toxicity | Stich et al. ([1981](#efs25005-bib-0253){ref-type="ref"})       |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| 2,5‐Dimethylfuran | *In vitro* micronucleus assay                | BM cells prepared from C57BL/6J mice                      | 48 and 96 μg/mL (1 h exposure)              | **Positive** (+/−S9)                                            | Same increase in micronuclei both in the absence and presence of S9                                                            | Fromowitz et al. ([2012](#efs25005-bib-0096){ref-type="ref"})   |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| 2,5‐Dimethylfuran | Single strand breaks by Comet assays         | Wild‐type and human hSULT /CYP2E1‐co‐expressing V79 cells | 48, 96, 144 and 192 μg/mL (30 min exposure) | **Positive:** both wild‐type and hSULT/CYP2E1‐co‐expressing V79 | Increase in breaks at \> 50% survival                                                                                          | Huffman et al. ([2016](#efs25005-bib-0131){ref-type="ref"})     |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+
| 2,5‐Dimethylfuran | Comet assays in kidney, colon and liver      | hSULT and wild‐type FVBN mice                             | Gavage: 75, 150, 300 mg/kg bw               | **Negative**: wild‐type mice                                    | Positive at a single dose in kidney and colon but not in the liver                                                             | Høie et al. ([2015](#efs25005-bib-0126){ref-type="ref"})        |
|                   |                                              |                                                           |                                             |                                                                 |                                                                                                                                |                                                                 |
|                   |                                              |                                                           |                                             | **Positive**: hSULT mice                                        | No evidence of interstrand crosslinks formation                                                                                |                                                                 |
+-------------------+----------------------------------------------+-----------------------------------------------------------+---------------------------------------------+-----------------------------------------------------------------+--------------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------+

CHO: Chinese hamster ovary.

John Wiley & Sons, Ltd

**Summary of genotoxicity studies on furan and methylated derivatives.**

Furan was unable to induce gene mutations in bacteria (with the exception of a single report showing a weak mutagenic effect). When furan genotoxic potential was investigated in mammalian cells *in vitro,* both negative and positive results were reported. In the majority of the studies, furan was able to induce chromosomal aberrations and sister chromatid exchanges. However, the role of metabolic activation in these studies is unclear, with one study showing positive results only in the presence of S9 and several others where furan genotoxicity was decreased by the presence of S9. In view of the volatility, quantitative considerations based on *in vitro* experiments with furan must be made with caution.

The primary microsomal metabolite of furan, via CYP2E1, is BDA. This can form DNA adducts at the exocyclic N atom of the dC, dG and dA nucleosides. *In vitro* studies indicate that BDA‐induced adducts on dG and dA are unstable, with the initial ethano adduct decomposing into substituted etheno‐acetaldehyde adducts. These secondary adducts retain a reactive aldehyde with the potential to form DNA inter‐strand crosslinks (ICLs). BDA is directly mutagenic in *S*. Typhimurium TA104, in which BDA‐induced DNA adducts were also identified. It also induces strand breaks and mutations in mammalian cells *in vitro*. One *in vitro* study suggests that BDA can induce ICLs in mammalian cells.

*In vivo* studies suggested that furan was able to bind covalently to DNA in the liver and kidney of repeatedly exposed rats. Although in one study a specific DNA adduct was not detected, in a separate study DNA adducts were detected but their molecular nature was not identified. It was demonstrated that these adducts are not identical to those induced in chemical model systems by the reactive BDA metabolite. In addition, in view of the low number of furan‐induced DNA adducts their biological significance remains to be clarified.

In several *in vivo* studies, no increase in chromosomal damage was observed either in the bone marrow or in peripheral blood of mice and rats exposed to furan. The single exception was the NTP study (1993) in which a dose‐related increase in chromosome aberrations in the bone marrow was found in mice following an acute treatment with unusually high doses of furan.

In rodent liver, the genotoxic potential of furan was mainly investigated by measuring strand breaks by Comet assays. This assay measures strand breaks and alkali‐labile sites, including apurinic/apyrimidinic (AP) sites, which might arise from the loss of a damaged base or as intermediates during base excision repair. In general, negative results have been reported. Two studies showed that DNA breaks/AP sites induced by repeated exposure to furan appear rapidly and disappear within a few hours post‐treatment. This observation might explain the negative results observed in several studies in which liver cells were analysed at late time points post‐treatment. Thus, observations based on Comet assays at late post‐treatment times are likely to be of limited relevance. The CONTAM Panel recognises that disappearance of strand breaks measured by the Comet assay does not necessarily indicate error‐free, non‐mutagenic DNA repair.

Evidence of chromosomal damage (micronuclei, chromosome aberrations and DSBs) was observed in proliferating, but not in resting, splenocytes of mice and rats repeatedly exposed to furan at the same doses used in the NTP carcinogenicity assay reported in 1993. These data indicate that cell proliferation is required to convert the primary furan‐induced DNA damage to detectable DNA lesions. This premutagenic DNA damage could be due to ICLs that require replication to be converted into frank lesions or secondary events associated with oxidative stress‐induced DNA damage.

Studies investigating the formation of ICLs following *in vivo* furan exposure were generally negative. Limited evidence comes from Comet assays in the liver of mice exposed to unusual high furan doses. DNA‐protein crosslinks were induced in hepatocytes from embryos following furan injection in turkey eggs.

It is possible that some of the genotoxic effects of furan are secondary to oxidative stress caused by repeated furan administration. Increased levels of ROS and 8‐oxodeoxyguanosine were indeed observed in sera of furan‐treated rats and mice. The sensitivity of DNA from the liver of treated animals to digestion by EndoIII and Fpg, enzymes that, respectively, act on oxidised purines and pyrimidines, confirms the presence of oxidatively damaged DNA after relatively short exposures to furan. Finally, DNA 8‐oxodeoxyguanosine persists in areas of furan‐induced rat cholangiofibrosis long after furan exposure had been discontinued.

However, furan‐induced oxidative stress is not associated with a clear induction of base substitutions in transgenic models. Furan is weakly mutagenic in the liver of a mouse transgenic model, with the mutational spectrum differing from that induced by BDA in cultured mouse cells. In contrast, consistent negative results, either in reporter or endogenous genes, were observed in transgenic rats. Moreover (GST‐P)‐positive foci, a marker of a preneoplastic phenotype in hepatocellular tumours, were increased in the liver of rats treated with carcinogenic doses of furan in the absence of any furan‐specific mutation. These data indicate that mutagenicity is not likely to contribute to the early stages of furan‐induced hepatocarcinogenesis.

Analysis of activating mutations in the *Ha‐ras* oncogene in liver tumours from furan‐treated B6C3F1 mice show a strong selective bias, with the vast majority being GC \> TA transversions at codon 61. Since this type of transversion is also the major mutational class in control animals, it cannot be excluded that this result simply reflects an expansion of pre‐existing spontaneous *Ha‐ras* mutations.

Information on the genotoxic properties of methylated furans is limited. Both 2‐methylfuran and 2,5‐dimethylfuran showed negative results in bacteria. There is some evidence that both compounds can induce chromosomal damage in mammalian cells *in vitro* and a limited evidence that 2,5‐dimethylfuran can induce DNA breaks, but not ICLs, *in vivo*.

**Concluding remarks**

*In vitro* tests have provided contradictory indications as to the genotoxicity of furan. It is possible that these studies may be hampered by technical difficulties arising from the specific physicochemical properties of this compound.

In contrast, the CYP2E1‐mediated metabolite of furan, i.e. BDA, can form DNA adducts, and possibly crosslinks, in *in vitro* assays and is able to directly induce mutations in bacteria and mammalian cells *in vitro*.

*In vivo,* furan can induce the formation of low levels of covalent DNA adducts in liver and kidney. However, the precise nature of these DNA adducts has not been established. Conflicting data were reported for the induction of DNA breaks in the liver. These discrepancies may be related to the timing of measurements, dosing and assays sensitivities. These breaks, likely reflecting oxidative stress‐induced DNA damage, occurred at doses showing limited liver cytotoxicity. A role for oxidative stress in furan‐induced liver carcinogenesis is suggested by molecular analysis of *Ha‐ras* mutations in furan‐induced liver tumours indicating an excess of GC \> TA transversions at codon 61 in mice. This is a mutational class commonly associated with oxidatively damaged DNA which is also present in spontaneous liver tumours. However, furan‐induced oxidative stress is not associated with a clear induction of base substitutions in transgenic rodent models. A single study suggests a weak mutagenic activity in a transgenic mouse model, while negative results were consistently reported in transgenic rat models. Finally, there is convincing evidence that chronic exposure to furan induces chromosomal damage in proliferating splenocytes from mice and rats, but the DNA lesions responsible for these effects remain undefined. In particular, it is unclear whether the observed chromosomal instability is due to direct damage to DNA (formation of ICLs or DNA adducts) or is the consequence of secondary events associated with oxidative stress‐induced DNA damage.

#### 3.1.2.5. Developmental and reproductive toxicity {#efs25005-sec-0048}

In F344 rats treated up to 8 mg/kg bw per day by gavage, no effect was observed in testes, epididymis, prostate, seminal vesicles, ovaries, uterus or vagina (Gill et al., [2010](#efs25005-bib-0105){ref-type="ref"}).

In contrast, Wistar rats with similar exposure but during weaning and post‐puberty (3--4 weeks old treated for 90 days) exhibited a significant increase in the weight of prostate glands and decreased weight of seminal vesicles at 8 but not at 4 mg/kg bw per day or below. Dose‐dependent histological changes (including some at the lowest dose tested of 2 mg/kg bw per day) were recorded in the testes, prostate gland, seminal vesicles and Leydig cells with an increase in apoptotic cells in the testes (Karacaoglu and Selmanoglu, [2010](#efs25005-bib-0142){ref-type="ref"}). No effects on sperm counts or sperm morphology were observed.

Steroidogenic acute regulating protein (stAR) mRNA was increased at all dose levels studied in F344 rats (0.03 mg/kg bw and above given daily for 90 days) while the mRNA for the cholesterol side‐chain cleavage enzyme (CYP11A1) was increased by furan at 8 mg/kg bw per day along with an increase in intratesticular testosterone suggesting an ability of furan to interfere with testicular steroidogenesis (Cooke et al., [2014](#efs25005-bib-0054){ref-type="ref"}).

Gill et al. ([2011](#efs25005-bib-0106){ref-type="ref"}) found no effect of furan on testes or ovaries in B6C3F1 mice when examined microscopically following doses up to 8 mg/kg bw per day by gavage, 5 days per week for 90 days.

Furan was studied in embryos of *Xenopus laevis* and found to be non‐teratogenic having 96 h LC~50~ and EC~50~ values that were very similar (approximately 44 and 40 mM, respectively Williams et al., [2014](#efs25005-bib-0281){ref-type="ref"}).

Kara et al. ([2016](#efs25005-bib-0141){ref-type="ref"}) used male Wistar rats, made diabetic through treatment with streptozotoxin, and exposed them to 40 mg/kg bw furan by gavage daily for 28 days. Testicular malondialdehyde levels, and the activities of CAT, GPx, SOD and GST were found to be higher than in the control and diabetic control animals and the effects were inhibited by treatment of animals with the antioxidant lycopene suggesting oxidative stress in testes. This was associated with a lowering of plasma FSH, LH and testosterone levels in animals treated with furan.

Male Sprague--Dawley rats (3--4 weeks old) were administered furan by gavage in corn oil at 4 mg/kg per day for 5 days per week for 90 days. This treatment also produced oxidative stress in testes as evidenced by an increase in malondialdehyde and decreased activity of antioxidant enzymes. These effects were associated with decreased plasma testosterone concentrations (El‐Akabawy and El‐Sherif, [2016](#efs25005-bib-0081){ref-type="ref"}).

In conclusion, histological changes in the testes, prostate gland, Leydig cells and seminal vesicles were observed in Wistar rats at 2 mg/kg bw (lowest dose of furan tested) and above given during weaning and post‐puberty. No histological effects in reproductive organs were observed in adult rats and mice up to 8 mg/kg bw.

### 3.1.3. Observations in humans {#efs25005-sec-0049}

In a study in Korea, blood (Lee et al., [2009](#efs25005-bib-0159){ref-type="ref"}) and urine (Jun et al., [2008](#efs25005-bib-0125){ref-type="ref"}) samples were collected from 100 volunteers (49% males, 51% males age ranging from 30 to 70 years; see also Section [3.1.1.6](#efs25005-sec-0040){ref-type="sec"}). The authors in the two study reports stated that the participants consumed a regular Korean diet and avoided large amounts of furan‐rich foods. However, they also stated that: 'Since a database on amounts of furan in the typical foods is not available so far, an actual intake of furan per individual was not shown in this study. Also, other factors such as smoking were not considered for actual intake of furan'. Furan could be detected in 56 urine samples out of 100 samples collected with average values of 0.5--1.3 μg/L, with a concentration above the LOQ (1.0 μg/L) in 15 volunteers. The highest concentration found was 3.14 μg/L. In 21 volunteers, furan could be detected in the plasma (LOD: 0.3 μg/L) with 17 samples above the LOQ (1.0 μg/L) ranging from 1.2 to 17.9 μg/L. From the data provided, it is not possible to correlate the outcome of plasma and urine analysis for the individual volunteers. No information is provided on the handling of non‐detects or on the handling of levels \< LOQ. It was not stated how much time elapsed between the last consumption of food and the collection of urine, and whether 24 h urines were collected or spot samples. However, in the paper Jun et al. ([2008](#efs25005-bib-0125){ref-type="ref"}), it was stated that that blood samples were collected after a 12 h fasting period.

Jun et al. ([2008](#efs25005-bib-0125){ref-type="ref"}) further investigated correlations between average urinary furan levels (above LOD) and plasma ALT, aspartate amino transferase (AST) and γ‐glutamyl transpeptidase (γ‐GT) as markers of liver toxicity. There were good correlations between ALT, AST and γ‐GT, but for urinary furan only a significant correlation with plasma γ‐GT activity was found, which remained significant when covariates like age, sex, body weight, triglyceride and diastolic blood pressure were taken into account. The study authors further mentioned that mean urinary furan levels in males were higher than in females and that a similar trend was observed for plasma furan levels. However, elsewhere in the paper, they mention that quantifiable levels of furan in plasma were not found in any of the volunteers, which invalidates this comparison. The study did not investigate correlations between plasma furan levels and plasma indicators of liver toxicity. Residual confounding cannot be excluded and no graphical representation was given of the regression observed. In addition, for only 15 individuals, quantifiable urinary furan levels were observed, which puts doubts to the validity of the observed correlation. From these two studies (Lee et al., [2009](#efs25005-bib-0159){ref-type="ref"}; Jun et al., [2008](#efs25005-bib-0125){ref-type="ref"}), it is impossible to conclude that at the reported levels of blood and urinary furan, there is an effect of furan on the liver.

These two studies (Jun et al. [2008](#efs25005-bib-0125){ref-type="ref"}; Lee et al., [2009](#efs25005-bib-0159){ref-type="ref"}) show many inconsistencies and are therefore of limited value for this opinion.

### 3.1.4. Mode of action {#efs25005-sec-0050}

**Mode of action in hepatocellular toxicity**

Furan depletes GSH and is cytotoxic to rodent hepatocytes both *in vitro* and *in vivo* evidently through CYP2E1‐mediated conversion to BDA (see Section [3.1.1.3](#efs25005-sec-0037){ref-type="sec"}). Likewise, the corresponding unsaturated aldehydes, acetylacrolein and methylbutenedial, were found to be reactive intermediates of 2‐ and 3‐methylfurans (Ravindranath et al., [1984](#efs25005-bib-0230){ref-type="ref"}).

Chen et al. ([1997](#efs25005-bib-0046){ref-type="ref"}) also concluded that reactions between BDA and amino acids may be involved in the toxicity of furan. Nunes et al. ([2016](#efs25005-bib-0203){ref-type="ref"}) provided evidence that a reactive BDA‐GSH adduct can bind to lysine 107 of histone H2B in male F344 rats treated with 0.92 mg/kg bw per day for 90 days.

*In vitro*, the EC~50~ has been estimated at 27.2 μg/mL in rat hepatocytes using an oxygen controlled closed system to avoid loss of furan by evaporation (Brueck et al., [2009](#efs25005-bib-0032){ref-type="ref"}). Hepatic toxicity associated with oxidative stress produced in mice by daily i.p. injection of furan (8 mg/kg bw) was inhibited by treatment with the antioxidant, salidroside, suggesting a role of ROS in hepatotoxicity (Yuan et al., [2013](#efs25005-bib-0285){ref-type="ref"}). Following a single dose of radiolabelled furan (2 mg/kg bw) in rats, protein binding analyses suggested particular disturbance of pathways related to mitochondrial energy production, redox regulation and protein folding that are likely to combine to alter cellular homeostasis leading to hepatotoxicity (Hamberger et al., [2010](#efs25005-bib-0119){ref-type="ref"}; Moro et al., [2012a](#efs25005-bib-0188){ref-type="ref"}). This is in accordance with the ability of furan to uncouple oxidative phosphorylation (Mugford et al., [1997](#efs25005-bib-0193){ref-type="ref"}). Twenty‐four hours after a single oral dose of 30 mg/kg bw to rats, a significant inhibition of activities of glyceraldehyde‐3‐phosphate dehydrogenase and succinate dehydrogenase, increased activity of enoyl‐CoA hydratase and enhanced production of ketone bodies, was indicative of inhibited glycolysis, enhanced fatty acid oxidation and mitochondrial dysfunction (Ramm et al., [2016](#efs25005-bib-0226){ref-type="ref"}).

Furan was found to significantly alter the level of thyroxine‐T4 and triiodothyronine‐T3 in rats at 0.12 mg/kg bw and above (Section [3.1.2.2](#efs25005-sec-0045){ref-type="sec"}) leading Gill et al. ([2010](#efs25005-bib-0105){ref-type="ref"}) to conclude on a NOAEL of 0.03 mg/kg bw in rats (90 day study). The elevation of triiodothyronine‐T3 and thyroxine‐T4 reported at 0.12 mg/kg bw and above may relate to altered hepatic metabolism relating to these hormones. However, no direct evidence is available.

Furan induced cholangiofibrosis which was extensive following 2 mg/kg bw per day but no significant incidence was found at 0.02, 0.04 or 0.092 mg/kg bw per day in rats (NCTR, [2015](#efs25005-bib-0195){ref-type="ref"}; Von Tungeln et al., [2017](#efs25005-bib-0270){ref-type="ref"}). Cholangiofibrosis is only observed in rodents. However, it is an adverse outcome, which has to be taken seriously with regard to risk assessment (Weber, [2017](#efs25005-bib-0275){ref-type="ref"}).

In conclusion, furan induces oxidative stress. BDA binds covalently to a range of target molecules, including proteins and GSH. These features lead ultimately to cell and tissue damage, mitochondrial dysfunction and fibrosis, primarily in the liver.

**Mode of action in carcinogenesis**

The observation that furan is also occurring in food has generated a number of new studies that try to explain the MoA underlying the observed carcinogenicity in animals (see Section [3.1.2.3](#efs25005-sec-0046){ref-type="sec"}). These studies have demonstrated the production of hepatocellular carcinomas, adenomas and cholangiocarcinomas in rodents. The formation of diagnosed cholangiocarcinoma appears to be a feature of a high dose (8 mg/kg bw) and secondary to hepatotoxicity.

Findings suggest that both genotoxic and non‐genotoxic modes contribute to furan carcinogenesis depending upon the level of exposure (dose and route), the tumour type, species and gender.

Furan can be metabolised by CYP2E1 to BDA and this represents a mechanism leading to hepatic cytotoxicity and possibly to genotoxicity in mammalian cells. The mechanism and potency of genotoxicity of furan *in vivo* is, however, uncertain (see Section [3.1.2.4](#efs25005-sec-0047){ref-type="sec"}). The dial metabolite (BDA) has been found to produce substituted 1,N^4^‐etheno‐2′‐dC; 1,N^6^‐etheno‐2′‐dA and 1,N^2^‐etheno‐2′‐dG adducts in chemical reactions (Byrns et al., [2002](#efs25005-bib-0037){ref-type="ref"}, [2004](#efs25005-bib-0038){ref-type="ref"}, [2006](#efs25005-bib-0039){ref-type="ref"}). The dC and dA adducts were also detected in *S. *Typhimurium strain TA104 treated with a mutagenic concentration of the dial metabolite (Byrns et al., [2006](#efs25005-bib-0039){ref-type="ref"}). Churchwell et al. ([2015](#efs25005-bib-0049){ref-type="ref"}) could not detect an elevation of the adduct BDA‐dC in furan‐treated rat liver DNA using LC--MS/MS after single doses up to 9.2 mg/kg bw or repeated dosing with 4.4 mg/kg bw (5 days per week) for up to 360 days. However, furan has been found to produce DNA adducts in rat tissues albeit at very low levels, suggesting a low potency (Neuwirth et al., [2012](#efs25005-bib-0196){ref-type="ref"}).

There is some evidence of chromosomal damage observed *in vivo*, but the underlying mechanism(s) has not been clarified at the molecular level (see Section [3.1.2.4](#efs25005-sec-0047){ref-type="sec"}). Since DNA crosslinking, DNA adducts or DNA oxidation are each potential mechanisms, it is not possible to determine if the chromosomal damage is direct or indirect.

Furan can also induce a range of cellular responses potentially relevant to cancer in rat and mouse liver. In rats, the most sensitive pathological endpoint following 2‐year exposure by gavage was cholangiofibrosis seen markedly at 0.2 mg/kg and above (NCTR, [2015](#efs25005-bib-0195){ref-type="ref"}; Von Tungeln et al., [2017](#efs25005-bib-0270){ref-type="ref"}). Increased BrdU‐labelling of hepatocytes, indicative of cell proliferation, also showed a lowest‐observed‐effect‐level (LOAEL) (statistically significant) of 2 mg/kg bw in rats administered furan by gavage 5 days per week for 5 and 28 days (Mally et al., [2010](#efs25005-bib-0173){ref-type="ref"}).

In mice, there was an increase in BrdU‐labelling in hepatocytes following treatment with 8 mg/kg bw but not 4 mg/kg bw furan for 28 days, 5 days per week (Cordelli et al., [2010](#efs25005-bib-0056){ref-type="ref"}). Subcapsular inflammation was seen in the mouse liver at the lowest dose level employed (0.5 mg/kg bw) when given 5 days per week for 3 weeks (Moser et al., [2009](#efs25005-bib-0192){ref-type="ref"}). In addition, after 90 days dosing (5 days per week) of mice hepatocyte apoptosis was observed with a NOAEL of 0.12 mg/kg bw (Gill et al., [2011](#efs25005-bib-0106){ref-type="ref"}). From their short‐ and long‐term toxicity studies in mice, Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) concluded that there was an association between furan‐induced hepatotoxicity, compensatory cell replication and liver tumour formation at 4 mg/kg bw furan.

Gene expression changes in the liver following furan doses of 4 and 40 mg/kg bw for up to 14 days in Sprague--Dawley rats were in accord with fibrosis (Hamadeh et al., [2004](#efs25005-bib-0118){ref-type="ref"}). Statistically significant changes in the expression of a number of genes involved in oxidative stress, apoptosis and cell‐cycle were seen in rats after 2 mg/kg bw per day furan over 90 days (Curran et al., 2014; Yauk et al., [2014](#efs25005-bib-0283){ref-type="ref"}; Dong et al., [2016](#efs25005-bib-0060){ref-type="ref"}) or following 4 weeks of treatment with 0.1 and 2 mg/kg bw furan (Chen et al., [2010](#efs25005-bib-0047){ref-type="ref"}). Male rats responded more than female rats. Genes associated with DNA repair, cell cycle and apoptosis were also altered in expression at 2 mg/kg and above in rats exposed by gavage daily up to 3 days (Ding et al., [2012](#efs25005-bib-0059){ref-type="ref"}). Following a single gavage dose of 30 mg/kg bw to male rats, a wave of compensatory hepatocyte proliferation following necrosis was associated with a transient increase in the expression of *c‐myc*,*c‐fos* and *Ha‐ras* genes. However, a later, sustained increase in expression of *c‐myc* was seen and suggested to be independent of cell proliferation (Butterworth et al., [1994](#efs25005-bib-0036){ref-type="ref"}).

*Gpt* delta rats were given furan at 0, 2 or 8 mg/kg bw per day by gavage for 13 weeks (assumed daily) and the frequency of hepatic mutations in *gpt* or Spi were not altered despite an increase in PCNA‐positive hepatocytes, cyclin d1 and cyclin e1 mRNA levels and in the number and area of GST‐P‐positive foci at 8 mg/kg bw. These results do not support a role of genotoxicity in the production of the observed GST‐P‐ positive foci (Hibi et al., [2017](#efs25005-bib-0122){ref-type="ref"}).

Furan doses of 0.92, 2.0 or 4.4 mg/kg bw per day for 360 days in F344 rats also caused a dose‐dependent hepatic global DNA demethylation and a sustained decrease in the levels of histone methylation (de Conti et al., [2014](#efs25005-bib-0051){ref-type="ref"}). Reduction of histone lysine acetylation following treatment of F344 rats with 8 mg/kg bw of furan 5 days per week up to 90 days persisted after removal of the treatment (de Conti et al., [2015](#efs25005-bib-0052){ref-type="ref"}). The p53 target microRNA, miR‐34a, was significantly increased at 2 mg/kg bw per day (Dong et al., [2016](#efs25005-bib-0060){ref-type="ref"}). de Conti et al. ([2016](#efs25005-bib-0053){ref-type="ref"}) showed that treatment of rats with furan at 0.92 or 2.0 mg/ kg bw per day for 90, 180 and 360 days led to increased expression of various microRNAs (miR‐34a, miR‐93, miR‐200a, miR‐200b and miR‐224) which was reversible following cessation of the dosing. In contrast, there was a sustained, reduced expression of miR‐375 in morphologically normal and in cholangiofibrotic liver tissue. This is a tumour suppressing microRNA involved in the regulation of Yes‐associated protein 1 which is a feature of hepatic carcinogenesis and the effects were seen in conjunction with increased methylation, both of cytosine in DNA and of lysine in histone H3K9 and H3K27 at the miR‐375 gene. BDA‐GSH binding to lysine 107 of histone H2B (see above, Nunes et al., [2016](#efs25005-bib-0203){ref-type="ref"}) may contribute to epigenetic interference.

In liver lesions of F344 male rats treated with furan (0.92 or 2 mg/kg bw daily for 104 weeks), 1,336 and 1,541 genes were found to be differentially expressed compared to control rat liver at the two doses, respectively. Of 1,001 transcripts mutually altered in expression at both doses, the expression level of a total of 42 of these was found to be negatively correlated with the methylation of their associated CpG Islands (Tryndyak et al., [2017](#efs25005-bib-0263){ref-type="ref"}). Thus, changes in DNA methylation appear to be involved in some of the gene expression changes induced by furan.

With regard to the induction of cholangiocarcinoma in rats, which is only seen at the top dose studied (8 mg/kg bw), evidence has been provided for an apparent sustained biliary cell and hepatocellular proliferation that persisted without recovery provided that the dosage is sufficient to cause extensive centrilobular hepatocellular toxicity (see Table [2](#efs25005-tbl-0002){ref-type="table"}; Hickling et al., [2010a](#efs25005-bib-0123){ref-type="ref"},[b](#efs25005-bib-0124){ref-type="ref"}). Indeed a biliary epithelial cell origin has been proposed for cholangiocarcinomas produced by furan (Sirica, [1996](#efs25005-bib-0247){ref-type="ref"}; Sirica et al., [1994a](#efs25005-bib-0248){ref-type="ref"},[b](#efs25005-bib-0249){ref-type="ref"}, [1997](#efs25005-bib-0250){ref-type="ref"}). Aberrant expression of HGF/SF expression in both furan--induced cholangiocarcinoma epithelium and in intestinal metaplastic epithelium, suggested that the latter are putative precancerous lesions (Lai et al., [2000](#efs25005-bib-0157){ref-type="ref"}). At a high dose of 30 mg/kg bw, this is associated with metaplasia in the liver and an inflammatory response involving excessive production of ROS, epigenetic changes and irreversible enhanced expression of DNA‐damage responsive genes, cytokines and microRNAs (Elmore and Sirica, [1991](#efs25005-bib-0082){ref-type="ref"}, [1992](#efs25005-bib-0083){ref-type="ref"}, [1993](#efs25005-bib-0084){ref-type="ref"}; Hickling et al., [2010a](#efs25005-bib-0123){ref-type="ref"},[b](#efs25005-bib-0124){ref-type="ref"}; Chen et al., [2012](#efs25005-bib-0048){ref-type="ref"}).

Changes in hepatic gene expression were also observed in mouse liver following furan exposure. Thus, in mice treated with a carcinogenic dose of 4 and 8 mg/kg bw per day, similar changes in hepatic gene expression were observed and the profile of expression changes differed from that at 2 mg/kg bw in which a more adaptive response was considered by the authors. Changes in the expression of NF‐kappaB and c‐Jun were suggestive of liver regeneration and oxidative stress‐mediated NRF2 activity. Chronic inflammation was suggested as a critical event in the transition between the adaptive changes and adversity (Jackson et al., [2014](#efs25005-bib-0135){ref-type="ref"}). Moreover, in mice treated for 3 weeks, long‐non‐coding RNA was differentially expressed at carcinogenic doses of 4 and 8 mg/kg bw but not at 1 or 2 mg/kg bw (Recio et al., [2013](#efs25005-bib-0232){ref-type="ref"}; Webster et al., [2014a](#efs25005-bib-0276){ref-type="ref"},[b](#efs25005-bib-0277){ref-type="ref"}). Cordelli et al. ([2010](#efs25005-bib-0056){ref-type="ref"}) found altered expression of genes involved in the DNA damage response in mice treated with 15 mg/kg bw per day furan for 28 days although this was not associated with a change in DNA methylation.

Yauk et al. ([2016](#efs25005-bib-0284){ref-type="ref"}) assessed the profile of gene expression produced by furan (68, 136 and 390 μg/mL, 4 h exposure) in human TK6 cells with rat liver S9 (induced by 5% ethanol to elevate CYP2E1). By comparing gene expression profiles for both genotoxic and non‐genotoxic chemicals, they concluded that the profile of furan matched that of a genotoxic chemical for 28 selected gene (TGx‐28.65) biomarkers. However, principal component analysis and dendrogram indicated that the profile of gene expression, albeit with a limited set of reporter genes for oxidative stress, was similar to acetaminophen that induces oxidative stress (Jaeschke et al., [2012](#efs25005-bib-0136){ref-type="ref"}) under the conditions of the study. Their analysis of micronuclei induction supported their conclusion that furan is clastogenic at high concentrations associated with oxidative stress. Furihata et al. ([2016](#efs25005-bib-0098){ref-type="ref"}) were able to discriminate furan from 8 genotoxic carcinogens based on the hepatic gene expression profile of 100 candidate marker genes at 4 and 48 h after an i.p. dosage (30 mg/kg bw) in B6C3F1 male mice. These two studies do not support a direct genotoxicity of furan.

A computational analysis sought significant disease associations with either furan or 2,5‐dimethylfuran using data from the Comparative Toxicogenomics Database. There were inferred associations between furan and lung neoplasms, liver injury and cirrhosis based on 21 gene interactions. There were no detected direct associations between 2,5‐dimethylfuran and disease (Phuong et al., [2012](#efs25005-bib-0222){ref-type="ref"}).

In human lung alveolar epithelial cells, 2,5‐dimethylfuran at concentrations up to 2 mM showed no effect on viability or changes in gene expression as assessed using a human microarray platform (Cheah et al., [2013](#efs25005-bib-0044){ref-type="ref"}).

In conclusion, when considering MoAs, the contributing factors are likely to vary according to dose, length of exposure and degree of severity of liver cellular damage, inflammation and regenerative hyperplasia.

It is possible that, based on the potential for genotoxicity (evidenced in some but not all studies *in vitro*, and limited evidence in *vivo* of some chromosomal damage of unknown origin), the mode of carcinogenic action of furan, in rats and mice, may involve genotoxicity. However, there is clear evidence for the involvement of indirect mechanisms in the carcinogenic MoA of furan. These include epigenetic changes, oxidative damage to DNA and regenerative hyperplasia, with all of these effects being accompanied by tissue damage. Extensive protein binding of the reactive metabolite BDA restricts access to DNA. On the other hand, protein binding may contribute to the epigenetic changes (histone binding). Theoretically inactivation of proteins involved in DNA processing may also contribute to genomic instability, however, no studies were conducted with furan.

In particular, oxidative stress with associated production of DNA 8‐oxodeoxyguanosine in liver and 8‐oxodeoxyguanosine in blood, gene expression alteration and epigenetic changes are evidently involved along with an inflammatory and cell proliferative component to the MoA. This is particularly evident in the liver of rodents at 2 mg/kg bw and above accompanied by toxicity.

### 3.1.5. Considerations of critical effects and dose--response analysis {#efs25005-sec-0051}

#### 3.1.5.1. Considerations of critical effects {#efs25005-sec-0052}

In rodents, furan was shown to be hepatotoxic and nephrotoxic when applied by oral gavage. The liver is the most sensitive organ. Furan leads to characteristic changes in markers related to hepatotoxicity as well as severe histopathological damage in the liver. The observed changes in blood parameters, including the effect on thyroid hormones, are considered secondary to changes in liver function. Hepatic toxicity is thought to be due to conversion of furan into the highly reactive metabolite, BDA. In long‐term experiments hepatic necrosis, cholangiofibrosis, regenerative hyperplasia, metaplasia and adenomas/carcinomas are observed. The CONTAM Panel noted that non‐neoplastic effects have been observed at low doses, i.e. cholangiofibrosis in a 2‐year study in male rats at doses as low as 0.2 mg/kg bw per day (NCTR, [2015](#efs25005-bib-0195){ref-type="ref"}) and an increase in serum T4 levels in a 90‐day study in male rats at doses of 0.12 mg/kg bw per day (Gill et al., [2010](#efs25005-bib-0105){ref-type="ref"}).

Neoplastic lesions comprise hepatocellular adenomas/carcinoma, mononuclear cell leukaemia, C‐cell adenoma/carcinoma and mesothelioma of the tunica vaginalis. The mononuclear cell leukaemia, C‐cell adenoma/carcinoma and mesothelioma of the tunica vaginalis were not considered critical for the risk assessment for reasons discussed in Section [3.1.2.3](#efs25005-sec-0046){ref-type="sec"}. The CONTAM Panel selected the incidence of hepatocellular adenomas/carcinoma as critical effect for the neoplastic changes.

There is clear evidence for the involvement of indirect mechanisms in the carcinogenic MoA of furan. These include epigenetic changes, oxidative damage to DNA and regenerative hyperplasia, with all of these effects being accompanied by tissue damage. In addition, extensive protein binding of the reactive furan‐metabolite BDA restricts access to DNA, and binding to histones may also contribute to the reported epigenetic changes.

There is limited evidence of a direct mechanism (i.e. direct interaction with DNA) in the carcinogenic action of furan. A very low level (see Section [3.1.1.4](#efs25005-sec-0038){ref-type="sec"}) of altered DNA bases was observed *in vivo* but their chemical structures could not be identified. These altered DNA bases are not identical to the adducts formed by reaction of the furan metabolite, BDA, with isolated DNA and DNA in bacteria. Nevertheless, there is evidence of chromosomal damage *in vivo*, but it is unknown whether this is caused by a direct or indirect mechanism.

The CONTAM Panel selected the incidence of cholangiofibrosis in male rats, increase in serum T4 in male and female rats and the incidence of hepatocellular adenoma and carcinoma in mice and male rats for the dose--response analysis of furan, but considered that there was insufficient information for the methylfurans.

#### 3.1.5.2. Dose--response analysis (including benchmark dose analysis) {#efs25005-sec-0053}

The BMD analysis performed followed the updated guidance of the Scientific Committee on BMD modelling (EFSA Scientific Committee, [2017](#efs25005-bib-0078){ref-type="ref"}) and a detailed description of the BMD analysis performed by the Panel can be found in Appendix [C](#efs25005-sec-0097){ref-type="sec"}. The reported BMD~10~, BMDL~10~ and BMDU~10~ have not been corrected for the applied dose regimen (i.e. 5 days per week), unless indicated.

As described in Section [3.1.5.1](#efs25005-sec-0052){ref-type="sec"}, the CONTAM Panel considered the induction of cholangiofibrosis in rats as a critical effect following oral exposure to furan. The CONTAM Panel selected the most recent chronic study with male rats for dose--response modelling of the incidence of cholangiofibrosis after 36 weeks and after 2 years (NCTR, [2015](#efs25005-bib-0195){ref-type="ref"}; Von Tungeln et al., [2017](#efs25005-bib-0270){ref-type="ref"}). This study is particularly suitable for dose--response modelling as 8 dose levels (0, 0.02, 0.044, 0.092, 0.2, 0.44, 0.92 and 2 mg/kg bw per day, 5 days per week for 104 weeks) were tested with a higher number of animals per dose group in the lower dose range (see Table [6](#efs25005-tbl-0006){ref-type="table"}). A benchmark dose analysis was performed using the EFSA web‐tool, which is based on the R‐package PROAST 61.3 (see Appendix [C](#efs25005-sec-0097){ref-type="sec"}). The default benchmark response (BMR) for quantal data was selected, i.e. an extra risk of 10% compared with the background risk. Using model averaging, the resulting BMDL~10~ for cholangiofibrosis after 36 weeks was 0.22 mg/kg bw and after 2 years 0.09 mg/kg bw (see Table [10](#efs25005-tbl-0010){ref-type="table"}).

Although the effects on thyroid hormones are considered as secondary to changes in liver function, the CONTAM Panel performed a dose--response analysis of the increase of the serum T4 levels in a 90‐day study in male and female rats (Gill et al., [2010](#efs25005-bib-0105){ref-type="ref"}). The BMD analysis showed that there was insufficient information in these data on the dose--response to calculate a BMDL (i.e. the BMDL--BMDU interval ranged from 0 to infinite). Since the effects are observed in the same dose range as cholangiofibrosis, the changes in thyroid hormones were not used further in the risk assessment.

The induction of hepatocellular adenomas or carcinomas following furan exposure has been reported in male rats and male and female mice. The CONTAM Panel selected the incidence of hepatocellular adenomas or carcinomas (combined) and hepatocellular carcinomas (only) in female mice after 2 years reported in two independent studies (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}; Moser et al., [2009](#efs25005-bib-0192){ref-type="ref"}) for BMD analysis, since this was a more robust data set covering the low dose‐range compared to the male mice and rats. A BMD analysis of the combined data from both studies (Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"}); see Appendix [C](#efs25005-sec-0097){ref-type="sec"}, Table [C.8](#efs25005-tbl-0050){ref-type="table"}), using the studies as a covariate, was performed. Model averaging was used. The resulting BMDL~10~ for hepatocellular adenomas or carcinomas was 1.84 mg/kg bw per day for both studies combined. For hepatocellular carcinomas alone, the shape of the dose--response curves of the two studies differed and the resulting BMDL~10~ were 4.18 and 4.82 mg/kg bw for the Moser et al. and the NTP study, respectively. When analysing the Moser et al. study alone, the BMDL~10~ values were 1.45 and 3.45 mg/kg bw per day for hepatocellular adenomas or carcinomas and hepatocellular carcinomas, respectively.

###### 

Summary of the BMD analysis, using model averaging

+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+-------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+
| Response variable                                                                                                                                                                                                                                                         | Species and sex | BMD~10~ (mg/kg bw per day)[a](#efs25005-note-0027){ref-type="fn"} | BMDL~10~ (mg/kg bw per day)[a](#efs25005-note-0027){ref-type="fn"} | BMDU~10~ (mg/kg bw per day)[a](#efs25005-note-0027){ref-type="fn"} |
+===========================================================================================================================================================================================================================================================================+=================+===================================================================+====================================================================+====================================================================+
| Cholangiofibrosis after 36 weeks                                                                                                                                                                                                                                          | Male rats       | 0.3                                                               | 0.22                                                               | 0.41                                                               |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+-------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+
| Cholangiofibrosis after 2 years                                                                                                                                                                                                                                           | Male rats       | 0.11                                                              | **0.09**                                                           | 0.12                                                               |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+-------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+
| Hepatocellular adenoma or carcinoma; combined data set from Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"})                                                                                                | Female mice     | 2.6                                                               | **1.84**                                                           | 4.00                                                               |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+-------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+
| Hepatocellular carcinoma; combined data set from Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) |                 |                                                                   |                                                                    |                                                                    |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+-------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+
| Female mice                                                                                                                                                                                                                                                               | 5.72            | 4.18                                                              | 7.24                                                               |                                                                    |
|                                                                                                                                                                                                                                                                           |                 |                                                                   |                                                                    |                                                                    |
| Female mice                                                                                                                                                                                                                                                               | 7.21            | 4.82                                                              | 9.10                                                               |                                                                    |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+-------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+
| Hepatocellular adenoma or carcinoma; data set from Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) only                                                                                                                                                         | Female mice     | 2.4                                                               | 1.45                                                               | 3.59                                                               |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+-------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+
| Hepatocellular carcinoma; data set from Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) only                                                                                                                                                                    | Female mice     | 5.34                                                              | 3.45                                                               | 7.55                                                               |
+---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+-----------------+-------------------------------------------------------------------+--------------------------------------------------------------------+--------------------------------------------------------------------+

For a 5 days per week dosing regimen.

John Wiley & Sons, Ltd

From this analysis, the CONTAM Panel selected the BMDL~10~ of 0.09 mg/kg bw per day (5 days per week dosing regimen) for the induction of cholangiofibrosis in male rats after 2 years as a reference point for non‐neoplastic effects. This corresponds to 0.064 mg/kg bw per day (correcting for the applied dose regimen of 5 days per week). For neoplastic effects, the CONTAM Panel considered that the combined data set from NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) and Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) on the incidence of hepatocellular adenomas and carcinomas in female mice after 2 years is the most robust data set to derive a reference point and selected the BMDL~10~ of 1.84 mg/kg bw per day (5 days per week dosing regimen). This corresponds to 1.31 mg/kg bw per day (correcting for the applied dose regimen of 5 days per week).

### 3.1.6. Possibilities for derivation of a health‐based guidance value (HBGV) {#efs25005-sec-0054}

Based on the available information, the CONTAM Panel concluded that there is clear evidence for the involvement of indirect mechanisms in the carcinogenic MoA of furan. However, there are also some indications for a direct genotoxic mechanism. Therefore, the CONTAM Panel considered it inappropriate to establish a tolerable daily intake (TDI). The CONTAM Panel selected a BMDL~10~ of 0.064 mg/kg bw per day for the incidence of cholangiofibrosis and a BMDL~10~ of 1.31 mg/kg bw per day for the incidence of hepatocellular adenomas or carcinomas as reference points and to use an MOE approach for the risk characterisation.

3.2. Occurrence data {#efs25005-sec-0055}
--------------------

### 3.2.1. Factors influencing furan and methylfurans levels in food {#efs25005-sec-0056}

Both the food matrix and the process variables will have an impact on the formation and loss of furan and methylfurans in foods. Currently, most of the information is related to furan. In view of its chemical properties, it is supposed that the formed furan is chemically stable during storage of foods, although limited studies examining stability are available (Guenther et al., [2010](#efs25005-bib-0114){ref-type="ref"}). Losses for furan are typically linked to its high volatility (evaporation). First, the factors impacting furan formation in foods and model systems will be summarised, followed by reviewing the factors influencing the evaporative losses of furan. Similarly, the available information on methylfurans will be discussed.

[**Factors influencing furan formation in food and model systems**]{.ul}

As outlined in Section [1.3.5](#efs25005-sec-0013){ref-type="sec"}, several precursors and formation mechanisms have been suggested. Most of these precursors have been identified in simplified model systems in which the complexity of a real food matrix cannot be mimicked. Indeed, it should be realised that in foods, multiple precursors can be present, and that their formation pathways may interfere with each other. It also seems that interaction with non‐precursor matrix components (e.g. starch) may impact the furan formation (e.g. Owczarek‐Fendor et al., [2010a](#efs25005-bib-0205){ref-type="ref"}).

Only a limited number of studies have tried to corroborate the specific role of particular precursors in real food systems for which stable isotope labelled precursors are necessary. Such studies revealed that the role of some precursors can be largely overestimated. Limacher et al. ([2008](#efs25005-bib-0164){ref-type="ref"}) reported that only 21% of the formed furan originated from the available sugars in the pumpkin puree studied, while the remaining 79% was suggested to result from lipids, although this reaction pathway was not considered or investigated.

In an acidic environment, it has been shown that sugars are less efficient precursors in model systems compared to neutral or alkaline conditions (e.g. Limacher et al., [2008](#efs25005-bib-0164){ref-type="ref"}; Owczarek‐Fendor et al., [2012](#efs25005-bib-0208){ref-type="ref"}). For ascorbic acid, an acidic pH favours the conversion to furan (e.g. Limacher et al., [2007](#efs25005-bib-0163){ref-type="ref"}; Owczarek‐Fendor et al., [2010a](#efs25005-bib-0205){ref-type="ref"}). Care needs to be taken in the interpretation of these observations as the pH of a model system is sometimes difficult to control, it varies as a function of the temperature, and some buffers, like phosphate, are supposed to enhance furan formation as well (e.g. Fan et al., [2008](#efs25005-bib-0088){ref-type="ref"}).

The redox potential is another matrix‐relevant parameter. The use of antioxidants in model systems reduces lipid peroxidation and furan formation (Becalski and Seaman, [2005](#efs25005-bib-0022){ref-type="ref"}). Metal ions, as pro‐oxidants have the opposite effect (Becalski and Seaman, [2005](#efs25005-bib-0022){ref-type="ref"}). It should be noticed that the different reports are not always consistent (Märk et al., [2006](#efs25005-bib-0176){ref-type="ref"}). Reduction of the available amount of oxygen in food products (in potato purées supplemented with, respectively, ascorbic acid, fructose and poly‐unsaturated fatty acids; Palmers et al., [2016](#efs25005-bib-0214){ref-type="ref"}) or model systems (Märk et al., [2006](#efs25005-bib-0176){ref-type="ref"}) resulted in a variable decrease in the furan formation.

The process variables time and temperature have an impact on furan levels in food. Sterilisation treatments typically result in higher furan levels compared to pasteurisation treatments (Fan et al., [2008](#efs25005-bib-0088){ref-type="ref"}). Dry heating, generally more intense than sterilisation or pasteurisation treatments, typically results in higher furan levels (Limacher et al., [2007](#efs25005-bib-0163){ref-type="ref"}, [2008](#efs25005-bib-0164){ref-type="ref"}). This is consistent with the observation that the highest concentrations of furan are reported in roasted coffee (EFSA, [2010c](#efs25005-bib-0068){ref-type="ref"}). Furan levels in coffee increase with the degree of roasting (Guenther et al., [2010](#efs25005-bib-0114){ref-type="ref"}; Altaki et al., [2011](#efs25005-bib-0009){ref-type="ref"}; Arisseto et al., [2011](#efs25005-bib-0014){ref-type="ref"}) and this effect is attributed to the increase in roasting temperature. Coffees with the same degree of roasting but roasted using different time--temperature conditions show different levels, with the highest levels observed after quick roasting at high temperature (Altaki et al., [2011](#efs25005-bib-0009){ref-type="ref"}). Also, during deep‐frying the applied time‐temperature combination influences the furan level. DTU ([2009](#efs25005-bib-0061){ref-type="ref"}) studied the levels of furan in chips and crisps during deep‐frying as a function of different time‐temperature combinations. No difference was observed in the level of furan in chips fried at 160°C for 6 mins or 175°C for 4 mins. However, higher levels were found in chips fried for 3 mins at 190°C. For crisps, the authors observed an increase in furan level with increased frying temperature and decreased frying time (7 mins at 150°C vs 3.5 mins at 190°C). In toast, on the other hand, the influence of increasing toasting time, without changing the toasting temperature, was studied. The level of furan increased with toasting time and consequently with the degree of browning.

In aqueous solutions, it was initially accepted that temperatures of 90--100°C resulted in a limited amount of furan formation and that typically higher temperatures were necessary (e.g. Fan et al., [2008](#efs25005-bib-0088){ref-type="ref"}; Owczarek‐Fendor et al., [2010a](#efs25005-bib-0205){ref-type="ref"}). Subsequently, it was shown that during storage at 35°C, thermally treated fruit juices were able to generate furan, while the same authors observed limited additional furan formation during storage of vegetable purées at 4°C (Palmers et al., [2015a](#efs25005-bib-0211){ref-type="ref"},[c](#efs25005-bib-0213){ref-type="ref"}). Presumably, precursors formed during thermal treatment or storage are further converted to furan during long‐term storage, without the need for additional thermal input. In comparison, conventional sterilisation techniques, high‐pressure high‐temperature sterilisation or alternative heat treatments (e.g. dielectric heating) resulted in a lower furan formation due to a lower time‐temperature impact (Palmers et al., [2015b](#efs25005-bib-0212){ref-type="ref"}).

In addition, the influence of ionising and UV‐C radiation on furan formation has been studied (Fan, [2005](#efs25005-bib-0085){ref-type="ref"}, [2015](#efs25005-bib-0086){ref-type="ref"}; Fan and Sokorai, [2008](#efs25005-bib-0087){ref-type="ref"}; Hu et al., [2016](#efs25005-bib-0130){ref-type="ref"}), but given the limited application of these techniques at EU level the Panel did not consider this for this opinion.

[**Factors influencing furan losses in food**]{.ul}

Van Lancker et al. ([2009](#efs25005-bib-0265){ref-type="ref"}) showed that the evaporation of furan is highly influenced by the composition of foods (e.g. lipids, starch). In foods such as coffee, although coffee is roasted at temperatures above 200°C, furan is still present. The retention of furan in this matrix can be explained by the interaction of furan with matrix components, such as the lipids and the low molecular weight extractables (Van Lancker et al., [2009](#efs25005-bib-0265){ref-type="ref"}).

Given the volatility of furan, various studies considered the evaporation of furan from samples before consumption, typically during reheating and open storage conditions (e.g. Kim et al., [2009](#efs25005-bib-0149){ref-type="ref"}; Fromberg et al., [2014](#efs25005-bib-0095){ref-type="ref"}; Palmers et al., [2015a](#efs25005-bib-0211){ref-type="ref"}). Appendix [D](#efs25005-sec-0110){ref-type="sec"}, Table [D.1](#efs25005-tbl-0063){ref-type="table"} gives an overview of furan concentrations in commercially processed foods, before and after heating by the consumer, reported in the scientific literature. As shown in Appendix [D](#efs25005-sec-0110){ref-type="sec"}, Table [D.1](#efs25005-tbl-0063){ref-type="table"}, limited evaporation occurs and variable results are obtained, depending upon the particular experimental conditions (e.g. time, temperature, stirring, type of container).

From the information available in scientific literature, the CONTAM Panel concluded that the influence of reheating commercially processed foods on furan levels is limited and highly dependent on the consumer behaviour which is not predictable. Moreover, it should be noted that some consumers might consume these products without heating.

During beverage preparation however, furan levels decrease substantially due to a combination of dilution, evaporation and partial extraction. Guenther et al. ([2010](#efs25005-bib-0114){ref-type="ref"}) estimated losses regardless of the dilution for each process/handling step of roasted coffee: grinding (40%), degassing (20%), shelf life (0% as long as original package is closed, 25% when original package is opened), brewing (55%) and standing time (10--35%). Several other studies investigated the effect of the brewing method in more detail. An overview of furan levels in coffee before and after brewing retrieved from those studies is provided in Appendix [D](#efs25005-sec-0110){ref-type="sec"}, Table [D.2](#efs25005-tbl-0064){ref-type="table"}. In this table, only the studies that provided sufficient information on any of the following parameters were retained: brewing method, amount of solid coffee used for brewing, volume of brew obtained and concentrations of furan before and after brewing. These data allowed the CONTAM Panel to calculate for each sample an overall reduction factor by dividing the furan concentration in the food as purchased by the furan concentration in the food as consumed. This reduction factor comprises a dilution and a loss factor. The loss factor is considered as an indicator for the amount of furan lost during the brewing process, regardless of the dilution effects. The higher the loss factor, the higher the amount of furan lost during the brewing process.

Although highly variable results are obtained, some trends were identified when merging the individual loss factors obtained throughout the different studies (Appendix [D](#efs25005-sec-0110){ref-type="sec"}, Table [D.2](#efs25005-tbl-0064){ref-type="table"}). The highest losses of furan were observed when whole coffee beans are used as a starting material, indicating that loss of furan does not only occur during the brewing process itself, but also during the grinding. When ground coffee was used as a starting material, the highest loss factors were obtained for boiled/Turkish coffee (Median = 11.6; P25 = 5.9; P75 = 18.5). Loss factors for filter coffees (Median = 4.2; P25 = 2.3; P75 = 5.9) were also found to be higher compared to espresso coffees (Median = 2.8; P25 = 2.3; P75 = 4.4). Altaki et al. ([2011](#efs25005-bib-0009){ref-type="ref"}) explained the higher transfer of furan to espresso brews by the higher pressure applied in the espresso machine which increases the furan extraction compared to a filter coffee maker. Also, the time difference between both brewing methods to prepare a cup of coffee may explain the higher levels of furan in espresso (± 30 s for espresso vs ± 100 s for filter coffee). For instant coffees, the loss of furan during beverage preparation is considered negligible as the median loss factor amounted to 1.1 (P25 = 1.0; P75 = 1.4).

Several researchers studied the impact of stirring and the standing‐time (time between preparation and consumption) on furan levels. In general, stirring the sample results in a decrease of furan, while variable effects have been observed during standing. Mesias and Morales ([2014](#efs25005-bib-0184){ref-type="ref"}) studied the effect of standing and stirring on the furan level in brewed coffee: Standing at room temperature for 5 min resulted in a loss of 74%, while standing at room temperature for 5 min in combination with 30 s stirring resulted in a loss of 64%. Stirring on the other hand for 5 min resulted in losses of 94% and coffee that was kept for 8 h in a sealed thermo had furan levels that were 98% lower. Also, Kim et al. ([2009](#efs25005-bib-0149){ref-type="ref"}) and Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"}) observed a decrease of the furan in brewed coffee during standing. Roberts et al. ([2008](#efs25005-bib-0234){ref-type="ref"}) on the other hand demonstrated that furan levels in composite foods that were left to stand without stirring did not change significantly, while stirring the foods resulted in lower furan levels. Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) on the other hand observed losses between 22% and 47% when baby food was standing for 5 min. For methylfurans, few studies are available. Palmers et al. ([2014](#efs25005-bib-0210){ref-type="ref"}) confirmed the susceptibility of heat‐treated tomato based products for 2‐methylfuran and 3‐methylfuran formation as reported in a survey of Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"}), while for other vegetable products (broccoli, carrot, pumpkin, potato) formation was restricted (up to 127 μg/kg in tomato product for the sum of 2‐ and 3‐methylfuran, others \< 20 μg/kg). It is, however, not clear which factors are responsible for these remarkable differences.

[**Factors influencing methylfurans levels in food**]{.ul}

Although amino acid degradation is considered as an important pathway in the 2‐methylfuran formation, addition of supplementary glucose to a pumpkin puree (stimulating the Maillard reaction) did not result in a significant increase of 2‐methylfuran (Limacher et al., [2008](#efs25005-bib-0164){ref-type="ref"}). From the methylfuran survey data, however, it is obvious that various factors should have an impact on the formation of methylfurans in foods (Becalski et al., [2010](#efs25005-bib-0024){ref-type="ref"}).

In contrast to furan, methylfurans seem to be prone to degradation or loss in some foods during storage. Palmers et al. ([2015a](#efs25005-bib-0211){ref-type="ref"}) observed that during the storage of pasteurised tomato purée at 35°C, a reduction was seen from 127 μg/kg to 13 μg/kg, while in other vegetable purée or fruit juices, this was not observed or at least not to this extent. The decrease observed at 4°C was lower (24%). The cause of the decrease is not known.

[**Summary**]{.ul}

The food characteristics, processing and cooking conditions, and the losses which occur mainly due to evaporation in the preparation of the food at the level of the consumer, affect the final concentration in the food as consumed.

### 3.2.2. Occurrence data submitted to EFSA {#efs25005-sec-0057}

Although the call for data requested the submission of chemical occurrence data on furan, 2‐methylfuran and 3‐methylfuran, only data for furan were made available within this framework. The data for the present assessment were provided by national authorities from Austria, Belgium, China, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Slovakia, Slovenia, Spain and United Kingdom, and by the European Breakfast Cereal Association (CEEREAL), the European Coffee Federation (ECF) and Specialised Nutrition Europe (SNE).

An initial number of 18,141 analytical results on furan in food were available. This data set also included the 5,500 records included in the latest report on furan in food (EFSA, [2011d](#efs25005-bib-0072){ref-type="ref"}). These 5,500 records were previously validated by EFSA and incorporated in the current assessment without further involvement of the data providers. The remaining data were subject to the validation processes described in Section [2.3.2](#efs25005-sec-0027){ref-type="sec"}, and data providers were invited to clarify possible inconsistencies identified by EFSA\'s DATA Unit. Where such a clarification was not received from the data provider, the CONTAM Panel was required to apply certain assumptions. These assumptions, and the number of records impacted are summarised in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.1.

Furthermore, the overall data set was carefully analysed before being used to estimate dietary exposure and a total of 378 records were excluded from the final data set. Criteria for exclusion of these analytical results are also detailed in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.1.

#### 3.2.2.1. Governmental data {#efs25005-sec-0058}

The data set retained for assessment included 10,370 analytical results from governmental organisations. As requested through the call for data, Member States reported analytical results for commercial foodstuffs as purchased, disregarding any further preparation, and commercial foodstuffs analysed as consumed after further preparation in the laboratory. Since the data set also included samples analysed both as purchased and as consumed, the number of analytical results reported above actually corresponds to a total of 9,663 samples. Samples were taken in 21 Member States (Figure [8](#efs25005-fig-0008){ref-type="fig"}) throughout the years 2004--2016 (Figure [9](#efs25005-fig-0009){ref-type="fig"}).

![Number of governmental samples reported by Member State](EFS2-15-e05005-g008){#efs25005-fig-0008}

![Number of governmental samples reported by year](EFS2-15-e05005-g009){#efs25005-fig-0009}

Apart from the above‐mentioned samples that were analysed both as purchased and as consumed (n = 707), available samples were analysed only once, either as purchased (n = 8,531) or as consumed (n = 237). For some remaining samples (n = 188), data providers did not clearly specify whether the samples were analysed as purchased or as consumed, but on the basis of the observed levels these samples were assumed to be analysed as purchased.

In view of the exposure assessment, the data were grouped at different FoodEx levels taking into consideration several factors including the similarities between food categories, the number of samples and the concentrations observed (Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.2). The CONTAM Panel agreed that where a sample was analysed both as purchased and as consumed, only the analytical result for the sample analysed as consumed would be retained for assessment because this is the most representative for the consumer exposure. Furthermore, in order to assess the impact of food and beverage preparation on the concentration levels of furan, reduction factors were calculated for each sample that was analysed both as purchased and as consumed (samples with left‐censored results were excluded). For those food categories where no dilution occurs during food preparation (i.e. heating of commercially processed foods), the median reduction factors are reported in Table [11](#efs25005-tbl-0011){ref-type="table"}.

###### 

Reduction of furan levels during heating of commercially processed foods for which no dilution occurs

  Food group                                            Number of samples   Median reduction factor[a](#efs25005-note-0028){ref-type="fn"}
  ----------------------------------------------------- ------------------- ----------------------------------------------------------------
  Grains and grain‐based products                       3                   1.1
  Vegetables and vegetable products (including fungi)   13                  1.1
  Legumes, nuts and oilseeds                            4                   1.3
  Fruit and fruit products                              1                   3.2
  Meat and meat products (including edible offal)       1                   1.6
  Herbs, spices and condiments                          18                  1.1
  Food for infants and small children                   157                 1.1
  Composite food (including frozen products)            130                 1.2
  Snacks, desserts and other foods                      2                   1

Note that in this specific case the reduction factor is equal to the loss factor.

John Wiley & Sons, Ltd

These data indicate that heating of commercially available foods (where no dilution occurs) has a limited impact on the levels of furan with median reduction factors generally ranging from 1 to 1.2. Median reduction factors in legumes, fruit and fruit products, and meat and meat products were higher (amounting to 1.3, 3.2 and 1.6, respectively), but the number of samples in these food groups was not considered sufficient to demonstrate that a significant loss of furan is expected during preparation of such food items. These findings are consistent with findings in scientific literature (see Section [3.2.1](#efs25005-sec-0056){ref-type="sec"}) and it was agreed that for these food categories further distinction between foods analysed as purchased or consumed would not be meaningful.

A similar analysis was attempted for foods and beverages where furan concentrations are expected to decline, not only due to the possible loss of furan during preparation, but also through the effect of dilution (i.e. cereal‐based products for infants and young children, infant and follow‐on formulae, and cocoa, tea, coffee and coffee imitate beverages). However, in most of these samples, the preparation method applied by the laboratories was not reported and it could not be assessed to what extent the decline of furan concentrations in these samples was driven by the effect of dilution or by the loss of furan during preparation. For these reasons, the information on coffee retrieved from scientific literature was considered more useful (Appendix [D](#efs25005-sec-0110){ref-type="sec"}, Table [D.2](#efs25005-tbl-0064){ref-type="table"}). Meanwhile, it was agreed that for these food categories furan concentrations in the food as purchased are not comparable to the furan concentrations in the food as consumed. Samples analysed as purchased were reported under the corresponding solid or powder, while the samples analysed as consumed were reported under the corresponding beverage or food.

The Panel also noted that the food category 'Coffee beans, roasted' may have been used by some Member States to report any unspecified roasted coffee sample (regardless whether it was ground or not). In order to allow for a better comparison between ground and unground roasted coffee, only the samples where the product description explicitly refers to grains or beans were retained in this food category. All other samples were reported as unspecified coffee beans and coffee products. A similar analysis was made for coffee imitates, in order to make a distinction between instant coffee imitates and coffee imitates for brewing.

Based on this classification, the highest number of samples was reported for 'Foods for infants and small children' with a particular attention to ready‐to‐eat meals for infants and young children (n = 2,090), and 'Vegetables and vegetable products (including fungi)', which includes the coffee beans and solid coffee products (n = 1,547) as well as the solid coffee imitates (n = 136). Other well‐represented food groups are composite foods (n = 1,292) and grains and grain‐based products (n = 1,207). These also correspond to the most relevant food categories in terms of furan levels.

The highest concentrations of furan were found in whole roasted coffee beans, with a mean value of 3,956 μg/kg and the highest individual value of 12,810 μg/kg. The mean values in ground roasted coffee (2,446 μg/kg) and unspecified coffee solids (2,186 μg/kg) were significantly lower, suggesting a loss of furan during the process of grinding, while the mean concentration in instant coffee powder was found to be even lower (429 μg/kg). A similar observation was made for coffee imitates where concentrations in solids for brewing (1,922 μg/kg) were higher compared to the instant powders (127 μg/kg). Due to the low number of left‐censored data within these food categories, the difference between lower bound and higher bound estimations was negligible.

In prepared salads and cereal‐ and vegetable‐based composite foods, mean furan concentrations ranged from 10 to 20 μg/kg, while in other composite foods (including the unspecified ones) mean levels ranged between 20 and 34 μg/kg. On average, levels in ready‐to‐eat meals for infants and young children were similar (31 μg/kg), but in this case, the quality of the data was not sufficient to allow for further disaggregation on the basis of the meal content. Comparable mean levels were also found in bread and rolls, raw pasta, breakfast cereals and fine bakery wares (16--30 μg/kg).

All remaining samples included a wide range of other foods, most of which are also expected to be commercially prepared foods (including canned and jarred products). Nevertheless, mean levels of furan in these food categories were generally found to be below 20 μg/kg, with the exception of soy sauce (32 μg/kg) and spirits (57 μg/kg).

Almost 90% of the samples were taken through objective, selective or convenient sampling while for the majority of the remaining samples the sampling strategy was not specified. Suspect sampling was reported for only 0.4% of the samples. However, the CONTAM Panel noted that there are no legal limits or indicative values for furan, and that the compound is present due to processing and not due to intentional use or environmental contamination. Therefore, the Panel considered it would be difficult in practice to identify suspect samples and that it cannot be excluded that the product was placed on the market. It was therefore decided to retain those samples in the data set.

The majority of the samples were analysed by means of different GC--MS techniques, except for approximately 27% of the samples where Member States did not provide a detailed classification of the method. LOQs were reported for more than 97% of the samples (Figure [10](#efs25005-fig-0010){ref-type="fig"}). Samples where the LOQ value was omitted either referred to a sample with quantifiable levels or to a sample with residues below the LOD.

![Distribution of reported limits of quantification in μg/kg, presented by food group\
Vertical line represent the median value, box outline represent 25th and 75th percentiles and whiskers represent 5th and 95th percentiles.](EFS2-15-e05005-g010){#efs25005-fig-0010}

Furan may also be a constituent of the food additive caramel colours and the food flavouring rum ether. Caramel colours were re‐evaluated by the ANS Panel (EFSA ANS Panel, [2011](#efs25005-bib-0075){ref-type="ref"}) and according to a refined exposure assessment combining all caramel colours (EFSA, [2012](#efs25005-bib-0073){ref-type="ref"}), the main contributors to the mean exposure of toddlers and children to caramel colours were identified as 'Dairy products and analogues', 'Salts, spices, soups, sauces, salads and protein products', 'Non‐alcoholic beverages', 'Edible ices' and 'Bakery wares'. For adults, elderly and very elderly, the main contributors to the mean exposure were 'Salts, spices, soups, sauces, salads and protein products', 'Non‐alcoholic beverages' and 'Alcoholic beverages, including alcohol‐free and low‐alcohol counterparts'. Rum ether was recently evaluated by the CEF Panel (EFSA CEF Panel, [2017](#efs25005-bib-0076){ref-type="ref"}). For this flavouring, a refined exposure assessment was not carried out, but use levels were reported for 'Edible ices', 'Confectionery', 'Chewing gum', Cereal and cereal products derived from cereal grains, roots and tubers, and pulses and legumes, excluding bakery wares of food category 7.0', 'Bakery wares', 'Meat and meat products', 'Salts, spices, soups, sauces, salads, protein products (including soya bean protein products) and fermented soya bean products', 'Non‐alcoholic beverages' and 'Alcoholic beverages'.

Although slightly different food classifications are applied in the area of food additives and flavourings, it can be concluded that the above reported food categories are covered by the available occurrence data on furan. It is therefore expected that most of the furan levels resulting from the use of caramel colours and rum ether have been captured in the final data set, possibly contributing to the relatively high levels of furan observed in certain food items (e.g. fine bakery wares, soy sauce and spirits).

Occurrence of 2‐methylfuran and 2,5‐dimethylfuran resulting from their use as a food flavouring is no longer expected since both substances were removed from the Union list of flavourings (see Section [1.3.4](#efs25005-sec-0012){ref-type="sec"}).

#### 3.2.2.2. Commercial data {#efs25005-sec-0059}

A total number of 7,393 analytical results reported by commercial organisations were retained. Samples analysed both as purchased and as consumed were in this case not reported; hence the available data set refers to the same number of samples. The highest number of samples was reported by ECF, mainly covering the years 2010--2016. From 2012 onwards, samples were also reported by CEEREAL and SNE (Figure [11](#efs25005-fig-0011){ref-type="fig"}).

![Number of samples reported by commercial organisations, presented by year\
CEEREAL: European Breakfast Cereal Association, ECF: European Coffee Federation, SNE: Specialised Nutrition Europe.](EFS2-15-e05005-g011){#efs25005-fig-0011}

In view of a possible comparison, the commercial data were grouped in the same way as for the governmental data (Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.2). Reported samples mainly referred to coffee beans and coffee products (n = 6,796), coffee beverages (n = 131), ready‐to‐eat meals for infants and young children (n = 348), and breakfast cereals (n = 67). All samples were analysed as purchased, except for the samples in coffee beverage which were assumed to be solid coffee samples analysed as consumed. However, as the corresponding solid samples could not be identified, a detailed impact assessment of coffee preparation on the levels of furan was not possible.

For most commercial data (over 99%), the sampling strategy remained unspecified but, as for the governmental data, this is not expected to have a major impact on the assessment.

Most samples were analysed using a GC--MS method, while for 114 samples in coffee beverage the data provider was not able to retrieve the adequate classification for the method. LOQs were reported for approximately 17% of the samples, ranging from 3 to 10 μg/kg. For the remaining samples LOQs were not reported, but all these samples referred to quantifiable levels of furan in roasted coffee beans (incl. ground coffee), instant coffee and coffee beverages.

In view of comparing the governmental and commercial data, several statistical tests were considered but they were not adequate, in particular, for those food categories with a high percentage of left‐censored data. Nevertheless, looking at the most predominant food categories (coffee beans and coffee products, coffee beverages, ready‐to‐eat meals for infants and young children, and breakfast cereals), commercial data were generally found to be higher or within the same range as the governmental data. One exception was identified for instant coffee powder where the mean of the governmental data is approximately 50% higher compared to the commercial data. Due to the high number of commercial samples, inclusion of the commercial data in the assessment would significantly lower the estimated mean for instant coffee powder. On the other hand, the CONTAM Panel also noted that furan levels in instant coffee liquid are relatively low and that contribution of instant coffee to the overall exposure is expected to be low, as already indicated in a previous assessment by EFSA ([2011d](#efs25005-bib-0072){ref-type="ref"}). The Panel therefore concluded that it would be appropriate to merge both data sets in view of the exposure assessment.

### 3.2.3. Previously reported occurrence data in the open literature {#efs25005-sec-0060}

EFSA and JECFA reviewed occurrence data on furan in foods up to 2010 (EFSA, [2011d](#efs25005-bib-0072){ref-type="ref"}; FAO/WHO, [2011](#efs25005-bib-0089){ref-type="ref"}). A literature search for recent reviews was conducted. However, since the occurrence of methylfurans was not addressed in the identified reviews, a separate search to identify papers regarding the occurrence of 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran was conducted. In addition, the VCF database[20](#efs25005-note-1023){ref-type="fn"} on volatile compounds in food was consulted to identify papers on methylfurans.

There are numerous citations reporting the occurrence of furan and methylfurans in the aroma profiles of foods, of which some examples are presented below. These studies refer mainly to commercially heat‐processed foods, however, some report the natural occurrence of furan and methylfurans in unprocessed foods.

It should be noted that some of the reviews described in this Section considered data that are included in the EFSA occurrence data set described in Section [3.3.2](#efs25005-sec-0063){ref-type="sec"}.

**A. Furan**

Several papers reviewing the occurrence of furan in food were published after 2010 (Moro et al., [2012b](#efs25005-bib-0189){ref-type="ref"}; Stadler, [2012](#efs25005-bib-0251){ref-type="ref"}; Mariotti et al., [2013](#efs25005-bib-0175){ref-type="ref"}; Seok et al., [2015](#efs25005-bib-0242){ref-type="ref"}; Santonicola and Mercogliano, [2016](#efs25005-bib-0237){ref-type="ref"}). These reviews conclude that the highest levels of furan occur in roasted coffee (powder and beans). High furan levels are also observed in foods that received a heat treatment in sealed containers such as baby foods, soups, baked beans and meat products. However, furan also occurs in low moisture foods that were not heated in a closed container, such as cereals, crackers, cookies (biscuits).

These conclusions are in accordance with JECFA review of furan including over 3,300 food samples from 14 EU countries and Switzerland. Additionally, data from 6 other countries were considered. The report of the review stated, 'The range of national mean levels of furan for foods with the highest contamination levels were as follows: roasted coffee (powder) (814--4,590 μg/kg), instant coffee (powder) (90--783 μg/kg), brewed roasted coffee (34--113 μg/kg), baby food (19--96 μg/kg), soya sauce (16--52 μg/kg), canned fish (6--76 μg/kg) and baked beans (27--581 μg/kg)' (FAO/WHO, [2011](#efs25005-bib-0089){ref-type="ref"}).

Besides the presence in commercially heat‐processed foods, furan has also been reported to occur in home‐cooked foods. Appendix [E](#efs25005-sec-0111){ref-type="sec"}, Table [E.1](#efs25005-tbl-0065){ref-type="table"} gives an overview of furan concentrations in home‐cooked foods reported in scientific literature. The reported levels are in general low (\< 10 μg/kg) except for home‐made toast, pizza, chips, candied potatoes, apple cake, caramel and crisps.

No furan (concentration \< LOQ of 2.4 μg/kg) was quantified in home‐made oatmeal porridge, home‐made soups, sweet and sour pork, meat sauce (Bolognese), omelette, mashed potatoes, marinated potato salad, syrup cake, cookies, caramel sauce, lemon cream, fruit compote, white bread and tea buns. Also, in meat balls, no furan was detected; however, in the crust of heavily fried meat balls, a level of 2.4 μg/kg was quantified (DTU, [2009](#efs25005-bib-0061){ref-type="ref"}; Fromberg et al., [2014](#efs25005-bib-0095){ref-type="ref"}). Arisseto et al. ([2012](#efs25005-bib-0015){ref-type="ref"}, [2013](#efs25005-bib-0016){ref-type="ref"}) studied the formation of furan during pressure cooking of beans, whole rice, soy beans, beef, pork, potato and cassava but no quantifiable results were measured (LOQ = 2.4 μg/kg). Furan was also not detected (LOD = 3 μg/kg) in microwaved chips (Crews, [2009](#efs25005-bib-0050){ref-type="ref"}) and freshly home‐cooked vegetable, cereal, potato and fruit‐based baby foods (LOD = 0.15 μg/kg) (Lachenmeier et al., [2009](#efs25005-bib-0155){ref-type="ref"}).

Juaniz et al. ([2016](#efs25005-bib-0139){ref-type="ref"}) studied the formation of furan in frozen precooked bread‐coated foods during frying at 190°C in fresh or reheated oil. The data are reported in a figure and therefore not included in Appendix [E](#efs25005-sec-0111){ref-type="sec"}, Table [E.1](#efs25005-tbl-0065){ref-type="table"}. Using fresh oil, the furan levels ranged from 16 μg/kg (fish fingers) to 115 μg/kg (onion rings). With the exception of ham croquettes and tuna pasties, furan levels were higher when reheated oil was used (ranging from 12 μg/kg in tuna pasties to 172 μg/kg in onion rings). Furan was not quantified (\< LOQ of 2.3 μg/kg) in chopped vegetables (yellow onion, green peper, cardoon, cabbage and chicory) that were fried (115/108°C) or griddled (150/110°C) with the exception of griddled onion (3.5 ± 0.3 μg/kg; mean ± standard deviation; n = 3).

**B. Co‐occurrence of furan with methylfurans**

Several studies have investigated the co‐occurrence of furan, 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran. Appendix [E](#efs25005-sec-0111){ref-type="sec"} Table [E.2](#efs25005-tbl-0066){ref-type="table"} gives an overview of the concentrations reported in studies in which furan and at least one methylfuran was analysed.

Health Canada published levels of furan, 2‐methylfuran and 3‐methylfuran for a wide range of different foods mainly packaged in cans or jars (n = 176; fruit products, vegetable products, mixed products, meat products, coffee and baby foods). The highest concentrations of 2‐methylfuran were reported for coffee. In all coffee samples (n = 3), 2‐methylfuran occurred at higher concentrations compared to furan, while 3‐methylfuran concentrations were well below the concentrations of furan. In all 17 samples of baby food, the levels of 2‐methylfuran and 3‐methylfuran were well below the levels of furan. For the other foods, the highest 2‐methylfuran concentrations (± 150 μg/kg) were found in a sample of baked beans, flakes of chicken and whole smoked oysters. In general, the 2‐methylfuran concentration was below the concentration of furan, but the CONTAM Panel noted that, particularly for canned/jarred tomatoes (including sauces and drinks), some meat products, salmon and tuna, higher or similar concentrations of 2‐methylfuran compared to furan were reported. As for 2‐methylfuran, the 3‐methylfuran concentration was generally below the concentration of furan, but the CONTAM Panel noted that, particularly for canned/jarred corn and tomatoes (including drinks), the concentration of 3‐methylfuran was higher than the concentrations reported for furan and 2‐methylfuran (Becalski et al., [2010](#efs25005-bib-0024){ref-type="ref"}).

The conclusions regarding the co‐occurrence of furan, 2‐methylfuran and 3‐methylfuran in coffee observed by Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"}) were confirmed by the same authors in 2016. Commercially brewed coffee (n = 40) and non‐brewed coffee (n = 48) samples were collected in Canada and analysed for the presence of furan, 2‐methylfuran and 3‐methylfuran. In all samples analysed, 2‐methylfuran was present at the highest concentrations and 3‐methylfuran at the lowest concentrations. In non‐brewed coffee, the highest 2‐methylfuran concentrations were reported for regular ground coffee, decaffeinated ground coffee and cartridge ground coffee (mean: 9,470, 10,400, 10,700 μg/kg, respectively). In comparison, the mean levels of furan in these coffees were 2,200, 2,450 and 2,360 μg/kg, respectively. Lower levels of furan, 2‐methylfuran and 3‐methylfuran were reported for instant coffee powder; the mean concentrations of 2‐methylfuran were 1,595 and 1,800 μg/kg in regular and decaffeinated instant coffee power, respectively, while the mean concentrations of furan were 233 and 329 μg/kg, respectively. For non‐brewed coffee, the authors reported mean 2‐methylfuran/furan proportions ranging from 4.24 to 6.84 and mean 3‐methylfuran/furan proportions ranging from 0.19 to 0.31. For commercially brewed coffee, the highest mean 2‐methylfuran concentration was reported for espresso (583 μg/kg), while lower mean concentrations were reported for medium roast or bold roast coffee (172 μg/kg) and decaffeinated coffee (184 μg/kg). The mean concentrations of furan in these coffees were 157, 38.7 and 53.1 μg/kg, respectively. For commercially brewed coffee, the authors reported mean 2‐methylfuran/furan proportions ranging from 3.5 to 4.4 and mean 3‐methylfuran/furan proportions ranging from 0.12 to 0.17 (Becalski et al., [2016](#efs25005-bib-0026){ref-type="ref"}).

Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"}) analysed heat‐processed Chinese foods samples for the presence of furan, 2‐methylfuran, 2,5‐dimethylfuran and other alkylfurans not in the scope of this Scientific Opinion. The study included soy sauce, vinegars, fruit juices, beer and other alcoholic beverages, milk and milk beverages, infant formula, coffee, salad sauce, tomato ketchup, baby‐food purees, chocolates and meat products. The information on the coffee samples was not included in this Scientific Opinion due to uncertainty regarding the coffee type and the representiveness for coffee on the EU market. 2,5‐Dimethylfuran was detected less frequently and at lower concentrations than furan and 2‐methylfuran in soy sauce and vinegar. In fruit juices, beer and other alcoholic drinks, 2‐methylfuran was most frequently detected; however, all three furans (i.e. furan, 2‐methylfuran, 2,5‐dimethylfuran) only occurred at low concentrations (≤ 2.4 μg/kg). 2,5‐Dimethylfuran was detected in 2 samples of raw milk at relatively high concentrations (34.5 and 88.8 μg/kg), while furan and 2‐methylfuran were not detected in these samples. Both compounds on the other hand occurred in one condensed milk sample and five milk powder samples at low but similar concentrations (≤ 8 μg/kg), while 2,5‐dimethylfuran was not detected. In infant formula, 2,5‐dimethylfuran was detected more frequently compared to 2‐methylfuran but in general at concentrations below the furan concentrations. 2,5‐Dimethylfuran was not detected in any of the samples of meat products (n = 11), chocolates (n = 6), tomato ketchup (n = 2), baby food purees (n = 11) and salad sauce (n = 1). In these food groups, furan and 2‐methylfuran were also not detected or at low levels (\< 3 μg/kg), with the exception of baby food purees, in which furan was detected at concentrations up to 16.2 μg/kg and 2‐methylfuran up to 13.5 μg/kg.

Chaichi et al. ([2013](#efs25005-bib-0042){ref-type="ref"}) analysed three coffee samples (ground, instant and a coffee‐mix) to evaluate the reliability of a newly developed a headspace liquid‐phase microextraction GC/MS method for the analysis of furan, 2‐methylfuran and 2,5‐dimethylfuran. 2‐methylfuran was in all three samples present at the highest concentration. Chaichi et al. ([2015](#efs25005-bib-0043){ref-type="ref"}) used the same method to analyse 67 coffee samples collected in supermarkets and hypermarkets in Tehran, Iran and the results confirm the occurrence of 2‐methylfuran at high levels in coffee. However, the CONTAM Panel noted that only for furan a labelled standard is used in this method and only to correct for the variation in injection volume. Therefore, these studies are not further considered in the assessment.

The co‐occurrence of furan, 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran in the headspace of brewed coffee has also been reported in several other studies (e.g. Kallio et al., [1990](#efs25005-bib-0140){ref-type="ref"}; Shimoda and Shibamoto, [1990](#efs25005-bib-0244){ref-type="ref"}; Leino et al., [1992](#efs25005-bib-0160){ref-type="ref"}).

Fromberg et al. ([2014](#efs25005-bib-0095){ref-type="ref"}) analysed furan, 2‐methylfuran and 2,5‐dimethylfuran in coffee samples (n = 15) and canned food (n = 12). The mean concentration of 2‐methylfuran in coffee (1,328 μg/kg) was higher than the concentration of furan (885 μg/kg) and 2,5‐dimethylfuran (217 μg/kg). In canned food, the highest mean concentration was reported for 2,5‐dimethylfuran (67 μg/kg), while the levels of furan and 2‐methylfuran were 20.5 and 4.7 μg/kg, respectively.

Habibi et al. ([2013](#efs25005-bib-0115){ref-type="ref"}) analysed six commercial baby food samples based on flour or cereals for the presence of furan, 2‐methylfuran and 2,5‐dimethylfuran. 2,5‐Dimethylfuran was the dominant component and furan was present at the lowest concentrations in all except one sample. Levels of 2,5‐dimethylfuran ranged from 69.42 to 230.25 μg/kg. These results are in contradiction with Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"}) that reported that 2,5‐dimethylfuran was below the LOQ (1 μg/kg) in all analysed commercial baby food purees (n = 11). However, it should be noted that these samples were fruit or vegetable based.

Bouseta et al. ([1992](#efs25005-bib-0030){ref-type="ref"}) analysed 84 honey samples to determine their aroma profiles using dynamic headspace GC--MS. Furan was reported to occur at concentrations up to 256 μg/kg (% of left‐censored data not reported). 2‐Methylfuran was detected in 15 samples (18%) at concentrations up to 29 μg/kg.

The co‐occurrence of furan and the methylfurans has also been reported in cooked meat. Galt and MacLeod ([1984](#efs25005-bib-0099){ref-type="ref"}) cooked beef for 1 or 4 h in an oven at 205°C and analysed the volatiles in the aroma. 3‐Methylfuran and traces of furan and 2‐methylfuran were present after 4 h but none of the compounds was present after 1 h. Also, in the volatiles from cooked mutton, the co‐occurrence of furan and 2‐methylfuran was reported (Nixon et al., [1979](#efs25005-bib-0198){ref-type="ref"}). Macleod and Ames ([1986b](#efs25005-bib-0170){ref-type="ref"}) studied the effect of heat on beef aroma in steak cooked at 104°C or 171°C for 1, 2 or 6 min. Traces of furan and 2‐methylfuran were detected but not in the same aroma isolates. The same authors reported the occurrence of 2‐methylfuran in ground beef that had been cooked at 104°C for 2 min followed by 171°C for 6 min (Macleod and Ames, [1986a](#efs25005-bib-0169){ref-type="ref"}). The occurrence of 2,5‐dimethylfuran was reported in roasted chicken at a concentration of 1 μg/kg (250°C for 75 min) (Noleau and Toulemonde, [1986](#efs25005-bib-0200){ref-type="ref"}) and in roast beef heated to internal temperatures of 85°C and 95°C at a concentration of 6.9 and 1.2 μg/kg, respectively (Vercellotti et al., [1987](#efs25005-bib-0267){ref-type="ref"}), while the other furan compounds studied in this opinion were not reported to be present.

In addition, EFSA received data from FoodDrinkEurope, representing the European food and drink industry, on the occurrence of furan, 2‐methylfuran and 3‐methylfuran in jarred baby foods, cereal flakes, roasted and grounded coffee, soluble coffee, infant cereals and tomato sauce. A few datapoints on 2,5‐dimethylfuran were also received; however, since no furan levels were reported for these samples, the data could not be used for the evaluation of the co‐occurrence of furan and the methylfurans. In all baby food samples (n = 35), the highest concentration was observed for furan. In infant cereals, on the other hand, the highest concentration was reported in general for 2‐methylfuran (mean: 15.4 μg/kg vs 7.3 and 1.6 μg/kg for furan and 3‐methylfuran, respectively). In cereal flakes, similar levels were reported for furan and 2‐methylfuran (mean: 22 and 24 μg/kg, respectively) while 3‐methylfuran was present at concentrations below or close to the reporting limit (5 μg/kg). A large data set on roasted and grounded coffee (n = 117) and soluble coffee (n = 64) confirmed the conclusion from the scientific literature that 2‐methylfuran occurs in coffee at concentrations higher than furan. In tomato sauce (n = 3), furan occurred at concentrations below the reporting limit, while both 2‐methylfuran and 3‐methylfuran were quantified although at low levels (≤ 10 μg/kg).

From the available data on the co‐occurrence of furan and methylfurans, the CONTAM Panel concluded that only for coffee, infant cereals, jarred baby‐food and cereal flakes a 2‐methylfuran/furan and 3‐methylfuran/furan ratio can be calculated (Appendix [E](#efs25005-sec-0111){ref-type="sec"}, Table [E.3](#efs25005-tbl-0067){ref-type="table"}). The reported ratios are calculated from the samples for which both furans were quantified. These food groups are also important contributors to furan exposure as shown in previous exposure assessments (see Section [3.3.3](#efs25005-sec-0064){ref-type="sec"}). For the other food groups, only limited data were available that does not allow drawing firm conclusions.

The CONTAM Panel noted the higher ratios for solid coffee compared to brewed coffee. This difference might be explained by the fact that 2‐ and 3‐methylfuran are more apolar compared to furan and consequently the extraction to the liquid phase might be lower. Since coffee is consumed in the liquid form, only data on brewed coffee were considered. From the available data, a median 2‐methylfuran/furan ratio of 4.0 was calculated (average 2‐methylfuran/furan ratio = 4.0) (Table [12](#efs25005-tbl-0012){ref-type="table"}). The overall median 3‐methylfuran/furan ratio for brewed coffee was 0.15 (average 3‐methylfuran/furan ratio = 0.15).

Based on a small data set (n = 18), the CONTAM Panel noted that similar concentrations of furan and 2‐methylfuran occur in cereal flakes and calculated a median 2‐methylfuran/furan ratio of 1.1. 3‐Methylfuran on the other hand occurred at lower concentrations and was only quantified in 5 out of the 18 samples with a median 3‐methylfuran/furan ratio of 0.15. Also, in infant cereals (n = 28), 2‐methylfuran was an important contributor to the total concentration of furans with a median 2‐methylfuran/furan ratio of 1.4 (average = 1.7) (ratio calculated from 15 samples). 3‐Methylfuran was only a minor contributor and the % of left‐censored data was high. The median 3‐methylfuran/furan ratio was 0.26 (ratio calculated from 5 samples).

Several data sources were identified reporting the co‐occurrence of furan and methylfurans in jarred baby foods (see Appendix [E](#efs25005-sec-0111){ref-type="sec"}, Table [E.2](#efs25005-tbl-0066){ref-type="table"}). The CONTAM Panel noted the differences in furan levels among different data sets. For example, Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"}) reported a mean furan concentration for Chinese baby food purees of 5.1 μg/kg (range: \< 1.0--16.2 μg/kg; n = 11) while higher levels were reported by FoodDrinkEurope (mean: 35.6 μg/kg; range: 20--67 μg/kg; n = 35). The CONTAM Panel noted that this mean value is close to the mean MB furan level of 31 μg/kg calculated from the data set used for dietary exposure (see Section [3.2.2](#efs25005-sec-0063){ref-type="sec"}). In addition, the profile of the furans was different, showing higher methylfuran/furan ratios for the Chinese data compared to the European data. Considering these differences and the uncertainty regarding the representativeness of samples collected outside Europe for the jarred baby foods available on the European market, the CONTAM Panel decided to use only the data on co‐occurrence submitted by FoodDrinkEurope. From these data a median 2‐methylfuran/furan ratio of 0.23 (ratio calculated from 22 samples) and a 3‐methylfuran/furan ratio of 0.17 (ratio calculated from 19 samples) were calculated.

###### 

Overview of calculated median methylfuran/furan ratios

  Food                Corresponding FoodEx categories                     Median 2‐methylfuran/furan ratio   Median 3‐methylfuran/furan ratio
  ------------------- --------------------------------------------------- ---------------------------------- ----------------------------------
  Coffee              Coffee beverage                                     4.0                                0.15
  Cereal flakes       Breakfast cereals                                   1.1                                0.15
  Infant cereals      Cereal‐based food for infants and young children    1.4                                0.26
  Jarred baby foods   Ready‐to‐eat meals for infants and young children   0.23                               0.17
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The CONTAM Panel noted that in canned/jarred tomatoes, 2‐methylfuran and 3‐methylfuran are important contributors to the total level of furans. This has also been observed in other canned/jarred tomato products such as tomato juices and tomato sauce. However, this observation is made on a small data set and the data are too limited to calculate ratios.

**C. 2‐methylfuran**

In addition to the studies on co‐occurrence described above, the occurrence of 2‐methylfuran has been reported by several authors. However, it should be noted that in most studies the volatile constituents were analysed.

2‐Methylfuran has been reported to occur in the volatile constituents of milk (Coppa et al., [2011](#efs25005-bib-0055){ref-type="ref"}), creams used as fillers of bakery products (Ramos et al., [2009](#efs25005-bib-0227){ref-type="ref"}), okra (Ames and Macleod, [1990](#efs25005-bib-0011){ref-type="ref"}) and roasted cocoa beans (Gill et al., [1984](#efs25005-bib-0104){ref-type="ref"}). Traces of 2‐methylfuran have been detected during analysis of volatile constituents in nectarines (Takeoka et al., [1988](#efs25005-bib-0256){ref-type="ref"}), acerola fruit (Pino and Marbot, [2001](#efs25005-bib-0223){ref-type="ref"}) and peppers (Rodríguez‐Burruezo et al., [2010](#efs25005-bib-0235){ref-type="ref"}). Also, in a study on tomato volatiles, 2‐methylfuran was found in one of 10 samples of tomato juice, albeit at a low concentration (9% of the standard, not quantified in the overall extractive). No 2‐methylfuran was reported for fresh tomatoes, tomato paste, tomato puree and canned diced tomatoes. Its presence was attributed to the heat processing of the cooked tomato product analysed (Marković et al., [2007](#efs25005-bib-0177){ref-type="ref"}).

Goldberg et al. ([1999](#efs25005-bib-0111){ref-type="ref"}) analysed 2‐methylfuran in 12 types of distilled spirits by HPLC‐UV. The highest concentrations were measured in bourbon (mean = 3,000 μg/L); however, it was also detected in Armagnac, cognac, rye whiskey, blended scotch and rum (concentrations not reported). The CONTAM Panel noted that the analysis was carried out using HPLC‐UV which is not commonly used for furan and methylfuran analysis (see Section [1.3.2](#efs25005-sec-0010){ref-type="sec"}). The occurrence of 2‐methylfuran in distilled spirits should therefore be confirmed by another technique.

**D. 3‐methylfuran**

The co‐occurrence of furan and 3‐methylfuran has been demonstrated in some studies as described above. 3‐methylfuran has also been reported to be present in the volatile compounds from wild rocket (*Diplotaxis tenuifolia* L.) during storage (Luca et al., [2016](#efs25005-bib-0168){ref-type="ref"}).

**E. 2,5‐dimethylfuran**

In addition to the studies on co‐occurrence described above, the occurrence of 2,5‐dimethylfuran has been reported by some authors. However, it should be noted that in most studies the volatile constituents were analysed.

Alasalvar et al. ([2003](#efs25005-bib-0006){ref-type="ref"}, [2004](#efs25005-bib-0007){ref-type="ref"}) published two reports from studies examining volatiles in hazelnut varieties. The average 2,5‐dimethylfuran levels found in roasted nuts was 431 μg/kg and ranged from 14 to 75 μg/kg in different varieties of unroasted nuts. Traces of 2,5‐dimethylfuran have been reported to occur in Rooibos tea (Habu et al., [1985](#efs25005-bib-0116){ref-type="ref"}) and in the volatile components of okra (Ames and Macleod, [1990](#efs25005-bib-0011){ref-type="ref"}) and cooked eggs (Macleod and Cave, [1975](#efs25005-bib-0172){ref-type="ref"}).

3.3. Dietary exposure assessment for humans {#efs25005-sec-0061}
-------------------------------------------

### 3.3.1. Mean and high dietary exposure {#efs25005-sec-0062}

Chronic dietary exposure was estimated across Europe following the methodology described in Section [2.6](#efs25005-sec-0030){ref-type="sec"}. Hence a total of 35 dietary surveys, carried out in 19 different Member States, were selected for this assessment. These dietary surveys and the number of subjects available per age class are described in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.3.

While the occurrence data for coffee and coffee imitates mainly referred to solid samples and a limited number of samples was available for coffee and coffee imitate beverages, most of the selected surveys reported consumption for coffee and coffee imitate beverages. Occurrence data from solid coffee and coffee imitate samples were therefore converted to the corresponding beverages by applying specific factors for dilution and loss of furan during brewing (see also Section [3.2.1](#efs25005-sec-0062){ref-type="sec"}). Concentrations from all samples (i.e. liquid samples and converted solid samples) were subsequently pooled to obtain a mean furan concentration for each beverage. Possible losses of furan during standing of coffee and coffee imitate beverages after brewing were not considered because this standing time is highly dependent on consumer behaviour and therefore not predictable. The adjusted concentrations for coffee and coffee imitate beverages obtained through this conversion are summarised in Table [13](#efs25005-tbl-0013){ref-type="table"}. On average, estimations for the major coffee types were consistent with the mean furan concentrations observed in the limited number of samples reported for those beverages.

###### 

Summary of the adjusted occurrence data for coffee and coffee imitate beverages

  Coffee beverage       DF[a](#efs25005-note-0030){ref-type="fn"}   LF[b](#efs25005-note-0031){ref-type="fn"}   Liquid samples   Solid samples[c](#efs25005-note-0032){ref-type="fn"}   Pooled samples[d](#efs25005-note-0033){ref-type="fn"}                     
  --------------------- ------------------------------------------- ------------------------------------------- ---------------- ------------------------------------------------------ ------------------------------------------------------- --------- ------- -------
  Coffee, Americano     18                                          2.3                                         164              51.2                                                   4,605                                                   2,361.2   4,769   56.8
  Coffee, macchiato     7                                           2.3                                         0                --                                                     4,605                                                   2,361.2   4,605   146.7
  Coffee, cappuccino    18                                          2.3                                         1                31                                                     4,605                                                   2,361.2   4,606   57
  Coffee, espresso      7                                           2.3                                         17               81.6                                                   4,605                                                   2,361.2   4,622   146.4
  Coffee, unspecified   18                                          2.3                                         179              59.7                                                   4,605                                                   2,361.2   4,784   57.1
  Coffee, with milk     18                                          2.3                                         0                --                                                     4,605                                                   2,361.2   4,605   57
  Imitates, brewed      18                                          2.3                                         0                --                                                     28                                                      1,921.9   28      46.4
  Imitates, instant     50                                          1                                           18               1                                                      108                                                     126.5     126     2.3
  Coffee, instant       63                                          1                                           54               4.9                                                    1,457                                                   309.5     1,511   4.9

DF: dilution factor; LF: loss factor; N: number of samples.

The dilution factors usually applied by EFSA for Americano, cappuccino, espresso and instant coffee were extrapolated to the other coffee (imitate) beverages, except for instant coffee imitates where (compared to the dilution factor for instant coffee) a more conservative dilution factor was suggested during the consultation of stakeholders.

For each brewing method, the loss factor selected by EFSA corresponds to the lowest reliable percentile (25th percentile) of the loss factors reported in Section [3.2.1](#efs25005-sec-0056){ref-type="sec"}.

All coffee drinks were assumed to be prepared from roasted and ground coffee beans, except for instant coffee and coffee imitates where a specific category of solid samples is available.

Prior to the pooling of liquid and solid samples, occurrence values for the solid samples were divided by the corresponding dilution and loss factors to obtain an estimate for the corresponding beverages as consumed.
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For those consumption events referring to the solid coffee or coffee imitate rather than the prepared beverage, only a loss factor was applied assuming that all these solids were consumed as a beverage and loss of furan occurred during the preparation of those beverages. An overview of all furan concentrations used for the chronic dietary exposure calculations (including the adjusted concentrations for coffee and coffee imitates) is provided in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.4.

Furthermore, EFSA identified a number of specific food categories where a consumption event may refer either to fresh produce or commercially processed products (Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.5). As the occurrence data for furan mainly refer to commercially processed products and furan is not expected to occur in fresh produce, exposure through these food categories would be overestimated. In view of reducing the uncertainty, consumption events reported for these food categories were analysed, identifying those that referred to a canned, jarred, brined, pickled, smoked or cured product. This analysis was performed by applying a text search to the original food description or by searching for the corresponding facet descriptor when a dietary survey was already coded according to the FoodEx2 classification. The overall contribution of commercially processed products was then calculated for each food category and each dietary survey. Considering that such products have been under‐reported in a number of surveys, only the highest contribution of commercially processed products among dietary surveys was retained for each food category (expressed in % in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.5), and subsequently applied to all consumers, regardless of the dietary survey. Any food item that is not listed in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.5 was assumed to be commercially processed.

Table [14](#efs25005-tbl-0014){ref-type="table"} summarises the chronic dietary exposure estimates for furan across the 35 dietary surveys. Detailed summary statistics on the exposure estimates calculated for each dietary survey are presented in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.6.

###### 

Summary statistics of chronic dietary exposure assessments to furan across European dietary surveys (baseline scenario)

  Age class[a](#efs25005-note-0035){ref-type="fn"}   N    Mean dietary exposure (μg/kg bw per day)                               
  -------------------------------------------------- ---- ------------------------------------------ ------ ------ ------ ------ ------
  Infants                                            6    0.14                                       0.21   0.40   0.49   0.87   0.99
  Toddlers                                           10   0.22                                       0.31   0.36   0.46   0.52   0.65
  Other children                                     18   0.19                                       0.27   0.28   0.36   0.45   0.52
  Adolescents                                        17   0.11                                       0.14   0.17   0.22   0.26   0.31
  Adults                                             17   0.11                                       0.14   0.32   0.35   0.50   0.54
  Elderly                                            14   0.12                                       0.15   0.32   0.36   0.58   0.61
  Very elderly                                       12   0.13                                       0.16   0.28   0.32   0.71   0.75

  **Age class** [a](#efs25005-note-0035){ref-type="fn"}   **N**   **95th percentile dietary exposure** [c](#efs25005-note-0037){ref-type="fn"} **(μg/kg bw per day)**                               
  ------------------------------------------------------- ------- ----------------------------------------------------------------------------------------------------- ------ ------ ------ ------ ------
  Infants                                                 5       0.27                                                                                                  0.42   1.11   1.27   1.60   1.82
  Toddlers                                                7       0.34                                                                                                  0.46   0.59   0.75   0.96   1.08
  Other children                                          18      0.29                                                                                                  0.40   0.47   0.60   0.75   0.86
  Adolescents                                             17      0.19                                                                                                  0.25   0.31   0.39   0.50   0.58
  Adults                                                  17      0.20                                                                                                  0.25   0.63   0.69   1.18   1.22
  Elderly                                                 14      0.24                                                                                                  0.28   0.66   0.70   1.25   1.27
  Very elderly                                            9       0.27                                                                                                  0.32   0.52   0.56   0.92   0.96

bw: body weight; LB: lower bound; N: number of surveys; UB: upper bound.

Section [2.4](#efs25005-sec-0028){ref-type="sec"} describes the age range within each age class.

Estimates were rounded to two decimal places.

The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically robust (EFSA, [2011a](#efs25005-bib-0069){ref-type="ref"}). Those estimates were not included in this table.
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The difference between LB and UB estimates was found to be small, indicating that the uncertainty due to left‐censored data is limited. The highest chronic exposures were estimated in the youngest population group, i.e. infants. Among the mean dietary exposures calculated for infants, the highest LB estimate amounted to 0.87 μg/kg bw per day while the highest UB estimated amounted to 0.99 μg/kg bw per day. Regarding the 95th percentile exposures, which refer to highly exposed consumers within a given dietary survey and age class, the highest estimates were also observed for infants ranging from 1.60 to 1.82 μg/kg bw per day (LB/UB). Dietary exposure in specific groups of the population, namely pregnant and lactating women, were within the range of exposure estimates in the adult population.

### 3.3.2. Contributions of different food groups {#efs25005-sec-0063}

Contribution of the different food groups across dietary surveys is summarised by age class in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.7. These contributions were calculated on the basis of the middle bound (MB) exposure estimates.

Food for infants and small children is the main contributor to the dietary exposure of infants to furan. At the MB exposure, ready‐to‐eat meals for infants and small children accounted for up to 70% of the exposure (median = 53%). One dietary survey did not report consumption of ready‐to‐eat meals for infants and small children, which resulted in the lowest exposure estimate among infant dietary surveys (see also Table [14](#efs25005-tbl-0014){ref-type="table"}). In this specific survey, where exposure is most likely underestimated, the main contributors to the exposure were infant and follow‐on formula liquid (48%). The contribution of food for infants and small children in toddlers is still important, but much lower compared to infants (max = 31%; median = 7%). In other age classes, contribution of this food group to the exposure is negligible.

The group of non‐alcoholic beverages was found to be the main contributor in adults, elderly and very elderly. For all three age classes, the median contribution among surveys exceeds 50% and contributions up to 85% were observed for specific surveys. Depending on the survey, these high contributions are driven by either Americano coffee, espresso coffee or unspecified coffee, which is consistent with the high concentrations of furan observed in coffee (see Section [3.2.2](#efs25005-sec-0063){ref-type="sec"}). Although high concentrations of furan were estimated for other coffee beverages, consumption of these beverages is less frequently reported and their contribution to the exposure is much lower. While non‐alcoholic beverages may still contribute significantly to the exposure of adolescents (max = 24%; median = 12%, also driven by coffee beverages), their contribution to younger age classes is low. It is also worth mentioning that in some surveys consumption of coffee was not reported as a beverage but as a solid, which is included in the FoodEx category of vegetables and vegetable products. This explains the high contribution of vegetables and vegetable products observed for certain surveys (21--47%). Excluding these surveys, however, contributions to furan exposure from vegetables and vegetable products are all below 10%.

Grains and grain‐based products is another important contributor throughout all age classes, in particular, for toddlers, adolescents and other children where it is the main contributor. The median contribution among surveys ranges from 14% for infants to 49% for adolescents, with contributions reaching up to 65% for certain surveys. A specific subcategory driving the contributions of this food group cannot be identified.

A last important contributor to the dietary exposure is the group of composite foods, accounting for more than 25% in several surveys. The main subcategories driving the contribution of this food group are ready‐to‐eat soups and, to a smaller extent, cereal‐based dishes.

Apart from a few exceptions, food groups other than those mentioned above generally accounted for less than 10% of the dietary exposure.

### 3.3.3. Additional dietary exposure scenarios {#efs25005-sec-0064}

In addition to the exposure assessment for furan reported under Section [3.3.1](#efs25005-sec-0062){ref-type="sec"}, hereafter referred to as the baseline scenario, specific scenarios were considered in order to assess the influence of several parameters, such as the impact of household preparation of food and the contribution of 2‐ and 3‐methylfuran to the dietary exposure. Each of these scenarios was based on the baseline scenario, including some additional assumptions which are further detailed in the following sections.

**Reheating of ready‐to‐eat meals for infants and small children**

The influence of reheating commercially processed foods on furan concentrations is limited and highly dependent on the consumer behaviour which is not predictable (see Section [3.2.1](#efs25005-sec-0062){ref-type="sec"}). It was therefore decided in the baseline scenario not to consider losses during re‐heating of ready‐to‐eat meals for infants and small children. However, ready‐to‐eat meals being the main contributor to the dietary exposure of infants, an additional scenario was considered where all ready‐to‐eat meals for infants and small children were assumed to be reheated in a hot‐water bath without lid. Among the heating techniques summarised in Appendix [D](#efs25005-sec-0110){ref-type="sec"}, Table [D.1](#efs25005-tbl-0063){ref-type="table"}, this heating technique leads to the highest losses of furan with a median reduction factor of 1.7. Hence, in view of this scenario, furan concentrations in ready‐to‐eat meals for infants and small children were divided by the aforementioned reduction factor.

Chronic dietary exposure estimates assuming that all ready‐to‐eat meals for infants and small children are re‐heated in a hot‐water bath (without lid) are summarised in Table [15](#efs25005-tbl-0015){ref-type="table"}, across all surveys. Detailed summary statistics on the exposure estimates calculated for each dietary survey are presented in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.8. Infants and toddlers being the only age classes affected by the current scenario, other age classes are not presented in Table [15](#efs25005-tbl-0015){ref-type="table"}.

###### 

Summary statistics of the specific scenario assessing chronic dietary exposure to furan across European dietary surveys, assuming that all ready‐to‐eat meals for infants and small children are re‐heated in a hot‐water bath (without lid)

  Age class[a](#efs25005-note-0039){ref-type="fn"}   N    Mean dietary exposure (μg/kg bw per day)                               
  -------------------------------------------------- ---- ------------------------------------------ ------ ------ ------ ------ ------
  Infants                                            6    0.14                                       0.21   0.29   0.37   0.61   0.72
  Toddlers                                           10   0.22                                       0.31   0.34   0.44   0.52   0.65

  **Age class** [a](#efs25005-note-0039){ref-type="fn"}   **N**   **95th percentile dietary exposure** [c](#efs25005-note-0041){ref-type="fn"} **(μg/kg bw per day)**                               
  ------------------------------------------------------- ------- ----------------------------------------------------------------------------------------------------- ------ ------ ------ ------ ------
  Infants                                                 5       0.27                                                                                                  0.42   0.70   0.84   1.15   1.32
  Toddlers                                                7       0.34                                                                                                  0.46   0.57   0.74   0.77   0.91

bw: body weight; LB: lower bound; N: number of surveys; UB: upper bound.

Section [2.4](#efs25005-sec-0028){ref-type="sec"} describes the age range within each age class.

Estimates were rounded to two decimal places.

The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically robust (EFSA, [2011a](#efs25005-bib-0069){ref-type="ref"}). Those estimates were not included in this table.
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Results indicate that heating of ready‐to‐eat meals for infants and small children is mainly expected to impact on the dietary exposure of infants. According to this scenario, the exposure estimates for infants are now in the same range as the exposure estimates for the adult population groups. Compared to the outcome of the baseline scenario for infants, the present scenario is expected to reduce the MB dietary exposure by 16--33% depending on the dietary survey. Only one dietary survey for infants was not impacted by the present scenario. However, as for the baseline scenario, this survey did not report consumption of ready‐to‐eat meals for infants and small children, and resulted in the lowest exposure estimate among all infant dietary surveys.

For toddlers, the impact on the mean dietary exposure is limited but for highly exposed consumers (95th percentile exposure) a reduction by up to 18% may be expected (median = 2%).

**Home‐cooking: toasting bread**

Furan has been reported in home‐cooked foods. The highest furan concentrations for these foods were reported for toasted bread and caramel (see Appendix [E](#efs25005-sec-0111){ref-type="sec"}, Table [E.1](#efs25005-tbl-0065){ref-type="table"}). Considering the importance of toasted bread in some diets, a scenario assessing the impact of toasting bread on the dietary exposure was considered by the CONTAM Panel.

For this scenario, a furan concentration of 260 μg/kg was assumed for all toasted bread, which corresponds to the highest mean concentration reported for fully browned toast in Appendix [E](#efs25005-sec-0111){ref-type="sec"}, Table [E.1](#efs25005-tbl-0065){ref-type="table"}. To identify consumption records referring to toasted bread, any consumption record containing 'toast' in its original food description was selected, and where the consumption data were already coded according to FoodEx2, consumption records containing the processing facet for toasting (A07HC) were also considered. Furthermore, any consumption record reported as toast bread was assumed to be toasted.

Chronic dietary exposure estimates for this scenario are summarised in Table [16](#efs25005-tbl-0016){ref-type="table"}, across all surveys. Detailed summary statistics on the exposure estimates calculated for each dietary survey are presented in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.9.

###### 

Summary statistics of the specific scenario assessing chronic dietary exposure to furan across European dietary surveys, assuming that all toasted bread is fully browned (home‐cooking)

  Age class[a](#efs25005-note-0043){ref-type="fn"}   N    Mean dietary exposure (μg/kg bw per day)                               
  -------------------------------------------------- ---- ------------------------------------------ ------ ------ ------ ------ ------
  Infants                                            6    0.14                                       0.21   0.41   0.49   0.90   1.01
  Toddlers                                           10   0.22                                       0.31   0.40   0.49   0.68   0.77
  Other children                                     18   0.19                                       0.27   0.33   0.41   0.47   0.55
  Adolescents                                        17   0.11                                       0.14   0.19   0.25   0.28   0.34
  Adults                                             17   0.13                                       0.16   0.32   0.36   0.57   0.61
  Elderly                                            14   0.14                                       0.17   0.33   0.37   0.63   0.66
  Very elderly                                       12   0.13                                       0.16   0.31   0.35   0.76   0.80

  **Age class** [a](#efs25005-note-0043){ref-type="fn"}   **N**   **95th percentile dietary exposure** [c](#efs25005-note-0045){ref-type="fn"} **(μg/kg bw per day)**                               
  ------------------------------------------------------- ------- ----------------------------------------------------------------------------------------------------- ------ ------ ------ ------ ------
  Infants                                                 5       0.27                                                                                                  0.42   1.11   1.27   1.75   1.94
  Toddlers                                                7       0.34                                                                                                  0.46   0.70   0.82   1.35   1.47
  Other children                                          18      0.29                                                                                                  0.40   0.60   0.71   0.91   1.00
  Adolescents                                             17      0.22                                                                                                  0.28   0.39   0.47   0.61   0.66
  Adults                                                  17      0.24                                                                                                  0.29   0.67   0.72   1.27   1.31
  Elderly                                                 14      0.30                                                                                                  0.33   0.73   0.76   1.32   1.36
  Very elderly                                            9       0.28                                                                                                  0.32   0.56   0.59   0.92   0.96

bw: body weight; LB: lower bound; N: number of surveys; UB: upper bound.

Section [2.4](#efs25005-sec-0028){ref-type="sec"} describes the age range within each age class.

Estimates were rounded to two decimal places.

The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically robust (EFSA, [2011a](#efs25005-bib-0069){ref-type="ref"}). Those estimates were not included in this table.
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Based on these results, toasted bread is expected to have a limited impact on the exposure of infants where the mean and the 95th percentile MB exposure estimates increased by up to 16% and 9%, respectively.

For all other age classes, the impact on the dietary exposure is very variable depending on the dietary survey. While a high number of exposure estimates remained unchanged compared to the baseline scenario, the highest increases were observed for the 95th percentile exposures (MB), ranging from 65% to 116% depending on the age class. These differences may partially be explained by the fact that some surveys did not clearly report consumption of toasted bread, but it is also expected that dietary habits may be different among Member States.

Nevertheless, the high increases reported above did not necessarily refer to the surveys giving the highest exposure estimates under the baseline scenario and, when comparing the maximum exposure estimates from the current scenario (Table [16](#efs25005-tbl-0016){ref-type="table"}) with the maximum exposure estimates from the baseline scenario (Table [14](#efs25005-tbl-0014){ref-type="table"}), the overall impact of toasting bread on the outcome of the exposure assessment is limited.

**Contribution of 2‐ and 3‐methylfuran to the exposure**

Due to the lack of occurrence data for 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran in food, these compounds could not be considered in the baseline exposure assessment. While for coffee beverages, breakfast cereals, cereal‐based food for infants and young children, and ready‐to‐eat meals for infants and young children, indicative ratios for 2‐ and 3‐methylfuran over furan were reported (see Section [3.2.3](#efs25005-sec-0060){ref-type="sec"}, Table [12](#efs25005-tbl-0012){ref-type="table"}), literature data were too limited to derive such ratios for 2,5‐dimethylfuran. Hence, in order to assess the possible contribution of 2‐ and 3‐methylfuran to the exposure, occurrence values for the food categories reported in Table [12](#efs25005-tbl-0012){ref-type="table"} were adjusted according to the following equation:

Mean~TF~ = Mean~F~ × (1 + Ratio~2MF/F~ + Ratio~3MF/F~)

Where:

Mean~TF~: mean concentration for the sum of furan, 2‐methylfuran and 3‐methylfuran

Mean~F~: mean concentration for furan

Ratio~2MF/F~: ratio of 2‐methylfuran over furan

Ratio~3MF/F~: ratio of 3‐methylfuran over furan

For those consumption events referring to a solid coffee product, the ratios derived for coffee beverage were applied assuming that these solids were consumed as a beverage.

The food categories adjusted for this scenario are expected to provide a good indication for the contribution of 2‐ and 3‐methylfuran to the overall exposure because these food categories were also identified as the main contributors to the exposure calculated under the baseline scenario.

Chronic dietary exposure estimates for the sum of furan, 2‐methylfuran and 3‐methylfuran are summarised in Table [17](#efs25005-tbl-0017){ref-type="table"}, across all surveys. Detailed summary statistics on the exposure estimates calculated for each dietary survey are presented in Annex [A](#efs25005-sec-0112){ref-type="sec"}, Table A.10.

###### 

Summary statistics of the specific scenario assessing chronic dietary exposure to the sum of furan, 2‐methylfuran and 3‐methylfuran across European dietary surveys

  Age class[a](#efs25005-note-0047){ref-type="fn"}        N                                                    Mean dietary exposure (μg/kg bw per day)                                                                                                
  ------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------------------------------- -------- -------- -------- ------ ------
  Infants                                                 6                                                    0.17                                                                                                  0.25     0.52     0.61     1.21   1.35
  Toddlers                                                10                                                   0.28                                                                                                  0.36     0.40     0.50     0.63   0.77
  Other children                                          18                                                   0.23                                                                                                  0.31     0.31     0.39     0.49   0.60
  Adolescents                                             17                                                   0.15                                                                                                  0.18     0.21     0.27     0.44   0.50
  Adults                                                  17                                                   0.21                                                                                                  0.24     1.14     1.18     2.25   2.29
  Elderly                                                 14                                                   0.27                                                                                                  0.30     1.15     1.19     2.64   2.68
  Very elderly                                            12                                                   0.26                                                                                                  0.30     1.02     1.05     3.27   3.31
  **Age class** [a](#efs25005-note-0047){ref-type="fn"}   **N**                                                **95th percentile dietary exposure** [c](#efs25005-note-0049){ref-type="fn"} **(μg/kg bw per day)**                                     
  **Minimum** [b](#efs25005-note-0048){ref-type="fn"}     **Median** [b](#efs25005-note-0048){ref-type="fn"}   **Maximum** [b](#efs25005-note-0048){ref-type="fn"}                                                                                     
  **LB**                                                  **UB**                                               **LB**                                                                                                **UB**   **LB**   **UB**          
  Infants                                                 5                                                    0.34                                                                                                  0.49     1.54     1.70     2.21   2.36
  Toddlers                                                7                                                    0.51                                                                                                  0.64     0.63     0.81     1.25   1.40
  Other children                                          18                                                   0.37                                                                                                  0.49     0.55     0.67     1.31   1.40
  Adolescents                                             17                                                   0.29                                                                                                  0.33     0.51     0.58     1.31   1.36
  Adults                                                  17                                                   0.46                                                                                                  0.50     2.66     2.70     5.73   5.78
  Elderly                                                 14                                                   0.96                                                                                                  0.98     2.92     2.96     6.11   6.14
  Very elderly                                            9                                                    0.78                                                                                                  0.84     2.34     2.37     4.00   4.02

bw: body weight; LB: lower bound; N: number of surveys; UB: upper bound.

Section [2.4](#efs25005-sec-0028){ref-type="sec"} describes the age range within each age class.

Estimates were rounded to two decimal places.

The 95th percentile estimates obtained on dietary surveys/age classes with less than 60 observations may not be statistically robust (EFSA, [2011a](#efs25005-bib-0069){ref-type="ref"}). Those estimates were not included in this table.
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When considering the sum of furan, 2‐methylfuran and 3‐methylfuran, the highest chronic exposures are estimated for adults, the elderly and the very elderly. In these cases, the highest mean exposure was calculated for the very elderly, ranging from 3.27 to 3.31 μg/kg bw per day (LB and UB estimates, respectively). Compared to the exposures calculated under the baseline scenario, the median contribution of 2‐ and 3‐methylfuran to the overall exposure amounted to 245%, going up to 317% for one survey. Looking at the highly exposed consumers (95th percentile exposure), the highest exposure is calculated for the elderly ranging from 6.11 to 6.14 μg/kg bw per day (LB and UB estimates, respectively). In this case, the median contribution of 2‐ and 3‐methylfuran corresponded to 351%, going up to 387% for one survey.

The high exposures calculated under this scenario for adults, elderly and very elderly are mainly driven by the high occurrence of 2‐methylfuran in coffee (four times higher than furan), while coffee was already the major contributor to the exposure of furan in these age classes (see also Section [3.3.2](#efs25005-sec-0063){ref-type="sec"}). For the younger age groups (infants, toddlers, adolescents and other children), the major contributors to the exposure were food for infants and small children, and grains and grain‐based products. The concentrations of 2‐ and 3‐methylfuran were much lower in these food groups. Therefore, in the younger age groups, the contribution of these two compounds to the overall exposure is estimated to be much lower than in the adult age groups.

### 3.3.4. Previously reported dietary exposure {#efs25005-sec-0065}

The occurrence of furan in food was reported annually by the EFSA ([2009](#efs25005-bib-0065){ref-type="ref"}, [2010c](#efs25005-bib-0068){ref-type="ref"}, [2011d](#efs25005-bib-0072){ref-type="ref"}). The report published in 2011 includes all data collected between 2004 and 2010. In addition, it presents exposure estimates for different populations. The analysis included a total of 5,050 analytical results for furan content in food submitted by 20 countries. Mean furan exposure across surveys was estimated to range between 0.03 and 0.59 μg/kg bw per day for adults, between 0.02 and 0.13 μg/kg bw per day for adolescents, between 0.04 and 0.22 μg/kg bw per day for other children, between 0.05 and 0.31 μg/kg bw per day for toddlers, and between 0.09 and 0.22 μg/kg bw per day for infants. A major contributor to exposure for adults was brewed coffee with an average of 85% of total furan exposure. Major contributors to furan exposure in toddlers and other children were fruit juice, milk‐based products and cereal‐based products, whereas in addition for toddlers jarred baby foods were major contributors. Table [18](#efs25005-tbl-0018){ref-type="table"} gives an overview of the reported exposure levels.

JECFA evaluated furan at its 72nd meeting in 2010 (FAO/WHO, [2011](#efs25005-bib-0089){ref-type="ref"}) and considered dietary exposure estimates for furan submitted by the USA, EU and Brazil. In general, the mean dietary exposure was between 0.25 and 1.17 μg/kg bw per day for adults, between 0.08 and 0.23 μg/kg bw per day for children 1--6 years of age, and between 0.27 and 1.01 μg/kg bw per day for infants. The high dietary exposure was between 0.6 and 2.22 μg/kg bw per day for adults and between 0.99 and 1.34 μg/kg bw per day for infants. Coffee was the main contributor to dietary furan exposure for adults, and breakfast cereals was the main contributor for children. Based on these data, JECFA decided to use for the risk characterisation a value of 1 μg/kg bw per day to represent mean dietary exposure and 2 μg/kg bw per day to represent high dietary exposure (see also Section [1.3.3](#efs25005-sec-0011){ref-type="sec"}).

In 2012, the Norwegian Food Safety Authority assessed the dietary exposure to furan as part of a full risk assessment (VKM, [2012](#efs25005-bib-0269){ref-type="ref"}; see also Section [1.3.3](#efs25005-sec-0011){ref-type="sec"}). The mean dietary exposure was the highest in 12‐month old infants; being 0.62 μg/kg bw per day (0.65 μg/kg bw per day in non‐breastfed infants). For adults (18--70 years old), the mean dietary furan exposure was 0.27 μg/kg bw per day. The 95th percentile dietary exposure was 1.43 μg/kg bw per day for 12‐month‐old infants and 0.77 μg/kg bw per day for adults. Coffee was the most important contributor to dietary furan exposure in adults. For the younger age groups, jarred baby food and breakfast cereals (especially sweet breakfast cereals) were the highest contributors.

The French Agency for Food, Environmental and Occupational Health & Safety (anses; Agence nationale de sécurité sanitaire alimentation, environment, travail) published in 2016 the outcome of a total diet study (TDS) in children younger than 3 years of age. The mean dietary exposure to furan was 0.14, 0.60, 0.84 and 0.37 μg/kg bw per day (UB) for 1--4 months, 5--6 months, 7--12 months and 13--36 months old infants, respectively. High dietary exposure (90th percentile) was 0.28, 1.29, 1.52 and 0.78 μg/kg bw per day for these age groups, respectively. For the youngest age group (1--4 months), jarred baby food (vegetables) and infant formula[27](#efs25005-note-1030){ref-type="fn"} were the main contributors and for the older age groups jarred baby food (vegetables/vegetables with meat/vegetables with fish) (anses, [2016](#efs25005-bib-0013){ref-type="ref"}).

Health Canada carried out a deterministic exposure assessment for furan and the sum of furan and 2‐methylfuran in 2010 using occurrence data reported by Becalski et al. ([2005](#efs25005-bib-0023){ref-type="ref"}, [2010](#efs25005-bib-0024){ref-type="ref"}). This exposure assessment was updated in 2016 using a probabilistic approach and the same occurrence data but more recent consumption data. The mean dietary exposure to furan and the sum of furan and 2‐methylfuran was the highest in infants (0.65 and 0.69 μg/kg bw per day, respectively) and toddlers (0.32 and 0.40 μg/kg bw per day, respectively). For adults (age groups greater than 18 years of age), the mean dietary exposures to furan and the sum of furan and 2‐methylfuran were 0.18 and 0.20 μg/kg bw per day, respectively. However, it should be noted that the presence of 2‐methylfuran in brewed coffee and rehydrated instant coffee was not taken into account in this assessment. Consequently, the exposure to furan and 2‐methylfuran of the age groups that consume coffee are expected to be higher than the estimated intakes. It should also be noted that foods such as toast, breakfast cereals and milk were not included in the exposure assessment. The major contributors to the dietary exposure of children up to 13 years of age were canned baked beans, fruit juices and sauces and condiments, while coffee was the most important contributor in all age classes greater than 18 years (Health Canada, [2016](#efs25005-bib-0121){ref-type="ref"}).

###### 

Overview of previously reported dietary exposure levels

  Age group[a](#efs25005-note-0051){ref-type="fn"}   Location             Mean dietary exposure (μg/kg bw per day   High dietary exposure (μg/kg bw per day   Reference
  -------------------------------------------------- -------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------------------------
  Infants                                            EU                   0.09--0.22                                0.89--0.97                                EFSA ([2011d](#efs25005-bib-0072){ref-type="ref"})
  Infants                                            USA, EU and Brazil   0.27--1.01                                0.99--1.34                                FAO/WHO ([2011](#efs25005-bib-0089){ref-type="ref"})
  Infants                                            France               0.14--0.84                                0.28--1.52                                Anses ([2016](#efs25005-bib-0013){ref-type="ref"})
  Infants                                            Norway               0.62--0.65                                1.43                                      VKM ([2012](#efs25005-bib-0269){ref-type="ref"})
  Infants                                            Canada               0.65                                      1.76                                      Health Canada ([2016](#efs25005-bib-0121){ref-type="ref"})
  Toddlers                                           EU                   0.05--0.31                                0.15--1.38                                EFSA ([2011d](#efs25005-bib-0072){ref-type="ref"})
  Toddlers                                           France               0.37                                      0.78                                      Anses ([2016](#efs25005-bib-0013){ref-type="ref"})
  Toddlers                                           Canada               0.32                                      0.70                                      Health Canada ([2016](#efs25005-bib-0121){ref-type="ref"})
  Children 1--6 years                                USA, EU and Brazil   0.08--0.23                                n.a.                                      FAO/WHO ([2011](#efs25005-bib-0089){ref-type="ref"})
  Other children                                     EU                   0.04--0.22                                0.06--0.46                                EFSA ([2011d](#efs25005-bib-0072){ref-type="ref"})
  Adolescents                                        EU                   0.02--0.13                                0.05--0.31                                EFSA ([2011d](#efs25005-bib-0072){ref-type="ref"})
  Adults (\> 18 years)                               EU                   0.03--0.59                                0.08--1.29                                EFSA ([2011d](#efs25005-bib-0072){ref-type="ref"})
  Adults                                             USA, EU and Brazil   0.25--1.17                                0.6--2.22                                 FAO/WHO ([2011](#efs25005-bib-0089){ref-type="ref"})
  Adults (18--70 years)                              Norway               0.27                                      0.77                                      VKM ([2012](#efs25005-bib-0269){ref-type="ref"})
  Adults (\> 18 years)                               Canada               0.14--0.21                                0.33--0.48                                Health Canada ([2016](#efs25005-bib-0121){ref-type="ref"})

n.a.: not available; bw: body weight.

Data are organised according to age classes specified in Section [2.4](#efs25005-sec-0028){ref-type="sec"} unless otherwise specified.
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### 3.3.5. Non‐dietary sources of exposure {#efs25005-sec-0066}

In addition to dietary exposure, exposure through inhalation during cooking occurs. Crews ([2009](#efs25005-bib-0050){ref-type="ref"}) measured furan in the air during cooking. Low and variable concentrations were detected when the cooking activity was less than 10 mins, while higher levels were observed when the cooking took longer than 10 mins. The authors calculated the amount of furan inhaled during cooking which varied between 11 and 523 ng furan depending on the food, the duration of the processing and type of processing technique. However, the authors indicated that these values should be considered as rough estimates only.

There are numerous reports of furan exposure through cigarette smoke. Furan is listed as one of the 'Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke' on the US Food and Drug Administration\'s website.[28](#efs25005-note-1031){ref-type="fn"} The exposure to furan per 'puff' (40 mL inhalation) was reported to be about 8.4 μg (Egle and Gochberg, [1979a](#efs25005-bib-0079){ref-type="ref"}). Pouli et al. ([2003](#efs25005-bib-0225){ref-type="ref"}) reported a higher level of furan in cigarette smoke than 2,5‐dimethylfuran (37.3 vs 19.4 μg/cigarette). The same observation was made by Hatzinikolaou et al. ([2006](#efs25005-bib-0120){ref-type="ref"}), although lower levels were reported (20.2 vs 10.7 μg/cigarette). Baek and Jenkins ([2004](#efs25005-bib-0018){ref-type="ref"}) reported besides the presence of furan and 2,5‐dimethylfuran in cigarette smoke also the presence of 2‐methylfuran at similar levels as furan.

Furan[29](#efs25005-note-1032){ref-type="fn"} and methylfurans are also used in industrial settings (see also Section [1.3.6](#efs25005-sec-0014){ref-type="sec"}).

3.4. Risk characterisation {#efs25005-sec-0067}
--------------------------

### 3.4.1. Furan {#efs25005-sec-0068}

**Non‐neoplastic effects**

The CONTAM Panel selected the BMDL~10~ of 0.064 mg/kg bw per day (corrected for the applied dose regimen of 5 days per week) for the induction of cholangiofibrosis in male rats after 2 years as reference point for the risk characterisation of the non‐neoplastic effects.

Comparison of the chronic dietary exposure to furan across dietary surveys and age groups reported above (Table [14](#efs25005-tbl-0014){ref-type="table"}) to this BMDL~10~ of 0.064 mg/kg bw per day, results in MOE values (Table [19](#efs25005-tbl-0019){ref-type="table"}) that range from 584 (minimum LB) to 65 (maximum UB) for the mean exposure estimates, and from 338 (minimum LB) to 35 (maximum UB) for the 95th percentile exposure estimates across dietary surveys and age groups.

###### 

Margins of exposure (MOE) values for the incidence of cholangiofibrosis across dietary surveys and age groups

  Age group        MOE calculated from mean dietary exposure   MOE calculated from P95 dietary exposure                                                         
  ---------------- ------------------------------------------- ------------------------------------------ ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  Infants          459                                         306                                        161   131   74    65    238   153   58    51    40    35
  Toddlers         292                                         207                                        179   140   124   99    189   140   109   86    67    60
  Other children   338                                         238                                        230   179   143   124   222   161   137   107   86    75
  Adolescents      584                                         459                                        378   292   247   207   338   257   207   165   129   111
  Adults           584                                         459                                        201   184   129   119   321   257   102   93    54    53
  Elderly          536                                         429                                        201   179   111   105   268   230   97    92    51    51
  Very elderly     495                                         402                                        230   201   91    86    238   201   124   115   70    67

N: number of dietary surveys; LB: lower bound; UB: upper bound; P95: 95th percentile.
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The CONTAM Panel considered that based on the available toxicity data and taking inter‐ and intra‐ species variations into account, a MOE of 100 or higher would be sufficient to conclude a low health concern for the non‐neoplastic effects. The calculated MOEs for the incidence of cholangiofibrosis are below 100 in a number of dietary surveys, particularly for the high percentile exposure estimates for the younger age groups (infants and toddlers) and adults (including elderly). The CONTAM Panel concluded that these MOEs indicate a health concern.

**Neoplastic effects**

The CONTAM Panel selected the BMDL~10~ of 1.31 mg/kg bw per day (corrected for the applied dose regimen of 5 days per week) for the induction of hepatocellular adenomas and carcinomas in female mice after 2 years as a reference point for the risk characterisation of the neoplastic effects.

Comparison of the chronic dietary exposure to furan across dietary surveys and age groups reported above (Table [14](#efs25005-tbl-0014){ref-type="table"}) to this BMDL~10~ of 1.31 mg/kg bw per day, results in MOE values (Table [20](#efs25005-tbl-0020){ref-type="table"}) that range from 11,948 (minimum LB) to 1,328 (maximum UB) for the mean exposure estimates, and from 6,917 (minimum LB) to 722 (maximum UB) for the 95th percentile exposure estimates across dietary surveys and age groups.

###### 

Margins of exposure (MOE) values for the incidence of hepatocellular adenomas and carcinomas across dietary surveys and age groups

  Age group        MOE calculated from mean dietary exposure   MOE calculated from P95 dietary exposure                                                                           
  ---------------- ------------------------------------------- ------------------------------------------ ------- ------- ------- ------- ------- ------- ------- ------- ------- -------
  Infants          9,388                                       6,259                                      3,286   2,682   1,511   1,328   4,868   3,129   1,184   1,035   821     722
  Toddlers         5,974                                       4,240                                      3,651   2,857   2,527   2,022   3,866   2,857   2,228   1,752   1,369   1,217
  Other children   6,917                                       4,868                                      4,694   3,651   2,921   2,527   4,532   3,286   2,796   2,190   1,752   1,528
  Adolescents      11,948                                      9,388                                      7,731   5,974   5,055   4,240   6,917   5,257   4,240   3,370   2,629   2,266
  Adults           11,948                                      9,388                                      4,107   3,755   2,629   2,434   6,571   5,257   2,086   1,905   1,114   1,077
  Elderly          10,952                                      8,762                                      4,107   3,651   2,266   2,155   5,476   4,694   1,991   1,878   1,051   1,035
  Very elderly     10,110                                      8,214                                      4,694   4,107   1,851   1,752   4,868   4,107   2,527   2,347   1,429   1,369

N: number of dietary surveys; LB: lower bound; UB: upper bound; P95: 95th percentile.
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For substances that are both genotoxic and carcinogenic, the EFSA Scientific Committee stated that an MOE of 10,000 or higher, if based on the BMDL~10~ from an animal carcinogenicity study, would be of low concern from a public health point of view (EFSA, 2005). The CONTAM Panel noted that, with the exception of some dietary surveys, the calculated MOEs are smaller than 10,000, which would indicate a health concern for substances that are both genotoxic and carcinogenic. However, there is uncertainty regarding the carcinogenic MoA of furan.

As discussed in Section [3.1.5](#efs25005-sec-0051){ref-type="sec"} on critical effects, there is clear evidence for the involvement of indirect mechanisms in the carcinogenic MoA of furan. These include epigenetic changes, oxidative damage to DNA and regenerative hyperplasia, with all these effects being accompanied by tissue damage. In addition, extensive protein binding of BDA restricts access to DNA, and binding to histones may also contribute to the reported epigenetic changes. There is limited evidence of a direct mechanism (i.e. direct interaction with DNA) in the carcinogenic action of furan. A very low level of altered DNA bases was observed *in vivo* but their chemical structures could not be identified. These altered DNA bases are not identical to the adducts formed by reaction of BDA with DNA. Nevertheless, there is evidence of chromosomal damage *in vivo*, but it is unknown whether this is caused by a direct or indirect mechanism.

Although there is uncertainty regarding the role of a direct genotoxic mechanism in the carcinogenic action of furan, the CONTAM Panel considered the resulting MOEs for hepatocellular adenomas and carcinomas as supporting evidence for its conclusion, based on the hepatotoxicity of furan, that the current exposure to furan indicates a health concern.

### 3.4.2. Additivity of furan and methylfurans {#efs25005-sec-0069}

For the methylfurans, insufficient information is available to identify a reference point. 2‐Methylfuran, 3‐methylfuran and 2,5‐dimethylfuran have all been shown to convert to reactive species via ring opening evidently via CYP2E1 similar to the metabolic pathway of furan. Also, as with furan, these methylfurans have been found to give rise to non‐extractable binding to protein (and, with 2‐methylfuran, to DNA) in the liver. Only limited information is available on 2‐methylfuran and 2,5‐dimethylfuran genotoxicity. There is possible involvement of alternative routes of metabolic activation for 2,5‐dimethylfuran. Finally, the hepatic toxicity of both 2‐ and 3‐methylfuran in rodents exhibited a potency of the same order of magnitude to that of furan. Based on the above comparisons, it was considered appropriate for hepatotoxicity to assume dose additivity for furan, 2‐methylfuran, 3‐methylfuran. However, since there is no information on hepatotoxicity of 2,5‐dimethylfuran *in vivo* the CONTAM Panel is unable to include this in the additivity assumption.

Due to the lack of occurrence data on methylfurans in the available data set, a scenario was designed to estimate the chronic dietary exposure to the sum of furan, 2‐methylfuran and 3‐methylfuran based on 2‐methylfuran/furan and 3‐methylfuran/furan ratios for some selected foods (see Section [3.3.3](#efs25005-sec-0064){ref-type="sec"}). Comparison of the chronic dietary exposure calculated for this scenario (Table [17](#efs25005-tbl-0017){ref-type="table"}) to the BMDL~10~ of 0.064 mg/kg bw per day for the incidence of cholangiofibrosis, results in MOE values (Table [21](#efs25005-tbl-0021){ref-type="table"}) that range from approximately 430 (minimum LB) to 20 (maximum UB) for the mean exposure estimates, and from 220 (minimum LB) to 10 (maximum UB) for the 95th percentile exposure estimates across dietary surveys and age groups.

###### 

Margins of exposure (MOE) values for the incidence of cholangiofibrosis based on a scenario for chronic dietary exposure to the sum of furan, 2‐methylfuran and 3‐methylfuran across dietary surveys and age groups

  Age group        MOE calculated from mean dietary exposure   MOE calculated from P95 dietary exposure                                                        
  ---------------- ------------------------------------------- ------------------------------------------ ----- ----- ----- ----- ----- ----- ----- ----- ---- ----
  Infants          378                                         257                                        124   105   53    48    189   131   42    38    29   27
  Toddlers         230                                         179                                        161   129   102   83    126   100   102   79    51   46
  Other children   280                                         207                                        207   165   131   107   174   131   117   96    49   46
  Adolescents      429                                         357                                        306   238   146   129   222   195   126   111   49   47
  Adults           306                                         268                                        56    54    29    28    140   129   24    24    11   11
  Elderly          238                                         214                                        56    54    24    24    67    66    22    22    11   10
  Very elderly     247                                         214                                        63    61    20    19    82    77    27    27    16   16

N: number of dietary surveys; LB: lower bound; UB: upper bound; P95: 95th percentile

Note: the additive exposure has been calculated as mg/kg bw per day and not on a molar basis.

John Wiley & Sons, Ltd

The CONTAM Panel noted that the calculated MOEs for the incidence of cholangiofibrosis are below 100 for more than 50% of the dietary surveys for the adult age groups (including elderly and very elderly) for both mean and high percentile exposure estimates. Also, for the younger age groups, MOEs below 100 were calculated for some dietary surveys. From these figures, it becomes clear that methylfurans may add significantly to the overall exposure and therefore increase the concern for hepatotoxicity.

3.5. Uncertainty analysis {#efs25005-sec-0070}
-------------------------

The evaluation of the inherent uncertainties in the assessment of exposure to furan and methylfurans has been performed following the guidance of the Opinion of the Scientific Committee related to Uncertainties in Dietary Exposure Assessment (EFSA, [2007](#efs25005-bib-0064){ref-type="ref"}). In addition, the report on 'Characterizing and Communicating Uncertainty in Exposure Assessment' has been considered (WHO/IPCS, [2008](#efs25005-bib-0278){ref-type="ref"}).

### 3.5.1. Assessment objectives {#efs25005-sec-0071}

The objectives of the assessment were clearly specified in the terms of reference.

### 3.5.2. Exposure scenario/exposure model {#efs25005-sec-0072}

To estimate chronic dietary exposure to furan, EFSA used a final data set containing 9,663 samples provided by governmental organisations and 7,393 samples provided by commercial organisations. The amount of occurrence data submitted differs considerably depending on food products and reporting data provider, with most of the samples (\~ 80%) collected in only five Member States (and \~ 60% originating from one single Member State). There is therefore uncertainty on whether possible country‐based differences in the levels of furan in diverse food commodities are well represented. Likewise, the lack of information on the analytical method used to analyse some food samples (\~ 30% of the governmental data) adds some uncertainty to the concentrations of furan reported for some food commodities.

Another uncertainty regarding the occurrence data refers to the roasting degree of coffee, as the available data did not allow differentiating furan concentrations in light, medium and dark roast coffee. While a consumer\'s preference for dark roast coffee is expected to increase the dietary exposure to furan, the exposure estimate for light roast coffee consumers will most likely be lower. Furthermore, in order to estimate the occurrence of furan in prepared coffee and coffee imitate beverages, certain assumptions were made on the dilution and loss of furan during beverage preparation. On average, estimations for the major coffee types were consistent with the furan concentrations measured in a limited number of beverage samples. Considering the wide variety of coffee preparation methods, uncertainty remains regarding other very specific preparation methods that may occur in practice. In addition, possible losses of furan during standing of beverages after brewing could not be considered in the present assessment because the standing time is highly dependent on consumer behaviour and therefore not predictable. Overall, these uncertainties may lead to an overestimation or underestimation of exposure.

Furan may also occur in food additives and flavourings, which may be used in a wide range of food products. While it is expected that most of the furan concentrations resulting from those uses have been captured in the final data set, some minor food products may not be covered by the available data hereby resulting in a minor underestimation of the exposure estimates.

Uncertainties and limitations related to the use of the EFSA Comprehensive Food Consumption Database have already been described by EFSA (EFSA, [2011a](#efs25005-bib-0069){ref-type="ref"}) and are not further detailed in this opinion. However, among those with a particular implication for the dietary exposure to furan, the uncertainty associated to commercially processed foods should be mentioned because for certain food groups (e.g. vegetables and vegetables products) consumption data have been mostly reported at the level of raw commodities (e.g. tomatoes), without systematic information on whether these were commercially processed products (e.g. canned tomatoes). Following a more detailed analysis of the Comprehensive Database, the highest contribution of commercially processed products among dietary surveys was derived for each food category and applied to all consumers, regardless of the dietary survey. Assuming the same contribution for all consumers may underestimate the upper tail exposures for high consumers of commercially processed products. However, as this contribution refers to the maximum contribution observed among dietary surveys, mean exposures are expected to be overestimated. Furthermore, eating occasions reported for composite food were assumed to be commercially processed as no information is available on whether they referred to homemade dishes or ready‐to‐eat foods. Also in this case, an overestimation of the exposure is likely.

The Comprehensive Database also contains limited information on consumer\'s preferences regarding coffee consumption (e.g. roasting degree, coffee type). In particular, unspecified coffee beverage is the most frequently reported coffee beverage in the Comprehensive Database. While these coffee beverages were handled as the most frequently consumed coffee within Europe (i.e. Americano coffee or filtered coffee), these consumption events might in fact refer to other coffee types with higher or lower furan concentrations. For several surveys, consumption events for coffee and coffee imitates were reported as the solid. Options for refinement of the exposure through solid coffee were limited and conservative assumptions were applied. Hence, an overestimation of the exposure is expected in these surveys.

Additional uncertainty in the exposure assessment to furan is related to the reheating of commercially processed foods, which may be particularly important for infants where ready‐to‐eat meals are the most important contributor to the exposure. While some reheating techniques have a very limited impact on the concentrations of furan (therefore not considered in the main exposure scenario), heating of a meal in a hot water bath without lid may decrease the exposure by approximately 15--30%. Due to the limited information, home‐cooking habits were also not considered in the main exposure scenario but the example of toasting bread was assessed in a separate scenario. While fully browned toasting of bread was found to increase significantly the exposure estimates for some population groups (up to 116%), the overall impact on the outcome of the assessment was limited.

The highest level of uncertainty is associated to the lack of occurrence data on 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran. While data for these compounds were too limited for consideration in the main exposure scenario, an additional scenario was elaborated where EFSA considered indicative occurrence values for 2‐ and 3‐methylfuran in the food categories contributing the most to the exposure. This scenario indicated that 2‐ and 3‐methylfuran may increase the exposure for adults, elderly and very elderly by more than 300%, and it is expected that exposure estimates would increase even more in case occurrence data for 2,5‐dimethylfuran would be available.

In addition to dietary exposure to furan and methylfurans, exposure via inhalation may occur in humans but this was not taken into account in this risk assessment.

### 3.5.3. Model input (parameters) {#efs25005-sec-0073}

Currently, no official standard methods are available for the analysis of furan and methylfurans in foods. Analytical results used for the exposure assessment were therefore obtained using different analytical methods and varying LOQ/LODs. Although a large proportion of left‐censored results was found in certain food groups (i.e. grains and grain‐based products, foods for infants and young children and composite foods), the difference between LB and UB estimates was found to be small, particularly for adults, elderly and very elderly where coffee is the main contributor to the dietary exposure. This indicates that the uncertainty due to left‐censored data is limited.

Furthermore, analytical methods for furan mostly rely on the use of headspace analysis, while a limited additional formation of furan during the equilibration of the sample in the headspace vials has been reported (see Section [1.3.2](#efs25005-sec-0010){ref-type="sec"}). This may result in a minor overestimation of furan concentrations in food.

### 3.5.4. Other uncertainties {#efs25005-sec-0074}

Although many studies on the toxicity of furan have been published, several sources of uncertainty have been identified. The greatest degree of uncertainty concerns the carcinogenic MoA of furan i.e. whether or not furan is directly genotoxic and the extent to which this may contribute to carcinogenicity at levels to which humans are exposed.

For studies that attempt to estimate concentrations of furan or methylfurans in cell cultures or in tissues, there is uncertainty regarding the loss via evaporation. This potentially could lead to an overestimate of exposure both *in vitro* and *in vivo*. *In vitro* studies that used a reduced headspace to avoid evaporation may have incurred oxygen depletion leading to compromised metabolic capacity, introducing uncertainty in the interpretation of the results. In tissues of dosed animals, the evaporation may affect the measured residual concentrations.

Regarding methylfurans, there are limited studies on absorption, metabolism and toxicity. Carcinogenicity data are limited to one study on 2,5‐dimethylfuran. In addition to the demonstrated ring opening of methylfurans, there is a theoretical possibility of oxidation of the side‐chain leading to furyl alcohols which can subsequently be activated by sulfonation, aldehydes and acids but this possibility has not been assessed. Therefore, a conclusion regarding the potential for the methylfurans to be carcinogenic in a similar way to furan cannot be made. Based on evidence of reactivity of metabolites and similarity in hepatotoxic potency, it was considered reasonable, despite uncertainty, to combine furan, 2‐methylfuran and 3‐methylfuran as an additive in assessment of hepatotoxicity.

### 3.5.5. Summary of uncertainties {#efs25005-sec-0075}

In Table [22](#efs25005-tbl-0022){ref-type="table"}, a summary of the uncertainty evaluation is presented, highlighting the main sources of uncertainty and indicating an estimate of whether the respective source of uncertainty might have led to an over‐ or underestimation of the exposure or the resulting risk.

###### 

Summary of qualitative evaluation of the impact of uncertainties on the risk assessment of the dietary exposure of furan and methylfurans in food

  Sources of uncertainty                                                                   Direction
  ---------------------------------------------------------------------------------------- --------------------------------------------
  Extrapolation of the occurrence data to the whole of Europe                              +/−[a](#efs25005-note-0056){ref-type="fn"}
  Lack of occurrence data in coffee in relation to its roasting degree                     +/−
  Assumptions on the preparation of coffee and coffee imitate beverages                    +/−
  Assumptions on the contribution of commercially processed foods to the consumption       +/−
  Assumptions on the consumption of unspecified coffee beverages                           +/−
  Exclusion of reheating commercially prepared foods in the baseline exposure scenario     \+
  Exclusion of home‐cooking practices in the baseline exposure scenario                    −
  Exclusion of methylfurans in the baseline exposure scenario                              −
  Evaporation of furan in tissues and cell cultures                                        −
  Potential for a direct genotoxic mechanism in the carcinogenic mode of action of furan   −
  Potential genotoxicity and carcinogenicity of methylfurans                               −
  Using an additive approach for furan and methylfurans regarding hepatotoxicity           +/−

\+ = uncertainty with potential to cause over‐estimation of exposure/risk; − = uncertainty with potential to cause under‐estimation of exposure/risk.

John Wiley & Sons, Ltd

The CONTAM Panel considered that the impact of the uncertainties on the risk assessment of furan is moderate and that the assessment is likely to be conservative. For methylfurans, due to a lack of data, no full assessment could be performed and the uncertainties in the assessment are large.

4. Conclusions {#efs25005-sec-0076}
==============

Furan, 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran are volatile compounds that are formed in foods during thermal processing. Furan can be formed in food from a variety of precursors including ascorbic acid, amino acids, carbohydrates, unsaturated fatty acids and carotenoids.

4.1. Occurrence/Exposure {#efs25005-sec-0077}
------------------------

To estimate chronic dietary exposure to furan, EFSA used a final data set containing 9,663 samples provided by governmental organisations and 7,393 samples provided by commercial organisations. Governmental data and commercial data were found to be comparable and it was considered appropriate to merge both data sets.Food characteristics, processing and cooking conditions, and the losses which occur mainly due to evaporation in the preparation of the food at the level of the consumer, determine the final concentration in the food as consumed.The highest concentrations of furan were found in whole roasted coffee beans, with a mean value of 4,579 μg/kg. Mean concentrations in ground roasted coffee (2,361 μg/kg) and unspecified coffee solids (2,186 μg/kg) were lower, suggesting a loss of furan during the process of grinding. High concentrations of furan were also found in coffee imitates for brewing (1,922 μg/kg), instant coffee powder (310 μg/kg) and instant coffee imitates (127 μg/kg).During coffee beverage preparation furan concentrations decrease substantially due to a combination of dilution, evaporation and partial extraction. Highest losses of furan during beverage preparation were observed for boiled/Turkish coffee (median loss factor of 11.6), and losses for filter coffees (median loss factor of 4.2) were also found to be higher compared to espresso coffees (median loss factor of 2.8). For instant coffees, the loss of furan during beverage preparation is considered negligible.Mean concentrations ranging from 20 to 57 μg/kg were found in composite foods (prepared salads, cereal‐based and vegetable‐based), ready‐to‐eat meals for infants and young children, soy sauce, bread and rolls, raw pasta, breakfast cereals, fine bakery wares and spirits. In all remaining samples, including a wide range of mainly commercially prepared foods, mean furan concentrations were below 20 μg/kg.Occurrence data for 2‐methylfuran, 3‐methylfuran and 2,5‐dimethylfuran were not provided, and from the available literature data on the co‐occurrence of furan and methylfurans, a 2‐methylfuran/furan and 3‐methylfuran/furan ratio was calculated only for coffee, infant cereals, jarred baby‐food and cereal flakes. Co‐occurrence data on 2,5‐dimethylfuran were too limited to derive such a ratio.The highest exposures to furan were estimated in the youngest population group, i.e. infants. The mean dietary exposures calculated for infants ranged from 0.14 to 0.99 μg/kg bw per day (minimum LB to maximum UB). Regarding the 95th percentile exposures, which refer to highly exposed consumers within a given dietary survey and age class, the highest estimates were also observed for infants ranging from 0.27 to 1.8 μg/kg bw per day (minimum LB to maximum UB).Ready‐to‐eat meals for infants and small children are the main contributor to the dietary exposure of infants. For adults, elderly and very elderly, the exposure is mainly driven by coffee. Grains and grain‐based products is the most contributing food group for toddlers, other children and adolescents, and it is also the second largest contributor in all other age classes. Other important contributors to the exposure of most age classes are ready‐to‐eat soups, and to a smaller extent, cereal‐based composite foods.Overall, the influence of reheating commercially processed foods on furan concentrations is limited and depends on the consumer behaviour. Regarding ready‐to‐eat meals for infants and young children, reheating the meals in a hot water bath (without lid) may reduce the dietary exposure of infants by approximately 15--30% depending on the dietary pattern. This results in an exposure comparable to the exposures in the adult age classes.In addition, furan can also be formed during home cooking. A scenario based on toasting bread, the process that caused the highest increase in the foods studied, showed that although for some specific subpopulations a significant increase of the exposure was observed the overall outcome of the exposure assessment (including all subpopulations) was not impacted.In the exposure scenario for the sum of furan, 2‐methylfuran and 3‐methylfuran, estimates for adults, elderly and very elderly showed the highest increase compared to the baseline scenario. The highest mean exposure, calculated for the very elderly, was approximately 3.3 μg/kg bw per day (LB = UB), while the highest 95th percentile exposure was approximately 6.1 μg/kg bw per day (LB = UB) for the elderly. This exposure was mainly driven by the high concentrations of 2‐methylfuran in coffee (four times higher than furan).

4.2. Hazard identification and characterisation {#efs25005-sec-0078}
-----------------------------------------------

**Toxicokinetics**

Furan After oral exposure to rats, furan is rapidly and extensively absorbed from the GI tract, distributed throughout the body and extensively metabolised to give carbon dioxide and polar metabolites in urine or bile/faeces.Furan has a very short half--life in liver and blood: approximately 40 min in liver and approximately 1.3 h in blood. Although at 24 h post‐dosing some furan‐related material could be extracted from liver tissue, 80% of the residual material in the liver appeared to be non‐extractable.The major route for elimination of furan is via metabolic conversion, resulting in opening of the furan ring and formation of BDA which is very reactive. BDA has never been directly measured. However, results with trapping agents and the identification of urinary and biliary metabolites provide strong evidence that BDA is indeed a prime reactive intermediate in the metabolism of furan.CYP2E1 is by far the most important monooxygenase that catalyses the conversion of furan into BDA.BDA reacts readily with amino acids, GSH and biogenic amines. A plethora of adducts has been reported. Elimination of these adducts via urine is biphasic: in first instance, the main excretion consists of BDA coupled to free amino acids or GSH. Later, the urinary excretion of furan‐related material is a result from protein turn‐over that liberates the furan‐damaged amino acid residues.BDA has direct reactivity towards DNA. However, the data suggest that BDA reacts readily with protein and non‐protein amino and thiol residues, thereby restricting access to DNA *in vivo*.It is currently impossible to select any furan metabolite as a quantitative biomarker of exposure. Furan may also be formed endogenously, which may need to be taken into account.

Methylfurans No oral studies have been performed with any of the three methylfurans considered in this opinion to address their kinetics in animals, but it is anticipated that the three methylfurans will be absorbed from the GI tract.Non‐extractable association of 2‐methylfuran with protein and DNA in the liver was reported after i.p. administration. For 2‐ and 3‐methylfuran data from *in vitro* studies are available that show that they may become associated (non‐extractable) with lung and liver microsomal proteins.The reactive metabolic intermediates of 2‐ and 3‐methylfuran are the *cis‐*enedials 3‐acetylacrolein (4‐oxopent‐2‐enal) and 2‐methylbut‐2‐enedial, respectively. Also, for 2,5‐dimethylfuran, ring opening results in the formation of a reactive intermediate, the *cis*‐enedione 3(*Z*)‐hexene‐2,5‐dione.Similar to BDA, the reactive intermediate formed from 2,5‐dimethylfuran reacts readily with amino acids and with GSH and corresponding structures for the adducts formed have been reported. For 2‐ and 3‐methylfuran metabolites, only very limited information is available, but from the structures of their primary metabolites and from studies with scavengers, it is anticipated that these will react with tissue components in a similar way to the primary metabolites of furan and 2,5‐dimethylfuran. For the methylfurans or their metabolites, there is no direct information on reactivity towards DNA. However, limited genotoxicity studies provide an indication that such interactions may occur.

**Toxicity**

Furan In experiments of a duration of up to 90 days, furan is strongly hepatotoxic and moderately nephrotoxic in rodents when applied by oral gavage. Rats seem to be more sensitive towards furan than mice. Furan leads to characteristic changes in serum markers related to hepatotoxicity as well as severe histopathological damage in the liver.The hepatotoxic effects are particularly pronounced in centrilobular and subcapsular areas and can be attenuated by suppression of CYP activity.After 90 days, significant increases in serum thyroid hormones were observed along with severe histopathological changes in the liver of male rats after a daily dose of 0.12 mg/kg bw, given 5 days a week.In long‐term studies, furan was associated with toxicity in the liver. Cholangiofibrosis was observed in rats as an early and sensitive response with significant increases after 36 weeks at doses of 0.44 mg/kg bw and above.In mice, hepatocellular adenoma/carcinoma occurred at 104 weeks at doses of 4 mg/kg bw and above. In rats, cholangiocarcinomas were observed at the top dose of 8 mg/kg bw. No relevant malignancies were observed at doses at or below 2 mg/kg bw up to 104 weeks.Furan did not induce gene mutations in bacteria.In the majority of the *in vitro* studies in mammalian cells, furan was able to induce chromosomal aberrations and sister chromatid exchanges; contrasting results were reported on the requirement for microsomal activation.BDA, the CYP2E1‐mediated metabolite of furan, formed DNA adducts at the exocyclic N atom of the dC, dG and dA nucleosides in *in vitro* model systems and in DNA from *S. *Typhimurium TA104. BDA was able to directly induce mutations in bacteria and strand breaks and mutations in mammalian cells *in vitro*.In rodents, furan induced very low levels of DNA adducts in liver and kidney. The chemical structures of these adducts could not be defined but were not identical to those induced by BDA in *in vitro* model systems.Conflicting data were reported for the induction of DNA breaks in the liver. These breaks, likely reflecting oxidative stress‐induced DNA damage, occurred at doses showing mild liver toxicity. Chronic exposure to furan‐induced chromosomal damage in proliferating splenocytes from mice and rats. The DNA lesions responsible for these effects remain undefined.No clear induction of base substitutions was observed in transgenic rat models. A weak mutagenic activity was suggested by a single study in a transgenic mouse model.An excess of GC \> TA transversions was observed at codon 61 of the *Ha‐ras* oncogene in furan‐induced liver tumours in mice. It is uncertain whether these mutations are the consequence of oxidative damage to DNA or reflect an expansion of pre‐existing spontaneous *Ha‐ras* mutations.Histological changes in the testes, prostate gland, Leydig cells and seminal vesicles were observed in Wistar rats at 2 mg/kg bw (lowest dose tested) and above given during weaning and post‐puberty. No histological effects in reproductive organs were observed in adult rats and mice up to 8 mg/kg bw.

Methylfurans The liver is the primary target organ with respect to acute and short‐term (\< 90 days) toxicity of 2‐ and 3‐methylfuran in rodents. Pulmonary toxicity was observed upon inhalation but also upon i.p. application. There is also indication for kidney toxicity of 3‐methylfuran after 90 days of exposure.No clear differences in structure--effect relationship for the investigated alkylated furans with respect to the pattern of adverse effects/the target organs were identified.Liver toxicity in male rats given 3‐methylfuran (28 or 90 days) or 2‐methylfuran (28 days) by gavage was found to be the most sensitive adverse endpoint for both compounds. Their toxic potency was reported to be in the same order of magnitude as that for furan.No information on the genotoxic properties of 3‐methylfuran and limited information for 2‐methylfuran and 2,5‐dimethylfuran is available. Both 2‐methylfuran and 2,5‐dimethylfuran showed negative results in bacteria. There is some evidence that both compounds induce chromosomal damage in mammalian cells *in vitro* and there is little evidence that 2,5‐dimethylfuran can induce DNA breaks *in vivo*.

**Mode of action** Furan induces oxidative stress. BDA binds covalently to a range of target molecules, including proteins and GSH. These features lead ultimately to cell and tissue damage, mitochondrial dysfunction and fibrosis, primarily in the liver.There is clear evidence for the involvement of indirect mechanisms in the carcinogenic MoA of furan. These include epigenetic changes, oxidative damage to DNA and regenerative hyperplasia, with all of these effects being accompanied by tissue damage.There is limited evidence of a direct mechanism (i.e. direct interaction with DNA) in the carcinogenic action of furan.The contributing factors in carcinogenesis are likely to vary according to dose, duration of exposure and degree of severity of liver cellular damage, inflammation and compensatory proliferation.

**Considerations of critical effects, dose--response modelling and possibilities for derivation of a health based guidance value** Since only few data are available on the effect of furan in humans, the CONTAM Panel used data in experimental animals for the hazard characterisation.For non‐neoplastic effects, the CONTAM Panel selected the BMDL~10~ of 0.09 mg/kg bw per day (5 days per week dosing regimen) for the induction of cholangiofibrosis in male rats after 2 years as reference point. This corresponds to 0.064 mg/kg bw per day (correcting for the applied dose regimen of 5 days per week).For neoplastic effects, the CONTAM Panel considered that the combined data set from NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) and Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) on the incidence of hepatocellular adenomas and carcinomas in female mice after 2 years is the most robust data set to derive a reference point and selected the BMDL~10~ of 1.84 mg/kg bw per day (5 days per week dosing regimen). This corresponds to 1.31 mg/kg bw per day (correcting for the applied dose regimen of 5 days per week).In view of some indications for a direct genotoxic mechanism in the carcinogenic MoA of furan, the CONTAM Panel decided that it was not appropriate to establish a TDI and used an MOE approach.The available information was insufficient to identify a reference point for the methylfurans. However, it was considered appropriate to assume dose additivity for hepatotoxicity of furan, 2‐methylfuran and 3‐methylfuran in the rat.

4.3. Risk characterisation {#efs25005-sec-0079}
--------------------------

For non‐neoplastic effects, MOE values that range from 584 (minimum LB) to 65 (maximum UB) for the mean exposure estimates, and from 338 (minimum LB) to 35 (maximum UB) for the 95th percentile exposure estimates across dietary surveys and age groups have been calculated. The calculated MOEs are below 100 in a number of dietary surveys, particularly for the high percentile exposure estimates for the younger age groups (infants and toddlers) and adults (including elderly). The CONTAM Panel concluded that these MOEs indicate a health concern.For neoplastic effects, MOE values that range from 11,948 (minimum LB) to 1,328 (maximum UB) for the mean exposure estimates, and from 6,917 (minimum LB) to 722 (maximum UB) for the 95th percentile exposure estimates across dietary surveys and age groups have been calculated.The CONTAM Panel noted that, with the exception of some surveys, the calculated MOEs for neoplastic effects of furan are smaller than 10,000, which, in accordance with the guidance given by the Scientific Committee, would indicate a health concern. However, there is uncertainty regarding the carcinogenic MoA of furan. The CONTAM Panel considered the resulting MOEs for hepatocellular adenomas and carcinomas as supporting evidence for its conclusion, based on the hepatotoxicity of furan, that the current exposure to furan indicates a health concern.Based on a scenario for chronic dietary exposure to the sum of furan, 2‐methylfuran and 3‐methylfuran, MOE values for the incidence of cholangiofibrosis range from approximately 430 (minimum LB) to 20 (maximum UB) for the mean exposure estimates, and from 220 (minimum LB) to 10 (maximum UB) for the 95th percentile exposure estimates across surveys and age groups have been calculated. From these figures, it becomes clear that methylfurans may add significantly to the overall exposure and therefore increase the concern for hepatotoxicity.

5. Recommendations {#efs25005-sec-0080}
==================

There is a need for additional data on the occurrence of methylfurans in food.There is a need for additional data on the changes of furan and methylfurans concentrations during the distinct stages of coffee preparation for all coffee types.Studies *in vivo* on the effect of furan on the genome to clarify the carcinogenic MoA are needed.Further information is needed on the toxicity, including the genotoxic properties, of methylfurans.

Documentation provided to EFSA {#efs25005-sec-0081}
==============================

Data on the co‐occurrence of furan, 2‐methylfuran and 3‐methylfuran in jarred baby foods, cereal flakes, roasted and grounded coffee, soluble coffee, infant cereals and tomato sauce. December 2016. Submitted by FoodDrinkEurope, outside the ad‐hoc call for occurrence data (see Section [2.3.1](#efs25005-sec-0026){ref-type="sec"}).Gill S, Kavanagh M, Cherry W, Bourque C, Caldwell D, Wang G and Bondy G. A 90‐Day Subchronic Gavage Toxicity Study in Fischer 344 Rats with 3‐methylfuran. August 2017. Submitted by Health Canada.

Abbreviations {#efs25005-sec-0082}
=============

ABTaminobenzotriazoleACB‐PCRallele‐specific competitive blocker‐polymerase chain reactionADMEabsorption, distribution, metabolism and excretionAICAkaike information criterionALPalkaline phosphataseALTalanine aminotransaminaseansesAgence nationale de sécurité sanitaire alimentation, environnement, travailAPapurinic/apyrimidinicBDA*cis*‐but‐2‐ene‐1,4‐dialdehydeBMDbenchmark doseBMDLbenchmark dose lower confidence limitBMDUbenchmark dose upper confidence limitBrdU5‐bromo‐2‐deoxyuridineBSObuthionine sulfoximineBUNblood urea nitrogenbwbody weightCAchromosomal aberrationsCEEREALEuropean Breakfast Cereal Association (),CHOChinese hamster ovaryCONTAMEFSA Panel on Contaminants in the Food ChainCyscysteineCYPcytochrome P450dA2'‐deoxyadenosineDATAEFSA Evidence Management UnitdC2'‐deoxycytidineDEMdiethylmaleatedG2'‐deoxyguanosineDPEDocumentation provided to EFSA by FoodDrinkEuropeDSBdouble strand breakdT2'‐deoxythymidineEC~50~half maximal effective concentrationECFEuropean Coffee FederationELISAenzyme‐linked immunosorbent assayFDAUS Food and Drug Administrationγ‐GTγ‐glutamyl transpeptidaseGCgas chromatographyGC‐SRI‐TOF‐MSgas chromatography‐selective reagent ionization‐time of flight‐mass spectrometryGIgastrointestinalGlnglutamineGluglutamateGSHglutathioneGST‐Pglutathione *S*‐transferase placental formHBGVhealth‐based guidance valueHPLChigh‐performance liquid chromatographyIARCInternational Agency for Research on CancerICLinter‐strand crosslinkIgimmunoglobulinILinterleukini.p.intraperitonealIPCSInternational Programme on Chemical SafetyJECFAJoint FAO/WHO Expert Committee on Food AdditivesK~ow~octanol/water partition coefficientLBlower boundLCleft‐censoredLC--MS/MSliquid chromatography/tandem mass spectrometryLC~50~lethal concentration, medianLD~50~lethal dose, medianLDLlow‐density lipoproteinLOAELlowest‐observed‐adverse‐effect levelLODlimit of detectionLOQlimit of quantificationLyslysineMaxmaximumMBmiddle‐boundMinminimumMLmaximum levelMoAmode of actionMOEmargin of exposureMSmass spectrometryMWmolecular weightNNumbern.r.not reportedNADHnicotinamide adenine dinucleotideNAC*N*‐acetylcysteinylNAL*N*‐acetyllysinylNASUS National Academy of SciencesNAT*N*‐acetyltransferaseNIEHSUS National Institute of Environmental Health SciencesNOAELno‐observed‐adverse‐effect levelNTPNational Toxicology ProgramOTZoxothiazolidinecarboxylatePBPKphysiologically based pharmacokineticPNDpost‐natal dayPTR‐MSproton‐transfer reaction mass spectrometryROSreactive oxygen speciesSCEsister chromatid exchangeSDHsorbitol dehydrogenaseSIMselective ion monitoringSNESpecialised Nutrition EuropeSPMEsolid‐phase microextractionSOPstandard operational procedureSSBsingle strand breakstARsteroidogenic acute regulating proteinSULTsulfotransferaseTDItolerable daily intakeTDStotal diet studyTNFtumour necrosis factorUBupper boundUDSunscheduled DNA synthesisUVultravioletVKMNorwegian Scientific Committee for Food SafetyWGWorking groupWHOWorld Health Organization

Appendix A -- Identification and selection of evidence relevant for the risk assessment of furan and methylfurans in food {#efs25005-sec-1083}
=========================================================================================================================

A.1. Literature search for supporting information for the assessment {#efs25005-sec-0083}
--------------------------------------------------------------------

A literature search for recent reviews, in combination with a limited literature search for topics not sufficiently covered by reviews, was used to identify the scientific literature. The used search strings and the number of results in web of science and PubMed are given below.

### A.1.1. Furan, 2‐methylfuran and 3‐methylfuran {#efs25005-sec-0084}

[***Search for reviews***]{.ul}

**A. Web of Science**

Used search string: TOPIC: (Furan OR 2‐methylfuran OR 3‐methylfuran) AND TOPIC: (food) Refined by: DOCUMENT TYPES: (REVIEW); Timespan=2006--2016; Search language=Auto

Results in Web of Science: 78

**B. PubMed**

Used search string: ((((Furan OR 2‐methylfuran OR 3‐methylfuran)) AND food) AND review) AND ("2006/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])

Results in PubMed: 26

[***Search for information regarding the occurrence, formation and analysis of 2‐methylfuran and 3‐methylfuran***]{.ul}

**A. Web of Science**

Used search string: TOPIC: (2‐methylfuran OR 3‐methylfuran) AND TOPIC: (food OR formation OR analys\*) Timespan=2006--2016; Search language=Auto

Results in Web of Science: 187

**B. PubMed**

Used search string: (((2‐methylfuran OR 3‐methylfuran)) AND (food OR formation OR analys\*)) AND ("2006/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])

Results in PubMed: 60

[***Search for previous exposure assessments***]{.ul}

**A. Web of Science**

Used search string: TOPIC: (furan OR 2‐methylfuran OR 3‐methylfuran) AND TOPIC: (exposure and food) NOT TOPIC: (PCDD OR PCDF); Timespan=2006--2016; Search language=Auto

Results in Web of Science: 228

**B. PubMed**

Used search string ((((furan OR 2‐methylfuran OR 3‐methylfuran)) AND (exposure and food)) NOT (PCDD OR PCDF)) AND ("2006/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])

Results in PubMed: 49

[***Overall results***]{.ul}

From these searches, 628 references were identified and after removal of the duplicates 466 references were screened for relevance.

### A.1.2. 2,5‐dimethylfuran {#efs25005-sec-0085}

[***Search for reviews***]{.ul}

**C. Web of Science**

Used search string: TOPIC: (2,5‐dimethylfuran) AND TOPIC: (food) Refined by: DOCUMENT TYPES: (REVIEW); Timespan=2006--2016; Search language=Auto

Results in Web of Science: 0

**D. PubMed**

Used search string: ((((2,5‐dimethylfuran)) AND food) AND review) AND ("2006/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])

Results in PubMed: 0

[***Search for information regarding the occurrence, formation and analysis of 2,5‐dimethylfuran***]{.ul}

**C. Web of Science**

Used search string: TOPIC: (2,5‐dimethylfuran) AND TOPIC: (food OR formation OR analys\*) Timespan=2006--2016; Search language=Auto

Results in Web of Science: 123

**D. PubMed**

Used search string: (((2,5‐dimethylfuran)) AND (food OR formation OR analys\*)) AND ("2006/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])

Results in PubMed: 66

[***Search for previous exposure assessments***]{.ul}

**C. Web of Science**

Used search string: TOPIC: (2,5‐dimethylfuran) AND TOPIC: (exposure and food) NOT TOPIC: (PCDD OR PCDF); Timespan=2006‐2016; Search language=Auto

Results in Web of Science: 5

**D. PubMed**

Used search string ((((2,5‐dimethylfuran)) AND (exposure and food)) NOT (PCDD OR PCDF)) AND ("2006/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])

Results in PubMed: 5

[***Overall results***]{.ul}

From these searches, 199 references were identified and after removal of the duplicates 159 references were screened for relevance.

### A.1.3. Coffee {#efs25005-sec-0086}

Since most of the occurrence data on coffee were reported for the solid, while most coffee consumption data were reported as liquid, the WG carried out an additional literature search to identify papers regarding furan and methylfurans in coffee.

**A. Web of Science**

Used search string: **TOPIC:** (coffee) *AND* **TOPIC:** (furan or 2‐methylfuran or 3‐methylfuran or 2,5‐dimethylfuran) *Indexes=SCI‐EXPANDED, SSCI, A&HCI, CPCI‐S, CPCI‐SSH, BKCI‐S, BKCI‐SSH, ESCI, CCR‐EXPANDED, IC Timespan=2006--2017*

Results in Web of Science: 114

**B. PubMed**

Used search string: ((("Coffee"\[Mesh\] or coffee)) AND (furan or 2‐methylfuran or 3‐methylfuran or 2,5‐dimethylfuran)) AND ("2006/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])

Results in PubMed: 53

From these searches, 167 references were identified and after removal of the duplicates 119 references were screened for relevance.

A.2. Literature search for hazard identification and characterisation {#efs25005-sec-0087}
---------------------------------------------------------------------

In addition to the literature search outsourced by EFSA (see NFI, [2017](#efs25005-bib-0197){ref-type="ref"} for further details), some specific searches were performed to identify the scientific literature. The used search strings and the number of results in web of science and PubMed are given below.

### A.2.1. Search for papers regarding the genotoxicity caused by *cis*‐2‐butene‐1,4‐dial {#efs25005-sec-0088}

**A. Web of Science**

Used search string: TOPIC: ("*cis*‐2‐butene‐1,4‐dial" OR "maleic dialdehyde") AND TOPIC: (genotox\* OR muta\* OR DNA OR damage OR repair OR clastogen\* OR aneugen\* OR chromosom\*); Timespan=1990--2016; Search language=Auto

Results in Web of Science: 152

**B. PubMed**

Used search string: ((("*cis*‐2‐butene‐1,4‐dial" OR "maleic dialdehyde")) AND (genotox\* OR muta\* OR DNA OR damage OR repair OR clastogen\* OR aneugen\* OR chromosom\*)) AND ("1990/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])

Results in Web of Science: 57

From these searches, 209 references were identified and after removal of the duplicates 141 references were screened for relevance.

### A.2.2. Search for papers regarding the toxicity of 2,5‐dimethylfuran {#efs25005-sec-0089}

#### A.2.2.1. Toxicokinetics {#efs25005-sec-0090}

**A. Web of Science**

Used search string: **TOPIC:** (2,5‐dimethylfuran) *AND* **TOPIC:** (absor\* OR tissue\* OR metaboli\* OR excret\* OR kinetic\* OR toxicokinetic\* OR pharmacokinetic\* OR degrad\* OR biotrans\*); Timespan=1990--2016; Search language=Auto

Results in Web of Science: 110

**B. PubMed**

Used search string: ((2,5‐dimethylfuran) AND ((absor\* OR tissue\* OR metaboli\* OR excret\* OR kinetic\* OR toxicokinetic\* OR pharmacokinetic\* OR degrad\* OR biotrans\*))) AND ("1990/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])

Results in Web of Science: 47

#### A.2.2.2. Toxicity in experimental animals {#efs25005-sec-0091}

**A. Web of Science**

Used search string: **TOPIC:** (2,5‐dimethylfuran) *AND* **TOPIC:** ((oral OR diet\* OR gavage OR feed OR food OR organ\* OR tissue\* OR cancer\* OR carcino\* OR tumor\* OR tumour\* OR tox\* OR immun\* OR teratogen\* OR rat OR mouse OR mice OR rabbit\*)); Timespan=1990--2016; Search language=Auto

Results in Web of Science: 98

**B. PubMed**

Used search string: **((2,5‐dimethylfuran) AND (oral OR diet\* OR gavage OR feed OR food OR organ\* OR tissue\* OR cancer\* OR carcino\* OR tumor\* OR tumour\* OR tox\* OR immun\* OR teratogen\* OR rat OR mouse OR mice OR rabbit\*)) AND ("1990/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])**

Results in Web of Science: 68

#### A.2.2.3. Genotoxicity and mode of action {#efs25005-sec-0092}

**A. Web of Science**

Used search string: **TOPIC:** ((2,5‐dimethylfuran) *AND* **TOPIC:** (genotox\* OR mode OR action OR mechanism\* OR muta\* OR DNA OR damage OR repair OR clastogen\* OR aneugen\* OR chromosom\*)); Timespan=1990--2016; Search language=Auto

Results in Web of Science: 102

**B. PubMed**

Used search string: **((2,5‐dimethylfuran) AND (genotox\* OR mode OR action OR mechanism\* OR muta\* OR DNA OR damage OR repair OR clastogen\* OR aneugen\* OR chromosom\*)) AND ("1990/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])**

Results in Web of Science: 36

#### A.2.2.4. Observations in humans {#efs25005-sec-0093}

**A. Web of Science**

Used search string: **TOPIC:** (2,5‐dimethylfuran) *AND* **TOPIC:** (epidemio\* OR biomarker\* OR exposure\* OR case\* OR poison\* OR cohort\* OR cross‐sectional OR random\* OR work\*); Timespan=2004--2016; Search language=Auto

Results in Web of Science: 80

**B. PubMed**

Used search string: **((2,5‐dimethylfuran) AND (epidemio\* OR biomarker\* OR exposure\* OR case\* OR poison\* OR cohort\* OR cross‐sectional OR random\* OR work\*)) AND ("2004/01/01"\[Date ‐ Publication\] : "3000"\[Date ‐ Publication\])**

Results in Web of Science: 35

From these searches, 576 references were identified and after removal of the duplicates 298 references were screened for relevance.

### A.2.3. Papers not included in this scientific opinion {#efs25005-sec-0094}

The list below gives an overview of the scientific papers (excluding abstracts and reviews) related to the toxicity and toxicokinetics of furan and methylfurans that were identified in the scientific literature (see Section [2.2](#efs25005-sec-0021){ref-type="sec"}) but not included in the opinion.

Bas H, Pandir D and Kalender S, 2016. Furan‐induced hepatotoxic and hematologic changes in diabetic rats: the protective role of lycopene. Arhiv za Higijenu Rada i Toksikologiju, 67, 194--203. <https://doi.org/10.1515/aiht-2016-67-2762>

Bluhm K, Seiler TB, Anders N, Klankermayer J, Schaeffer A and Hollert H, 2016. Acute embryo toxicity and teratogenicity of three potential biofuels also used as flavor or solvent. The Science of the Total Environment, 566--567, 786‐795. <https://doi.org/10.1016/j.scitotenv.2016.05.055>

Carrette LL, Gyssels E, De Laet N and Madder A, 2016. Furan oxidation based cross‐linking: a new approach for the study and targeting of nucleic acid and protein interactions. Chemical Communications, 52, 1539--1554. <https://doi.org/10.1039/c5cc08766j>

Carrette LL, Morii T and Madder A, 2013. Toxicity inspired cross‐linking for probing DNA‐peptide interactions. Bioconjugate Chemistry, 24, 2008--2014. <https://doi.org/10.1021/bc400327q>

Dang NL, Hughes TB, Miller GP and Swamidass SJ, 2017. Computational approach to structural alerts: furans, phenols, nitroaromatics, and thiophenes. Chemical Research in Toxicology, 30, 1046--1059. <https://doi.org/10.1021/acs.chemrestox.6b00336>

Deferme L, Wolters J, Claessen S, Briede J and Kleinjans J, 2015. Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chemical Research in Toxicology, 28, 1636--1646. <https://doi.org/10.1021/acs.chemrestox.5b00222>

Doyle M, Sexton KG, Jeffries H and Jaspers I, 2007. Atmospheric photochemical transformations enhance 1,3‐butadiene‐induced inflammatory responses in human epithelial cells: the role of ozone and other photochemical degradation products. Chemico‐Biological Interactions, 166, 163--169. <https://doi.org/10.1016/j.cbi.2006.05.016>

Fry JR, Hammond AH, Garle MJ and Lal K, 1993. Comparison of xenobiotic‐mediated cytotoxicity in rat cultured‐hepatocytes and the V79 Chinese‐Hamster lung fibroblast cell‐line ‐ can metabolically‐activated hepatotoxins be identified by selective cytotoxicity to hepatocytes. Atla‐Alternatives to Laboratory Animals, 21, 8--12.

Garcia‐Gomez D, Bregy L, Barrios‐Collado C, Vidal‐de‐Miguel G and Zenobi R, 2015. Real‐time high‐resolution tandem mass spectrometry identifies furan derivatives in exhaled breath. Analytical Chemistry, 87, 6919--6924. <https://doi.org/10.1021/acs.analchem.5b01509>

Hamadeh HK, Jayadev S, Gaillard ET, Huang Q, Stoll R, Blanchard K, Chou J, Tucker CJ, Collins J, Maronpot R, Bushel P and Afshari CA, 2004. Integration of clinical and gene expression endpoints to explore furan‐mediated hepatotoxicity. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 549, 169--183. <https://doi.org/10.1016/j.mrfmmm.2003.12.021>

Higgins LG, Cavin C, Itoh K, Yamamoto M and Hayes JD, 2008. Induction of cancer chemopreventive enzymes by coffee is mediated by transcription factor Nrf2. Evidence that the coffee‐specific diterpenes cafestol and kahweol confer protection against acrolein. Toxicology and Applied Pharmacology, 226, 328--337. <https://doi.org/10.1016/j.taap.2007.09.018>

Huang Q, Jin X, Gaillard ET, Knight BL, Pack FD, Stoltz JH, Jayadev S and Blanchard KT, 2004. Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants. Mutation Research, 549, 147--167. <https://doi.org/10.1016/j.mrfmmm.2003.12.020>

Inamdar AA, Masurekar P and Bennett JW, 2010. Neurotoxicity of fungal volatile organic compounds in *Drosophila melanogaster*. Toxicological Sciences, 117, 418--426. <https://doi.org/10.1093/toxsci/kfq222>

Kamijima M, Sobue G, Ichihara G, Shibata E, Ono Y, Kondo H, Villanueva MB, Itoh T, Mitsuma T and Takeuchi Y, 1996. Toxic effects of hexane derivatives on cultured rat Schwann cells. Toxicology, 108, 25--31.

Lai GH and Sirica AE, 1999. Establishment of a novel rat cholangiocarcinoma cell culture model. Carcinogenesis, 20, 2335--2340.

McMurtry RJ and Mitchell JR, 1977. Renal and hepatic necrosis after metabolic activation of 2‐substituted furans and thiophenes, including furosemide and cephaloridine. Toxicology and Applied Pharmacology, 42, 285--300. <https://doi.org/10.1016/0041-008x(77)90005-9>

Muller A, Briviba K, Graf V, Greiner R, Herrmann C, Kuballa T and Stahl MR, 2013. UV‐C treatment using a Dean vortex technology ‐ impact on apple juice enzymes and toxicological potential. Innovative Food Science & Emerging Technologies, 20, 238--243. <https://doi.org/10.1016/j.ifset.2013.07.010>

Ochi T and Ohsawa M, 1985. Participation of active oxygen species in the induction of chromosomal aberrations by cadmium chloride in cultured Chinese hamster cells. Mutation Research, 143, 137--142.

Pandir D, 2015. Assessment of the DNA damage in human sperm and lymphocytes exposed to the carcinogen food contaminant furan with comet assay. Brazilian Archives of Biology and Technology, 58, 773--780. <https://doi.org/10.1590/s1516-89132015050269>

Radaeva S, Ferreira‐Gonzalez A and Sirica AE, 1999. Overexpression of C‐NEU and C‐MET during rat liver cholangiocarcinogenesis: a link between biliary intestinal metaplasia and mucin‐producing cholangiocarcinoma. Hepatology, 29, 1453--1462. <https://doi.org/10.1002/hep.510290524>

Ramos‐Marquez ME, Grijalva G and Armendariz‐Borunda J, 2002. Ductular hyperplasia is characterized by an over expression of c‐Myc in bile duct ligation plus furan injured rats: possible role of interleukin‐6. Hepatology Research, 22, 127--138. <https://doi.org/10.1016/s1386-6346(01)00121-8>

Sahlberg B, Gunnbjornsdottir M, Soon A, Jogi R, Gislason T, Wieslander G, Janson C and Norback D, 2013. Airborne molds and bacteria, microbial volatile organic compounds (MVOC), plasticizers and formaldehyde in dwellings in three North European cities in relation to sick building syndrome (SBS). The Science of the Total Environment, 444, 433--440. <https://doi.org/10.1016/j.scitotenv.2012.10.114>

Sprankle CS, Goldsworthy TL, Goldsworthy SM, Wilson DM and Butterworth BE, 1994. Expression of the hepatocyte growth factor and *c‐MET* genes during furan‐induced regenerative cell proliferation in the livers of B6C3F~1~ mice and F‐344 rats. Cell Proliferation, 27, 529--539. <https://doi.org/10.1111/j.1365-2184.1994.tb01490.x>

Stanley LA, Blackburn DR, Devereaux S, Foley J, Lord PG, Maronpot RR, Orton TC and Anderson MW, 1994. Ras mutations in methylclofenapate‐induced B6C3F1 and C57BL/10J mouse liver tumours. Carcinogenesis, 15, 1125--1131.

Upreti KK, Das M and Khanna SK, 1991. Role of antioxidants and scavengers on argemone oil‐induced toxicity in rats. Archives of Environmental Contamination and Toxicology, 20, 531--537.

Vu CC and Peterson LA, 2005. Synthesis of a 2'‐deoxyguanosine adduct of cis‐2‐butene‐1,4‐dial, a reactive metabolite of furan. Chemical Research in Toxicology, 18, 1012--1017. <https://doi.org/10.1021/tx049647d>

Walinder R, Ernstgard L, Johanson G, Norback D, Venge P and Wieslander G, 2005. Acute effects of a fungal volatile compound. Environmental Health Perspectives, 113, 1775--1778.

Wang J, Yang Z, Lin L, Zhao Z, Liu Z and Liu X, 2012. Protective effect of naringenin against lead‐induced oxidative stress in rats. Biological Trace Element Research, 146, 354--359. <https://doi.org/10.1007/s12011-011-9268-6>

Zaidi SI, Agarwal R, Eichler G, Rihter BD, Kenney ME and Mukhtar H, 1993. Photodynamic effects of new silicon phthalocyanines: *in vitro* studies utilizing rat hepatic microsomes and human erythrocyte ghosts as model membrane sources. Photochemistry and Photobiology, 58, 204--210.

A.3. EFSA guidance documents applied for the risk assessment {#efs25005-sec-0095}
------------------------------------------------------------

The following EFSA guidance pertaining to risk assessment were followed for the development of the risk assessment: EFSA (European Food Safety Authority), 2005. Opinion of the Scientific Committee on a request from EFSA related to a harmonised approach for risk assessment of substances which are both genotoxic and carcinogenic. EFSA Journal 2005;282, 1--31.EFSA (European Food Safety Authority), 2007. Guidance of the Scientific Committee on a request from EFSA related to Uncertainties in Dietary Exposure Assessment. EFSA Journal 2007;4(12):438, 54 pp. <https://doi.org/10.2903/j.efsa.2007.438>EFSA (European Food Safety Authority), 2009. Guidance of the Scientific Committee on transparency in the scientific aspects of risk assessments carried out by EFSA. Part 2: general principles. EFSA Journal 2009;1051, 1--22.EFSA (European Food Safety Authority), 2010. Standard sample description for food and feed. EFSA Journal 2010;8(1):1457, 54 pp. <https://doi.org/10.2903/j.efsa.2010.1457>EFSA (European Food Safety Authority), 2010. Management of left‐censored data in dietary exposure assessment of chemical substances. EFSA Journal 2010;8(3):1557, 96 pp. <https://doi.org/10.2903/j.efsa.2010.1557>EFSA (European Food Safety Authority), 2011. Use of the EFSA Comprehensive European Food Consumption Database in Intakes Assessment. EFSA Journal 2011;9(3):2097, 34 pp. <https://doi.org/10.2903/j.efsa.2011.2097>EFSA Scientific Committee 2011. Scientific Opinion on genotoxicity testing strategies applicable to food and feed safety assessment. EFSA Journal 2011;9(9):2379, 69 pp. DOI: <https://doi.org/10.2903/j.efsa.2011.2379>EFSA Scientific Committee [2012](#efs25005-bib-0077){ref-type="ref"}. Guidance on selected default values to be used by the EFSA Scientific Committee, Scientific Panels and Units in the absence of actual measured data. EFSA Journal 2012;10(3):2579, 32 pp. <https://doi.org/10.2903/j.efsa.2012.2579>EFSA Scientific Committee, [2012](#efs25005-bib-0077){ref-type="ref"}. Scientific Opinion on Risk Assessment Terminology. EFSA Journal 2012;10(5):2664, 43 pp. DOI: <https://doi.org/10.2903/j.efsa.2012.2664>EFSA Scientific Committee, Hardy A, Benford D, Halldorsson T, Jeger MJ, Knutsen KH, More S, Mortensen A, Naegeli H, Noteborn H, Ockleford C, Ricci A, Rychen G, Silano V, Solecki R, Turck D, Aerts M, Bodin L, Davis A, Edler L, Gundert‐Remy U, Sand S, Slob W, Bottex B, Abrahantes JC, Marques DC, Kass G and Schlatter JR, 2017. Update: use of the benchmark dose approach in risk assessment. EFSA Journal, 15, n/a‐n/a. <https://doi.org/10.2903/j.efsa.2017.465>

Appendix B -- Effects of different alkylfurans in experimental animals {#efs25005-sec-0096}
======================================================================

Compound/speciesTreatmentOutcomeReference**2‐methylfuran**Rat≥ 1,218 μmol/kg bw, i.p. (single exposure)**Liver** necrosis, **pulmonary** bronchiolar lesionsRavindranath et al. ([1986](#efs25005-bib-0231){ref-type="ref"})Rat, Fischer 344, male5, 18, 37, 73, 146, 305 μmol/kg bw per day by gavage over 28 daysMild histological lesions and inflammatory infiltrations in the **liver**, Changes in serum cholesterol and T3, T4Gill et al. ([2014](#efs25005-bib-0107){ref-type="ref"})**3‐methylfuran**Mouse, NIH Swiss, male100--200 mg (radiolabelled)/kg bw i.p. single exposure or 200 μmol (radiolabelled)/L, **inhalation**, 1 h**Bronchiolar** necrosis, binding of radioactivity in the lung, 8 h after i.p. injection or 24 h after inhalationBoyd et al. ([1978](#efs25005-bib-0031){ref-type="ref"})Rat, CD/CR, female Syrian hamster, female148 and 322 μmol/L, **inhalation**, 1 hHamster: **Bronchiolar** necrosis after 1 day Rat: **Bronchiolar** necrosis after 1 dayHaschek et al. ([1983](#efs25005-bib-0304){ref-type="ref"})Mouse, BALB/c, male14 and 37 μmol/L, **inhalation**, 1 h**Bronchiolar** necrosis after 1 dayHaschek et al. ([1984](#efs25005-bib-0303){ref-type="ref"})Mouse, ICR, male3,094 μmol/kg bw i.p., (single exposure)No effects in liver and kidney after 24 hWiley et al. ([1984](#efs25005-bib-0280){ref-type="ref"})Mouse, ICR, male2,600 and 3,100 μmol/kg bw i.p. (single exposure)Severe **bronchiolar** necrosis after 24 hGammal et al. ([1984](#efs25005-bib-0100){ref-type="ref"})Syrian hamster, male and female344 μmol/L, **inhalation**, 2 h once a week over 10 weeksNo pulmonary effectsWitschi et al. ([1985](#efs25005-bib-0310){ref-type="ref"})Rat, Fischer 344, male1, 4, 18, 37, 73, 146 and 305 μmol/kg bw per day by gavage over 28 daysHistological and gross changes of the **liver**, changes in serum liver enzymes, increase in serum T3 and T4Gill et al. ([2015](#efs25005-bib-0108){ref-type="ref"})Rat, Fischer 344, male and female0, 0.2, 1, 3, 12 and 49 μmol/kg bw by gavage over 90 days (5 days per week)**Liver** lesions, **kidney** lesions, increase in markers for liver and kidney injury in serumGill et al. ([2017](#efs25005-bib-0302){ref-type="ref"}, in press)**2‐ethylfuran**Mouse, Swiss, male2,081 μmol/kg bw, i.p. (single exposure)**Hepatic** centrilobular and **rena**l proximal tubular necrosis after 36 hMcMurtry and Mitchell (1977)Mouse, ICR, male2,600 μmol/kg bw, i.p.**Kidney**: proximal tubular necrosis **liver**: focal hydropic degeneration after 24 hWiley et al. ([1984](#efs25005-bib-0280){ref-type="ref"})Mouse, ICR, male2,600 μmol/kg bw, i.p. (single exposure)Severe **bronchiolar** necrosis after 24 hGammal et al. ([1984](#efs25005-bib-0100){ref-type="ref"})**3‐ethylfuran**Mouse, ICR, male3,100 μmol/kg bw, i.p. (single exposure)**Kidney**: proximal tubular necrosis **liver**: focal hydropic degeneration after 24 hWiley et al. ([1984](#efs25005-bib-0280){ref-type="ref"})Mouse, ICR, male3,100 μmol/kg bw, i.p. (single exposure)Severe **bronchiolar** necrosis, slight perivascular oedema after 24 hGammal et al. ([1984](#efs25005-bib-0100){ref-type="ref"})**3‐pentylfuran**Mouse, ICR, male1,800 μmol/kg bw, i.p. (single exposure)**Kidney:** proximal tubular necrosis, **liver**: centrilobular necrosis after 24 hWiley et al. ([1984](#efs25005-bib-0280){ref-type="ref"})Mouse, ICR, male1,800 and 2,600 μmol/kg bw, i.p. (single exposure)No pulmonary effects after 24 hGammal et al. ([1984](#efs25005-bib-0100){ref-type="ref"})[^1]

Appendix C -- Benchmark dose analysis {#efs25005-sec-0097}
=====================================

The text below describes the benchmark dose (BMD) analysis of the incidence of cholangiofibrosis in male rats and the incidence of hepatocellular adenomas/carcinomas in female mice. BMD analysis was done according to the EFSA guidance (EFSA Scientific Committee, [2017](#efs25005-bib-0078){ref-type="ref"}). The following was applied in all analyses.

**Software used**

Results are obtained using the R‐package bmdModeling. Fitting benchmark dose models is based on the R‐package proast61.3.Averaging results from multiple fitted benchmark dose models is based on the methodology in Wheeler and Bailer ([2008](#efs25005-bib-0309){ref-type="ref"}).

**Model averaging**

Model averaging was used for all tested endpoints.

**Dose--response model sets**

No deviation from the recommended defaults. Default set of fitted models:ModelNumber of parametersFormulaNull1y = aFullNo of groupsy = groupmeanLogistic2$\begin{array}{r}
{\text{y} = \frac{1}{1 + \exp( - \text{a} - \text{bx})}} \\
\end{array}$Probit2$\text{y} = \text{pnorm}((\text{x} - \text{a}) \cdot \text{b})$Log‐logistic3$\begin{array}{r}
{\text{y} = \text{a} + \frac{1 - \text{a}}{1 + \exp\left( {\text{c} \cdot \log\left( \frac{\text{b}}{\text{x}} \right)} \right)}} \\
\end{array}$Log‐probit3$\text{y} = \text{a} + {(1 - \text{a})} \cdot \text{pnorm}\left( {\text{c} \cdot \log\left( \frac{\text{x}}{\text{b}} \right)} \right)$Weibull3$\text{y} = \text{a} + {(1 - \text{a})}\left( {1 - \exp\left( {- \left( \frac{\text{x}}{\text{b}} \right)^{c}} \right)} \right)$Gamma3y = pgamma(bx; c)Two‐stage3$\text{y} = \text{a} + {(1 - \text{a})}\left( {1 - \exp\left( {- \frac{\text{x}}{\text{b}} - \text{c}\left( \frac{\text{x}}{\text{b}} \right)^{2}} \right)} \right)$

**Procedure for selection of BMDL**

There was no deviation from the procedure described in the flow chart to obtain the final BMD confidence interval.

![Flow chart for selection of BMDL](EFS2-15-e05005-g012){#efs25005-fig-0012}

C.1. Incidence of cholangiofibrosis {#efs25005-sec-0098}
-----------------------------------

### C.1.1. Data description {#efs25005-sec-0099}

Data from male F344/N NCTR rats treated for 36 weeks or 2 years with furan in corn oil by gavage 5 times per week (NCTR, [2015](#efs25005-bib-0195){ref-type="ref"}). Doses used in this BMD analysis were not adjusted for the dose regimen and the reported results consequently correspond to a 5 days per week dosing regimen.

The analysed endpoints are: cholangiofibrosis after 36 weeks of treatment (Cholfib_36Wk);cholangiofibrosis after 2 years of treatment (Cholfib_2y).

###### 

Data on the incidence of cholangiofibrosis used for BMD analysis

  Dose (mg/kg bw per day)[a](#efs25005-note-0059){ref-type="fn"}   After 36 weeks of treatment   After 2 years of treatment        
  ---------------------------------------------------------------- ----------------------------- ---------------------------- ---- -----
  0.000                                                            0                             20                           0    149
  0.020                                                            0                             20                           0    150
  0.044                                                            0                             20                           0    99
  0.092                                                            0                             20                           1    100
  0.200                                                            0                             20                           38   50
  0.440                                                            6                             20                           49   49
  0.920                                                            17                            20                           47   50
  2.000                                                            19                            20                           49   49

N: number of animals; bw: body weight.

For a 5 days per week dosing regimen.

John Wiley & Sons, Ltd

### C.1.2. Selection of the BMR {#efs25005-sec-0100}

A default benchmark response (BMR) of 10% (extra risk compared with the background risk) and a 90% interval around the BMD were selected as recommended by EFSA Scientific Committee ([2017](#efs25005-bib-0078){ref-type="ref"}).

### C.1.3. Results for the incidence of cholangiofibrosis after 36 weeks {#efs25005-sec-0101}

###### 

Result for the incidence of cholangiofibrosis after 36 weeks using model averaging

  Model          Number of parameters   Log‐likelihood   AIC      BMD    BMDL   BMDU   Converged   Accepted AIC
  -------------- ---------------------- ---------------- -------- ------ ------ ------ ----------- --------------
  Null           1                      −92.10           186.20   NA     NA     NA     Yes         
  Full           8                      −24.64           65.28    NA     NA     NA     Yes         
  Logistic       2                      −32.17           68.34    0.35   0.27   0.44   Yes         No
  Log‐logistic   3                      −25.78           57.56    0.31   0.22   0.39   Yes         Yes
  Log‐probit     3                      −25.97           57.94    0.30   0.21   0.38   Yes         Yes
  Weibull        3                      −28.99           63.98    0.24   0.16   0.33   Yes         No
  Gamma          3                      −27.38           60.76    0.28   0.19   0.37   Yes         No
  Two‐stage      3                      −29.27           64.54    0.27   0.23   0.33   No          No

AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower confidence limit; BMDU: benchmark dose upper confidence limit.

John Wiley & Sons, Ltd

It was noted that the Probit model of the PROAST version 61.3 was not fitting the data.

###### 

Model weights used in model averaging

                            Logistic   Log‐logistic   Log‐probit   Weibull   Gamma
  ------------------------- ---------- -------------- ------------ --------- -------
  Estimated model weights   0          0.48           0.4          0.02      0.1

John Wiley & Sons, Ltd

Given 1,000 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD values and the BMDU is the 95th percentile.

Estimated the BMD based on the averaged response model which is a weighted average of the accepted models' response values.

###### 

Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week dosing regimen) for the incidence of cholangiofibrosis after 36 weeks using model averaging

  BMD   BMDL   BMDU
  ----- ------ ------
  0.3   0.22   0.41

John Wiley & Sons, Ltd

![Averaged dose--response model for the incidence of cholangiofibrosis after 36 weeks](EFS2-15-e05005-g013){#efs25005-fig-0013}

### C.1.4. Results for the incidence of cholangiofibrosis after 2 years {#efs25005-sec-0102}

###### 

Result for the incidence of cholangiofibrosis after 2 years using model averaging

  Model          Included covariate(s)   Number of parameters   Log‐likelihood   AIC      BMD    BMDL   BMDU   Converged   Accepted AIC
  -------------- ----------------------- ---------------------- ---------------- -------- ------ ------ ------ ----------- --------------
  Null                                   1                      −401.99          805.98   NA     NA     NA     Yes         
  Full                                   8                      −44.50           105.00   NA     NA     NA     Yes         
  Logistic                               2                      −100.79          205.58   0.11   0.10   0.13   Yes         No
  Log‐logistic                           3                      −60.70           127.40   0.11   0.09   0.12   Yes         No
  Log‐probit                             3                      −66.76           139.52   0.10   0.09   0.11   Yes         No
  Weibull                                3                      −89.97           185.94   0.08   0.07   0.09   Yes         No
  Gamma                                  3                      −78.53           163.06   0.10   0.08   0.11   Yes         No
  Two‐stage                              3                      −93.07           192.14   0.10   0.09   0.11   No          No

AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower confidence limit; BMDU: benchmark dose upper confidence limit.

John Wiley & Sons, Ltd

It was noted that none of the fitted models is at least as good as the full model; all fitted models' AIC values are larger than full model\'s AIC + 2. However, the confidence band contains the observed values (see Figure [C.3](#efs25005-fig-0014){ref-type="fig"}), and therefore, it was decided that model averaging can be used. Nevertheless, it is recommended to generate more data on the incidence of cholangiofibrosis in the dose range 0.092--0.2 mg/kg bw per day to better characterise the dose--response.

It was noted that the Probit model of the PROAST version 61.3 was not fitting the data.

###### 

Model weights used in model averaging

                            Logistic   Log‐logistic   Log‐probit   Weibull   Gamma
  ------------------------- ---------- -------------- ------------ --------- -------
  Estimated model weights   0.000      0.998          0.002        0.000     0.000

John Wiley & Sons, Ltd

Given 1,000 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD values and the BMDU is the 95th percentile.

Estimated the BMD based on the averaged response model which is a weighted average of the accepted models' response values.

###### 

Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5‐day per week dosing regimen) for the incidence of cholangiofibrosis after 2 years using model averaging

  BMD    BMDL   BMDU
  ------ ------ ------
  0.11   0.09   0.12

John Wiley & Sons, Ltd

![Averaged dose--response model for the incidence of cholangiofibrosis after 2 years](EFS2-15-e05005-g014){#efs25005-fig-0014}

C.2. Incidence of hepatocellular adenomas/carcinomas in female mice {#efs25005-sec-0103}
-------------------------------------------------------------------

### C.2.1. Data description {#efs25005-sec-0104}

Hepatocellular adenomas and carcinomas in female B6C3F1 mice have been reported in two separate 2‐year carcinogenicity assays with furan (NTP, [1993](#efs25005-bib-0201){ref-type="ref"} and Moser et al., [2009](#efs25005-bib-0192){ref-type="ref"}). A combined analysis of the Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) data was performed (see Table [4](#efs25005-tbl-0004){ref-type="table"} of the opinion), as well as an analysis for the Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) data alone. Doses used in this BMD analysis were not adjusted for the dose regimen and the reported results consequently correspond to a 5‐day per week dosing regimen.

###### 

Data on the incidence of hepatocellular adenomas/carcinomas in female mice used for BMD analysis

  Dose (mg/kg bw per day)[a](#efs25005-note-0063){ref-type="fn"}   n hepatocellular adenomas and carcinomas   n hepatocellular carcinomas   n total   Reference
  ---------------------------------------------------------------- ------------------------------------------ ----------------------------- --------- -----------------------------------------------------------
  0.0                                                              3                                          0                             36        Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})
  0.0                                                              7                                          2                             50        NTP ([1993](#efs25005-bib-0201){ref-type="ref"})
  0.5                                                              8                                          4                             72        Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})
  1.0                                                              6                                          2                             53        Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})
  2.0                                                              5                                          1                             41        Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})
  4.0                                                              12                                         2                             36        Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})
  8.0                                                              29                                         11                            39        Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})
  8.0                                                              34                                         7                             50        NTP ([1993](#efs25005-bib-0201){ref-type="ref"})
  15.0                                                             50                                         27                            50        NTP ([1993](#efs25005-bib-0201){ref-type="ref"})

N: number of animals; bw: body weight.

For a 5 days per week dosing regimen.

John Wiley & Sons, Ltd

### C.2.2. Selection of the BMR {#efs25005-sec-0105}

A default benchmark response (BMR) of 10% (extra risk compared with the background risk) and a 90% interval around the BMD were selected as recommended by EFSA Scientific Committee ([2017](#efs25005-bib-0078){ref-type="ref"}).

### C.2.3. Results for the incidence of hepatocellular adenomas and carcinomas as reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) {#efs25005-sec-0106}

A combined analysis of the incidence of hepatocellular adenomas and carcinomas reported in two separate studies (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}; Moser et al., [2009](#efs25005-bib-0192){ref-type="ref"}) was performed, using study as a covariate. The effect of study as covariate was not significant and therefore the data from both studies were merged.

###### 

Result for the incidence of hepatocellular adenomas and carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) using model averaging

  Model          Number of parameters   Log‐likelihood   AIC      BMD    BMDL   BMDU   Converged   Accepted AIC
  -------------- ---------------------- ---------------- -------- ------ ------ ------ ----------- --------------
  Null           1                      −279.17          560.34   NA     NA     NA     Yes         
  Full           7                      −166.62          347.24   NA     NA     NA     Yes         
  Logistic       2                      −168.70          341.40   2.00   1.73   2.30   Yes         Yes
  Probit         2                      −168.44          340.88   1.83   1.61   2.09   Yes         Yes
  Log‐logistic   3                      −169.19          344.38   3.42   2.45   4.75   Yes         No
  Log‐probit     3                      −168.54          343.08   3.41   2.50   4.46   Yes         No
  Weibull        3                      −167.20          340.40   3.02   2.08   4.20   Yes         Yes
  Gamma          3                      −167.79          341.58   3.22   2.23   4.32   Yes         Yes
  Two‐stage      3                      −167.81          341.62   2.39   2.16   2.66   Yes         Yes

AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower confidence limit; BMDU: benchmark dose upper confidence limit.

John Wiley & Sons, Ltd

###### 

Model weights used in model averaging

                            Logistic   Probit   Log‐logistic   Log‐probit   Weibull   Gamma   Two‐stage
  ------------------------- ---------- -------- -------------- ------------ --------- ------- -----------
  Estimated model weights   0.16       0.2      0.04           0.07         0.26      0.14    0.14

John Wiley & Sons, Ltd

Given 1,000 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD values and the BMDU is the 95th percentile.

Estimated the BMD based on the averaged response model which is a weighted average of the accepted models' response values.

###### 

Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week dosing regimen) for the incidence of hepatocellular adenomas/carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) using model averaging

  BMD   BMDL   BMDU
  ----- ------ ------
  2.6   1.84   4

John Wiley & Sons, Ltd

![Averaged dose--response model for the incidence of hepatocellular adenomas/carcinomas after 2 years reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP (1993)](EFS2-15-e05005-g015){#efs25005-fig-0015}

### C.2.4. Results for the incidence of hepatocellular carcinomas as reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) {#efs25005-sec-0107}

A combined analysis of the incidence of hepatocellular carcinomas reported in two separate studies (NTP, [1993](#efs25005-bib-0201){ref-type="ref"}; Moser et al., [2009](#efs25005-bib-0192){ref-type="ref"}) was performed, using study as a covariate. The effect of study as covariate was significant and the studies were therefore not combined.

###### 

Result for the incidence of hepatocellular carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"}), using study as a covariate and using model averaging

       Model          Included covariate(s)   Number of parameters   Log‐likelihood   AIC      BMD -- study.Moser   BMDL -- study.Moser   BMDU -- study.Moser   BMD -- study.NTP   BMDL -- study.NTP   BMDU -- study.NTP   Converged   Accepted AIC
  ---- -------------- ----------------------- ---------------------- ---------------- -------- -------------------- --------------------- --------------------- ------------------ ------------------- ------------------- ----------- --------------
  1    Null                                   1                      −165.92          333.84   NA                   NA                    NA                    NA                 NA                  NA                  Yes         
  2    Full                                   7                      −125.20          264.40   NA                   NA                    NA                    NA                 NA                  NA                  Yes         
  3    Logistic                               2                      −126.28          256.56   6.26                 5.46                  7.14                  6.26               5.46                7.14                Yes         Yes
  4    Logistic       a                       3                      −126.05          258.10   5.91                 5.00                  7.19                  5.91               5.00                7.19                Yes         Yes
  5    Logistic       b                       3                      −125.22          256.44   5.13                 4.22                  6.66                  6.73               5.75                7.80                Yes         Yes
  6    Logistic       a, b                    4                      −125.20          258.40   5.14                 4.22                  6.65                  6.61               5.30                8.08                Yes         Yes
  7    Probit                                 2                      −126.30          256.60   5.74                 5.00                  6.59                  5.74               5.00                6.59                Yes         Yes
  11   Log‐logistic                           3                      −125.95          257.90   6.44                 4.81                  7.95                  6.44               4.81                7.95                Yes         Yes
  12   Log‐logistic   a                       4                      −125.93          259.86   6.45                 4.83                  7.94                  6.45               4.83                7.94                Yes         No
  13   Log‐logistic   b                       4                      −124.55          257.10   5.87                 4.62                  7.19                  7.90               5.85                9.91                Yes         Yes
  14   Log‐logistic   a, b                    5                      −124.52          259.04   5.88                 4.62                  7.18                  8.01               5.88                10.94               Yes         No
  15   Log‐probit                             3                      −125.87          257.74   6.49                 4.94                  7.91                  6.49               4.94                7.91                Yes         Yes
  16   Log‐probit     a                       4                      −125.84          259.68   6.49                 4.95                  7.90                  6.49               4.95                7.90                Yes         No
  17   Log‐probit     b                       4                      −124.50          257.00   5.90                 4.66                  7.22                  7.82               5.91                9.59                Yes         Yes
  18   Log‐probit     a, b                    5                      −124.49          258.98   5.90                 4.66                  7.22                  7.88               5.91                10.38               Yes         No
  19   Weibull                                3                      −126.04          258.08   6.36                 4.62                  7.99                  6.36               4.62                7.99                Yes         Yes
  20   Weibull        a                       4                      −126.03          260.06   6.36                 4.62                  7.99                  6.36               4.62                7.99                Yes         No
  21   Weibull        b                       4                      −124.60          257.20   5.80                 4.53                  7.15                  7.99               5.76                10.14               Yes         Yes
  22   Weibull        a, b                    5                      −124.56          259.12   5.82                 4.53                  7.13                  8.13               5.80                11.29               Yes         No
  23   Gamma                                  3                      −125.93          257.86   6.44                 4.77                  7.94                  6.44               4.77                7.94                Yes         Yes
  24   Gamma          a                       4                      −125.91          259.82   6.45                 4.78                  7.93                  6.45               4.78                7.93                Yes         No
  25   Gamma          b                       4                      −124.52          257.04   5.86                 4.61                  7.19                  7.88               5.85                9.73                Yes         Yes
  26   Gamma          a, b                    5                      −124.50          259.00   5.87                 4.61                  7.18                  7.97               5.87                10.57               Yes         No
  27   Two‐stage                              3                      −126.23          258.46   5.80                 5.09                  6.71                  5.80               5.09                6.71                Yes         No
  28   Two‐stage      a                       4                      −126.23          260.46   5.79                 5.08                  6.72                  5.79               5.08                6.72                Yes         No
  29   Two‐stage      b                       4                      −125.88          259.76   5.09                 3.99                  6.96                  5.99               5.17                7.06                Yes         No
  30   Two‐stage      a, b                    5                      −125.87          261.74   5.07                 3.98                  6.96                  6.01               5.17                7.16                Yes         No

AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower confidence limit; BMDU: benchmark dose upper confidence limit.

John Wiley & Sons, Ltd

It was noted that the Probit implementation in PROAST version 61.3 does not support covariate adjustment.

###### 

Model weights used in model averaging

                            Logistic   Probit   Log‐logistic   Log‐probit   Weibull   Gamma   Two‐stage
  ------------------------- ---------- -------- -------------- ------------ --------- ------- -----------
  Estimated model weights   0.19       0.18     0.14           0.15         0.13      0.14    0.07

John Wiley & Sons, Ltd

Given 200 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD values and the BMDU is the 95th percentile.

Estimated the BMD based on the averaged response model which is a weighted average of the accepted models' response values.

###### 

Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week dosing regimen) for the incidence of hepatocellular carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP ([1993](#efs25005-bib-0201){ref-type="ref"}) using model averaging

                BMD    BMDL   BMDU
  ------------- ------ ------ ------
  study.Moser   5.72   4.18   7.24
  study.NTP     7.21   4.82   9.10

John Wiley & Sons, Ltd

![Averaged dose--response model for the incidence of hepatocellular carcinomas after 2 years reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) and NTP (1993)](EFS2-15-e05005-g016){#efs25005-fig-0016}

### C.2.5. Results for the incidence of hepatocellular adenomas and carcinomas as reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) {#efs25005-sec-0108}

###### 

Result for the incidence of hepatocellular adenomas and carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) using model averaging

  Model          Number of parameters   Log‐likelihood   AIC      BMD    BMDL   BMDU   Converged   Accepted AIC
  -------------- ---------------------- ---------------- -------- ------ ------ ------ ----------- --------------
  Null           1                      −148.52          299.04   NA     NA     NA     Yes         
  Full           6                      −114.48          240.96   NA     NA     NA     Yes         
  Logistic       2                      −114.94          233.88   2.03   1.71   2.41   Yes         Yes
  Probit         2                      −115.09          234.18   1.87   1.59   2.21   Yes         Yes
  Log‐logistic   3                      −114.65          235.30   2.78   1.76   3.87   Yes         Yes
  Log‐probit     3                      −114.62          235.24   2.85   1.89   3.88   Yes         Yes
  Weibull        3                      −114.73          235.46   2.62   1.53   3.88   Yes         Yes
  Gamma          3                      −114.66          235.32   2.76   1.65   3.88   Yes         Yes
  Two‐stage      3                      −114.82          235.64   2.34   2.02   2.77   No          Yes

AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower confidence limit; BMDU: benchmark dose upper confidence limit.

John Wiley & Sons, Ltd

###### 

Model weights used in model averaging

                            Logistic   Probit   Log‐logistic   Log‐probit   Weibull   Gamma
  ------------------------- ---------- -------- -------------- ------------ --------- -------
  Estimated model weights   0.26       0.23     0.13           0.13         0.12      0.13

John Wiley & Sons, Ltd

Given 200 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD values and the BMDU is the 95th percentile.

Estimated the BMD based on the averaged response model which is a weighted average of the accepted models' response values.

###### 

Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week dosing regimen) for the incidence of hepatocellular adenomas and carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) using model averaging

  BMD   BMDL   BMDU
  ----- ------ ------
  2.4   1.45   3.59

John Wiley & Sons, Ltd

![Averaged dose--response model for the incidence of hepatocellular adenomas and carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})](EFS2-15-e05005-g017){#efs25005-fig-0017}

### C.2.6. Results for the incidence of hepatocellular carcinomas as reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) {#efs25005-sec-0109}

###### 

Result for the incidence of hepatocellular carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}), using model averaging

  Model          Number of parameters   Log‐likelihood   AIC      BMD    BMDL   BMDU   Converged   Accepted AIC
  -------------- ---------------------- ---------------- -------- ------ ------ ------ ----------- --------------
  Null           1                      −71.83           145.66   NA     NA     NA     Yes         
  Full           6                      −59.59           131.18   NA     NA     NA     Yes         
  Logistic       2                      −61.78           127.56   5.14   4.22   6.66   Yes         Yes
  Probit         2                      −61.94           127.88   4.89   3.92   6.60   Yes         Yes
  Log‐logistic   3                      −63.31           132.62   2.85   1.66   5.21   Yes         No
  Log‐probit     3                      −61.34           128.68   5.84   4.06   8.24   Yes         Yes
  Weibull        3                      −63.19           132.38   2.88   1.69   5.11   Yes         No
  Gamma          3                      −61.35           128.70   5.97   4.02   7.95   Yes         Yes
  Two‐stage      3                      −61.95           129.90   5.07   3.98   6.95   Yes         No

AIC: Akaike information criterion; BMD: benchmark dose; BMDL: benchmark dose lower confidence limit; BMDU: benchmark dose upper confidence limit.

John Wiley & Sons, Ltd

###### 

Model weights used in model averaging

                            Logistic   Probit   Log‐logistic   Log‐probit   Weibull   Gamma   Two‐stage
  ------------------------- ---------- -------- -------------- ------------ --------- ------- -----------
  Estimated model weights   0.29       0.25     0.02           0.16         0.03      0.16    0.09

John Wiley & Sons, Ltd

Given 200 generated data sets, the BMDL is the 5th percentile of all parametric bootstrap BMD values and the BMDU is the 95th percentile.

Estimated the BMD based on the averaged response model which is a weighted average of the accepted models' response values.

###### 

Calculated BMD, BMDL and BMDU values (mg/kg bw per day for a 5 days per week dosing regimen) for the incidence of hepatocellular carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"}) using model averaging

  BMD    BMDL   BMDU
  ------ ------ ------
  5.34   3.45   7.55

John Wiley & Sons, Ltd

![Averaged dose--response model for the incidence of hepatocellular carcinomas reported by Moser et al. ([2009](#efs25005-bib-0192){ref-type="ref"})](EFS2-15-e05005-g018){#efs25005-fig-0018}

Appendix D -- Factors influencing furan and methylfuran levels in food {#efs25005-sec-0110}
======================================================================

###### 

Influence of heating by the consumer on furan levels in commercially heat‐processed foods as reported in scientific literature

+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Matrix                                   | n                                        | Concentration (μg/kg)[e](#efs25005-note-0074){ref-type="fn"} | Reduction factor[d](#efs25005-note-0073){ref-type="fn"} | Reference |                                                            |
+==========================================+==========================================+==============================================================+=========================================================+===========+============================================================+
| **Foods for infants and small children** |                                          |                                                              |                                                         |           |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Varied vegetables                        | 3                                        | 7.3 ± 0.6                                                    | 6.0 ± 0.3[a](#efs25005-note-0070){ref-type="fn"}        | 1.2       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 5.2 ± 0.2[a](#efs25005-note-0070){ref-type="fn"}        | 1.4       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 4.0 ± 0.2[c](#efs25005-note-0072){ref-type="fn"}        | 1.8       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Vegetables cream with pasta              | 3                                        | 29 ± 1                                                       | 25 ± 1[a](#efs25005-note-0070){ref-type="fn"}           | 1.2       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 22 ± 1[a](#efs25005-note-0070){ref-type="fn"}           | 1.3       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 17 ± 1[c](#efs25005-note-0072){ref-type="fn"}           | 1.7       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Chicken stew with vegetables             | 3                                        | 38 ± 2                                                       | 32 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 1.2       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 25 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 1.5       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 18 ± 1[c](#efs25005-note-0072){ref-type="fn"}           | 2.1       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Chicken with rice                        | 3                                        | 16 ± 1                                                       | 15 ± 1[a](#efs25005-note-0070){ref-type="fn"}           | 1.1       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 13 ± 1[a](#efs25005-note-0070){ref-type="fn"}           | 1.2       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 10 ± 1[c](#efs25005-note-0072){ref-type="fn"}           | 1.6       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Pea with pork meat                       | 3                                        | 53 ± 3                                                       | 60 ± 3[a](#efs25005-note-0070){ref-type="fn"}           | 0.9       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 41 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 1.3       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 32 ± 1[c](#efs25005-note-0072){ref-type="fn"}           | 1.7       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Pork meat with pasta and vegetables      | 3                                        | 49 ± 2                                                       | 46 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 1.1       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 32 ± 3[a](#efs25005-note-0070){ref-type="fn"}           | 1.5       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 23 ± 2[c](#efs25005-note-0072){ref-type="fn"}           | 2.1       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Beef meat with rice                      | 3                                        | 44 ± 3                                                       | 46 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 1.0       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 34 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 1.3       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 25 ± 2[c](#efs25005-note-0072){ref-type="fn"}           | 1.8       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Jardinière beef meat                     | 3                                        | 51 ± 3                                                       | 56 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 0.9       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 41 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 1.2       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 35 ± 2[c](#efs25005-note-0072){ref-type="fn"}           | 1.5       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Lamb meat stew with potato               | 3                                        | 34 ± 2                                                       | 37 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 0.9       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 25 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 1.4       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 22 ± 2[c](#efs25005-note-0072){ref-type="fn"}           | 1.5       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Lamb meat stew with green bean           | 3                                        | 43 ± 2                                                       | 36 ± 3[a](#efs25005-note-0070){ref-type="fn"}           | 1.2       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 30 ± 1[a](#efs25005-note-0070){ref-type="fn"}           | 1.4       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 23 ± 1[c](#efs25005-note-0072){ref-type="fn"}           | 1.9       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Monkfish with potato                     | 3                                        | 84 ± 4                                                       | 85 ± 1[a](#efs25005-note-0070){ref-type="fn"}           | 1.0       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 65 ± 3[a](#efs25005-note-0070){ref-type="fn"}           | 1.3       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 45 ± 3[c](#efs25005-note-0072){ref-type="fn"}           | 1.9       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Hake with rice                           | 3                                        | 69 ± 3                                                       | 76 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 0.9       | Altaki et al. ([2017](#efs25005-bib-0010){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 55 ± 2[a](#efs25005-note-0070){ref-type="fn"}           | 1.3       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 45 ± 2[c](#efs25005-note-0072){ref-type="fn"}           | 1.5       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Chicken                                  | 1[m](#efs25005-note-0082){ref-type="fn"} | 23 ± 6[f](#efs25005-note-0075){ref-type="fn"}                | 17 ± 19[g](#efs25005-note-0076){ref-type="fn"}          | 1.4       | Hasnip et al. ([2006](#efs25005-bib-0305){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 18 ± 17[c](#efs25005-note-0072){ref-type="fn"}          | 1.3       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Vegetable                                | 1[m](#efs25005-note-0082){ref-type="fn"} | 32 ± 8[f](#efs25005-note-0075){ref-type="fn"}                | 31 ± 35[g](#efs25005-note-0076){ref-type="fn"}          | 1.0       | Hasnip et al. ([2006](#efs25005-bib-0305){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 20 ± 19[c](#efs25005-note-0072){ref-type="fn"}          | 1.6       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Retort packaged baby food 1              | n.r.                                     | 28.3 ± 0.5                                                   | 19.0 ± 1.2[a](#efs25005-note-0070){ref-type="fn"}       | 1.5       | Kim et al. ([2009](#efs25005-bib-0149){ref-type="ref"})    |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 20.8 ± 1.1[b](#efs25005-note-0071){ref-type="fn"}       | 1.4       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Retort packaged baby food 2              | n.r.                                     | 10.8 ± 0.6                                                   | 9.1 ± 0.5[a](#efs25005-note-0070){ref-type="fn"}        | 1.2       | Kim et al. ([2009](#efs25005-bib-0149){ref-type="ref"})    |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 9.6 ± 0.2[b](#efs25005-note-0071){ref-type="fn"}        | 1.1       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Soybean milk 1                           | n.r.                                     | 4.3 ± 0.3                                                    | 4.3 ± 0.2[a](#efs25005-note-0070){ref-type="fn"}        | 1.0       | Kim et al. ([2009](#efs25005-bib-0149){ref-type="ref"})    |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 3.6 ± 0.2[b](#efs25005-note-0071){ref-type="fn"}        | 1.2       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Soybean milk 2                           | n.r.                                     | 14.9 ± 0.8                                                   | 12.0 ± 0.4[a](#efs25005-note-0070){ref-type="fn"}       | 1.2       | Kim et al. ([2009](#efs25005-bib-0149){ref-type="ref"})    |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 12.3 ± 0.2[b](#efs25005-note-0071){ref-type="fn"}       | 1.2       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Infants vegetable meal                   | 1                                        | 45[n](#efs25005-note-0083){ref-type="fn"}                    | 23[l](#efs25005-note-0081){ref-type="fn"}               | 2         | DTU ([2009](#efs25005-bib-0061){ref-type="ref"})           |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| **Herbs, spices and condiments**         |                                          |                                                              |                                                         |           |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Tomato‐based sauce                       | 1[m](#efs25005-note-0082){ref-type="fn"} | 12 ± 3[f](#efs25005-note-0075){ref-type="fn"}                | 6 ± 6[h](#efs25005-note-0077){ref-type="fn"}            | 2.0       | Hasnip et al. ([2006](#efs25005-bib-0305){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 9 ± 10[b](#efs25005-note-0071){ref-type="fn"}           | 1.3       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 7 ± 8[a](#efs25005-note-0070){ref-type="fn"}            | 1.7       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 6 ± 7[b](#efs25005-note-0071){ref-type="fn"}            | 2.0       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Sweet and sour vegetable sauce           | 1                                        | 13[n](#efs25005-note-0083){ref-type="fn"}                    | 7[l](#efs25005-note-0081){ref-type="fn"}                | 1.8       | DTU ([2009](#efs25005-bib-0061){ref-type="ref"})           |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| **Composite food**                       |                                          |                                                              |                                                         |           |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Baked beans                              | 1[m](#efs25005-note-0082){ref-type="fn"} | 24 ± 6[f](#efs25005-note-0075){ref-type="fn"}                | 31 ± 35[g](#efs25005-note-0076){ref-type="fn"}          | 0.8       | Hasnip et al. ([2006](#efs25005-bib-0305){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 24 ± 23[h](#efs25005-note-0077){ref-type="fn"}          | 1.0       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Baked beans                              | 1                                        | 102[n](#efs25005-note-0083){ref-type="fn"}                   | 42[l](#efs25005-note-0081){ref-type="fn"}               | 2.4       | DTU ([2009](#efs25005-bib-0061){ref-type="ref"})           |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Stew                                     | 1[m](#efs25005-note-0082){ref-type="fn"} | 25 ± 6[f](#efs25005-note-0075){ref-type="fn"}                | 17 ± 16[h](#efs25005-note-0077){ref-type="fn"}          | 1.5       | Hasnip et al. ([2006](#efs25005-bib-0305){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 26 ± 30[b](#efs25005-note-0071){ref-type="fn"}          | 1.0       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 17 ± 19[a](#efs25005-note-0070){ref-type="fn"}          | 1.5       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 16 ± 19[b](#efs25005-note-0071){ref-type="fn"}          | 1.6       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Korean seasoned pork canned              | n.r.                                     | 45.2 ± 1.5                                                   | 31.6 ± 4.7[i](#efs25005-note-0078){ref-type="fn"}       | 1.4       | Kim et al. ([2009](#efs25005-bib-0149){ref-type="ref"})    |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 24.3 ± 8.5[j](#efs25005-note-0079){ref-type="fn"}       | 1.9       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Luncheon meat canned                     | n.r.                                     | 3.9 ± 0.5                                                    | 2.9 ± 0.4[i](#efs25005-note-0078){ref-type="fn"}        | 1.3       | Kim et al. ([2009](#efs25005-bib-0149){ref-type="ref"})    |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 2.7 ± 0.9[j](#efs25005-note-0079){ref-type="fn"}        | 1.4       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Meat sauce                               | 1                                        | 40[n](#efs25005-note-0083){ref-type="fn"}                    | 16[l](#efs25005-note-0081){ref-type="fn"}               | 2.5       | DTU ([2009](#efs25005-bib-0061){ref-type="ref"})           |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Tomato soup                              | 1                                        | 25[n](#efs25005-note-0083){ref-type="fn"}                    | 32[g](#efs25005-note-0076){ref-type="fn"}               | 0.8       | Crews ([2009](#efs25005-bib-0050){ref-type="ref"})         |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 26[h](#efs25005-note-0077){ref-type="fn"}               | 1.0       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Vegetable soup                           | 1[m](#efs25005-note-0082){ref-type="fn"} | 17 ± 4[f](#efs25005-note-0075){ref-type="fn"}                | 19 ± 11[h](#efs25005-note-0077){ref-type="fn"}          | 0.9       | Hasnip et al. ([2006](#efs25005-bib-0305){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 21 ± 15[g](#efs25005-note-0076){ref-type="fn"}          | 0.8       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Soup                                     | 10                                       | 7--47                                                        | 1--16[l](#efs25005-note-0081){ref-type="fn"}            | 1.5--12.5 | DTU ([2009](#efs25005-bib-0061){ref-type="ref"})           |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Vegetables canned                        | 1[m](#efs25005-note-0082){ref-type="fn"} | 4 ± 2[f](#efs25005-note-0075){ref-type="fn"}                 | 4 ± 5[h](#efs25005-note-0077){ref-type="fn"}            | 1.0       | Hasnip et al. ([2006](#efs25005-bib-0305){ref-type="ref"}) |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 3 ± 5[b](#efs25005-note-0071){ref-type="fn"}            | 1.3       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 3 ± 4[a](#efs25005-note-0070){ref-type="fn"}            | 1.3       |                                                            |
|                                          |                                          |                                                              |                                                         |           |                                                            |
|                                          |                                          |                                                              | 3 ± 4[b](#efs25005-note-0071){ref-type="fn"}            | 1.3       |                                                            |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Tuna canned                              | n.r.                                     | 12.6 ± 0.1                                                   | 2.5 ± 0.2[k](#efs25005-note-0080){ref-type="fn"}        | 5.0       | Kim et al. ([2009](#efs25005-bib-0149){ref-type="ref"})    |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+
| Mackerel pike canned                     | n.r.                                     | 13.7 ± 0.9                                                   | 3.1 ± 0.3[k](#efs25005-note-0080){ref-type="fn"}        | 4.4       | Kim et al. ([2009](#efs25005-bib-0149){ref-type="ref"})    |
+------------------------------------------+------------------------------------------+--------------------------------------------------------------+---------------------------------------------------------+-----------+------------------------------------------------------------+

N: number of samples.

Heating experiments that were not considered relevant for heating carried out by consumers were not added to this table (e.g. heating baby food for 1 h at 80°C). Experiments for which the furan concentrations were below the LOD/LOQ were not included in this table.

Microwave; without lid (uncapped jar/dish/open casserole).

Microwave; with lid (glass/plastic lid).

Hot water bath; without lid (uncapped jars).

Calculated from (mean) concentrations reported by the authors by dividing the furan concentration in the food as purchased by the furan concentration in the food as consumed.

Mean ± standard deviation unless stated otherwise.

Mean ± measurement uncertainty (including uncertainty due to analysis and heating).

Microwave; without specification regarding lid.

Saucepan heating with stirring.

Microwave; heating to 50°C; without specification regarding lid.

Microwave; heating to 70°C; without specification regarding lid.

Heating without a lid to 100°C.

Calculated based on % of furan left after heating as reported by the authors; heating unspecified.

Heating experiments were carried out at least in duplicate.

Single concentration.
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###### 

Influence of beverage preparation by the consumer on furan levels as reported in scientific literature

  Coffee type               N    Amount of solid (g)[a](#efs25005-note-0084){ref-type="fn"}   Volume of brew (mL)[a](#efs25005-note-0084){ref-type="fn"}   Concentration (μg/kg)[a](#efs25005-note-0084){ref-type="fn"}   Dilution factor[a](#efs25005-note-0084){ref-type="fn"}   Loss factor[a](#efs25005-note-0084){ref-type="fn"}   Overall reduction factor[a](#efs25005-note-0084){ref-type="fn"} ^,^ [b](#efs25005-note-0085){ref-type="fn"}   Reference              
  ------------------------- ---- ------------------------------------------------------------ ------------------------------------------------------------ -------------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ---------------------- --------------------------------------------------------------
  **Ground coffee**                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Boiled/Turkish coffee     16   50                                                           500                                                          3,457.5 (1,373--5,580)                                         29 (12--81)                                              10                                                   11.6 (3.6--45.6)                                                                                              115.9 (35.9--455.7)    Arisseto et al. ([2011](#efs25005-bib-0014){ref-type="ref"})
  Espresso                  7    5                                                            75                                                           1,770 (1,490--2,020)                                           43 (28--60)                                              15                                                   2.5 (1.7--4.3)                                                                                                37.3 (26.1--64.3)      Kuballa et al. ([2005](#efs25005-bib-0307){ref-type="ref"})
  Espresso                  5    8                                                            64 (62--67)                                                  3,493 (2,254--5,938)                                           98 (72--199)                                             8 (7.8--8.4)                                         4.6 (2.1--6.4)                                                                                                37 (17.6--49.6)        Zoller et al. ([2007](#efs25005-bib-0287){ref-type="ref"})
  Filter coffee             20   50                                                           500                                                          3,457.5 (985--5,697)                                           97.5 (19--279)                                           10                                                   4 (2--7.8)                                                                                                    39.6 (20--78.4)        Arisseto et al. ([2011](#efs25005-bib-0014){ref-type="ref"})
  Filter coffee             1    32                                                           740                                                          2,080                                                          46.7                                                     23.1                                                 1.9                                                                                                           44.5                   Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Filter coffee             3    40                                                           1,000                                                        1,892 (1,681--1,966)                                           56.7 (51.5--64.3)                                        25                                                   1.4 (1--1.5)                                                                                                  34.7 (26.1--36.7)      DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Filter coffee             15   40                                                           850                                                          1,790 (790--3,390)                                             15 (8--66)                                               21.3                                                 6.4 (1.1--8.9)                                                                                                135.6 (23.3--190)      Kuballa et al. ([2005](#efs25005-bib-0307){ref-type="ref"})
  Filter coffee             1    8                                                            130                                                          1,438                                                          40                                                       16.3                                                 2.2                                                                                                           36                     Zoller et al. ([2007](#efs25005-bib-0287){ref-type="ref"})
  French press/infusion     1    51                                                           1,000                                                        2,080                                                          77.6                                                     19.6                                                 1.4                                                                                                           26.8                   Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  **Coffee beans**                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Espresso                  6    10                                                           150                                                          4,725 (3,510--6,100)                                           91.5 (57--115)                                           15                                                   3.5 (2.1--6.2)                                                                                                52.5 (30.8--93.7)      Kuballa et al. ([2005](#efs25005-bib-0307){ref-type="ref"})
  Filter coffee (machine)   5    40                                                           850                                                          4,910 (3,600--6,100)                                           16 (9--33)                                               21.3                                                 15.7 (5.1--23.9)                                                                                              333.8 (109.1--508.3)   Kuballa et al. ([2005](#efs25005-bib-0307){ref-type="ref"})
  Filter coffee (manual)    5    40                                                           850                                                          4,910 (3,600--6,100)                                           20 (17--24)                                              21.3                                                 12 (8.1--14)                                                                                                  254.2 (171.4--296.7)   Kuballa et al. ([2005](#efs25005-bib-0307){ref-type="ref"})
  French press/infusion     5    40                                                           850                                                          4,910 (3,600--6,100)                                           51 (33--66)                                              21.3                                                 4.5 (3.5--6.5)                                                                                                95.4 (74.4--137.6)     Kuballa et al. ([2005](#efs25005-bib-0307){ref-type="ref"})
  **Cartridge coffee**                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Not specified             3    8 (7--9)                                                     210                                                          2,300 (2,110--2,660)                                           59.1 (57.6--59.2)                                        26.3 (23.3--30)                                      1.5 (1.5--1.5)                                                                                                38.9 (35.7--46.2)      Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  **Instant coffee**                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Instant coffee            2    2                                                            60                                                           960 (820--1,100)                                               31.5 (28--35)                                            30                                                   1                                                                                                             30.4 (29.3--31.4)      Altaki et al. ([2009](#efs25005-bib-0301){ref-type="ref"})
  Instant coffee            2    1.4 (1.2--1.5)                                               112.5 (75--150)                                              977.5 (625--1,330)                                             5.5 (4.3--6.6)                                           81.3 (62.5--100)                                     2.2 (2--2.3)                                                                                                  173.4 (145.3--201.5)   DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Instant coffee            7    10                                                           500                                                          530 (240--2,200)                                               11 (3--25)                                               50                                                   1.5 (0.8--3.1)                                                                                                75.7 (41.8--157.1)     Kuballa et al. ([2005](#efs25005-bib-0307){ref-type="ref"})
  Instant coffee            14   2 (1.7--2)                                                   150 (65--150)                                                1,702 (44--2,150)                                              19 (1--51.3)                                             75 (32.5--89.8)                                      1.1 (0.6--1.4)                                                                                                82.4 (41.9--97.9)      Zoller et al. ([2007](#efs25005-bib-0287){ref-type="ref"})

Median (range).

The overall reduction factor is calculated by dividing the furan concentration in the food as purchased by the furan concentration in the food as consumed. This reduction factor comprises a dilution and a loss factor.

John Wiley & Sons, Ltd

Appendix E -- Previously reported occurrence data {#efs25005-sec-0111}
=================================================

###### 

Levels of furan in home‐cooked foods reported in scientific literature

  Processing/matrix                                   Concentration (μg/kg)   Reference                                                                                                 
  --------------------------------------------------- ----------------------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------
  **Toasting**                                                                                                                                                                          
  White bread                                         \< 2                    39 ± 48[a](#efs25005-note-0087){ref-type="fn"} (n = 5)                                                    Hasnip et al. ([2006](#efs25005-bib-0305){ref-type="ref"})
  White bread                                         \< 3--3 (n = 3)         260 (187--385)[b](#efs25005-note-0088){ref-type="fn"} (n = 5)                                             Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Wholemeal bread                                     \< 3--3 (n = 3)         150 (32--229)[b](#efs25005-note-0088){ref-type="fn"} (n = 7)                                              Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Bread                                               \< 2.4 (n = 2)          \< 2.4--179[c](#efs25005-note-0089){ref-type="fn"} ^,^ [k](#efs25005-note-0097){ref-type="fn"} (n = 11)   DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Toast bread                                         \< 2 (n = 2)            \< 2--18 (n = 4)                                                                                          Zoller et al. ([2007](#efs25005-bib-0287){ref-type="ref"})
  **Baking**                                                                                                                                                                            
  Part baked bread                                    \< 3 (n = 1)            7 (3--11)[d](#efs25005-note-0090){ref-type="fn"} (n = 4)                                                  Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Cookies                                             \< 3 (n = 1)            7 (5--9)[d](#efs25005-note-0090){ref-type="fn"} (n = 4)                                                   Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Pizza (chilled)                                     \< 3 (n = 1)            4 (\< 3--6)[d](#efs25005-note-0090){ref-type="fn"} (n = 4)                                                Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Pizza (frozen)                                      3 (n = 1)               19 (10--27)[d](#efs25005-note-0090){ref-type="fn"} (n = 4)                                                Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Breaded chicken pieces                              \< 3 (n = 1)            7 (6--8)[d](#efs25005-note-0090){ref-type="fn"} (n = 4)                                                   Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Breaded vegetables                                  \< 3 (n = 1)            6 (4--9)[d](#efs25005-note-0090){ref-type="fn"} (n = 5)                                                   Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Breaded fish                                        \< 3 (n = 1)            5 (4--5)[d](#efs25005-note-0090){ref-type="fn"} (n = 5)                                                   Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Cream potatoes                                      n.r.                    \< 2.4--2.4[h](#efs25005-note-0094){ref-type="fn"} (n = 2)                                                DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Chips (oven)                                        3 (n = 1)               (\< 3--3)[d](#efs25005-note-0090){ref-type="fn"} (n = 4)                                                  Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Chips made from industrially made products (oven)                           3--15[g](#efs25005-note-0093){ref-type="fn"} (n = 9)                                                      DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Apple pie                                                                   4.4 (n = 1)                                                                                               DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Apple cake                                                                  23.4 (n = 1)                                                                                              DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Frying                                                                                                                                                                                
  Fish meat balls                                     \< 2.4 (n = 1)          \< 2.4--3.1[c](#efs25005-note-0089){ref-type="fn"} (n = 4)                                                DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Candied potatoes                                                            3.3--15.5[h](#efs25005-note-0094){ref-type="fn"} (n = 3)                                                  DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Pancake                                                                     \< 2.4--2.6[c](#efs25005-note-0089){ref-type="fn"} (n = 5)                                                DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Caramel                                             \< 2 (n = 2)            51--570[g](#efs25005-note-0093){ref-type="fn"} ^,^ [j](#efs25005-note-0096){ref-type="fn"} (n = 4)        Zoller et al. ([2007](#efs25005-bib-0287){ref-type="ref"})
  **Deep‐frying**                                                                                                                                                                       
  Chips made from fresh potatoes                      \< 3 (n = 1)            12 (8--16)[e](#efs25005-note-0091){ref-type="fn"} (n = 4)                                                 Crews ([2009](#efs25005-bib-0050){ref-type="ref"})
  Chips made from industrially made products                                  11--21[f](#efs25005-note-0092){ref-type="fn"} (n = 9)                                                     DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Crisps made from fresh potatoes                                             12--51[f](#efs25005-note-0092){ref-type="fn"} (n = 10)                                                    DTU ([2009](#efs25005-bib-0061){ref-type="ref"})
  Dried slices of white, purple and sweet potato                              6--43[f](#efs25005-note-0092){ref-type="fn"} ^,^ [i](#efs25005-note-0095){ref-type="fn"}                  Yuan et al. ([2016](#efs25005-bib-0311){ref-type="ref"})
  **Roasting**                                                                                                                                                                          
  Fresh onion                                         \< 2 (n = 1)            \< 3--5 (n = 2)                                                                                           Zoller et al. ([2007](#efs25005-bib-0287){ref-type="ref"})

N: number of samples.

Mean ± measurement uncertainty; toasting for 4 min in a preheated domestic toaster.

Mean (range); until fully browned.

Range; different toasting/roasting/frying degrees.

Mean (range); baked in a pre‐heated oven set at 190--220°C.

Mean (range); fried at 180°C in rapeseed oil for 6 min, followed by 3 min at 190°C.

Range; different time‐temperature combinations.

Range; different heating temperatures.

Range; completely home‐made or made from an industrially made product.

Numbers read from a graph.

For one sample, a concentration of 1,956 μg/kg was reported; however, the authors indicated that this was unedible due to the bitter taste.

The level of 179 μg/kg was reported for black toast.

John Wiley & Sons, Ltd

###### 

Co‐Occurrence of furan and methylfurans in commercially processed foods

  Matrix                                                                            n     Concentration (μg/kg)[a](#efs25005-note-0099){ref-type="fn"}   Reference                                                                                                                              
  --------------------------------------------------------------------------------- ----- -------------------------------------------------------------- ----------- -------------------- -------- ------------------ ------- --------------------- ------------------------------------------- --------------------------------------------------------------
  **Grains and grain‐based products**                                                                                                                                                                                                                                                           
  Cereal flakes                                                                     18    9--63                                                          22.3        12--86               23.5     \< RL (5)--6       3.3     n.a.                  n.a.                                        DPE[c](#efs25005-note-0101){ref-type="fn"}
  **Vegetables and vegetable products (including fungi)**                                                                                                                                                                                                                                       
  Artichoke hearts                                                                  1     8.5                                                            8.5         4.6                  4.6      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Asparagus                                                                         4     2.8--11.4                                                      5.5         \< LOD (1)--3.2      2.3      \< LOD (1)--4.4    2.6     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Beets                                                                             4     11.7--338                                                      100.4       1.6--30.0            9.0      \< LOD (1)--4.3    3.2     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Mushrooms                                                                         5     11.3--26.0                                                     17.2        8.4--12.4            10.2     \< LOD (1)--1.2    0.6     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Tomatoes                                                                          5     6.3--19.6                                                      14.3        16.5--42.0           24.8     86.9--144          111.8   n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Carrots                                                                           5     26.9--70.9                                                     43.9        4.1--22.0            8.9      \< LOD (1)--11.8   4.3     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Corn                                                                              5     28.1--52.1                                                     36.1        5.9--14.2            8.9      57.9--151          116     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Hearts of palm                                                                    2     1.1--1.6                                                       1.4         \< LOD (1)           0.5      1.4--2.7           2.1     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Ground roasted coffee                                                             1     4,590                                                          4,590       8,680                8,680    450                450     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Ground roasted coffee                                                             117   762--5434                                                      3,145       4,724--34,378        18,338   190--2,597         694     n.a.                  n.a.                                        DPE[c](#efs25005-note-0101){ref-type="fn"}
  Regular ground coffee                                                             15    715--2800                                                      2,200       4,890--13,100        9,470    311--615           447     n.a.                  n.a.                                        Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Cartridge ground coffee                                                           3     2,110--2,660                                                   2,360       9,440--13,100        10,700   427--555           508     n.a.                  n.a.                                        Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Decaffeinated ground coffee                                                       7     1,640--3,450                                                   2,450       6,570--13,500        10,400   274--628           463     n.a.                  n.a.                                        Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Decaffeinated instant coffee powder                                               7     32.0--896                                                      329         129--6,150           1,800    9.01--213          75.2    n.a.                  n.a.                                        Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Instant coffee                                                                    2     279--547                                                       413         759--764             761.5    40.4--48.6         44.5    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Regular instant coffee powder                                                     7     46.8--742                                                      233         200--6,200           1,595    11.9--270          72.9    n.a.                  n.a.                                        Becalski et al., [2016](#efs25005-bib-0026){ref-type="ref"})
  Instant coffee                                                                    64    17--3,394                                                      627         135--15,932          2,472    10--1,853          161     n.a.                  n.a.                                        DPE[c](#efs25005-note-0101){ref-type="fn"}
  **Starchy roots and tubers**                                                                                                                                                                                                                                                                  
  Potatoes                                                                          4     20.2--114                                                      65.2        \< LOD (1)--2.7      1.7      \< LOD (1)--1.5    1.0     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  **Legumes, nuts and oilseeds**                                                                                                                                                                                                                                                                
  Green and waxy beans                                                              5     48.5--69.7                                                     59.8        9.1--29.3            17.9     7.1--20.9          13.2    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Beans                                                                             5     29.6--83.8                                                     54.7        3.0--15.5            8.6      3.9--7.6           5.8     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Chick peas                                                                        5     26.8--73.5                                                     40.3        13.9--21.6           18.2     5.5--8.8           7.2     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Kidney beans                                                                      5     18.2--195                                                      75.5        3.4--15.6            6.9      4.7--10.9          6.8     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  **Fruit and fruit products**                                                                                                                                                                                                                                                                  
  Applesauce                                                                        5     6.3--19.2                                                      11.1        3.7--14.3            7.7      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Mixed fruit                                                                       4     4.8--51.2                                                      27.2        1.6--7.1             5.0      \< LOD (1)--1.1    0.7     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Peaches                                                                           2     13.4--21.9                                                     17.7        4.6--9.6             7.1      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Pineapple                                                                         3     3.4--6.7                                                       4.8         1.9--3.8             2.9      1.2--2.5           2.0     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  **Meat and meat products (including edible offal**)                                                                                                                                                                                                                                           
  Flakes of chicken                                                                 1     29.8                                                           29.8        152                  152      2.9                2.9     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Flakes of ham                                                                     3     13.9--14.6                                                     14.2        58.1--85.7           76.1     \< LOD (1)--1.6    1.1     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Luncheon meat                                                                     1     39.0                                                           39.0        24.4                 24.4     1.7                1.7     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Meat products                                                                     11    \< LOQ (1.0)--1.3                                              0.6         \< LOQ (1.0)--2.6    0.7      n.a.               n.a.    \< LOQ (1.0)          0.5                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  Meat spreads                                                                      5     51.0--172                                                      100.7       26.2--54.8           36.9     10.4--28.8         17.9    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  **Fish and other seafood (including amphibians, reptiles, snails and insects)**                                                                                                                                                                                                               
  Oysters                                                                           1     171                                                            171         149                  149      28.3               28.3    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Salmon                                                                            5     9.3--18.1                                                      13.4        38.8--109            65.3     7.9--16.1          12.2    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Sardines in water, oil or sauce                                                   4     17.5--65.5                                                     33.5        15.9--21.6           18.0     1.3--5.2           2.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Tuna                                                                              5     15.4--27.9                                                     21.8        14.4--39.6           24.8     1.2--1.7           1.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  **Milk and dairy products**                                                                                                                                                                                                                                                                   
  Milk and milk beverages                                                           15    \< LOQ (1.0)--8.0                                              2.2         \< LOQ (1.0)--7.9    2.1      n.a.               n.a.    \< LOQ (1.0)--88.8    8.7                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  **Sugar and confectionary**                                                                                                                                                                                                                                                                   
  Chocolates                                                                        6     \< LOQ (1.0)                                                   0.5         \< LOQ (1.0)--1.4    0.7      n.a.               n.a.    \< LOQ (1.0)          0.5                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  **Fruit and vegetable juices**                                                                                                                                                                                                                                                                
  Juice and drinks                                                                  3     6.7--16.7                                                      13.1        1.3--2.0             1.6      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Clamato                                                                           3     6.7--9.5                                                       8.3         \< LOD (1)           0.5      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Cocktail                                                                          1     10.8                                                           10.8        3.7                  3.7      2.6                2.6     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Fruit juices                                                                      15    \< LOQ (0.5)--1.9                                              0.5         \< LOQ (0.5)--2.0    0.8      n.a.               n.a.    \< LOQ (0.5)--0.5     0.3                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  Tomato drinks                                                                     4     4.3--14.1                                                      8.0         9.5--20.6            13.5     22.9--55.7         42.0    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  **Non‐alcoholic beverages (excepting milk‐based beverages)**                                                                                                                                                                                                                                  
  Brewed coffee                                                                     1     820                                                            820         3,900                3,900    n.a.               n.a.    n.a.                  n.a.                                        Ochiai et al. (2014)
  Brewed medium roast or bold roast coffee                                          16    25.1--69.5                                                     38.7        109--287             172      5.0--9.5           6.4     n.a.                  n.a.                                        Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Coffee                                                                            15    47--2,821                                                      885         117--5,982           1,328    n.a.               n.a.    32--466               217                                         Fromberg et al. ([2014](#efs25005-bib-0095){ref-type="ref"})
  Decaffeinated coffee                                                              12    6.63--121                                                      53.1        24.4--365            184      1.1--12.0          6.7     n.a.                  n.a.                                        Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Espresso coffee                                                                   12    34.9--352                                                      157         135--1,360           583      6.5--39.3          19.0    n.a.                  n.a.                                        Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  **Alcoholic beverages**                                                                                                                                                                                                                                                                       
  Alcoholic drinks                                                                  3     \< LOQ (0.5)                                                   0.3         \< LOQ (0.5)--2.0    0.9      n.a.               n.a.    \< LOQ (0.5)--0.5     0.3                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  Beer                                                                              13    \< LOQ (0.5)--0.8                                              0.4         \< LOQ (0.5)--2.4    0.9      n.a.               n.a.    \< LOQ (0.5) --3.4    0.6                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  **Herbs, spices and condiments**                                                                                                                                                                                                                                                              
  Ketchup                                                                           4     28.7--286                                                      101.6       2.5--18.1            8.9      \< LOD (1)--11.3   6.7     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Tomato ketchup                                                                    2     1.8--2.1                                                       2.0         \< LOQ (1.0)--2.7    1.6      n.a.               n.a.    \< LOQ (1.0)          0.5                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  Chilli sauce                                                                      2     72.8--89.2                                                     81.0        5.4--13.5            9.5      3.8--17.3          10.6    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Seafood sauce                                                                     2     7.7--77.3                                                      42.5        1.2--20.6            10.9     \< LOD (1)--7.3    3.9     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Soy sauce                                                                         14    7.3--63.8                                                      33.1        1.7--43.6            15.2     n.a.               n.a.    \< LOQ (0.5)--10.8    2.9                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  Worcestershire sauce                                                              1     17.4                                                           17.4        4.2                  4.2      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Vinegar                                                                           15    \< LOQ (0.5)--34.3                                             10.3        \< LOQ (0.5)--34.5   8.5      n.a.               n.a.    \< LOQ (0.5)--2.0     0.5                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  **Food for infants and small children**                                                                                                                                                                                                                                                       
  Baby‐food purees                                                                  11    \< LOQ (1.0)--16.2                                             5.1         \< LOQ (1.0)--13.5   3.6      n.a.               n.a.    \< LOQ (1.0)          0.5                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  Banana graham pie                                                                 1     43.9                                                           43.9        4.9                  4.9      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Chicken cacciatore                                                                1     331                                                            331         35.5                 35.5     22.9               22.9    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Junior oatmeal with mixed fruit                                                   1     120                                                            120         9.5                  9.5      5.1                5.1     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Infant formulas                                                                   12    \< LOQ (1.0)--27.8                                             10.5        \< LOQ (1.0)--4.4    1.3      n.a.               n.a.    \< LOQ (1.0)--17.1    3.9                                         Shen et al. ([2016](#efs25005-bib-0243){ref-type="ref"})
  Infant formula with iron (add water)                                              1     26.7                                                           26.7        8.7                  8.7      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Squash                                                                            1     66.2                                                           66.2        7.5                  7.5      1.6                1.6     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Strained blueberry                                                                1     32.1                                                           32.1        2.6                  2.6      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Strained carrots                                                                  1     27.8                                                           27.8        2.6                  2.6      \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Strained creamed corn                                                             1     51.5                                                           51.5        16.6                 16.6     4.3                4.3     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Strained custard                                                                  1     199                                                            199         50.2                 50.2     1.0                1.0     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Strained green beans                                                              1     78.3                                                           78.3        7.4                  7.4      3.2                3.2     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Strained strawberries                                                             1     8.5                                                            8.5         1.18                 1.18     \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Strained mixed vegetables                                                         1     54.0                                                           54.0        4.2                  4.2      1.6                1.6     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Strained peas                                                                     1     82.4                                                           82.4        10.5                 10.5     3.1                3.1     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Strawberries                                                                      1     27.4                                                           27.4        1.41                 1.41     \< LOD (1)         0.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Sweet potatoes                                                                    1     239                                                            239         15.7                 15.7     17.5               17.5    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Commercial baby foods based on flour or cereals                                   6     22.7--88.2                                                     38.6        30.5--88.8           68.3     n.a.               n.a.    69.4--230.3           153.1                                       Habibi et al. ([2013](#efs25005-bib-0115){ref-type="ref"})
  Vegetable and beef jars                                                           1     128                                                            128         18.8                 18.8     6.6                6.6     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Vegetable/chicken jars                                                            1     121                                                            121         14.3                 14.3     9.5                9.5     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Baby food in jar                                                                  35    20--67                                                         35.6        \< RL (5)--12        6.8      \< RL (5)--12      5.2     n.a.                  n.a.                                        DPE[c](#efs25005-note-0101){ref-type="fn"}
  Infant cereals                                                                    28    \< RL (5)--32                                                  8.3         7--118               15.4     \< RL (5)--9       3.4     n.a.                  n.a.                                        DPE[c](#efs25005-note-0101){ref-type="fn"}
  **Composite food (including frozen products)**                                                                                                                                                                                                                                                
  Baked beans                                                                       5     368--824                                                       580.6       61.4--152            91.3     9.3--20.4          13.5    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Pasta sauce                                                                       3     15.2--42.7                                                     32.8        4.1--13.2            9.1      3.6--8.6           5.8     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Peanut butter                                                                     1     10.6                                                           10.6        9.2                  9.2      3.2                3.2     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Pizza sauce                                                                       4     24.2--111                                                      59.6        10.7--25.6           16.1     7.9--11.9          9.8     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Salsa                                                                             3     10.8--25.8                                                     19.3        4.8--7.9             6.5      7.4--12.5          9.1     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Canned food                                                                       12    \< LOD (2.4)--47                                               20.5        \< LOD (2.4)--8.0    4.7      n.a.               n.a     \< LOD (2.4) -- 105   67[d](#efs25005-note-0102){ref-type="fn"}   Fromberg et al. ([2014](#efs25005-bib-0095){ref-type="ref"})
  Chilli con carne                                                                  5     241--863                                                       386.4       35.9--73.0           51.8     25.2--55.7         38.8    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Gourmet antipasto                                                                 1     27.0                                                           27.0        46.4                 46.4     9.1                9.1     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Pasta meals                                                                       5     151--1,230                                                     396.4       22.9--105            41.9     10.2--49.5         18.8    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Stew and meatball entrees                                                         4     34.6--1,030                                                    308.6       6.6--132             46.5     2.0--58.9          17.6    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Cream of mushroom (soup)                                                          1     93.5                                                           93.5        11.5                 11.5     1.7                1.7     n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Tomato paste                                                                      5     59.7--200                                                      123.0       24.2--76.8           50.4     14.9--98.2         51.6    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Tomato sauce                                                                      5     17.0--35.5                                                     23.6        3.1--45.7            15.8     5.8--86.8          24.5    n.a.                  n.a.                                        Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Tomato sauce                                                                      3     \< RL (5)                                                      0.3         6--10                8.3      5--7               6.3     n.a.                  n.a.                                        DPE[c](#efs25005-note-0101){ref-type="fn"}

DPE: documentation provided to EFSA by FoodDrinkEurope; LOD: limit of detection; LOQ: limit of quantification; n.a. not analysed n: number of samples; RL: reporting limit.

Applied method of analysis was headspace sampling followed by analysis using GC--MS unless stated otherwise.

The mean values were calculated by EFSA using the middle bound approach if they were not provided in the publication.

Data on the co‐occurrence of furan, 2‐methylfuran and 3‐methylfuran in jarred baby foods, cereal flakes, roasted and grounded coffee, soluble coffee, infant cereals and tomato sauce. December 2016. Submitted by FoodDrinkEurope to EFSA, outside the ad hoc call for occurrence data

Calculated using mean values reported by the authors.

John Wiley & Sons, Ltd

###### 

2‐Methylfuran/furan and 3‐methylfuran/furan ratios in commercially processed foods

  Food                                                           n     Concentration (μg/kg)[a](#efs25005-note-0104){ref-type="fn"}   Mean ratio[b](#efs25005-note-0105){ref-type="fn"}   Median ratio    Reference                                                                                                                        
  -------------------------------------------------------------- ----- -------------------------------------------------------------- --------------------------------------------------- --------------- ----------- --------------- ------ --------------------------------------------- --------------- --------------- --------------- --------------------------------------------------------------
  **Grains and grain‐based products**                                                                                                                                                                                                                                                                                                      
  Cereal flakes                                                  18    9--63                                                          22.3                                                12--86          23.5        \< RL (5)--6    3.3    1.10                                          0.17 (n = 5)    1.12            0.15 (n = 5)    DPE[d](#efs25005-note-0107){ref-type="fn"}
  **Vegetables and vegetable products (including fungi)**                                                                                                                                                                                                                                                                                  
  Ground roasted coffee                                          1     4,590                                                          4,590                                               8,680           8,680       450             450    1.89                                          0.10            --              --              Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Ground roasted coffee                                          117   762--5,434                                                     3,145                                               4,724--34,378   18,338      190--2,597      694    5.9                                           0.2             5.7             0.2             DPE[d](#efs25005-note-0107){ref-type="fn"}
  Regular ground coffee                                          15    715--2,800                                                     2,200                                               4,890--13,100   9,470       311--615        447    4.30                                          0.20            n.r.            n.r.            Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Cartridge ground coffee                                        3     2,110--2,660                                                   2,360                                               9,440--13,100   10,700      427--555        508    4.53                                          0.22            n.r.            n.r.            Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Decaffeinated ground coffee                                    7     1,640--3,450                                                   2,450                                               6,570--13,500   10,400      274--628        463    4.24                                          0.19            n.r.            n.r.            Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Decaffeinated instant coffee powder                            7     32.0--896                                                      329                                                 129--6,150      1,800       9.01--213       75.2   5.47                                          0.23            n.r.            n.r.            Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Instant coffee                                                 2     279--547                                                       413                                                 759--764        761.5       40.4--48.6      44.5   2.06                                          0.12            n.r.            n.r.            Becalski et al. ([2010](#efs25005-bib-0024){ref-type="ref"})
  Regular instant coffee powder                                  7     46.8--742                                                      233                                                 200--6,200      1,595       11.9--270       72.9   6.84                                          0.31            n.r.            n.r.            Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Instant coffee                                                 64    17--3,394                                                      627                                                 135--15,932     2,472       10--1,853       161    4.26                                          0.39            3.85            0.22            DPE[d](#efs25005-note-0107){ref-type="fn"}
  **Non‐alcoholic beverages (excepting milk‐based beverages)**                                                                                                                                                                                                                                                                             
  Brewed coffee                                                  1     820                                                            820                                                 3,900           3,900       n.a.            n.a.   4.76                                          --              --              --              Ochiai et al. (2014)
  Brewed medium roast or bold roast coffee                       16    25.1--69.5                                                     38.7                                                109--287        172         5.0--9.5        6.4    4.4                                           0.17            4.2             0.17            Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Coffee                                                         15    47--2,821                                                      885                                                 117--5,982      1,328       n.a.            n.a.   1.50[e](#efs25005-note-0108){ref-type="fn"}   --              n.r.            --              Fromberg et al. ([2014](#efs25005-bib-0095){ref-type="ref"})
  Decaffeinated coffee                                           12    6.63--121                                                      53.1                                                24.4--365       184         1.1--12.0       6.7    3.5                                           0.13            3.7             0.15            Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  Espresso coffee                                                12    34.9--352                                                      157                                                 135--1,360      583         6.5--39.3       19.0   3.7                                           0.12            3.9             0.14            Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"})
  **Food for infants and small children**                                                                                                                                                                                                                                                                                                  
  Baby food in jar                                               35    20--67                                                         35.6                                                \< RL (5)--12   6.8         \< RL (5)--12   5.2    0.24 (n = 22)                                 0.19 (n = 19)   0.23 (n = 22)   0.17 (n = 19)   DPE[d](#efs25005-note-0107){ref-type="fn"}
  Infant cereals                                                 28    \< RL (5)--32                                                  8.3                                                 7--118          15.4        \< RL (5)--9    3.4    1.71 (n = 15)                                 0.33 (n = 5)    1.4 (n = 15)    0.26 (n = 5)    DPE[d](#efs25005-note-0107){ref-type="fn"}

2MF/F: 2‐methylfuran/furan ratio; 3MF/F: 3‐methylfuran/furan ratio; DPE: Documentation provided to EFSA by FoodDrinkEurope; n.a.: not analysed; n.c.: not calculated; n.r. not reported; n: number of samples; RL: reporting limit.

Applied method of analysis was Headspace sampling followed by analysis using GC--MS unless otherwise stated.

The ratios were estimated by EFSA, with the exception of those food products reported in Becalski et al. ([2016](#efs25005-bib-0026){ref-type="ref"}) where the ratios were provided and are reproduced in this table. Ratios were only calculated when both furan and the methylfuran was quantified.

The mean values were calculated by EFSA using the middle bound approach if they were not provided in the publication.

Data on the co‐occurrence of furan, 2‐methylfuran and 3‐methylfuran in jarred baby foods, cereal flakes, roasted and grounded coffee, soluble coffee, infant cereals and tomato sauce. December 2016. Submitted by FoodDrinkEurope to EFSA, outside the ad hoc call for occurrence data.

Calculated using mean values reported by the authors.

John Wiley & Sons, Ltd

Annex A -- Occurrence data submitted to EFSA and dietary exposure assessment for humans {#efs25005-sec-0112}
=======================================================================================

Annex [A](#efs25005-sec-0112){ref-type="sec"} can be found in the online version of this output, under the section 'Supporting information', at: <http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2017.5005/full>

**Description**: The annex is an excel file which presents tables from Tables A1--A10 on furan occurrence and dietary exposure assessment for humans.

Supporting information
======================

###### 

Occurrence data submitted to EFSA and dietary exposure assessment for humans

###### 

Click here for additional data file.
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[^1]: bw: body weight; i.p.: intraperitoneal.
